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Abstract
Cholinergic dysfunction has been associated with cognitive abnormalities in a
variety

of

neurodegenerative

and

neuropsychiatric

disorders,

including

Alzheimer’s Disease (AD). Cumulative use of drugs with anticholinergic activity is
associated with increased risk for dementia and AD. Also, cholinergic function
has been implicated in predicting the development of key neuropathological
hallmarks seen in AD. However, the relationship between cholinergic dysfunction
and conservation of cognitive ability as well as neuronal cell maintenance is not
fully understood. Here, we tested how information processing and distinct
molecular mechanisms associated with AD are regulated by cholinergic tone in
genetically-modified mice in which cholinergic transmission was altered by
targeting the vesicular acetylcholine transporter (VAChT), a protein required for
acetylcholine storage and release. We assessed the long-term consequences of
loss of central cholinergic signalling for hippocampal vulnerability to age-induced
stress. We show that deletion of forebrain-specific ACh release leads to agerelated increases in neuronal vulnerability, protein aggregation, tau Thr-231
phosphorylation and misfolding, and neuroinflammation. Moreover, inhibition of
forebrain cholinergic neurotransmission led to a disturbance in adult hippocampal
neurogenesis, highlighted by decreased proliferation and cell survival in neural
precursor cells. Additionally, we measured long-term potentiation of Schaffer
collateral-CA1 synapses in vivo and assessed information processing by using a
mouse touchscreen version of Paired Associates Learning task (PAL).
Acquisition in the mouse PAL task was impaired in forebrain-specific VAChT-

ii

deficient mice, suggesting a critical role for cholinergic tone. Accordingly,
synaptic plasticity in the hippocampus in vivo was disturbed, but not completely
abolished, by decreased hippocampal cholinergic signalling. In contrast, spatial
memory was relatively preserved. Moreover, we assessed the functional
consequence of impaired neurogenesis by testing pattern separation using a
Location Discrimination task. Mice with compromised cholinergic signalling were
impaired when stimuli were presented with small separation, but not when stimuli
were presented with high separation, suggesting that deficient cholinergic tone
has major consequences on pattern separation. The pathological changes in the
hippocampus

we

observed

in

VAChT-deficient

mice

have

important

consequences as they presented age-related deterioration in spatial navigation.
Our findings provide a refined understanding of the importance of acetylcholine in
modulating molecular mechanisms and key cognitive behaviours involved in AD.
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Chapter 1

1.

Introduction

1.1 Central cholinergic system

Acetylcholine (ACh) was the first neurotransmitter to be identified in the
mammalian nervous system (Loewi, 1921), and succeeding decades of research
have implicated ACh in regulating vital physiological roles in both the central
nervous system (CNS) and peripheral nervous systems (PNS). In the periphery,
ACh is a fast-acting neurotransmitter in the autonomic ganglia and the
neuromuscular junction (Changeux 2010). Central cholinergic neurotransmission
modulates neuronal excitability, coordinates neuronal firing rates, and influences
release of other neurotransmitters (Zhang and Sulzer 2004; Higley et al. 2011).
Central cholinergic activity has been shown to influence a number of brain
functions including attention, memory, sleep, and drug abuse (Reviewed in
(Everitt and Robbins 1997; Hasselmo and Giocomo 2006)). Moreover,
degeneration of the cholinergic system is thought to underlie some of the
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cognitive and behavioural impairments seen in neurodegenerative diseases
(Whitehouse et al. 1981; Lehericy et al. 1993).

ACh in the CNS originateS mainly from projection neurons, which innervate
target cells in various areas of the brain (Figure 1) (Reviewed in (Picciotto et al.
2012)). Most cholinergic projection neurons originate from nuclei found in the
medial habenula (Ren et al. 2011), the basal forebrain nuclei, which consists of
the nucleus basalis of Meynert (NBM) (extending to the substantia innominata;
SI, in the rodent brain), the medial septum (MS), the horizontal and vertical
diagonal bands of Broca (HDBB and VDBB) (Mesulam et al. 1983; Zaborszky
2002), as well as the brainstem cholinergic nuclei, which is comprised of the
pedunculopontine nucleus (PPN), and the laterodorsal tegmental nucleus (LDT)
(Mesulam et al. 1984) (Figure 1).

Basal forebrain cholinergic nuclei provide vast innervations throughout the
mammalian brain. In the early 80’s Mesulam and colleagues assessed the basal
forebrain cholinergic system in the rat and classified the nuclei according to their
innervated regions (Mesulam 1983). Cholinergic neurons projecting from the MS
and VDB to the hippocampus were referred to as Ch1, and Ch2, respectively
(Figure 1). The main source of cholinergic neurotransmission to the hippocampus
is the MS, which is also referred to as the septohippocampal pathway (Lewis and
Shute 1967). The hippocampus receives approximately 90% of its cholinergic
input from the MS through the fimbria-fornix fibers, which then innervates the
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hippocampus through the stratum oriens (SO) (Dutar et al. 1995). Cholinergic
projections from the HDB, referred to as Ch3, project predominantly to the
olfactory bulb while NBM and SI projections, referred to as Ch4, innervate the
neocortex and the amygdala. Other neuronal types are also part of the basal
forebrain

nuclei,

including

GABAergic

neurons,

glutamatergic

neurons,

neuropeptides (neuropeptide Y, somatostatin) and neurons containing different
calcium binding proteins (calbindin, calretinin, and parvalbumin) (Gritti et al.
2003; Zaborszky et al. 2005). These basal forebrain cholinergic nuclei have been
implicated in regulating several aspects of cognition, including memory (Dunnett
and Fibiger 1993; Woolf 1997) and attention (Sarter and Bruno 1997).

According to Mesulam’s nomenclature (Mesulam et al. 1983), the brainstem
cholinergic system is subdivided into Ch5, which refers to cholinergic neurons in
the PPN, and Ch6, which refers to cholinergic neurons in the LDT. Both Ch5 and
Ch6 cholinergic nuclei predominantly innervate the thalamus (Figure 1).
Additionally, PPN cholinergic nuclei innervate the posterior lateral hypothalamus
(Ford et al. 1995), the midbrain, the inferior and superior colliculi and pontine
regions (Mena-Segovia et al. 2008). These PPN cholinergic neurons have been
associated with sleep and wakefulness, and memory (Kessler et al. 1986; Lima
et al. 2012).

In the striatum, cholinergic innervation comes mainly from interneurons that are
characterized by tonically active ACh-release. Striatal cholinergic interneurons
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comprise approximately 1% of striatal cells (Phelps et al. 1985) and have been
proposed to play a critical role in behavioural flexibility (Okada et al. 2014).

Figure 1. Schematic overview of the rodent central cholinergic system.
Cholinergic striatal interneurons provide local innervation while projection
neurons in the basal forebrain system: medial septum (MS;Ch1), vertical limbs of
the diagonal band of Broca (VDB;Ch2) and horizontal limbs of the diagonal band
of Broca (HDB;Ch3), nucleus basalis of Meynert (NBM;Ch4), and substantia
innominate (SI;Ch4) innervate the hippocampus, anterior cingulate gyrus,
olfactory bulb, the corticle mantle, respectively. Brainstem cholinergic nuclei:
pedunculopontine (PPN;Ch5) and laterodorsal tegmental (LDT;Ch6) innervate
the hindbrain, thalamus, hypothalamus, and basal forebrain.
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1.1.1 Regulation of central cholinergic signalling

ACh genesis is dependent on the uptake of choline into the presynaptic cell by
the high-affinity choline transporter (CHT1). CHT1 acts as the rate-limiting step
for ACh production as it regulates the transport of choline from the extracellular
space, necessary for ACh synthesis and release, into the presynaptic nerve
terminal, (Kuhar and Murrin 1978; Brandon et al. 2004). Choline and intracellular
acetyl-CoA are then used for ACh synthesis by choline acetyltransferase (ChAT)
(Hersh et al. 1996). ChAT is mainly localized in the cytoplasm of cholinergic
nerve terminals, and is regulated by the influx of calcium (Ca2+) and
phosphorylation by kinases (Rylett 1989; Schmidt and Rylett 1993). ChAT activity
is in kinetic excess in cholinergic nerve terminals; hence, ChAT does not appear
to represent a rate-limiting step for ACh production (Brandon et al. 2004). Once
synthesized, ACh is packaged into synaptic vesicles by the vesicular
acetylcholine transporter (VAChT) to form a quantum, which determines the
minimum amplitude of a postsynaptic potential (Fatt and Katz 1951,
1952)(Reviewed in (Van der Kloot and Molgo 1994; Prado et al. 2013)). ACh is
then released by exocytosis (Figure 2) (Song et al. 1997; Lima Rde et al. 2010).
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Once in the synaptic cleft, ACh can bind to muscarinic ACh receptors (mAChRs)
or nicotinic ACh receptors (nAChRs). Alternatively, remaining synaptic ACh is
degraded by acetylcholinesterase (AChE) (Ellman et al. 1961), a membrane
enzyme regulated by a proline-rich membrane anchor (PRiMA) (Perrier et al.
2002) (Figure 2).

A large body of evidence indicates that VAChT activity plays a critical role in
regulating ACh storage and release (Reviewed in (Prado et al. 2013)). VAChT is
a 12 transmembrane protein with a molecular mass of 75 kDa, that is part of a
Major Facilitator Superfamily of transporters (Alfonso et al. 1993; Varoqui and
Erickson 1996; Vardy et al. 2004). VAChT is part of the vesicular monamine
transporter (VMAT) family (VMAT1 and VMAT2) and belongs to the SLC18
family of proton/neurotransmitter antiporters, which regulate the release of
neurotransmitters (Erickson et al. 1994; Reimer et al. 1998). VAChT is found in
synaptic vesicles (Varoqui and Erickson 1998; Krantz et al. 2000). To package
and transport ACh, VAChT uses the electrochemical gradient generated by a Vtype proton ATPase (Parsons et al. 1993; Parsons 2000). VAChT exchanges two
luminal protons for a cytoplasmic ACh molecule (Nguyen et al. 1998).

Intriguingly, the VAChT gene lies uninterrupted within the first intron of the ChAT
gene and in the same transcriptional orientation (Bejanin et al. 1994; Erickson et
al. 1994). Because of this unique organization this genomic site has been called
“cholinergic gene locus” (Bejanin et al. 1994; Erickson et al. 1994), a term used
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to define a cluster of functionally related genes that are regulated and transcribed
as a unit (Jacob and Monod 1961; Eiden 1998). This complex genetic
organization allows multiple mRNA expression of VAChT and ChAT in a cellspecific

manner

throughout

the

nervous

system.

Despite

this

unique

organization, evidence suggests that there are independent regulatory processes
specific for either VAChT or ChAT as well as shared regulatory elements. For
example, it has been demonstrated that VAChT and ChAT genes require specific
silencer elements to repress expression of these genes in non-cholinergic cells
(De Gois et al. 2000). On the other hand, studies in cell lines suggest
independent regulation of ChAT and VAChT mRNA levels (Malik et al. 2000;
Dolezal et al. 2001).

A number of studies highlight the importance of VAChT in regulating cholinergic
signalling across species. In Caenorhabditis elegans (C. elegans), mutations that
eliminate the VAChT gene (named unc-17) function were lethal (Alfonso et al.
1993), highlighting the physiological importance of VAChT in storage of ACh.
Likewise, VAChT expression in rodents (Erickson et al. 1994; Prado et al. 2006)
and humans (Roghani et al. 1994) is critical for ACh storage and release, as
genetic knockout VAChT mice die shortly after birth (de Castro et al. 2009).
VAChT expression is essential for regulating the amount of ACh stored and
released. For example, overexpression of VAChT in Xenopus neurons
significantly increased the number of miniature excitatory postsynaptic potentials
(EPSPs), suggestive of an increase in vesicles storing ACh (Song et al. 1997). In
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vivo studies showed that decreased VAChT levels severely compromise
packaging of ACh into synaptic vesicles and therefore reduce ACh release by
nerve terminals (Prado et al. 2006; de Castro et al. 2009; Lima Rde et al. 2010).
In mice with 70% reduction in VAChT levels, electrophysiological recordings in
neuromuscular junctions demonstrated marked reductions in endplate potentials
and miniature endplate potentials, indicative of quantal content, compared to
wild-type controls (Lima Rde et al. 2010). Conversely, overexpression of VAChT
enhances ACh secretion (Song et al. 1997; Nagy and Aubert 2012; Kolisnyk et
al. 2013). Indeed, due to the unique organization of the cholinergic gene locus,
transgenic mice generated using a bacterial artificial chromosome (BAC)
containing the ChAT gene to express channelrhodopsin-2 protein under the
ChAT promoter present elevated mRNA and protein VAChT levels (Kolisnyk et
al. 2013). Importantly, these mice presented a functional increase in synaptic
ACh levels along with impairments in cognition and enhanced physical
endurance (Kolisnyk et al. 2013). These findings indicate that VAChT levels
regulate ACh storage and release.
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Figure 2. Schematic representation of a cholinergic synapse. Choline is
taken up into presynaptic cell by CHT1, once in the nerve terminal ChAT
synthesizes ACh and is loaded and released by VAChT. Once in the synapse
ACh signals through mAChRs (M), or nAChRs (N). Remaining ACh in the
synapse is degraded into acetate and choline by AChE. Key represents
unlabeled symbols due to space limitations.
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1.1.2 Muscarinic receptors

ACh action is mediated through two classes of receptors: muscarinic
acetylcholine receptors and nicotinic acetylcholine receptors (mAChRs and
nAChRs, respectively). Muscarinic receptors consist of 5 receptor subtypes (M1M5), which are prototypical members of the superfamily of G-protein-coupled
receptors, and are found both pre- and post-synaptically throughout the brain
(Wess 1996). mAChR subtypes M1, M3, and M5 are linked to the Gq proteins,
which activate phospholipase C, whereas M2 and M4 subtypes are coupled to
Gi/o type G-proteins, which negatively couple to adenylate cyclase (Wess 1996;
Wess et al. 2003).

The five-receptor subtypes of the mAChR are expressed throughout the brain in
both neurons and glia, and most cell types express at least two or more subtypes
(Wess 1996; Caulfield and Birdsall 1998; Volpicelli and Levey 2004). The M1,
M4, and M5 mAChR subtypes are mainly found in the CNS while the M2 and M3
mAChR subtypes are expressed in both the PNS and the CNS (Wess 1996;
Wess et al. 2007). ACh-mediated activation of mAChRs has been shown to
modulate an array of phospholipases, ion channels, and protein kinases through
activated G-protein α-subunits and βγ complexes (Wess 1996; Nathanson 2000;
Lanzafame et al. 2003). These diverse biochemical effects lead to distinct
electrophysiological responses depending on the subtype of cell stimulated
(Wess 1996; Wess et al. 2007). The levels of expression of each subtype vary
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within brain regions; for example, in humans, the M1 mAChR subtype is highly
expressed (35-60% of all mAChR binding sites) in regions associated with
cognitive processes such as the hippocampus and the neocortex (Volpicelli and
Levey 2004). In contrast, M2 and M4 mAChR subtypes are abundantly found in
the basal forebrain, and the striatum, respectively (Levey et al. 1991). The M3
and M5 mAChR subtypes are expressed at low levels in the CNS (Levey et al.
1991). Diverse effects could occur depending on the location as well as the
mAChR subtype stimulated. For instance, post-synaptic stimulation of M1/M5
receptors increases neuronal excitability of cortical neurons (Douglas et al.
2002), while presynaptic M2 receptors decrease glutamate release from
corticostriatal synapses (Higley et al. 2009). M2 receptors located on presynaptic
cholinergic nerve terminals in the hippocampus and cortex mediate inhibition of
ACh release (Quirion et al. 1995; Zhang et al. 2002). Thus, central M2 receptors
have been proposed as a potential pharmacological target in that blocking M2
receptor activity would enhance cholinergic signalling in AD patients (Quirion et
al. 1995; Carey et al. 2001).

In vivo, activation of M1 mAChRs modulates excitatory synaptic transmission via
N-methyl-D-aspartate (NMDA)-receptor potentiation (Marino et al. 1998). M1
knockout mice exhibit selective cognitive impairments in tasks requiring
interactions between the hippocampus and cortex (Anagnostaras et al. 2003).
Moreover, evidence shows that activation of M1 mAChRs induces long-term
potentiation (LTP), suggesting that M1 mAChRs could play a role in regulating
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hippocampal plasticity (Buchanan et al. 2010; Giessel and Sabatini 2010; Dennis
et al. 2015). Because of the low expression of M3 mAChRs in the CNS, little is
known regarding their role in cognition; however, M3 mAChRs have been
implicated in regulating smooth muscle contractility and salivary secretion
(Caulfield 1993; Eglen et al. 1996). Similar to M1 mAChR knockout mice, M5
mAChR knockout mice have impaired hippocampal LTP, as well as deficits in the
Y-maze task and object recognition (Araya et al. 2006). Additionally, M2
knockout mice display impairments in working memory, cognitive flexibility, and
hippocampal plasticity (Seeger et al. 2004). Mice lacking the M4 mAChR subunit,
however, showed no impairments in spatial and working memory, while social
interaction was abnormal in M4 knockout mice compared to controls (Koshimizu
et al. 2012). Furthermore, evidence shows that M4 mAChRs play an important
role in regulating locomotion, as well as modulating prepulse inhibition (Gomeza
et al. 1999; Felder et al. 2001). These findings illustrate the distinct behavioural
outcomes by modulating each muscarinic receptor subtype in the CNS.

1.1.3 Nicotinic receptors

Nicotinic receptors are non-selective, excitatory cation channels with a molecular
mass of 290 kDA (Changeux et al. 1998; Picciotto 2003). These receptors are
encoded by 12 genes, and occur as homomeric or heteromeric clusters of a large
family of α- (α2-α10) and β- (β2-β4) subunits (Gotti et al. 2007). Nicotinic
receptors are permeable to sodium (Na+), potassium (K+), and Ca2+ ions,
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depending on their subtype composition (Gotti et al. 2006). In the CNS, the two
main nicotinic receptor subtypes are the homomeric α7, and the heteromeric
α4β2 subunits (Hill et al. 1993; Zoli et al. 1995). One of the differences regarding
these nAChRs is their propensity to desensitization. α7 nAChRs are rapidly
desensitized to high concentrations of ACh while α4β2 nAChRs are slowly
desensitized (McGehee and Role 1995; Mansvelder et al. 2002). Experiments
demonstrate high levels of expression of α7 and α4β2 in the hippocampus
(Seguela et al. 1993); and indicate that these receptors mediate distinct forms of
hippocampal plasticity (Ji et al. 2001). nAChRs have high affinity for nicotine and
low concentrations of nicotine significantly enhance excitatory transmission in
hippocampal neurons (Gray et al. 1996). Activation of nAChRs excites target
cells and it is associated with fast synaptic transmission through regulating the
release of many neurotransmitters, including ACh (Vidal and Changeux 1993;
Marchi and Raiteri 1996). For example, nicotinic stimulation enhances ACh
release from murine synaptosomes (Rowell and Winkler 1984), while the use of
nicotinic antagonists in striatal brain slices attenuates evoked dopamine release
by 90% (Zhou et al. 2001). Experiments show that this modulation of
neurotransmitter release is region-, and subtype-specific. For instance, α4/α6β2
nAChRs mediate the release of dopamine in the striatum, while the α3β4
nAChRs mediate ACh release in the intrapeduncular nucleus (Grady et al. 2001).
Furthermore, the location of nAChRs dictates the effects they would have on
neurotransmitter release and synaptic plasticity (Ji et al. 2001; Gu and Yakel
2011). That is, activation of α7 nAChRs on hippocampal interneurons blocks LTP
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responses in pyramidal cells, while presynaptic activation of nAChRs in
pyramidal cells increases glutamate release and LTP (Ji et al. 2001). This
suggests that nAChRs, through pre and postsynaptic mechanisms, are involved
in regulating synaptic plasticity through distinct receptor subtypes.

At the behavioural level, nAChRs have been majorly implicated in mediating cue
detection during attentional performance (McGaughy et al. 1999; Parikh et al.
2010). Indeed, there is strong evidence linking nicotine to enhancement of
attention in humans (Lawrence et al. 2002), and rodents (Young et al. 2004).
Local infusions of nicotine into the prefrontal cortex in rats significantly enhance
response accuracy in the five choice serial reaction time task (5-CSRTT) (Hahn
et al. 2003). Special focus has been on investigating the effects of β2-containing
nAChRs and α7 nAChRs, which are widely expressed in the brain (Gotti et al.
2007). For example, the use of α7 agonist R3487/MEM 3454 and 5-HT3 receptor
antagonist improves sustained attention in rats (Rezvani et al. 2009).
Furthermore, low dose injections of α7 agonists (PHA-543,613, and PNU282,987) improves attentional performance of wild-type mice, while high doses
impair attentional performance in the 5-CSRTT (Kolisnyk et al. 2015).
Interestingly, α7 nAChR knockout mice display impairments in attentional
performance in the 5-CSRTT; these deficits however, were reversed by
administration of β2 nAChR agonist (Kolisnyk et al. 2015). Indeed, mice lacking
the β2 nAChR subunit exhibit impairments in attentional performance in the 5CSRTT (Guillem et al. 2011). Interestingly, these deficits were reversed by
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reexpression of the β2 subunit by viral injections of a β2-eGFP bi-cistronic vector
in the prelimbic region of medial prefrontal cortex (Guillem et al. 2011). These
findings suggest that α7 and β2 nAChRs play a critical role in regulating
attention.

1.2 Alzheimer’s Disease

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder first
described by Alois Alzheimer in 1906, and is the most common form of dementia.
Dementia refers to a class of disorders characterized by deterioration of thinking
ability and memory. Behavioural and psychological symptoms of dementia
include memory loss, reasoning loss, attention deficits, delusions, hallucinations,
agitation, and depression (Finkel et al. 1996; Pinto et al. 2011). Pathological
hallmarks of AD and decline in quality of life occur gradually, with dementia being
the end stage. Patients diagnosed with AD typically endure a decade of
progressive

increase

in

AD-related

pathological

processes

before

the

presentation of clinical symptoms (Jack et al. 2009). This slow but inevitable
progression of AD places a substantial burden on patients, families, caregivers,
and society. In 2010, approximately 36 million individuals worldwide were
diagnosed with AD, and it was estimated to cost the world an alarming $604
billion (World Alzheimer Report, 2010). These figures are projected to triple by
2050 (World Alzheimer Report, 2010), calling out the need for novel therapeutic
targets in AD.
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AD is associated with vigorous forebrain neuropathology, with two major
pathological hallmarks being amyloid beta (A
tangles (Ballard et al. 2011). Both A

) plaques and neurofibrillary

and neurofibrillary tangles induce

progressive neuronal dysfunction and subsequent neuronal death, resulting in
severe brain atrophy and loss of cognitive function (Selkoe 2003). Moreover, AD
patients also exhibit central vascular impairments, characterized by decreased
blood flow to the brain leading to compromised clearance of A

(Reviewed in

(Zlokovic 2011)). This consequently aids the progressive neuropathology and cell
death observed in AD. In addition to these neuropathology processes, loss of
cholinergic tone is considered to be one of the earliest pathological events that
occur in AD (Perry et al. 1978; Bowen and Davison 1980).

1.2.1 Amyloid Pathology

In patients with AD, the formation of amyloid plaques is a key feature that has
been proposed to underlie neurodegeneration and deteriorating cognition
(Reviewed in (Selkoe and Schenk 2003)). In AD, plaque deposition occurs
initially in the basal areas of the neocortex then propagates to the hippocampus,
and ultimately propagates to other subcortical regions (Braak and Braak 1991).
Amyloidosis refers to the pathological process where deposits of 5-10 nm of
amyloid fibrils progressively accumulate in the extracellular spaces of tissues
(Selkoe 1991). Amyloid plaques consist mainly of A peptides, which are derived
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from the amyloid precursor protein (APP) (Selkoe 2003). APP is a type 1
transmembrane protein that consists of 695-770 amino acids and undergoes
endoproteolytic cleaving through one of two pathways: a non-amyloidogenic, and
an amyloidogenic (A -yielding) pathway (Reviewed in (LaFerla et al. 2007). In
the non-amyloidogenic pathway, APP is cleaved at the A

domain by the α-

secretase enzyme, and as a result, a larger ectodomain named sAPPα and a
smaller carboxyl-terminal fragment (C83) are generated (Kojro and Fahrenholz
2005). In the amyloidogenic pathway, the β-secretase enzyme cleaves APP,
generating the sAPP

ectodomain and retaining the C99 amino acids peptide

membrane-bound. C99 is then cleaved from the amino terminus by the gammasecretase enzyme to release A

. This process yields A

1-40

or A

1-42

depending on the cleavage site. To note, the 42-residue variant is more
hydrophobic than the 40-residue variant of A

and is the major constituent of

amyloid plaques seen in AD (Jarrett et al. 1993). Mutations in the genes that
encode APP or the enzyme presenilin 1 (PS1), which forms the catalytic domain
of the larger gamma secretase complex, can lead to AD (De Strooper et al.
1999)(Reviewed in (De Strooper 2010)).

The amyloid hypothesis states that mutations in these genes significantly
increase A

-42 production and accumulation, which in turn triggers the

oligomerization of A -42 leading to formation of amyloid plaques (Hardy and
Selkoe 2002). The deposition of A -42 plaques has consequences on synaptic
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function and triggers inflammatory responses (Rogers et al. 1996). Furthermore,
deposition of A -42 plaques has been thought to contribute to tangle formation
due to alterations in kinase activity (Lewis et al. 2001)(Reviewed in (Hardy et al.
1998).

Several lines of work have demonstrated that soluble oligomers of A

are major

contributors to the synaptic impairments seen in AD (Lambert et al. 1998; Mucke
et al. 2000; Walsh et al. 2002; Ferreira and Klein 2011). A

toxicity can be

mediated via binding to a wide range of receptors, which activates distinct
signalling pathways. For example, the cellular prion protein (PrPc) is an A
oligomers-receptor, and has been shown to mediate A
synaptic dysfunction (Lauren et al. 2009). A

oligomers-induced

oligomers have also been shown

to bind with high affinity to the α7 nAChR, and have been associated with
triggering synaptic dysfunction and cognitive impairments (Wang et al. 2000;
Dziewczapolski et al. 2009). Moreover, extracellular A

oligomers bind to the

cell surface to N-methyl-D-aspartate receptors (NMDARs) and elicit synaptic
dysfunction through an increase in production of reactive oxygen species
(Snyder et al. 2005; De Felice et al. 2007). In addition, A

oligomer-mediated

inhibition of NMDAR synaptic plasticity was shown to be mediated by the
metabotropic glutamate-5 receptor (mGluR5) (Hu et al. 2014), Studies in
hippocampal slices demonstrated that A

oligomers lead to an NMDAR-

independent long-term depression (LTD), an effect that was blocked by mGluR5
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antagonists (Li et al. 2009). Further experiments have shown that A

oligomers

and the PrPc form a complex with mGluR5 to induce synaptic toxicity (Um et al.
2013). Additionally, A oligomers were shown to induce nerve growth factor
(NGF)-mediated cell death via the induction of the p75 neurotrophin receptor
(p75NTR) (Yamamoto et al. 2007), which is part of the tumor necrosis receptor
superfamily (Hansma et al. 1995). These pathological mechanisms are thought
to be major contributors to the neuronal dysfunction and neuronal cell death
observed in dementia (Hardy and Selkoe 2002).

Different mouse models of AD have been generated and widely used to
investigate molecular mechanisms leading to pathology and altered cognition. In
vivo, imaging studies in mice overexpressing APP and PS1 (APP/PS1) reveal
plaque formation at 3 months of age, which in turn leads to oxidative stress and
cell death in surrounding cells (Xie et al. 2013). One of the widely used AD
mouse models is the 3xTgAD mouse model. This mouse model expresses the
human APPSwedish and tauP301L transgenes, and the PS1M146V knockin (Oddo et al.
2003). The 3xTgAD model develops AD-like pathology in an age-dependent
manner, highlighted by plaque deposition, and tangle formation (Oddo et al.
2003; Billings et al. 2005). Studies in the 3xTg-AD mouse model have
demonstrated that intracellular Aβ accumulation worsens synaptic health and
underlies cognitive impairments (Billings et al. 2005). Moreover, LTP deficits
were observed in 3xTg-AD mice prior to plaque and tangle pathology, suggesting
that increased levels of intracellular A

levels impair synaptic plasticity (Oddo et
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al. 2003). Similarly, intracellular A

is present in AD patients even prior to

plaque and tangle formation, suggesting that intracellular A

accumulation is an

early event in neuronal pathology (Gouras et al. 2000; Wegiel et al. 2007).
However, this is controversial as these results may be due to non-specific
binding of the antibody to APP. Nonetheless, extracellular amyloid plaque
deposition was found to be poorly linked to the cognitive decline seen in AD
(Kelley and Petersen 2007). Moreover, experimental AD models showed that the
disruption of connectivity within the hippocampal neural circuitry and synaptic
loss caused by A

occurred well before plaque formation (Redwine et al. 2003;

Wu et al. 2004). In addition to the A

toxicity on synaptic integrity, studies have

demonstrated that PS1 mutation in the 3xTg-AD mouse model impairs
cholinergic-mediated hippocampal plasticity (Wang et al. 2009). Moreover, 6
month-old 3xTg-AD mice display decreased levels of α7 nAChRs in regions
where intraneuronal A

accumulates, including the hippocampus (Oddo et al.

2005). Interestingly, administration of an M1 agonist in 3xTg-AD mice was shown
to be sufficient to rescue cognitive deficits in the spatial Morris Water Maze
(MWM), and attenuated A

and tau pathology (Caccamo et al. 2006).

Additionally, in aged 3xTg-AD mice, treatment with a α7 nAChR agonist
significantly reversed cognitive impairments in these mice compared to agematched controls, however, neuropathological hallmarks including A

deposits

were unchanged (Medeiros et al. 2014). These findings are in line with a number
of studies that have demonstrated that A

binds to the α7 nAChR with high
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affinity, resulting in receptor internalization and increased intracellular A levels
(Wang et al. 2000; Nagele et al. 2002). Indeed, human studies reveal high
immunoreactivity of amyloid in basal forebrain cholinergic neurons in early adult
life (Baker-Nigh et al. 2015). These findings suggest that oligomerization of A in
these basal forebrain cholinergic neurons during aging could contribute to the
neurodegeneration observed in cholinergic neurons in AD.

1.2.2 Tauopathy

Another major hallmark of AD is the formation of neurofibrillary tangles (NFT).
Neurofibrillary tangles are mainly composed of hyper-phosphorylated and
aggregated forms of tau, a microtubule-associated protein (MAP), which
accumulates in neurons leading to neuronal apoptosis (Iqbal and Grundke-Iqbal
2006). The tau protein is encoded my a single MAPT gene on chromosome 17,
and is alternatively spliced to six protein isoforms in the adult human brain
(Goedert et al. 1989). As a microtubule protein, tau interacts with tubulin to
stabilize its assembly into microtubules and aids their structural stability
(Weingarten et al. 1975). Tau is found predominantly in neurons and regulates
axonal transport, elongation, and maturation (Stamer et al. 2002)(Reviewed in
(Wang and Mandelkow 2016)). The biological functioning of tau is regulated by
its phosphorylation.
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In normal conditions, tau carries approximately two phosphates per molecule,
while in AD; phosphorylation of tau is increased to eight phosphates per
molecule (Kopke et al. 1993). There are 85 identified potential phosphorylation
sites in the tau isoform (24NR) (80 Ser or Thr, and 5 Ty), of which 17 Thr-Pro or
Ser-Pro motifs have been linked to the hyperphosphorylation phenotype
observed in AD (Hanger et al. 2009). In AD, hyperphosphorylation of tau
consequently leads to the accumulation of intracellular neurofibrillary tangles
(NFT) and paired helical filaments (PHF) (Kidd 1963). Under pathological
conditions, a misbalance of tau binding to microtubules leads to high levels of
unbounded tau in the cytosol, which in turn leads to conformational changes that
causes aggregation of tau (Reviewed in (Ballatore et al. 2007)). Once
aggregated in the cell, pretangles are formed, which ultimately undergo a
structural rearrangement to form

-sheet-positive PHFs and NFTS (Galvan et al.

2001; Maeda et al. 2007). Formation of these PHFs and NFTs has been
proposed to be dependent on the rate of phosphorylation, which would determine
the concentration of unbound tau fractions in the cytosol (Reviewed in (Ballatore
et al. 2007)). Furthermore, both total and phosphorylated levels of tau have been
effectively correlated to cognitive deficits in AD (Buerger et al. 2002; Kelley and
Petersen 2007; Diniz et al. 2008). It has been suggested that modulation of
tauopathy in AD occurs via key kinases and phosphatases, including GSK3
and CDK5 (Hanger et al. 1992; Shelton and Johnson 2004). Indeed, transgenic
mouse models overexpressing GSK3

showed increased phosphorylation of tau

and hippocampal neurodegeneration (Engel et al. 2006). Similarly, transgenic
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mice overexpressing CDK5 displayed increased numbers of NFTs (Noble et al.
2003). This suggests that these kinases are key players in triggering ADtauopathy.

3xTg-AD mice, which express the P301L mutation in tau and APP/PS1 mutations
(Oddo et al. 2003), progressively develop tau pathology at 6-12 months of age
(Oddo et al. 2003). This manifestation of tau pathology could be identified using
antibodies that detect the amount of phosphorylation at specific residues
including Ser202, Thr 205, Ser 231, Ser396 and Ser404 (LaFerla and Oddo
2005). 3xTg-AD mice display working memory impairments in the 8-arm radial
maze task as early as 2 months (Stevens and Brown 2015). Thus, both Aβ and
neurofibrillary tangles seem to induce progressive neuronal dysfunction and
subsequent death, resulting in severe brain atrophy and loss of cognitive function
(Selkoe 2003).

1.2.3 Neuroinflammation

Neuroinflammation is a secondary response to insult in the CNS that leads to
activation of glial cells. Microglia are found throughout the CNS with the highest
density of expression in the hippocampus, basal ganglia, and the substantia
nigra. In AD, increased microglial activation is a key hallmark, which in turn leads
to enhanced release of pro-inflammatory cytokines and abnormal phagocytosis.
The pro-inflammatory cytokines released by microglia include tumour necrosis
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factor-α (TNF-α), interleukin-1

(IL-1

), interleukin-6 (IL-6), and reactive oxygen

species (Reviewed in (Block et al. 2007)). In AD, over activation of microglia
precedes the development of cognitive impairments and are typically found
surrounding aggregated Aβ plaques (McGeer et al. 1987; Veerhuis et al. 1999).
In early phases of AD, these microglia are thought to contribute to Aβ clearance
(El Khoury et al. 2007). In late AD however, evidence shows that Aβ plaques
activate microglia, which releases neurotoxic, and proinflammatory factors that
ultimately trigger neuronal death (Hickman et al. 2008). Recent work has
demonstrated that mutations in the Triggering receptor expressed on myeloid
cells 2 (TREM2) is involved in increasing the risk of developing AD (Jonsson et
al. 2013). TREM2 is expressed by microglia and experiments show that loss of
one copy of TREM2 significantly increases Aβ plaque accumulation in 5xFAD
mice (Wang et al. 2015). Furthermore, recent findings illustrate that
administration of interleukin 33 (IL-33) rescues synaptic plasticity deficits in an
APP/PS1 AD mouse model (Fu et al. 2016). Post administration of IL-33
injections, soluble A

levels were significantly reduced by increased microglial

phagocytic activity (Fu et al. 2016). These findings suggest that the innate antiinflammatory response may serve as a target for AD.

In mouse models of AD, the inflammatory response is less severe and does not
precede the hallmarks of the disease as seen in humans (Reviewed in
(Duyckaerts et al. 2008)). Nonetheless, 3xTgAD mice presented early microglial
activation (3 months of age), which preceded plaque Aβ deposition (12 months of
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age) (Janelsins et al. 2005). Interestingly, this inflammatory response was
characterized by increased expression of the pro-inflammatory markers: TNF-α
and monocyte chemoattractant protein-1 (MCP-1), which coincided with the high
accumulation of intracellular Aβ at 3 months of age (Janelsins et al. 2005).

A number of studies trigger neuroinflammation responses using injections of
lipopolysaccharide (LPS) (Hauss-Wegrzyniak et al. 1998; Kitazawa et al. 2005),
which is an endotoxin that induces a cellular stress response. Upon
administration, LPS forms a complex with CD14, which interacts with the toll-like
receptor-4 (TLR-4), and activates microglia leading to secretion of proinflammatory cytokines including IL-1, IL-6, IL-12, and TNF-α (Reviewed in
(Rivest 2009)). Indeed, experiments involving neuroinflammation in rats using
ventricular infusions of LPS to the basal forebrain have demonstrated increased
microglial activation in the basal forebrain (Wenk et al. 2000). Chronic basal
forebrain LPS infusion significantly decreases activity of ChAT in the basal
forebrain (Willard et al. 1999) and triggers activation of caspase-3, caspase-8,
and caspase-9 activity in the ventral caudate region (Wenk et al. 2000). These
findings suggest that cholinergic neurons are selectively vulnerable to the toxic
effects of chronic neuroinflammation. In line with these findings, data from
separate studies demonstrate that systemic administration of cholinesterase
inhibitor, galantamine, significantly suppresses TNF-α expression induced by
systemic LPS injections (Pavlov et al. 2009). Interestingly, this effect was blocked
by administration of atropine, a muscarinic receptor antagonist, suggesting a
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critical role for cholinergic signalling in central inflammatory responses (Pavlov et
al. 2009).

Studies using infusion of LPS in the fourth ventricle show that 2 weeks after last
of infusion of LPS, microglial activation was substantially attenuated in all areas
of the brain except the hippocampus, suggesting a regional vulnerability to
neuroinflammation (Hauss-Wegrzyniak et al. 1998). The findings of these studies
indicate that while systemic-induced inflammation provides insight regarding the
inflammatory cellular responses in the CNS, it is not an ideal approach to model
the chronic inflammatory responses observed in AD. This is due to the
confounding factor of systemic inflammation induced by using LPS. Moreover,
using mouse models overexpressing specific cytokines may also not provide a
faithful model of the endogenous inflammatory responses observed in AD.

The recent development of Designer Receptors Exclusively Activated by
Designer Drugs (DREADDs) has provided means of activating or inhibiting a
specific cell type (Armbruster et al. 2007)(Reviewed in (Roth 2016)). This
technology utilizes engineered-GPCRs that bind to designed ligands to elicit
either silencing or enhancement of neuronal or non-neuronal activation. One of
these engineered receptors is the human Gαq M3-muscarinic receptor (Schmidt
et al. 2003; Armbruster et al. 2007). The modified receptor, referred to as
hM3Dq, does not bind ACh but can be activated by the inert metabolite
clozapine-N-Oxide (CNO), to trigger Gα-q-mediated signalling pathways.
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Modified M4-muscarinic receptors are also available. Armbruster et al.
demonstrated that the use of CNO on hM4Di-DREADD in hippocampal neurons
elicits neuronal inhibition through Gαi-mediated signalling (Armbruster et al.
2007). Indeed, increasing evidences show in vivo CNO mediated activation or
silencing of neurons using either hM3Dq-DREADD or hM4Di-DREADD,
respectively (Krashes et al. 2011; Ray et al. 2011; Atasoy et al. 2012; Garner et
al. 2012).

A recent study demonstrated that activation of M3 mAChRs modulates microglia
function (Pannell et al. 2016). Using calcium imaging in cultured adult mouse
cortical microglia, it was determined that 8% of cultured microglia responded to
carbachol. In the same study, treatment of the adult cortical microglia with
interferon-gamma, a pro-inflammatory cytokine, resulted in an increase in the
number of carbachol-sensitive microglia to 60%. Moreover, analysis of the
expression of the M3 mAChR using quantitative PCR (qPCR) showed an
upregulation in adult cortical microglia treated with interferon-gamma, an effect
that was blocked by treatment with an M3-specific antagonist (Pannell et al.
2016). Importantly, these elegant experiments demonstrated that microglia that
had upregulation of M3 mAChR also expressed the major histocompatibility
complex (MHC-I and MHC-II), indicative of functionally activated microglia
(Pannell et al. 2016). Due to the lack of a faithful model of central inflammatory
response seen in AD, DREADDs may serve as a tool to investigate how chronic
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activation of central inflammatory responses plays a role in the pathogenesis of
AD.

1.2.4 Cholinergic dysfunction

Bartus and colleagues were the first to formulate the cholinergic hypothesis in AD
(Bartus et al. 1982). This hypothesis states that loss of central cholinergic
neurotransmission plays a key role in the cognitive decline observed in AD.
Moreover, deterioration of basal forebrain cholinergic neurons has been
positively correlated with cognitive impairments in AD (Perry et al. 1978;
Collerton 1986; DeKosky et al. 1992). This is mainly highlighted by loss of
different cholinergic markers such as ChAT (DeKosky et al. 1992), AChE
(DeKosky et al. 1992), and VAChT (Chen et al. 2011). As such, decades of
research led to the development of FDA approved cholinergic drugs to treat AD:
donepezil, galantamine, and rivastigmine (Schneider et al. 2014). Cholinergic
agonists approved for treatment in AD enhance central cholinergic signalling by
inhibiting the activity of the acetylcholinesterase enzyme, which normally
degrades synaptic ACh (Massoulie et al. 1993)(Reviewed in (Buccafusco and
Terry 2000). However, evidence shows that these cholinergic agents present
modest effects in treating patients with mild cognitive impairment (MCI) (Doody et
al. 2009), an early cognitive impairment proposed to precede AD. The modest
effect of these clinical trials could be due to heterogeneity of the MCI-diagnosed
patients as many of the symptoms of MCI may be caused by different disorders,
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and that not all MCI patients necessarily develop AD (Petersen et al. 1999;
Schneider et al. 2014). The development of the Free and Cued Selective
Reminding Test (FCSRT) was shown to detect prodromal AD within MCI patients
(Sarazin et al. 2007). Interestingly, in prodromal AD patients, an annual daily
dose of donepezil (10mg) reduced the annual percentage change of total
hippocampal volume by 45% (Dubois et al. 2015). This suggests that donepezil
may play a protective role on hippocampal atrophy and cognition in patients atrisk of developing AD.

Imaging studies demonstrate progressive neurodegeneration in the basal
forebrain cholinergic system, the hippocampus, and cortex in AD, and in patients
with MCI (Teipel et al. 2005; Grothe et al. 2010; Grothe et al. 2012; Kilimann et
al. 2016). Indeed, magnetic resonance imaging (MRI) experiments reveal that
decreased volume of the basal forebrain and the hippocampus significantly
predicts conversion from MCI to AD (Brueggen et al. 2015). Moreover,
postmortem analysis of protein and mRNA levels of VAChT demonstrated
substantial decrease in the levels of VAChT in the frontal cortex of AD patients,
indicating that storage and release of ACh is compromised in AD (Chen et al.
2011). Similarly, there is a reduction in expression of M2 mAChR subtype and
nicotinic receptors in cortical areas in patients with AD (Mash et al. 1985; London
et al. 1989). Despite the substantial cholinergic depletion in projection regions of
the basal forebrain cholinergic system, striatal interneurons and thalamic
cholinergic signalling from the brainstem cholinergic nuclei remain preserved in
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AD (Mesulam 2004). This highlights the selective vulnerability of the basal
forebrain cholinergic system and its projections sites, including the cortex and
hippocampus in AD.

Mounting evidence has linked the long-term use of drugs with anticholinergic
properties to cognitive decline and increased dementia (Ancelin et al. 2006;
Carriere et al. 2009; Jessen et al. 2010; Fox et al. 2011; Gray et al. 2015).
Indeed, use of the anticholinergic drug oxybutynin chloride for more than 3 years
has been shown to increase risk of developing dementia (Gray et al. 2015). Use
of drugs with anti-muscarinic activity for more than 2 years in Parkinson’s
disease (PD) patients triggered approximately a 2-fold increase in amyloid
deposition, compared to untreated controls (Perry et al. 2003). Similarly, there
was a significant increase in neurofibrillary tangle densities in patients treated
with these anti-cholinergic drugs, compared to untreated controls (Perry et al.
2003). Interestingly, PD patients treated with anti-muscarinic drugs for less than
2-years did not increase levels of amyloidosis nor tangle formation (Perry et al.
2003). This suggests that long-term loss of cholinergic signalling may be related
to AD-like pathology.

1.3 Cholinergic regulation of hippocampal function

A large number of studies demonstrate that cholinergic neurotransmission plays
a critical role in modulating hippocampal LTP, a molecular correlate of learning
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and memory. In vitro, experiments show that cholinergic agonists facilitate LTP
(Auerbach

and

Segal

1996).

Likewise,

in

vivo

stimulation

of

the

septohippocampal pathway enhanced LTP (Galey et al. 1994). Conversely,
lesions to the septohippocampal pathway and administration of scopolamine, a
mAChR antagonist, attenuated hippocampal LTP, suggesting that cholinergic
signalling via mAChR activity could mediate hippocampal synaptic plasticity
(Leung et al. 2003). Indeed, M2 mAChR-deficient mice had abolished
hippocampal short-term potentiation (STP) and a significant reduction of LTP
after high-frequency stimulation (Seeger et al. 2004). Moreover, there is evidence
suggesting that M1 mAChRs could play a role in regulating hippocampal
plasticity (Wess 2004; Buchanan et al. 2010; Dennis et al. 2016).

The involvement of nicotinic receptor activity has also been heavily implicated in
mediating forms of hippocampal synaptic plasticity. In vitro application of nicotine
on hippocampal brain slices facilitates LTP (Fujii et al. 1999). Moreover,
experimental evidence using optogenetics to activate cholinergic inputs reveals
that induction of distinct forms of hippocampal synaptic plasticity is timingdependent (Gu and Yakel 2011). Optogenetic activation of cholinergic input to
the CA1 100 milliseconds (ms) prior to Schaffer collaterals (SC) stimulation
resulted in α7 nAChR-mediated LTP, while 10 ms prior to SC stimulation led to
short-term depression (STD) (Gu and Yakel 2011). Additionally, activation of
cholinergic signalling 10 ms after SC stimulation induced mAChR-mediated LTP
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(Gu and Yakel 2011). These results demonstrate the temporal precision of the
septohippocampal pathway in modulating distinct forms of synaptic plasticity.

Data from in vivo microdialysis studies in rats demonstrate that hippocampal ACh
levels are increased in learning and memory tasks (Hironaka et al. 2001; Chang
and Gold 2003). Moreover, systemic administration of cholinergic agonists
reverses memory impairments induced by lesions to the medial septum or fornix
in rats (Decker et al. 1992; Levin et al. 1993). Notably, hippocampal infusions of
physostigmine, an AChE inhibitor, rescues memory impairments induced by
intra-septal inactivation by muscimol (GABA agonist) infusions in rats (Degroot
and Parent 2000). This suggests a critical role of hippocampal cholinergic
signalling in modulating memory-related behaviours.

Selective elimination of cholinergic neurons from medial septum using
immunotoxins in rodents has also been used to investigate the role of ACh
signalling in the hippocampus and cortex. It is somewhat controversial whether
selective 192 IgG-saporin lesions of septohippocampal cholinergic neurons can
lead to significant impairments in hippocampal-dependent learning and memory
tasks in rodents. This is because some reports find a modest effect of lesions on
memory tasks (Berger-Sweeney et al. 1994; Baxter and Gallagher 1996; Pizzo et
al. 2002; Frick et al. 2004; Parent and Baxter 2004), whereas others find a
myriad of deficits (Walsh et al. 1996; Janis et al. 1998; Gil-Bea et al. 2011). The
inconsistency in these studies could be attributed, at least in part, to cholinergic
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neurons expressing more than one class of neurotransmitter transporters and
secreting two neurotransmitters (Gras et al. 2008; El Mestikawy et al. 2011;
Guzman et al. 2011; Prado et al. 2013; Nelson et al. 2014; Saunders et al. 2015;
Munster-Wandowski et al. 2016). Therefore, it is difficult to interpret results with
toxin lesions for specific contributions of neurotransmitters in neurons that
release 2 chemical messengers. Importantly, evidence suggests that GABA can
be released from basal forebrain cholinergic projection neurons. Optogenetic
activation of cortical cholinergic axons induce GABA-mediated inhibitory
postsynaptic currents in cortical neurons (Saunders et al. 2015). Conversely,
selective deletion of the GABA transporter in cholinergic neurons abolished the
postsynaptic

responses

mediated

by

optogenetic

cholinergic

activation

(Saunders et al. 2015).

In the striatum, glutamate is co-released with ACh due to the presence of the
vesicular glutamate transporter (VGLUT3), which is highly expressed in striatal
cholinergic

interneurons

(Guzman

et

al.

2011;

Higley

et

al.

2011).

Cotransmission by cholinergic neurons needs to be considered when
investigating the role of ACh in behaviour studies using neuronal lesions. Here
we use genetic targeting of either VAChT or ChAT using the Cre/lox system to
interfere with ACh release, which has provided a way for investigating specific
contributions of ACh when there is co-transmission (Guzman et al. 2011; Martyn
et al. 2012; Kolisnyk et al. 2013; Prado et al. 2013).
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1.3.1 Behavioural tasks to assess hippocampal function

Since it was developed by Richard Morris (Morris 1984), the Morris water maze
(MWM) has been widely utilized by researchers to assess spatial learning and
memory in animals. The spatial version of this task involves an open circular pool
that is filled with water, with a small platform submerged in a fixed location. An
animal is placed in the pool from each of four different starting locations, and is
required to use distal cues placed around the pool to search for the hidden
platform (See Chapter 2.13). Performance in the MWM task depends on intact
hippocampal function (Morris et al. 1982; Brandeis et al. 1989)(Reviewed in
(D'Hooge and De Deyn 2001)). For example, septohippocampal lesion studies in
rats cause impairments in spatial acquisition of the MWM (Morris et al. 1982).
Moreover, evidence suggests that performance in this task is dependent on
NMDAR function (Morris et al. 1986; Bannerman et al. 1995), and correlates with
hippocampal long-term potentiation (Jeffery and Morris 1993; Moser et al. 1998).

While the MWM provides insight regarding spatial navigation in rodents,
evidence shows that performance in the MWM can be affected by stress
(Holscher 1999). Hence, considering that performance in the MWM is aversively
motivated, one cannot exclude motivation and the level of stress as potential
factors in the animals’ performance in this task.
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The recent development of automated touchscreen behavioural testing for
rodents has improved cognitive testing. These touchscreen tasks are analogous
to the paradigms and methodologies used in humans, hence, facilitating
translational studies between rodents and humans (Morton et al. 2006; Talpos et
al. 2009; Talpos et al. 2010; McCarthy et al. 2011; Romberg et al. 2011). One of
the touchscreen tasks available is Paired Associates Learning (PAL). This task
requires subjects/animals to associate objects with their matched locations on an
automated touch screen. Performance in PAL, as well as in other pairedassociate tasks, depends on intact hippocampal function in humans and rats
(Talpos et al. 2009; de Rover et al. 2011) Deficits in the PAL test have been
detected consistently in AD (Blackwell et al. 2004) and schizophrenia (Wood et
al. 2002; Barnett et al. 2005). PAL performance has been shown to correlate with
severity of affective symptoms and daily functioning in schizophrenia (Barnett et
al. 2005). In dementia, PAL has been shown to differentiate between MCI and
AD (Blackwell et al. 2004).

Another cognitive domain that is associated with intact hippocampal function is
pattern separation. Pattern separation is defined as the filtering of similar
representations into less similar outputs (Colgin et al. 2008) and is one of the
functions associated with newly born neurons in the dentate gyrus region of the
hippocampus (Treves et al. 2008). Specifically, the two-choice location
discrimination task has been widely used as a functional assessment of adult
hippocampal neurogenesis. This task requires rodents to discriminate between
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spatially proximate stimuli (Clelland et al. 2009; McTighe et al. 2009). Lesions in
the dentate gyrus impaired pattern separation in rats using a different task
(Gilbert et al. 2001), while low dose of X-irradiation to ablate hippocampal
neurogenesis in mice disrupted pattern separation in the two-choice location
discrimination task (Clelland et al. 2009). Conversely, genetic deletion of the proapoptotic BAX gene in Nestin-positive NSCs significantly increased newborn
survival cells in the hippocampus and neurogenesis-mediated LTP (Sahay et al.
2011). Importantly, genetic deletion of BAX in Nestin expressing NSCs enhanced
pattern separation (Sahay et al. 2011), supporting an important role of
hippocampal NSCs in modulating pattern separation. Moreover, fMRI studies in
humans reveal specific activity of the dentate gyrus during pattern separation
(Bakker et al. 2008). Together, these results suggest that the dentate gyrus
region of the hippocampus plays a critical role in filtering spatially related
contexts.

1.3.2 Regulation of adult hippocampal neurogenesis

Neurogenesis is defined as the production of new neurons, and occurs mainly in
two regions of the adult mammalian brain; the subgranular zone (SGZ) of the
dentate gyrus in the hippocampus, and the subventricular zone (SVZ) of the
lateral ventricle (Altman 1969; Cameron and McKay 1998; Eriksson et al. 1998).
These regions are referred to as neurogenic niches due to the unique complex
microenvironment critical for neural stem cell (NSC) development (Ma et al.
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2010). In the adult hippocampus, new neurons are generated in the SGZ then
differentiate into mature neurons in the granular cell layer of the dentate gyrus,
where they are functionally integrated into the hippocampal circuitry (van Praag
et al. 2002). There are two types of NSCs in the SGZ: type 1 cells refer to a
radial dormant population of GFAP, SOX2, and Nestin- positive cells (Figure 3)
(Mu et al. 2010);

and type 2 cells are composed of actively non-radial

proliferating cells (Sox2-positive cells) that generate both astrocytes and
neuroblasts (Doublecortin-positive, Figure 3) (Mu et al. 2010). Not all neurogenic
cells survive; only approximately 50% of newly born cells become functionally
integrated into the hippocampal circuitry in the rat (Cameron and McKay 2001).

The surviving cells in the SGZ project their dendrites to the molecular layer of the
dentate gyrus and send projections to CA3 pyramidal cells, becoming fully
mature neurons (NeuN-positive) that are integrated into the hippocampal circuitry
(Figure 3). A large number of signalling molecules are involved in regulating
neurogenesis, including the Wnt signalling pathway. Activation of the Wnt/βcatenin pathway enhances NSC proliferation expression (Kuwabara et al. 2009).
Wnt signalling through the GSK3β/β-catenin pathway maintains the potency of
neural progenitor cells (Wexler et al. 2009). Indeed, selective inhibition of Wnt
signalling in the dentate gyrus of the hippocampus significantly decreases the
number of newly born neurons (Lie et al. 2005; Clelland et al. 2009; Jessberger
et al. 2009) suggesting a critical role of Wnt signalling in adult hippocampal
neurogenesis.
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On the other hand, newly born neurons in the SVZ migrate anteriorly to the
olfactory bulb through the rostral migratory system, where they become
functional local interneurons (Altman 1969; Kornack and Rakic 2001). Adult SVZ
neurogenesis has been thought to be associated with subependymal astrocytes,
which function as NSCs to produce Mash1-positive progenitors (Parras et al.
2004; Paez-Gonzalez et al. 2014). These cells then differentiate into
Doublecortin-positive neuroblasts before migrating to the olfactory bulb.
Experiments have shown that adult SVZ neurogenesis is mainly involved in
mating (Mak et al. 2007), and in adult paternal recognition of offspring (Mak and
Weiss 2010).

Regulation of adult neurogenesis in the SVZ has been demonstrated to be
associated with a number of neurotransmitters, including ACh (Liu et al. 2005;
Platel et al. 2010)(Reviewed in (Young et al. 2011)). In vitro studies show that
ACh significantly increases Doublecortin-positive cells (Paez-Gonzalez et al.
2014). Moreover, Peaz-Gonzalez et al. identified a population of cholinergic
neurons that innervate the SVZ neurogenic region. Using optogenetics the
authors demonstrated that these cholinergic neurons modulate SVZ neurogenic
proliferation via fibroblast growth factor receptor signalling (Paez-Gonzalez et al.
2014). These elegant experiments highlight the importance of cholinergic
signalling in regulating adult neurogenesis in the SVZ (Paez-Gonzalez et al.
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2014). The functionality of these cholinergic neurons in adult SVZ neurogenesismediated behaviours however, remains undetermined.

Newly born neurons in the hippocampus play an essential role in learning and
memory (Gould et al. 1999; van Praag et al. 1999). An increase in neurogenesis
by exercise (van Praag et al. 1999) is associated with enhanced hippocampal
synaptic plasticity and improved cognitive performance in mice (van Praag et al.
1999). Selective lesions of basal forebrain cholinergic neurons using the
immunotoxin 192 IgG-saporin has been shown to significantly decrease
neurogenesis in both SVZ and SGZ (Cooper-Kuhn et al. 2004). Moreover,
lesions to the basal forebrain cholinergic neurons increased the numbers of
apoptotic cells in the subgranular zone of the hippocampus, suggesting that
cholinergic input to the hippocampus is required for maintenance of adult
neurogenesis (Cooper-Kuhn et al. 2004). Similarly, mice lacking the

2 subunit

of the nicotinic acetylcholine receptor display impairments in adult hippocampal
neurogenesis, characterized by a decrease in cell proliferation in the dentate
gyrus (Harrist et al. 2004). Systemic injections of donepezil, a cholinesterase
inhibitor, enhanced survival of newborn neurons, but not proliferation, in both
neurogenic regions in mice (Kaneko et al. 2006). Experiments also demonstrate
that scopolamine, a muscarinic receptor antagonist, reduced the number of
newborn cells in the rat hippocampus. Furthermore, administration of
oxotremorine, a non-selective muscarinic agonist, significantly increased cell
proliferation in a dose-dependent manner in rats (Van Kampen and Eckman
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2010). These findings point to cholinergic signalling as a potential modulator of
adult hippocampal neurogenesis.

Figure 3. Illustration depicting neurogenesis in the subgranular zone in the
hippocampus (SGZ). In the SGZ layer, type 1 cells are a radial dormant
population of cells that express GFAP, SOX2, and Nestin. Type 2 NSCs are
composed of actively non-radial proliferating cells (Sox2-positive cells) that
generate both astrocytes and neuroblasts (Doublecortin-positive) that ultimately
become mature neurons (NeuN-positive) and functionally incorporate into the
hippocampal circuitry.

41

1.4 Rationale and Hypothesis

Loss of basal forebrain cholinergic signalling and hippocampal atrophy are major
hallmarks in AD (Perry et al. 1978; Bowen and Davison 1980). However, the
specific contribution of cholinergic neurotransmission in AD pathology and
cognitive deficits still remains unclear.

The overall objective of this thesis is to determine the long-term effects of
cholinergic deficiency on molecular hallmarks of AD, as well as elucidating the
role of forebrain cholinergic tone in regulating hippocampal-dependent cognitive
functions. To address this, the specific aims of this thesis are:

1) Generate and characterize a mouse model of forebrain-specific
cholinergic dysfunction.
2) Elucidate the consequences of long-term cholinergic failure on
hippocampal neurogenesis and neuropathology.
3) Determine the contribution of forebrain cholinergic signalling in
regulating hippocampal-dependent cognitive function.

We hypothesize that forebrain cholinergic tone is required for hippocampal
resilience, and distinct forms of cognitive processing.
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Chapter 2

2. Materials and Methods

2.1 Ethics Statement
All procedures were performed in accordance with the Canadian Council of
Animal Care guidelines at the University of Western Ontario with an approved
animal protocol (2008-127). We followed the ARRIVE guidelines (Kilkenny et al.
2010), hence mice were randomized for behavioural tests and the experimenter
was blind to the genotype. Animals were housed in groups of three per cage
without environmental enrichment in a temperature-controlled room (12:12 light
to dark cycles), and food and water were provided ad libitum for most
experiments. Animals that underwent touchscreen testing were housed in pairs;
food-restricted to no more than 85% of their original weight, and they were
maintained at the target weight for the duration of behavioural testing. 3 monthold male mice were used for behavioural studies.

2.2 Animals

Generation of VAChTflox/flox mice was previously described (Martins-Silva et al.
2011). VAChTNkx2.1-Cre-flox/wt mice were generated by crossing VAChTflox/flox (mixed
C57BL/6J x 129/SvEv background, backcrossed to C57BL/6J for five
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generations)

with

the

Nkx2.1-Cre

mouse

line

(C57BL/6J-Tg(Nkx2-1-

cre)2Sand/J), purchased from The Jackson Laboratory (JAX stock no. 008661).
Offspring was then intercrossed to generate VAChTNkx2.1-Cre-flox/flox mice.
VAChTNkx2.1-Cre-flox/flox mice and littermate controls used in this study were
generated by crossing VAChTNkx2.1-Cre-flox/flox to VAChTflox/flox. The reporter mouse
line Nkx2.1(td-Tomato) was generated by crossing B6.Cg-Gt(ROSA)26Sortm9(CAGtdTomato)Hze

/J mice (Jackson Laboratory stock no. 007909) with the Nkx2.1-Cre

mouse line (JAX stock no. 008661). The reporter mouse line VGLUT3 (tdTomato)

was

tdTomato)Hze

generated

by

crossing

B6.Cg-Gt(ROSA)26Sor tm14(CAG-

/J mice (JAX stock no. 007914) with the VGLUT3-Cre mouse line

(Tg(Slc17a8-icre)1Edw/SealJ, JAX stock no. 018147). We generated
VAChTD2-Cre-flox/flox mice by crossing VAChTflox/flox with the D2-Cre mouse line (D2Cre mice (Drd2, Line ER44) obtained from the GENSAT. We then intercrossed
VAChTD2-Cre-flox/wt to obtain VAChTD2-Cre-flox/flox mice. The D2-Cre-ChAT-flox/flox
mouse line was generated by crossing Chattm1(cre/ERT)Nat with the D2-Cre mouse
line (D2-Cre mice (Drd2, Line ER44) obtained from the GENSAT. Cx3cr1CreER
mice

(JAX

stock

no.

021160)

were

intercrossed

with

B6;129-

Gt(ROSA)26Sortm1(CAG-CHRM3/Cit)Ute mice (JAX stock no. 026220) , to obtain Cre
recombination; offspring were injected with tamoxifen 75mg/kg intraperitoneally
once daily for 5 days. A summary of the mice used and relevant
references are highlighted in Table 1.
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Mouse model

VAChT N kx 2 .1 -C re -flo x /flo x

Commercial nomenclature
N.A

References
(Al-Onaizi et al.
2016)

Nkx2.1-Cre
Nkx2.1-Cre; td-Tomato

C57BL/6J-Tg(Nkx2-1-cre)2Sand/J
N.A

(Xu et al. 2008)
(Al-Onaizi et al.
2016)

VGLUT3-Cre; td-

N.A

Tomato
VAChT flo x /flo x

N.A

(Martins-Silva et al.
2011)

VAChT D 2 -C re -flo x /flo x

N.A.

ChAT D 2 -C re -flo x /flo x

N.A

Cx3cr1CreER-DREADD

N.A

Table 1. Summary of the mouse models used in this thesis.

(Guzman et al. 2011)
This thesis
This thesis
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2.3 Immunohistochemistry

Mice were anesthetized with ketamine (100 mg/kg) and xylazine (25 mg/kg) in
0.9% sodium chloride, and then euthanized by transcardiac perfusion:
phosphate-buffered

saline

(PBS,

pH=7.4)

for

3

minutes

and

4%

paraformaldehyde for 5 minutes. Brains were harvested and placed in 4%
paraformaldehyde in 1× PBS at 4 °C for 4 hours, they were kept at 4 °C until
sliced using a vibratome. Brain sections (40

m) were prepared and free-floating

sections in 1× PBS (one per well in a 24-well plate) were permeabilized with
0.4% Triton X-100 in 1× PBS for 1 hour. Non-specific epitopes were blocked
using a solution of 1× PBS /0.4% Triton X-100 containing 0.1% glycine (wt/vol),
0.1% lysine (wt/vol), 1% BSA (wt/vol) and 1% normal donkey serum (wt/vol).
Next, primary antibodies (Table 2) were incubated in blocking buffer overnight at
4 °C. Sections were then washed five times in 1× PBS/0.4% Triton X-100 (10
minutes each). Hoechst 3342 (Life Technologies. Bibco, Carlsbad, CA, USA) (2–
5

g/ml1) and secondary antibodies (Table 2) were diluted in blocking buffer

and slices were incubated for 1 hour at room temperature. Sections were
visualized by Zeiss LSM 510Meta (Carl Zeiss, Oberkochen, Germany) confocal
system (10x, 40x, 63x objective, 488-nm Ar laser and 633-nm HeNe laser were
used for excitation of fluorophores).
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Primary Antibody

Source

Secondary antibody

anti-Vesicular acetylcholine

Synaptic Systems (catalog

anti-488 (1:500) ThermoFisher

transporter (VAChT; 1:500)

#139103)

(catalog #A-11034)

anti- Choline

Merck Millipore (catalog

anti-488 (1:500) ThermoFisher

Acetyltransferase (ChAT;

#AB144P)

(catalog #A27012

anti- Choline transporter

Dr. R. Jane Rylett (The University

anti-488 (1:500) ThermoFisher

(CHT1; 1:500)

of Western Ontario, London, ON)

(catalog #A-11034)

anti-Doublecortin (DCX;

Abcam (catalog #18723)

anti-488 (1:500) ThermoFisher

1:200)

1:1000)
anti-Ki67 (Ki67; 1:1000)

(catalog #A-11034)
Abcam (catalog #ab15580)

anti-488 (1:500) ThermoFisher
(catalog #A-11034)

anti-BrdU (1:500)

BioLegend (catalog #339810)

anti-Biotin-633 (1:500) SigmaAldrich (catalog
#SAB4600144)

anti-CD68 (1:200)

Abcam (catalog #ab955)

anti-633 (1:500) ThermoFisher
(catalog #A-21052)

anti-Cleaved Caspase-3

ThermoFisher (catalog #PA5-

anti-633 (1:500) ThermoFisher

(1:500)

16335)

(catalog #A-21070)

anti-AT180 (1:1000)

ThermoFisher (catalog #EN-

anti-488 (1:500),
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MN1040)

ThermoFisher (catalog #A11001)

anti-PSD95 (1:200)

ThermoFisher (catalog #MA1-046)

anti-488 (1:500),
ThermoFisher (catalog #A11001)

anti-IBA1 (1:500)

anti-HA (1:500)

Wako Laboratory Chemicals

anti-488 (1:500) ThermoFisher

(catalog #019-19741)

(catalog #A-11034)

Bioleged (catalog #901502)

anti-633 (1:500) ThermoFisher
(catalog #A-21052)

Table 2. List of primary antibodies, sources, and secondary antibodies
used in this thesis as part of the immunohistochemistry protocol.
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2.4 Western Blotting

Brain tissues were frozen in a mixture of dry ice and ethanol and were stored at 80°C. To isolate and extract protein, tissues were homogenised in 10mM TrisHCl pH 7.5, 150mM NaCl, 1mM EDTA, 1% Triton X-100, and protease inhibitor
cocktail (Sigma-Aldrich, catalog# P8340). Extracts were left on ice for 15 minutes
post-homogenization and then centrifuged at 10,000xg for 20 minutes at 4°C.
Next, the supernatant was collected and protein concentration was determined
using the Bradford assay (Bradford, 1976). 30-60 µg of protein lysates were then
separated using SDS-PAGE and transferred onto PVDF membranes. Immunoblotting was performed as previously described (Martins-Silva et al. 2011;
Kolisnyk et al. 2013; Kolisnyk et al. 2013). Antibodies used were anti-VAChT
(1:1000) (catalog #139103; Synaptic Systems), anti-Synaptophysin (1:200)
(catalog #S5768; Sigma-Aldrich), anti-Doublecortin (DCX; 1:1000) (catalog
#18723; Abcam), anti-AT180 (1:1000) (catalog #EN-MN1040; ThermoFisher),
and anti-

-actin (catalog #ab49900; Abcam). Band intensities were quantified

using FluoroChemQ software (Thermo Fisher Scientific).

2.5 Quantitative RT-PCR

To measure mRNA expression, total RNA was extracted from freshly dissected
hippocampal tissue, using the Aurum Total RNA for fatty and fibrous tissue kit
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(Bio-Rad Laboratories, Mississauga, Canada) according to the manufacturer's
instructions. Total RNA from hippocampal tissue was eluted in 80 µl of Elution
solution. Quantification and quality control of RNA in the extracted samples was
done by microfluidic analysis using Agilent 2100 Bioanalyzer (Agilent
Technologies Inc. Palo Alto, CA, USA). Next, 20 µl of cDNA was synthesized
from 500 ng of total RNA using the High Capacity cDNA Reverse Transcription
Kit (Applied Biosystems, Streetsville, Canada) according to the manufacturer’s
instructions. qPCR was then performed on the cDNA on a CFX-96 Real Time
System (Biorad) using iQ SYBR GREEN SUPERMIX (Biorad). PCRs were
cycled 40 times after denaturation (95 C for 3 minutes) and a non-template
reaction was used as a negative control.

-actin gene expression was to

normalize data, and relative quantification of gene expression was performed
with the DDCT method.

2.6 Thioflavin S Staining

Thioflavin S staining was performed by incubating mounted sections (30µm) with
a series of graded ethanol: 100% for 3 minutes, 95% for 3 minutes, 70% for 3
minutes, 50% for 3 minutes. Next, sections were washed with water, twice for 3
minutes. Next, sections were incubated in a solution of 0.05% Thioflavin S in
50% ethanol, rinsed in ethanol 100% followed by water (Sun et al. 2002).
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2.7 Silver staining

Assessment

of argyrophilic cells

in

the

hippocampus

was

done

using NeuroSilverTM staining kit II (FD NeuroTechnologies, Inc., Baltimore, MD),
which provides detection of degenerating neurons, including neuronal somata,
axons, and terminals.

2.8 Stereotaxic injections of adeno-associated virus (AAV)

To obtain selective deletion of VAChT in the medial septum, mice were
anesthetized with ketamine (100 mg/kg) and xylazine (25 mg/kg) in 0.9% sodium
chloride, and 1

l (titer of ~1013 GC/ml) of AAV8-GFP-Cre- or control virus

(AAV8-GFP, Vector BioLabs, Eagleville, PA, USA) was injected into the medial
septum/vertical limb of the diagonal band (0.98 AP, 0.1 LL and 4.1 DV) of
VAChTflox/flox mice. The injecting micropipette was inserted and left for 2 minutes
to stabilize. After stabilization, a 0.2 µl per minute infusion was performed using a
micropump followed by a 30 minutes rest period to allow local diffusion of the
virus and avoid virus efflux. The micropipette was then slowly removed and the
scalp sutured. A recovery period of 4 weeks was given before behavioural testing
to allow transgene expression.
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2.9 Electrophysiology

Animals were anesthetized with urethane (1 g/kg i.p.) and placed in a stereotaxic
apparatus. Atropine methyl nitrate was administered (5 mg/kg i.p.) to reduce
airway secretions during stereotaxic surgery. Animal body temperature was
monitored using a feedback controlled rectal thermometer and kept between
36.5°C and 37°C using a heating pad. Stimulating electrodes were placed into
stratum radiatum at P 1.8, L 2.3 or P 2.5, L2.4 (Franklin and Paxinos 2008) to
stimulate Schaeffer collaterals projecting from CA3 to CA1(Hutchison et al.
2009). A silicon probe, with 16 electrodes separated by 50 µm on a vertical
shank, was placed in area CA1 at P 2.2, L 1.8. Laminar profiles of the average (4
sweeps) field excitatory postsynaptic potentials evoked by single pulse
stimulation of the Schaffer collaterals at 1.5-2 x threshold stimulus intensity.
Current-source density analysis using 100 µm step size was used to determine
current sources and sinks. The maximal slope (of 1 ms duration) during the rising
phase of the excitatory sink, at its maximum in CA1 stratum radiatum, was used
for LTP assessment. After a stable baseline of the excitatory sink slope was
established for 30 minutes (coefficient of variation (SEM/mean) of the sink slopes
<0.05), a high-frequency tetanus (100 Hz for 1s) was delivered at 2-3 x threshold
intensity, and the response was measured for 120 minutes after the tetanus. For
each mouse, the slope of the excitatory sink was normalized by the average
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value of the baseline, and LTP across mice was averaged and reported as a
multiple of the baseline slope.

2.10 Open Field Locomotion

Measurement of spontaneous locomotor activity in a novel environment was
performed as previously described (Pierce and Kalivas 2007; de Castro et al.
2009). Mice were put in an open field box (20 cm x 20 cm width, 30 cm length),
and movement was tracked and recorded via VersaMax Animal Monitoring
System (AccuScan Instruments Inc., Columbus, OH). Mice were allowed to freely
move in the novel environment for 120 minutes. Movement (cm) per 5-minute
interval was obtained by VersaMax analysis, which analyses infrared beam
breaks.

2.11 Metabolic Assessment

To assess metabolic activity in mice, we measured oxygen consumption, carbon
dioxide production, respiratory exchange ratio, food and water intake, and
physical activity using the Comprehensive Lab Animal Monitoring System
(CLAMS) using Oxymax software (Columbus Instruments, Columbus, OH). Mice
were individually housed in the metabolic cages at 24°C and provided with free
access to powdered standard rodent chow and water. Following an initial 16-hour
habituation period, measurements were taken every 10 minutes for 24 hours (12-
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hour light/12-hour dark cycle). Volume of oxygen consumption and carbon
dioxide production measurements were normalized to body mass. For total
activity, ambulatory activity, and inactivity periods (sleep) the Opto-M3 Activity
Monitor and Oxymax algorithms (Columbus Instruments, OH) were used.

2.12 Morris Water Maze

The spatial version of the MWM was performed as previously described
(Vorhees and Williams 2006; Martyn et al. 2012; Kolisnyk et al. 2013). Testing
was performed in a 1.5-meter-diameter pool with 25°C water. A hidden platform
was submerged in a constant location 1 cm below the surface of the water in one
of the four arbitrarily defined quadrants, and spatial cues were distributed around
the pool (posters, streamers, and plastic props). Mice were given four 90-second
trials for the duration of 4 days to find the hidden platform, with an inter-trial
interval (ITI) of 15 minutes. The animals were introduced to the pool from
different locations within the pool for each trial. Mice that did not find the platform
within the 90 seconds were gently guided to the platform. On the fifth day, spatial
memory recall was tested by a 60-second probe trial, where the hidden platform
is removed and the amount of time the animal spends in the target quadrant is
calculated. To test reversal learning, the hidden platform was relocated to the
opposite quadrant, where the animals were given four 90-second trials for 4
days. On the fifth day, the animals were given a 60-second probe trial. Data were
analyzed using ANY-Maze video tracking software (Stoelting Co.).
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The classification of search strategies mice employed during training was defined
as previously described (Garthe et al. 2009, Wolfer et al. 2000). An experimenter
blind

to

genotypes scored

search

strategies

as

follows: (1) thigmotaxis,

characterized by maintaining close proximity to the wall (>70% trial within 10-cm
of wall); (2) random search, illustrated by global swimming with no classified
strategy; (3) scanning, characterized by a preference for the central pool area
(>50% trial within 35-cm of pool center); (4) chaining, characterized by searching
near the correct radial distance of the platform to the wall (>75% trial 20–50-cm
from the pool center, <15% within 10-cm of wall, and <10% within 20-cm of pool
center); (5) directed search, characterized by a preference for a passageway
toward the platform or platform quadrant (>80% trial within a 50-cm-wide region
from the start point to the platform); (6) focal search, characterized by a highly
localized search near the platform (≥50% trial in a circular target zone with a 15cm radius); (7) direct swim, characterized by a maintained heading toward the
platform (Little to no deviation in path to reach platform from start point). Total
block lengths were the sum of all blocks for one strategy and one mouse.

The cued variation of the MWM was performed as described previously (Vorhees
& Williams, 2006). The cued variation was used to assess goal-directed
behavior. Mice were tested for 2 d using novel platform and starting location
combinations. For this variation, the platform was at water level and a cue was
placed on it (a plastic block). Sessions were recorded for both tests and were
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analyzed using the ANY-Maze Software.

2.13 Rotarod

To measure motor coordination, an accelerating rotarod (San Diego Instruments;
San Diego, CA) was used as previously described (Prado et al. 2006; de Castro
et al. 2009). Prior to testing, mice were allowed to habituate to the rod for 5
seconds. During the first 100 seconds of testing, the rotarod rotates at 5
revolutions per minute (RPM), and then accelerates to 15 RPM for the next 100
seconds, then 25-RPM for the next 100 seconds, and 35 RPM for the final 100
seconds. Mice were given ten trials with a 10-minute inter-trial interval in their
home cage. The trial ended when a mouse falls off the rod or completed 400
seconds on the rod. The rod was cleaned with 70% ethanol. On the following
day, the conditions remained the same, except mice were placed on the
accelerating rotarod for four trials.

2.14 Wire Hang Test

The wire hang test was performed as previously described (Sango et al. 1996;
Prado et al. 2006; Deacon 2013). Each mouse was placed on a wire-grid; the
experimenter then slowly inverted and suspended the wire approximately 40 cm
above a foam mat. The amount of time from the inversion of the wire till the
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mouse fell from the wire was measured, with a 60 second limit. Each mouse was
given an inter-trial interval of 30 seconds in its home cage.

2.15 Grip Strength

Forelimb grip strength was assessed using a grip strength meter (Columbus
Intstruments, Columbus, OH) (Prado et al. 2006). Each mouse grasped the pull
bar of the apparatus with their forelimbs only and the experimenter gently pulled
the mouse backwards by the tail maintaining mouse body horizontally. The force
applied to the bar prior to the release of the grasp was recorded. The average of
3 measurements were recorded and an inter-trial interval of 30 seconds was
given to each mouse in their home cage.

2.16 Forced swim test

To assess depressive-like behaviour, mice were subjected to the forced swim
test (Martyn et al. 2012). Mice were placed in the testing room to acclimate to the
environment for one hour. Next, each mouse was placed in a 2 L beaker with 1.8
L of water (25-27°C) for 6 minutes. A video camera was placed above the beaker
and immobility time, and distance swam were recorded and analyzed using ANYMaze software (Stoelting Co., IL). The first minute of activity was not used for the
analysis, that is, graphs show information from 2-6 minutes of the test. Water
was changed after every 2 mice completed testing.
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2.17 Tail Suspension Test

Mice were assessed for depressive-like behaviour as previously described
(Martyn et al. 2012). Mice were suspended from a metal bar 30 cm above a table
by their tail, using a masking take placed at the tip of the tail, for 6 minutes. A
video camera was placed in front of the rod facing the suspended mouse.
Sessions were recorded and immobility time and immobility episodes from 2-6
minutes were recorded using ANY-Maze software (Stoelting Co., IL).

2.18 Paired Associates Learning Training Phase

Prior to training, mice were food restricted until they reached approximately 85%
of their original weight. Training of the animals to the PAL task was previously
described (Figure 4) (Talpos et al. 2009). Briefly, the training phase for the mice
in the touchscreen chambers involved a habituation session, where they were
placed in the chambers with the lights off for 20 minutes to habituate to the
environment for 2 days. Next, mice were put in the chamber with the same
parameters as in the habituation phase, but this time a 150µl reward (strawberry
milkshake; Saputo Dairy Products, Canada) was introduced in the reward
receptacle. Every time the mouse attended to the reward in the reward
receptacle, a tone was played. This 40 minutes training session was done for the
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next 2 days until mice completed 36 trials in 60 minutes (Habituation; phase 1).
Mice were then trained to associate the reward with a 30 second presentation of
training stimuli, which varied in brightness, shape, and pattern, on one of the 3
screens (Initial touch training; phase 2). Mice were required to touch any of the
screens whenever the stimulus was presented in order to receive the reward,
which was paired with a tone. A new trial was automatically initiated once the
mice collected the reward. This was done until the mice completed 36 trials in 60
minutes for one day. Next, mice were required to touch the stimulus that is
displayed randomly in one of the 3 windows in order to receive the reward (Must
touch stimuli training; phase 3). Mice are only moved to next training after
completing 36 trials in 60 min for one day. In the next training phase food is
delivered and tray light is turned on. The mouse must nose poke and exit the
reward tray before a stimulus is displayed randomly on the screen (Must initiate;
phase 4). This was done until mice completed 36 trials in 60 minutes for one day.

Next, animals go to the last phase of the training program required for the PAL
task. This training phase is referred to as “punish incorrect” (phase 5). This
phase is similar to the previous one, but if the mouse touched the incorrect
screen i.e. one of the blank screens, it was presented with a 5-second time-out.
This time-out was accompanied by the presentation of a bright light in the
chamber. Criterion to successfully proceed from this training phase was 23
correct responses out of 30 trials in 60 minutes for 2 consecutive days. Next,
both experimental groups were subjected to acquisition training, where two
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stimuli were displayed at the same time during a trial. One was in the correct
location (S+) and the other was in the incorrect location (S-). Mice were required
to touch the correct stimulus (S+) presented on one of the three screens to
complete a trial and receive the reward. In this acquisition phase, mice were on
an unpunished version where touching the S- was ignored. A completion of a trial
was only considered when the mouse touches the S+. Criterion for this training
phase is completion of 36 trials in one session (one day). All mice from both
experimental groups were able to reach criterion in acquisition training. A
summary of the training phases is shown in Figure 4.
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Figure 4. Brief description of the parameters and criterion for the operant
conditioning and pretraining phases prior to being tested on the PAL task.
(A) Habituation; phase 1, (B) Initial touch; phase 2, (C) Must touch; phase 3, (D)
Must initiate, phase 4, (E) Punish incorrect; phase 5, (F) dPAL acquisition.
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2.19 Paired Associates Learning

After successfully completing the training phase, mice were place on a PAL task
(dPAL), which involves a different stimulus being presented in each trial (Figure
5). A trial starts in dPAL when the mouse initiates it by touching the food
receptacle, which triggers the display of both S+ and S- on the screen. S+ refers
to when the stimulus is in the correct location, and S- refers to when the stimulus
is in the incorrect location. There were six possible trial types and three different
stimuli were presented (flower, plane, and spider). Within trials, an S+ is: the
flower presented in the left window, the plane in the middle window, or the spider
in the right window. Thus, mice are required to learn to associate a stimulus to its
correct location. A response by touching the S- resulted in a 10s time-out and
the chamber light was activated for 10s, acting as an indication for an incorrect
response for the mouse. After 10s, the next initiation by the mouse was
considered a correction error trial, where the same S+ and S- were presented as
for the unsuccessful previous trial. The number of correction trials was not
counted towards the total number of trials performed per session. An S+
response however, led to a tone, as well as the reward being dispensed in the
receptacle.
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Figure 5. Image depicting the six possible trial types that were presented
during the dPAL task. (A) The flower image is S+ when presented in screen 1,
(B) The spider image is S+ when presented in screen 3, (C) the airplane image is
S+ when presented in screen 2.
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2.20 Two-Choice Location Discrimination task

Operant conditioning and pretraining on the touchscreen system was performed
as described in the PAL training, except a mask containing 5 windows was used,
instead of 3. Next, mice were put on the 2-choice location discrimination task.
Mice were required to touch one of two illuminated screens (e.g. S+ is in the
most left screen) until a criterion of 9/10 consecutive correct trials was achieved.
After criterion was achieved the separation of the illuminated screens was
presented with either a high degree of separation (easy; 3 blank screens
separating the illuminated screens), or a low degree of separation (hard; 1 blank
screen separating the illuminated screens). Mice were tested on this task for 10
days. Next, the designated correct location of the screen was switched to the
other location (e.g. S+ is now in the most right screen). Mice were tested on this
task for 10 days. Groups of mice were counterbalanced across the separations.
Data were analyzed by averaging the number of trials required by each mouse
on each separation (easy and hard) during 20 days of testing.

2.21 Quantification of labeled cells

After completion of training phases, 4 mice from each testing group were injected
with BrdU 50mg/kg i.p. once daily for 3 days. Quantification of immunolabeled
cells in the dentate gyrus of the hippocampus was performed as previously
described (Clelland et al. 2009). One-in-twelve series of 40

m brain sections
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from each animal was immunostained (see section 2.3 immunohistochemistry).
Using confocal microscopy, immunolabaled cells in the dentate gyrus were
counted using 63x objective (Zeiss LSM 510Meta, Carl Zeiss, Oberkochen,
Germany). Estimation of the total number of positively labeled cells per
hippocampus was obtained by multiplying the number by 12.

2.22 RNA Sequencing
Mouse hippocampal tissue was rapidly dissected and total RNA was extracted
from individual samples using the PureLink RNA Mini Kit (Ambion). 2 µg of total
RNA were then sent to the Centre for Applied Genomics, The Hospital for Sick
Children, where the cDNA library was prepared using the TruSeq Stranded Total
Sample Preparation kit (Illumina) and run in a HiSeq 2500 platform with coverage
of 200-250 million pair reads per lane. 5 animals were run per lane to obtain
enough coverage for alternative splicing analysis (50 million pair reads per
sample). The sequenced reads were aligned to the mouse genome using the
TopHat program against the mouse genome in Ensembl (version EnsMart72) to
enable quantification of splice junctions in addition to gene level measurements.
Differential gene expression analysis was conducted using the Bioconductor
DESeq package which accounts for the binomial distribution (Anders and Huber
2010).

Datasets

are

available

on

ArrayExpress

(http://www.ebi.ac.uk/arrayexpress/) under accession number E-MTAB-3897.
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2.23 Statistical Analysis

All data are expressed as mean ± SEM. Graphpad and Sigmastat 3.5 software
were used for statistical analysis. Comparison between two experimental groups
was done with Student’s t-test. When several experimental groups or treatments
were analyzed, two-way analysis of variance (ANOVA) or two-way ANOVA with
repeated measures (RM) were used as required. When appropriate, a
Bonferonni post-hoc analysis test was used.
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Chapter 3

3.

Results

3.1 Generation of forebrain-specific cholinergic deficient
mouse model

3.1.1

Targeting forebrain cholinergic neurons in the mouse

brain

As we intended to use Nkx2.1-Cre transgenic mice to generate a mouse model
with VAChT gene deletion specifically from forebrain cholinergic neurons, it was
important to determine whether the Nkx2.1 promoter would in fact drive Cre
expression in forebrain cholinergic neurons and also if cholinergic neurons from
other brain areas would not express Cre. Nkx2.1 is a homeodomain-containing
transcription factor that is expressed in mice at embryonic day E9 and is
restricted to the ventral pallidal telencephalon (Sussel et al. 1999; Xu et al. 2008).
To assess the brain areas where Nkx2.1-Cre is expressed and co-localizes with
cholinergic neurons, we used a Rosa-26-tdTomato reporter mouse line. In this
reporter mouse line, the Rosa26 locus expresses tdTomato, a DsRed fluorescent
protein variant. Upon recombination, Cre excises the stop codon, which is
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flanked by loxP sequences upstream from the translational initiation codon of
tdTomato, allowing translation of the protein (Figure 6A). We crossed Rosa-26tdTomato mice with Nkx2.1-Cre mice and performed immunohistochemistry
analysis to evaluate the localization of Cre-mediated expression in cholinergic
neurons. Co-localization analysis of choline transporter (CHT1) expression, and
tdTomato expression indicated that these two proteins are present in the same
cells mainly in the basal forebrain (95% co-localization) and the striatum (38%
co-localization), while no co-localization was observed in the Mo5 motor nucleus
or the pedunculopontine nucleus (PPN) (Table 3; Figure 6B-D). These findings
indicated that Nkx2.1-Cre mice could be utilized to eliminate floxed genes
specifically from forebrain cholinergic neurons.

Using the same genetic approach, we investigated if the vesicular glutamate
transporter (VGLUT3) promoter drives Cre expression in forebrain cholinergic
neurons. We crossed Rosa-26-tdTomato mice with VGLUT3-Cre mice and
assessed co-localization with ChAT. We observed that there was approximately
82% co-localization between ChAT and tdTomato in the basal forebrain, 80% in
the striatum and 2% co-localization in the PPN (Table 4; Figure 7A). Although the
VGLUT3 promoter also showed to drive Cre expression in forebrain cholinergic
neurons, these results showed that Cre expression was observed in a higher
population of cholinergic basal forebrain neurons when we used the Nkx2.1
promoter. Thus, we decided to use the Nkx2.1-Cre to target forebrain cholinergic
neurons in our studies.
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Figure 6. Nkx2.1-Cre drives Cre expression in forebrain cholinergic
neurons. (A) Scheme illustrating Nkx2.1-Cre transgene and reporter system for
Cre-mediated recombination in Rosa26-tdTomato mice. (B) Expression pattern
of Cre detected by tdTomato fluorescence in the brain of NKx2.1-Cre;tdTomato
mice (Scale bar, 2 mm). (C-D) Expression of Cre detected by tdTomato
fluorescence and co-localization analysis with CHT1 in different regions in the
brain

of

NKx2.1-Cre;tdTomato

mice.

B.F=

basal

forebrain,

PPN=

pedunculopontine nucleus, Mo5= motor trigeminal nucleus (Scale bar, 50 µm)
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Table 3. Percentage of colocalization between cells that express CHT1 and
Cre-mediated tdTomato fluorescence in different regions of the brain of
NKx2.1-Cre;tdTomato mice.
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Figure 7. Expression of Cre detected by tdTomato fluorescence and colocalization analysis with ChAT in different regions in the brain of VGLUT3Cre;tdTomato

mice.

NbM=

Nucleus

pedunculopontine nucleus (Scale bar, 50 µm)

Basalis

Meynert,

PPN=
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Table 4. Percentage of colocalization between cells that express ChAT and
Cre-mediated tdTomato fluorescence in different regions of the brain of
VGLUT3-Cre;tomato mice.
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3.1.2

Elimination of cholinergic tone in forebrain projection

neurons

Decreased VAChT levels severely compromises packaging of ACh into synaptic
vesicles and subsequently decrease ACh release by nerve terminals (Prado et
al. 2006; de Castro et al. 2009). Similarly, overexpression of VAChT increases
ACh release (Song et al. 1997; Kolisnyk et al. 2013). Genetic targeting of either
VAChT (Guzman et al. 2011; Martyn et al. 2012), or ChAT (Patel et al. 2012)
using the Cre/lox system has provided a way for investigating specific
contributions of ACh when there is co-transmission (Prado et al. 2013). We bred
a mouse line containing the floxed allele of VAChT (VAChTflox/flox) with an Nkx2.1Cre transgenic line to obtain mice with VAChT deletion restricted to the forebrain:
VAChTNkx2.1-Cre-flox/flox mice. Using immunohistochemistry, we assessed VAChT
expression in the hippocampus of VAChTflox/flox and VAChTNkx2.1-Cre-flox/flox
littermates. Our analysis revealed decreased VAChT immunoreactivity in the
hippocampus of VAChTNkx2.1-Cre-flox/flox mice compared to controls (Figure 8A-B).
Moreover, immunoblot analysis shows that VAChT levels in the prefrontal cortex
(t(4)=6.162, p=0.0035), hippocampus (t(4)=4.461, p=0.0097) and striatum
(t(4)=8.625, p=0.0010) were severely diminished in VAChTNkx2.1-Cre-flox/flox mice
(Figure 8C-E). In contrast, VAChT levels remained unchanged in the brainstem
of VAChTNkx2.1-Cre-flox/flox compared to controls (t(4)=1.040, p=0.3571, Figure 8F).
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Figure 8. VAChT deletion from forebrain projection neurons.

(A)

Representative 3-dimensional reconstructed Z stack immuno-flourescence
images of VAChT (green) and Hoechst (blue) in the CA1 and CA3 regions of the
hippocampus in VAChTflox/flox (n=3) and (B) VAChTNkx2.1-Cre-flox/flox mice (n=3)
(Scale bar= 100µm). VAChT expression and quantification from Western blots in
the whole cortex (C), hippocampus (D), striatum (E), brainstem (F) in
VAChTflox/flox (clear bars) and VAChTNKx2.1-Cre-flox/flox (dark bars) mice. VAChT
expression was normalized to synaptophysin (n= 4, data are mean ± SEM.
**P<0.01).
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3.2 Determining the contributions of cholinergic signalling
for hippocampal health

3.2.1

Long-term deficient cholinergic tone leads to agedependent protein aggregation

The pathogenic spread of protein aggregation in neurons is a hallmark of several
neurodegenerative diseases, including AD (Walsh and Selkoe 2016). To
investigate the consequences of long-term cholinergic deficiency on hippocampal
neuropathology, we evaluated pathology in the hippocampus of young (3-6
month old) and old (11-14 month old) VAChTNkx2.1-Cre-flox/flox mice. Aged VAChTdeficient mice exhibited an increase in hippocampal Thioflavin-S positive
aggregates compared to age-matched controls (Figure 9A, 11-14 month old
mice). High-power micrographs revealed intracellular localization rather than
extracellular deposits of Thioflavin-S aggregates (Figure 9A). Interestingly, 3-6
month old VAChTNkx2.1-Cre-flox/flox mice did not present this alteration (Figure 9B).
Moreover, control experiments with aged Nkx2.1-Cre mice failed to show any
Thioflavin-S positive aggregates (Figure 9C). These results suggest that longlasting decrease in cholinergic signalling leads to intracellular deposits of protein
aggregates.
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Figure 9. Aged VAChT-deficient mice present protein aggregates in the
hippocampus in an age-dependent manner. (A) Representative images of
Thioflavin-S staining of the hippocampus of aged (11-14 month old) controls and
VAChTNKx2.1-Cre-flox/flox mice (n=5, Scale bar, 100µm and 20 µm for the inset). (B)
Very mild Thioflavin-S positive staining in 3-6 month old VAChTNkx2.1-Cre-flox/flox
mice. (C) Absence of Thioflavin-S positive staining in 11-14 month old C57BL/6JNkx2.1-Cre mice, compared to 11-14 month old VAChTNkx2.1-Cre-flox/flox mice (n=3).
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3.2.2

Deficient cholinergic tone leads to hippocampal tau

hyperphosphorylation

In AD, increased levels of soluble Aβ peptides are thought to precede abnormal
phosphorylation of the microtubule associated protein tau (Iqbal et al. 2010).
Previous reports suggested that cholinergic activity and tau phosphorylation
might

be

inter-related

(Hellstrom-Lindahl

2000).

Therefore,

we

used

immunofluorescence to assess levels of the AT180 tau epitope (T231/S235) in
the hippocampus of VAChT-deficient mice. This phosphorylation-dependent
antibody specific to pT231 has been shown to label approximately 70% of paired
helical filaments (PHF) in AD brains (Goedert et al. 1994). Phosphorylation at this
epitope reduces the binding of tau to microtubules (Lim et al. 2008).
Immunofluorescence

imaging

revealed

a

robust

increase

in

AT180

immunoreactivity in the hippocampus of VAChTNkx2.1-Cre-flox/flox mice compared to
aged-matched controls (Figure 10A 11-14 month-old mice). To test if the positive
immunoreactivity of pTau in VAChT-deficient mice is associated with an induction
of pathological tau, immunofluorescence with MC1 antibody was performed.
Positive reactivity of conformation-dependent MC1 antibody depends on the
proximity of N terminal (aa 7-9) and C-terminal (313-333) amino acid sequences
of tau, which is one of the earliest alterations of tau in AD (Wolozin et al. 1986;
Weaver

et

al.

2000).

Immunostaining

with

MC1

revealed

positive

immunoreactivity in the hippocampus of aged cholinergic-deficient mice, but not
in

age-matched

controls

(Figure

10B).

In

agreement

with

the
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immunofluorescence data, hippocampal extracts of VAChTNkx2.1-Cre-flox/flox mice
showed approximately four-fold increases in pTau immunoreactive bands,
including higher order oligomers detected with AT180, when compared to
controls (Figure 10C and F). On the other hand, total tau and pTauS262 levels
were unmodified in VAChT-deficient mice (Figure 10D-F). Taken together, our
data indicate that deletion of hippocampal VAChT induces hyperphosphorylation
of tau and leads to tau pathological conformation as detected by MC1, both of
which are consistently observed in AD.
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Figure 10. VAChT-deficient mice present hippocampal tauopathy. (A)
Phosphorylated Tau levels monitored by immunolabeling with phosphorylationdependent antibodies specific to pT231. Representative images of pT231 and
Hoechst labeling in the hippocampus of 11-14 month old controls (left) and
VAChTNkx2.1-Cre-flox/flox (right) mice. (n=3, Scale bar, 100µm). (B) Representative
images of MC1 and Hoechst labeling in the CA1 region of the hippocampus of
controls (left) and VAChTNkx2.1-Cre-flox/flox (right) mice. (n=3, Scale bar, 100µm). (C)
Western blot analysis of controls (VAChTflox/flox) and VAChTNkx2.1-Cre-flox/flox aged
(11-14 month old) hippocampal samples for tau using phosphorylationdependent anti-tau antibodies pT231, (D) Ser 262 and (E) for total Tau protein
expression. (F) Quantification of Western blots. pT231, Ser 262, and total tau
expression were normalized to actin (n= 4, data are mean ± SEM. **P<0.01).
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3.2.3

Long-term hippocampal cholinergic signalling is
required for target cell maintenance

In AD, an increase in inflammatory markers’ expression and apoptosis are
consistently seen (DeKosky and Scheff 1990; Smale et al. 1995; Rogers and
Shen 2000). To test whether decreased cholinergic signalling affects vulnerability
of target cells in the hippocampus we used silver staining and activation of
caspase-3 analysis in hippocampal slices. Aged (11-14 months old) VAChTdeficient mice presented intensified silver staining compared to controls; this
increased silver staining was not observed in 3-6 months old VAChT-deficient
mice (Figure 11A-B), suggesting that long-lasting decrease in cholinergic
signalling may increase the vulnerability of hippocampal neurons. In addition,
activated caspase-3, a marker of apoptosis, was augmented in young (3-6
months old) VAChTNkx2.1-Cre-flox/flox mice compared to controls (Figure 11C).
However, aging (11-14 months old) significantly increased the number of
apoptotic cells in VAChT-deficient mice when compared to age-matched controls
(Figure 11C).

To test whether cholinergic signalling affects inflammatory responses in target
cells in the hippocampus, we assessed microglial activation in VAChTNkx2.1-Creflox/flox

mice and controls (Figure 11D). We found that the expression of CD-68, a

marker of activated microglia was increased in the hippocampus of VAChTNkx2.1-
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Cre-flox/flox

mice compared to controls (Figure 11D). Moreover, transcript levels of

inflammatory markers: Il-1β and IL-6 were up regulated in the hippocampus of
VAChT-deficient mice (Figure 11D).
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Figure 11. VAChT-mutant mice show increased neuronal vulnerability in the
hippocampus. (A) Representative images of silver staining in the CA1 region of
young (3-6 months) and aged (11-14 months) mice. Scale bar, 100µm. (B)
Quantification of silver stain-positive cells between young and aged hippocampi
of controls (VAChTflox/flox; gray bars) and VAChTNkx2.1-Cre-flox/flox (red bars). (n=5,
data are mean ± SEM. **P<0.01). (C) Representative immunofluorescence
images for activated-caspase 3 labeling in the hippocampi of young (Top) and
aged (Bottom) mice. Quantification of activated caspase-3 immunoreactivity in
young and aged hippocampi of controls (VAChTflox/flox; gray bars) and
VAChTNkx2.1-Cre-flox/flox

(red

bars).

(D)

Immunofluorescence

imaging

and

quantification showing CD-68 immunoreactivity in the hippocampus of aged
VAChTNkx2.1-Cre-flox/flox mice as well as levels of IL-1

transcripts as measured by

qRT-PCR (t(10)=2.312, p=0.0434, n=6) and IL-6 transcripts as measured by qRTPCR (t(10)=2.882, p=0.0204). (Data are mean +/- S.E.M., *P<0.05, n=6 for qPCR
analysis). (n= 3 for immunofluorescence, data are mean ± SEM. *P<0.05,
**P<0.01, Scale bar, 100µm)
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3.2.4

Generating a mouse line to investigate cholinergic

microglial activation

Based on our findings of increased neuroinflammation due to decreased
cholinergic tone, it seemed of importance to investigate how cholinergic tone can
regulate microglial activation. One possibility to explain these results is that
chronic cholinergic modulation of microglia, via activation of muscarinic or
nicotinic receptors maintains microglial inflammatory responses in check. In
order to start to address this possible modulation, we have generated a new
mouse model in which muscarinic modulation can be regulated exclusively in
microglia. To do that, we used the Cre technology to generate a mouse that
expresses the DREADD hM3Dq specifically in microglia. To generate these
mice, we intercrossed Cx3cr1CreER mice (Parkhurst et al. 2013) with B6;129Gt(ROSA)26Sortm1(CAG-CHRM3/Cit)Ute (Gq-DREADD)

mice

(Roth

2016).

Gq-

DREADD mice carry HA-hM3Dq-pta-mCitrine in the ROSA locus, with a loxPflanked STOP codon to prevent transcription of the downstream HA-hM3Dq-ptamCitrine gene. Cx3cr1CreER mice express tamoxifen-inducible Cre recombinase
under the control of the Cx3cr1 promoter, which was previously shown to target
myeloid cells (Parkhurst et al. 2013). Upon tamoxifen-induced Cre expression,
the flanked STOP codon would be excised and expression of HA-tagged hM3Dq
should be allowed, specifically in Cx3cr1-positive cells. To specifically target

83
microglia from the Cx3xr1-positive cells, we waited 30 days post-tamoxifen
injection prior to examine the brains of these mice. This delay was given to
account for unwanted recombination of peripheral myeloid Cx3xr1- positive cells.
Peripheral Cx3xr1 cells would initially undergo recombination, but because of
their high turnover rate (van Furth and Cohn 1968), non-recombined cells would
replace them in the absence of tamoxifen in their body (Parkhurst et al. 2013).
On the contrary, microglia have a low turnover rate (Lawson et al. 1992) and
therefore, the recombined cell population should be maintained even after
tamoxifen dissipates (Parkhurst et al. 2013).
To determine whether we have generated mice expressing Gq-DREADD in
microglia, we used immunohistochemistry to probe for anti-HA, and assessed
the percentage of co-localization with IBA1 (microglia-specific marker) in 30 µm
sections of the hippocampus of mice treated with tamoxifen (Figure 12A). Our
studies revealed approximately 87% co-localization between anti-HA positive
cells and IBA1-positive cells in the hippocampus of these mice (Figure 12B). We
observed no labeling with HA in sections from mice that were not treated
previously with tamoxifen. This high degree of co-localization suggests that this
model may be utilized for assessing the consequences of activation of central
inflammatory responses using chemogenetics. Experiments with this new mouse
model in the laboratory confirmed that activation of microglia in culture with
clozapine-N-Oxide (CNO) specifically activates intracellular calcium signalling
only in microglia previously treated with tamoxifen (not shown).
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Figure 12. Expression of hM3Dq in microglia. (A) Reconstructed 3D Z-Stack
immunofluorescence images of Iba1 (green) and anti-HA (red) in the prefrontal
cortex region of the mouse. (B) Representative immunofluorescence images of
Hoechst (blue), Iba1 (green), and anti-HA (red). Graph indicates co-localization
analysis in the hippocampi of Cx3cr1CreER-DREADD mice. (n= 4, Scale bar, 100µm)
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3.2.5 Hippocampal cholinergic deficits starting in adulthood
Our experiments suggest that long-term loss of cholinergic signalling leads to
increased neuronal vulnerability and apoptosis in the hippocampus. However,
because VAChTNkx2.1-Cre-flox/flox mice show abolished cholinergic tone from
embryonic stages it was important to determine if the effects observed were not
due to developmental deficits. To investigate that, we evaluated pathology in the
hippocampus of adult VAChTflox/flox mice that received stereotaxic injections of
AAV8-GFP-Cre in the medial septum and vertical limb of the diagonal band
(MS/VDB). Aged (12-16 months old) VAChTflox/flox mice received stereotaxic
injections of AAV8-GFP-Cre (n=5) or AAV8-GFP (n=3) virus to their medial
septum and vertical limb of the diagonal band (MS/VDB) as described (Al-Onaizi
et al. 2016) and 6 months post-injections, we assessed VAChT levels and
pathology in the hippocampus (Figure 13A-B).

We found that hippocampal VAChT levels were decreased approximately 50%
(t(6)=2.925, p=0.0265, Figure 13A-B) in AAV8-GFP-Cre injected mice, compared
to controls. Analysis of AT180 tau epitope (T231/S235) immunoreactivity in the
hippocampus in both groups showed no differences in labeling (Figure 13C).
Silver deposits showed a tendency to be increased in AAV8-GFP-Cre injected
mice, but without overall significant statistical difference (t(6)=1.983, p=0.0946,
Figure 13D). In contrast, activated caspase-3, a marker of apoptosis, was
augmented in aged VAChTflox/flox mice injected with AAV8-GFP-Cre compared to
AAV8-GFP injected VAChTflox/flox controls (t(6)=2.659, p=0.0376, Figure 13E-F).
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Figure 13. Neuropathology analysis in AAV8-GFP-Cre injected VAChTflox/flox
mice.

(A)

Representative

images

of

VAChT

immunoreactivity

in

the

hippocampus and (B) quantification of aged VAChTflox/flox GFP injected controls
and VAChTflox/flox Cre injected mice. (C) Representative images of pT231 and
Hoeschst labeling in the hippocampus of VAChTflox/flox GFP injected controls and
VAChTflox/flox Cre injected mice (Scale bar, 100µm). (D) Representative images
and quantification of silver staining in the CA1 region VAChTflox/flox GFP injected
controls

and

VAChTflox/flox Cre

injected

mice

(Scale

bar,

100µm.

(E)

Representative immunofluorescence images and (F) quantification for activatedcaspase 3 labeling in VAChTflox/flox GFP (n=3) injected controls and VAChTflox/flox
Cre injected mice (n=5). (Data are mean ± SEM. *P<0.05, **P<0.01, Scale bar,
100µm)
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3.2.6

Hippocampal long-term potentiation in mice with
deficient cholinergic tone

Synaptic plasticity is a critical component of hippocampal function and is thought
to form the cellular basis of learning and memory (Gu and Yakel 2011; Kanju et
al. 2012). Mice with reduced VAChT levels present deficits in LTP in
hippocampal slices in vitro (Martyn et al., 2012). Thus, we aimed to determine
whether these deficits are reproducible in vivo in VAChTNkx2.1-Cre-flox/flox mice. . We
examined LTP of the synapse of the Schaffer collaterals on hippocampal CA1
neurons in anaesthetised mice. VAChTNkx2.1-Cre-flox/flox mice showed decreased
LTP which lasted about 90 minutes post-tetanus delivery while LTP in
VAChTflox/flox mice was maintained for 120 minutes (t(9)=3.911, p=0.0036, Figure
14A-B). This indicates that the lack of cholinergic signalling disturbs synaptic
plasticity in hippocampal CA1 area in vivo.

88

Figure 14. Hippocampal LTP is disrupted in forebrain-specific VAChT
knockout mice in vivo. (A) Normalized slopes of the excitatory sink recorded at
CA1 stratum radiatum (apical dendrites) of VAChTflox/flox (clear squares, n=5) and
VAChTNkx2.1-Cre-flox/flox (dark circles, n=6) mice. Baseline was monitored for 30
minutes prior to tetanus delivery (t=0), and post-tetanic response was monitored
for 120 minutes. A 1-second 100 Hz train, delivered at 2-3 times the threshold
intensity (arrow), induced higher and more prolonged potentiation in VAChTNkx2.1Cre-flox/flox

mice than VAChTflox/flox controls. Insets show representative current sink

time response taken at 80 minutes (red traces), overlaid on the pre-tetanus
baseline response (black traces), from each genotype. (B) Normalized excitatory
sink slope averaged across 30 minute time intervals (mean ± SEM) in
VAChTflox/flox and VAChTNkx2.1-Cre-flox/flox mice, with significant difference between
mouse

groups

at

90-120

minutes

(t(9)=3.911,

p=0.0036)
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3.2.7

Cholinergic tone is required for adult hippocampal

neurogenesis

Cholinergic signalling has been implicated in modulating neurogenesis (CooperKuhn et al. 2004; Kaneko et al. 2006), and neurogenesis contributes to
hippocampal function (Shors et al. 2001). Initial genome-wide transcriptome
analysis indicated that genes related to neurogenesis were differentially
expressed in the hippocampus of VAChTNkx2.1-Cre-flox/flox mice compared to control
mice (not shown; Benjamin Kolisnyk). In agreement, qPCR analysis confirmed
changes in expression of many neurogenesis-related genes (Figure 15A).
Therefore, we sought to investigate if neurogenesis was altered in the
hippocampi of VAChT-deficient mice. A key step in neurogenesis is the
proliferation of cell precursors in the dentate gyrus, thus we analyzed the
immunoreactivity of the proliferation marker Ki67 in the dentate gyrus of
VAChTNkx2.1-Cre-flox/flox mice (Figure 15B). Quantification of Ki67 expression
revealed a decrease in the number of proliferating cells in the SGZ of the
hippocampus of VAChTNkx2.1-Cre-flox/flox mice in comparison to controls (t(6)=2.455,
p=0.0433) (Figure 15C).

Moreover, immunoreactivity of the neuroblast-specific marker, doublecortin,
revealed decreased expression in the SGZ of the hippocampus of VAChTNkx2.1Cre-flox/flox

mice compared to controls (Figure 15D). Quantification using
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immunoblot analysis showed that doublecortin expression was decreased
(t(6)=3.838, p=0.0086) in VAChT-deficient mice, suggesting that decreased
cholinergic tone affects neuroblast formation in the hippocampus (Figure 15E).
Furthermore, 24-hour BrdU labeling in VAChT-deficient mice revealed a
significant decrease in the number of BrdU-positive cells in the SGZ of the
hippocampus, compared to controls (t(6)=5.174, p=0.0021) (Figure 15F-G).
Together, these findings suggest that hippocampal cholinergic tone may be
critical in regulating proliferation as well as differentiation of neuronal precursor
cells.
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Figure 15. VAChTNkx2.1-Cre-flox/flox mice show impaired neurogenesis in the
subgranular zone of the hippocampus. (A) Transcript levels measured by
qPCR of neurogenesis-related genes identified by whole-transcriptome analysis.
(B) Immunoreactivity and (C) quantification of the number Ki67-positive cells in
the dentate gyrus of VAChTNkx2.1-Cre-flox/flox and controls. (D) Doublecortin
immunoreactivity in the dentate gyrus of VAChTNkx2.1-Cre-flox/flox and controls. (E)
Immunoblot analysis and quantification of doublecortin expression in the
hippocampus of VAChTNkx2.1-Cre-flox/flox and controls.(F-G) BrdU expression and
quantification in the dentate gyrus of controls and VAChTNkx2.1-Cre-flox/flox mice.
(n=4, data are mean ± SEM. *P<0.05, **P<0.01, ***P<0.0001).
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3.3

Behavioural characterization of forebrain-specific

VAChT-deficient mice

3.3.1 Neuromuscular analysis of VAChTNkx2.1-Cre-flox/flox mice

In order to understand whether cholinergic deficiency leads to cognitive deficits,
we examined several behavioural parameters in the VAChT-deficient mice. To
investigate if deletion of VAChT has consequences on neuromuscular
performance, we performed a battery of motor

tasks.

VAChTflox/flox

and

VAChTNKx2.1-Cre-flox/flox mice show no differences in performance in the wire-hang
test (t(10)=1.0, p=0.341, Figure 16A) and the grip force test (t(10)=0.124, p=0.903,
Figure 16B). In addition, we analyzed motor skill learning using the rotarod.
Performance of VAChTNKx2.1-Cre-flox/flox mice was very similar to VAChTflox/flox
control mice, (Two-way RM ANOVA shows an effect of days F(13,65)=5.821,
p<0.0001, no genotype effect, F(1,5)=0.310, p=0.6014, and no interaction
F(13,65)=0.652, p=0.801, Figure 16C), suggesting that forebrain cholinergic
deficiency does not have major impact on neuromuscular performance.

One potential limitation regarding Cre recombinase-expressing mouse lines is
that the Cre transgene might lead to non-specific effects aside from excision of
the target gene. Thus, we assessed the behavioural phenotype of mice that only
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express Cre, but do not contain the targeted floxed alleles (Nkx2.1-Cre mice).
Mice were initially assessed on neuromuscular function. In the wire-hang test,
Nkx2.1-Cre mice were no different from wild-type C57BL/6 littermates in time
spent hanging upside down from a wire netting (t(10)= 0.447, p=0.664, Figure
17A). Similarly, Nkx2.1-Cre mice displayed no impairments in the grip force test,
compared to controls (t(10)=0.255, p=0.803, Figure 17B). We also analyzed motor
skill learning using the rotarod. Performance of Nkx2.1-Cre mice was very similar
to C57BL/6 control mice (Two-way RM ANOVA shows an effect of days
F(13,91)=5.149, p<0.0001, no genotype effect, F(1,7)=0.084, p=0.779, and no
interaction F(13,91)=0.662, p=0.7938, Figure 17C).
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Figure 16. Neuromuscular testing on VAChTflox/flox and VAChTNkx2.1-Creflox/flox

mice. (A) Wire-hang test; VAChTflox/flox(white) and VAChTNkx2.1-Cre-

flox/flox

(black) mice. (B) Grip force; VAChTflox/flox(white) and VAChTNkx2.1-Cre-

flox/flox

(black) mice. (C) Performance in the rotarod; VAChTflox/flox(white, n=8) and

VAChTNkx2.1-Cre-flox/flox (black, n=8) mice.
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Figure 17. Neuromuscular testing on C57BL/6 littermates and Nkx2.1-Cre
mice. (A) Wire-hang test; WT littermate controls (C57BL/6 white, n=6), and
Nkx2.1-Cre (gray, n=6). (B) Grip force; WT littermate controls (C57BL/6, white,
n=6), and Nkx2.1-Cre (gray, n=6). (C) Performance in the rotarod; WT littermate
controls (C57BL/6, white, n=6), and Nkx2.1-Cre (gray, n=6). (B) Grip force;
(C57BL/6 white squares, n=8), and Nkx2.1-Cre (gray circles, n=8).
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3.3.2
flox/flox

Spontaneous locomotor activity in VAChTNkx2.1-Cremice

Previous experiments have highlighted the involvement of cholinergic tone in
locomotion (Leanza et al. 1996; Mattsson et al. 2004; Martins-Silva et al. 2011;
Martyn et al. 2012). Therefore, we assessed locomotion in VAChTNkx2.1-Cre-flox/flox
mice using automated locomotor boxes. We found that VAChTNkx2.1-Cre-flox/flox mice
were significantly hyperactive compared to controls (Two-way ANOVA shows an
effect of time F(11,154)=15.07, p<0.0001, an effect of genotype F(1,14)=12.75,
p=0.0031, and no interaction F(11,154)=1.293, p=0.233, Figure 18A).

The regulation of motor activity by cholinergic signalling has been examined,
however, the contribution of cholinergic input from distinct brain regions remains
unclear. Previously, our group has reported that glutamate co-released from
cholinergic striatal interneurons, but not acetylcholine, is involved in the
regulation of locomotor activity in the striatum (Guzman et al. 2011). Because
VAChTNkx2.1-Cre-flox/flox mice show decreased VAChT expression also in the
striatum, we decided to further investigate the involvement of striatal vs.
hippocampal/cortical cholinergic signalling. Our previous findings regarding the
role of striatal cholinergic tone involved targeting of VAChT. Here we asked if
striatal cholinergic tone is not involved in locomotion using mice with selective
removal of ChAT in the striatum (ChATD2-Cre-flox/flox). In order to do this, we
crossed the D2-Cre BAC transgenic mouse line generated by GENSAT with a
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ChAT floxed mouse line (Misgeld et al. 2002). Previous work from our laboratory
using this Cre mouse line demonstrated that Cre expression is restricted to the
striatum (Guzman et al. 2011). Data analysis showed that ChATD2-Cre-flox/flox mice
were not hyperactive compared to ChATflox/flox controls during the first hour of
locomotor activity testing (Two-way ANOVA shows an effect of time
F(11,110)=6.234, p<0.0001, no effect of genotype F(1,10)=0.621, p=0.448, and an
interaction effect F(11,110)=2.077, p=0.0277, Figure 18B). These findings suggest
that striatal cholinergic tone does not seem to play a major role in modulating
locomotor activity.
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Figure 18. Locomotor activity in cholinergic-deficient mice. (A) Horizontal
activity in an open field for VAChTflox/flox(white, n=8) and VAChTNkx2.1-Creflox/flox

(black, n=8) mice was measured over 1 hour period (B) Horizontal activity

in an open field for ChATflox/flox (white, n=6) and ChAT-D2-Cre-flox/flox (black, n=6)
mice was measured over 1 hour period. (Data are mean ± SEM. *P<0.05,
**P<0.01).
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3.3.3 Metabolic analysis in VAChT-deficient mice

Cholinergic tone can regulate metabolic homeostasis (reviewed in (Picciotto et al.
2012)). To investigate whether decreased forebrain cholinergic tone affects
homeostasis, VAChTNKx2.1-Cre-flox/flox mice were assessed in closed metabolic
cages. Weight analysis of young adult mice (3 months old) indicated that
forebrain VAChT-deficient mice are significantly leaner compared to agematched controls (t(16)=5.398, p<0.0001, Figure 19A). Metabolic analysis
revealed no significant differences in respiratory exchange rate between
VAChTNKx2.1-Cre-flox/flox in the light (t(11)=0.552, p=0.599) or dark (t(11)=0.948,
p=0.363) cycles (Figure 19). Assessment of locomotor activity during the 24-hour
period in the metabolic cages confirmed that VAChT-deficient mice were
hyperactive in the dark cycle (t(11)=2.345, p=0.038), but not the light cycle
(t(11)=0.647, p=0.531), compared to controls (Figure 19C).

Sleep analysis revealed that VAChTNKx2.1-Cre-flox/flox mice had significantly fewer
sleep bouts cycles (t(11)=2.997, p=0.0121, Figure 19D) and decreased sleep
duration cycle (t(11)=2.357, p=0.033, Figure 19E) during the dark cycle, but not
the light cycle when compared to controls. Food consumption and water
consumption showed similar profiles for both VAChTNKx2.1-Cre-flox/flox and
VAChTflox/flox

mice

(Two-way

RM

ANOVA

shows

an

effect

of

time

F(139,1529)=457.4, p<0.0001, no effect of genotype F(1,11)=1.618, p=0.250, and an
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interaction effect F(139,1529)=5.215, p<0.001, Figure 19F) (Two-way RM ANOVA
shows an effect of time F(139,1529)=647.2, p<0.0001, no effect of genotype
F(1,11)=5.076, p=0.065, and an interaction effect F(139,1529)=15.27, p<0.0001,
Figure 19G). In addition, similar results were obtained for heat profile during 24hour period in the metabolic cages (Two-way RM ANOVA shows an effect of
time F(139,1529)=6.490, p<0.0001, no effect of genotype F(1,11)=0.2990, p=0.594,
and no interaction F(139,1529)=1.125, p=0.161, Figure 19H).
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Figure 19. Metabolic analysis in VAChTNkx2.1-Cre-flox/flox mice. (A) Body weight
at time of metabolic cage analysis. (B) Respiratory exchange rate analysis. (C)
Home cage locomotor activity. ON indicates when light is turned on, and OFF
indicates when light is turned off in testing room. (D) Sleep bouts. (E) Sleep time.
(F) Cumulative food consumption. (G) Cumulative water consumption. (H) Heat
profile during 24-hour period in metabolic cages. VAChTNkx2.1-Cre-flox/flox n=7,
VAChTflox/flox n=6 (Data are mean ± SEM. *P<0.05, **P<0.01, ***P<0.0001).
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3.3.5

Assessment

of

depressive-like

behaviour

in

cholinergic-deficient mice

Previous experiments have shown that cholinergic signalling plays a critical role
in modulating depressive-like behaviour in rodents (Caldarone et al. 2004). An
increase in cholinergic tone leads to a pro-depressive phenotype, while blocking
cholinergic signalling through either muscarinic, or nicotinic receptors, leads to
anti-depressant-like effects (Rabenstein et al. 2006; Drevets et al. 2013).
Furthermore, there is evidence suggesting that enhancing hippocampal
cholinergic tone promotes depressive-like behaviours in mice (Mineur et al.
2013). Therefore, we tested whether deficient forebrain cholinergic tone has an
effect on depressive-like behaviour. In the forced swim test, VAChTNkx2.1-Cre-flox/flox
mice were similar to littermate controls in time spent immobile (t(18)=1.128,
p=0.274, Figure 20A), as well as the distance covered swimming (t(18)=0.539,
p=0.595, Figure 20B). We also assessed depressive-like behaviour in the tailsuspension test. Similar to the forced swim test, VAChTNkx2.1-Cre-flox/flox mice did
not differ from littermate controls in the tail-suspension test (t(9)=1.305, p=0.224,
Figure 20C).

Next, in an attempt to dissect the specific contributions of striatal vs.
hippocampal/cortical cholinergic signalling to depressive-like behaviours we
tested ChATD2-Cre-flox/flox mice and controls on the same behavioural tests. We
found that striatal-specific deficient mice displayed an anti-depressant-like
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phenotype compared to controls in the immobility time in the forced swim test
(t(10)=2.710, p=0.0219, Figure 21A), and immobility time in the tail-suspension
test (t(10)=2.301, p=0.044, Figure 21C). These results indicate that decreased
striatal cholinergic signalling leads to an anti-depressive like phenotype in mice,
suggesting a role for striatal cholinergic signalling in the modulation of
depression.
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Figure 20. Depressive-like analysis in forebrain cholinergic-deficient mice.
(A) Immobility time in the final four minutes of testing in the forced swim test. (B)
Total distance swam in the final four minutes of testing in the forced swim test,
VAChTNkx2.1-Cre-flox/flox n=10, VAChTflox/flox n=10. (C) The total immobility time in the
final four minutes of testing in the tail-suspension test VAChTNkx2.1-Cre-flox/flox n=5
VAChTflox/flox n=6. (Data are mean ± SEM).
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Figure 21. Depressive-like analysis in striatal cholinergic-deficient mice. (A)
Immobility time in the final four minutes of testing in the forced swim test. (B)
Total distance swam in the final four minutes of testing in the forced swim test,
ChATD2-Cre-flox/flox n=6, ChATflox/flox n=6. (C) The total immobility time in the final
four minutes of testing in the tail-suspension test ChATD2-Cre-flox/flox n=6,
ChATflox/flox n=6. (Data are mean ± SEM).
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3.4 Determining the contributions of forebrain cholinergic
signalling to cognitive functioning

3.4.1

Forebrain cholinergic signalling is required for paired
associates learning

The paired associates learning (PAL) test has been shown to efficiently detect
cognitive alterations that are consistently observed in AD (Swainson et al. 2001;
Blackwell et al. 2004; de Rover et al. 2011). The PAL task requires sophisticated
processing of information for proper association of images with specific locations.
VAChTNkx2.1-Cre-flox/flox mice and their matched controls were assessed on the PAL
task using an automated touchscreen system (Figure 22A).

Prior to being subjected to the PAL task, both experimental groups go through a
number of different types of training sessions (initial touch, must touch stimuli,
must initiate and punish incorrect) to learn how to operate the touchscreen. At
these sessions they learn for instance, to touch the screen when a stimulus is
presented and to initiate the task by inserting the head into the reward chamber.
This pre-training also includes the “punish incorrect” phase, when only one
stimulus is presented randomly in one of the 3 screens, and mice are taught to
touch the screen that shows the stimulus. Mice from both experimental groups
were able to reach criterion in all these phases of the pre-training. No differences
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were observed between the two genotypes (t(12)=0.0749, Figure 22B). These
data also indicate that VAChT-deficient mice are able to learn that they need to
touch the screen when an image is shown, which argues that VAChT-deficient
mice do not present any major visual impairment.

During the course of the 9 weeks following training, mice were tested on the
dPAL task. We observed that control mice significantly improved their accuracy
performance, while VAChTNkx2.1-Cre-flox/flox did not (Two-way RM ANOVA shows
significant effect of weeks F(8,48)=21.11, p<0.0001, an effect of genotype
F(1,6)=56.94, p=0.0003, and an interaction effect F(8,48)=2.871, p=0.0074, Figure
22C). VAChTflox/flox mice (controls) were able to improve performance reaching
77% ± 1 accuracy by week 9 (Figure 22C). In contrast, peak accuracy
performance of VAChTNkx2.1-Cre-flox/flox mice in the dPAL task during the same
period was 58% ± 2 (Figure 22C). Although VAChTNkx2.1-Cre-flox/flox mice were able
to perform the 36 trials required in each one-hour session, they failed to
associate the stimulus to its correct location. Their poor performance was also
reflected in the number of correction errors performed (Figure 22D). VAChTNkx2.1Cre-flox/flox

mice failed to decrease the number of correction errors made over the

course of 9 weeks, while control mice improved the number of correction errors
performed during the course of the study (Two-Way RM ANOVA shows
significant effect of weeks F(8,48)=12.05, p<0.0001, an effect of genotype
F(1,6)=39.41, p=0.0008, and an interaction effect F(8,48)=1.224, p=0.0306, Figure
22D). Correct response latency was not different between the two groups over
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the course of 9 weeks (Two-Way RM ANOVA shows significant effect of weeks
F(8,48)=7.508, p<0.0001, no effect of genotype F(1,6)=2.437, p=0.1695, and no
interaction F(8,48)=1.195, p=0.3220, Figure 22E). Furthermore, VAChTNkx2.1-Creflox/flox

mice were no different from controls when the latency to collect the reward

was measured, which indicated that motivation was not a factor in their poor
performance (Two-way RM ANOVA shows a significant effect of weeks
F(8,48)=7.596, p<0.0001, no effect of genotype F(1,6)=0.0001380, p=0.7681, and
no interaction F(8,48)=0.6061, p=0.7681 Figure 22F). In summary, VAChTNkx2.1-Creflox/flox

mice were able to learn that they had to touch the screen when the images

were shown; however, they failed in making associations, that is, they were
unable to assign each image to a specific position. Videos of mice performing in
the PAL task can be downloaded from:
http://cercor.oxfordjournals.org/content/early/2016/01/22/cercor.bhv349.long
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Figure 22. VAChTNKx2.1-Cre-flox/flox mice display impairments in the acquisition
of PAL. (A) Image depicting a mouse performing the task, where the flower is
shown as S+ and the airplane as S-. (B) Number of sessions required by both
experimental groups to reach criterion during the operant conditioning,
pretraining, and training phases (Habituation; phase 1) (Initial touch training;
phase 2) (Must touch stimuli training; phase 3) (Must initiate; phase 4)(Punish
incorrect; phase 5). (C-F) Data for acquisition of the dPAL task for VAChTflox/flox
(n=7 clear squares) and VAChTNKx2.1-Cre-flox/flox (n=7 dark circles) mice. Each week
represents five testing sessions of 36 trials each (C) Mean accuracy. (D) Mean
correction errors. (E) Response latency. (F) Reward collection latency. (Data are
mean ± SEM. *P<0.05, **P<0.01, ***P<0.0001).
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3.4.2 VAChTNkx2.1-Cre-flox/flox mice exhibit a mild impairment in
spatial memory

Given the strong deficit of association of the image with its correct location in the
PAL task, it seemed of importance also to evaluate spatial memory in these
mice. Spatial memory is widely used to assess information acquisition and
storage in the hippocampus, but cholinergic dysfunction has only mild effects in
the MWM in mice (Moreau et al. 2008; Martyn et al. 2012). Here we evaluated
spatial memory in VAChTNkx2.1-Cre-flox/flox mice.

Our data showed that spatial

learning on the MWM was mildly affected in VAChTNkx2.1-Cre-flox/flox mice (3-6
month old) when compared to age-matched controls (Two-way RM ANOVA
shows a significant effect of days F(3,30)=37.2, p<0.0001, no effect of genotype
F(1,10)=4.790, p=0.0535, and no interaction F(3,30)=0.9567, p=0.4259, Figure 23A).
Both groups improved in the distance taken to reach the target quadrant during
the course of 4 days, however VAChTNkx2.1-Cre-flox/flox mice were less effective to
find the platform (Two-way RM ANOVA shows a significant effect of days
F(3,30)=32.2, p<0.0001, an effect of genotype F(1,10)=12.58, p=0.0053, and no
effect of interaction F(3,30)=0.5597, p=0.6458, Figure 23B]. No significant
differences were observed between the two groups in the speed to reach the
platform (Two-way RM ANOVA shows a significant effect of days F(3,30)=14.11,
p<0.0001, no effect of genotype F(1,10)=0.9260, p=0.3586, and no interaction
F(3,30)=1.805, p=0.1675, Figure 23C]. On the probe trial of the MWM, both groups
of mice spent significantly more time in the target quadrant compared to the
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opposite quadrant (Two-way ANOVA shows a significant effect of quadrant,
F(3,80)=39.58, p<0.0001, and an interaction effect F(3,80)= 2.914, p=0.0394, Figure
23D), post-hoc analysis revealed that both groups spent significantly more time
in the target quadrant. However, VAChTNkx2.1-Cre-flox/flox mice had significantly
fewer platform crosses compared to littermate controls (t(20)=2.795, p=0.0112,
Figure 23E), suggesting that they exhibit a mild impairment in spatial memory
recall compared to controls.

We also analyzed the strategies (Figure 24A) these mice used to learn where the
platform is located. As observed in Figure 24B, both VAChTNkx2.1-Cre-flox/flox and
VAChTflox/flox mice used a more direct strategy to reach the platform (strategies
5/6/7) and there was no difference between genotypes, indicating no major
impairments in learning in VAChTNkx2.1-Cre-flox/flox mice. To assess cue-driven
learning in VAChTNkx2.1-Cre-flox/flox mice, the cued version of the MWM was used.
Our data showed that cued learning on the MWM was not affected in
VAChTNkx2.1-Cre-flox/flox mice (3-6 month old) when compared to age-matched
controls (Two-way RM ANOVA shows a significant effect of days F(1,26)=15.03,
p=0.0006, no effect of genotype F(1,26)=0.1468, p=0.7048, and no interaction
F(1,26)=0.0771, p=0.7834, Figure 25A). Furthermore, no significant differences
were observed between the two groups in the speed to reach the platform (Twoway RM ANOVA shows a significant effect of days F(1,26)=11.78, p=0.0020, no
effect of genotype F(1,26)=0.07437, p=0.7872, and no interaction F(1,26)=0.01525,
p=0.9027, Figure 25B]
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Figure 23. Performance of VAChTNkx2.1-Cre-flox/flox mice in the MWM.
VAChTflox/flox (clear squares, n=11) and VAChTNkx2.1-Cre-flox/flox (dark circles, n=11)
mice were tested in the spatial paradigm of the MWM. The data average four 90s trials per day were plotted. (a) Latency, (b) Distance, (c) Speed, (d) The
percentage of time spent in each quadrant of the pool was measured on day 5 in
a 60-s probe trial with the platform removed. (e) Number of platform crosses
during the probe trial. (f) Representative path traces for two VAChTflox/flox and two
VAChTNkx2.1-Cre-flox/flox mice in the probe trial. The target quadrant is in the lower
right. Data are mean ± SEM. *P<0.05, **P<0.01. T, target; O, opposite; L, left; R,
right.
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Figure 24. Learning strategies of VAChTNkx2.1-Cre-flox/flox mice. (A) Strategy plot
reflecting the mean strategy-recruitment values for the first and fourth trials of
each day for young mice. (B) Quantification comparison of total block length
values of individual mice and their employed strategies over the course of 4-day
training period. Grey bars represent control mice and red bars represent VAChTdeficient mice. (n= 8, data are mean ± SEM)
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Figure 25. Cued memory analysis of VAChTNkx2.1-Cre-flox/flox mice. Mice were
subject to the cued version of the MWM. A. Primary latency to find the platform.
B. Speed traveled to the platform.. The average of four 90-s trials per day is
plotted. *p<0.05, VAChTflox/flox n=6, VAChTNkx2.1-Cre-flox/flox n=8.
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3.4.3

VAChTNkx2.1-Cre-flox/flox mice show deficits in cognitive

flexibility

Previous work has shown that rats with 192 IgG-saporin lesions restricted to
NBM show cognitive flexibility impairments (Cabrera et al. 2006). To investigate
cognitive flexibility, VAChTNkx2.1-Cre-flox/flox mice were tested on the reversal
learning protocol of the MWM. During the course of 4 days, while control mice
significantly improved in their latency to find the hidden platform VAChTNkx2.1-Creflox/flox

mice showed a significant deficit (Two-way RM ANOVA shows a significant

effect of days F(3,30)=8.632, p=0.0003, main effect of genotype F(1,10)= 11.17,
p=0.0075, and no interaction F(3,30)=1.501, p=0.2342, Figure 26A-C). Notably, on
the probe trial, control mice spent considerably more time in the target quadrant
compared to the other quadrants (Two-way ANOVA shows a significant effect of
quadrant, F(3,80)=7.226, p=0.0002, and an interaction effect

F(3,80)= 3.133,

p=0.0301, Figure 26D), while VAChTNkx2.1-Cre-flox/flox mice visited all quadrants
almost equally. The number of platform crosses was also higher for control mice
compared to VAChT deficient mice (t(20)=2.797, p=0.0111, Figure 26E). These
results indicate that, different from control mice, VAChTNkx2.1-Cre-flox/flox mice were
unable to extinguish the previously learned position and relearn the new position
of the hidden platform.
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Figure 26. Reversal learning is affected in VAChTNkx2.1-Cre-flox/flox mice.
VAChTflox/flox (clear squares, n=11), VAChTNkx2.1-Cre-flox/flox (dark circles, n=11)
were tested in the reversal paradigm of the MWM. Data averages of four 90-s
trials per day were plotted. (A) Latency to reach the platform, (B) Distance to
reach the platform, (C) Speed to reach the platform, (D) The percentage of time
spent in each quadrant of the pool measured on day 5 in a 60-s probe trial with
the platform removed. (E) Number of platform crosses during the probe trial. (F)
Representative path traces for two VAChTflox/flox and two VAChTNkx2.1-Cre-flox/flox in
the probe trial. The target quadrant is in the upper left. Data are mean ± SEM.
*P<0.05, **P<0.01. T, target; O, opposite; L, left; R, right.
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To investigate the possibility of Cre-recombinase mediating these spatial
impairments in VAChT-mutant mice, we assessed spatial navigation using the
MWM task in mice expressing Cre-recombinase (Nkx2.1-Cre). As observed in
Figure 27A latency to reach the platform was not different between groups (Twoway RM ANOVA shows an effect of days F(3,12)=90.03, p<0.0001, no effect of
genotype F(1,4)= 0.020, p=0.894, and

no interaction F(3,12)=1.102, p=0.3861).

Similar results were obtained for distance travelled (Two-way RM ANOVA shows
an effect of days F(3,12)=52.81, p<0.0001, no effect of genotype F(1,4)=0.182,
p=0.691, and no interaction F(3,12)=0.806, p=0.514, Figure 27B). Furthermore, no
differences were observed in speed (Two-way RM ANOVA shows an effect of
days F(3,12)=5.927, p<0.0001, no effect of genotype F(1,4)=0.052, p=0.830, and no
interaction F(3,12)=0.556, p=0.653, Figure 27C). In the probe trial, Nkx2.1-Cre
mice did not differ from C57BL/6 littermate controls in terms of preference for the
target quadrant (Two-way ANOVA shows a significant effect of quadrant,
F(3,24)=46.63, p<0.0001, no effect of genotype, F(1,8)=, p=0.167, and no interaction
F(3,24)=0.990, p=0.414, Figure 27D). To assess cognitive flexibility, Nkx2.1-Cre
mice were tested on the reversal learning protocol of the MWM. During the
course of 4 days, both C57BL/6 and Nkx2.1-Cre mice significantly improved in
their latency to find the hidden platform (Two-way RM ANOVA shows a
significant effect of days F(3,12)=8.809, p=0.0023, no effect of genotype F(1,4)=
0.368, p=0.576, and no interaction F(3,12)=0.347, p=0.792, Figure 27E). Similarly,
no differences were observed in distance (Two-way RM ANOVA shows a
significant effect of days F(3,12)=12.92, p=0.0005, no effect of genotype F(1,4)=
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0.784, p=0.425, and no interaction F(3,12)=0.937, p=0.452, Figure 27F) or speed
(Two-way RM ANOVA shows a significant effect of days F(3,12)=5.423, p=0.013,
no effect of genotype F(1,4)=0.248, p=0.644, and no interaction F(3,12)=0.484,
p=0.699, Figure 27G). Notably, on the probe trial, control and Nkx2.1-Cre mice
spent considerably more time in the target quadrant compared to the other
quadrants (Two-way ANOVA shows a significant effect of quadrant, F(3,24)=13.5,
p<0.0001, no effect of genotype, F(1,8)=, p=0.328, and no interaction F(3,24)=0.271,
p=0.845, Figure 27H). Together, these results indicate that Cre expression has
no profound consequences on neuromuscular performance, spatial acquisition,
and cognitive flexibility.
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Figure 27. Performance of Nkx2.1-Cre mice in the MWM. WT littermate
controls (C57BL/6, clear squares, n=6) and Nkx2.1-Cre (dark circles, n=6) mice
were tested in the spatial paradigm of the MWM. The data average four 90-s
trials per day were plotted. (A) Latency, (B) distance, (C) speed. (D) Probe trial
data indicating the percentage of time spent in each quadrant of the pool was
measured on day 5 in a 60-s probe trial with the platform removed. Reversal
learning data in the MWM. (E) Latency, (F) distance, (G) speed. (H) Probe trial
data indicating the percentage of time spent in each quadrant of the pool was
measured on day 5 in a 60-s probe trial with the platform removed. (Data are
mean ± SEM. *P<0.05, **P<0.01, ***P<0.0001).
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3.4.4 VAChTNkx2.1-Cre-flox/flox mice show impaired performance
in a two-choice location discrimination task

Because young (3-6 month old) VAChT deficient mice presented impairments in
neurogenesis,

we

sought

to

investigate

whether

these

deficits

have

consequences on performance on a task thought to be dependent on adult
hippocampal neurogenesis (Clelland et al. 2009). VAChTNkx2.1-Cre-flox/flox mice were
tested on a two-choice spatial discrimination task. Mice were required to touch
one of two illuminated screens (e.g. S+ is in the most left screen) until a criterion
of 9/10 consecutive correct trials were achieved. Once criterion was reached, a
reversal occurred where the other location (e.g. S+ is now in the rightmost
screen). In addition, the separation of the illuminated screens was presented with
either a high degree of separation (easy; 3 blank screens separating the
illuminated screens), or a low degree of separation (hard; 1 blank screen
separating the illuminated screens) (Figure 28A). VAChT-deficient mice
performed similarly to controls in the number of trials they took to reach criterion
in the high separation (t(6)=0.5541, p=0.6034) (Figure 28B). However, at the low
separation, VAChTNkx2.1-Cre-flox/flox mice exhibited impaired performance in the
task, highlighted by an increased number of trials to reach criterion compared to
controls (t(6)=5.137, p= 0.0119)(Figure 28B).
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To evaluate the number of newly generated neurons during performance on the
acquisition of the two-choice location discrimination task, mice were injected with
BrdU on the day they began the acquisition. After completion of behavioural
testing, mice were killed and their brains were analyzed for BrdU expression.
Immunoreactivity data showed a significant decrease in the number of newborn
cells in the subgranular zone of this hippocampus in VAChTNkx2.1-Cre-flox/flox mice
compared to controls (t(4)=3.366, p=0.0282) (Figure 28C-D). To note, it does not
appear that performance in the two-choice location discrimination task
significantly enhanced BrdU labelling in both controls and VAChT-deficient mice,
compared to baseline expression. Together, our findings suggest that
hippocampal cholinergic tone not only disrupts neurogenesis, but also has a
functional consequence on pattern separation.
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Figure 28. Elimination of hippocampal cholinergic signalling disrupts
pattern separation. (A) Schematic of stimuli presented in either the high (left) or
low (right) separations (B) The number of trials to reach criterion in the high and
low separations in the two-choice spatial discrimination task for VAChTNkx2.1-Creflox/flox

and controls (C-D) BrdU expression and quantification in the dentate gyrus

of controls and VAChTNkx2.1-Cre-flox/flox mice. (n=3, data are mean ± SEM. *P<0.05).
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3.4.5

Long-lasting cholinergic depletion impairs learning

strategies

Given that VAChTNkx2.1-Cre-flox/flox mice presented age-dependent pathology in the
hippocampus, we then asked whether long-lasting cholinergic failure worsens
cognitive function. To answer this question we chose to investigate aged mice in
the spatial version of the MWM, as young (3-6 months old) VAChT-deficient mice
showed only minor deficits in this task (Figure 24). As can be observed in (Figure
29A-B), aged (11-14 month old) VAChT-deficient mice took significantly longer
and swam a greater distance than age-matched controls to find the platform
across the four days of acquisition of the MWM task.

On the probe trial, VAChT-deficient mice showed no preference to the target
quadrant, whereas controls did (Figure 29C). Furthermore, aged VAChT-deficient
mice used distinct strategy preferences to find the platform, indicating that their
deteriorated performance was due to modified learning capacities. The search
strategies used by each animal was based on a fixed set of criteria (Figure 29D).
While at a young age, both controls and VAChTNkx2.1-Cre-flox/flox mice predominantly
used more direct strategies to reach the platform (strategies 5/6/7, Figure 24);
aged VAChT-deficient mice used random swimming predominantly as their
strategy to acquire the task (strategy 2, Figure 29E). On the other hand, aged
control mice maintained the use of more direct strategies. Aged VAChT-deficient
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mice also exhibited deficits in the probe trial (Figure 29E). Taken together, these
results suggest that long-term cholinergic deficiency in VAChTNkx2.1-Cre-flox/flox mice
worsened spatial information acquisition.
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Figure 29. Performance of aged VAChTNkx2.1-Cre-flox/flox mice in the MWM.
VAChTflox/flox (grey circles, n=8) and VAChTNkx2.1-Cre-flox/flox (red squares, n=8) mice
were tested in the spatial paradigm of the MWM. The data average four 90-s
trials per day were plotted. (A) Latency, (B) Distance, (C) The percentage of time
spent in each quadrant of the pool was measured on day 5 in a 60-s probe trial
with the platform removed. (D) Representative examples of the 7 classified
criteria to score the strategies mice used to perform in the MWM. Strategies are
color coded. (E) Strategy plot reflecting the mean strategy-recruitment values for
the first and fourth trials of each day for aged mice. Quantification comparison of
total block length values of individual mice and their employed strategies over the
course of 4-day training period. Grey bars represent control mice and red bars
represent VAChT-deficient mice. (n= 8, data are mean ± SEM. *P<0.05
**P<0.01).
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Chapter 4

4.

Discussion

4.1 Generation of a forebrain-specific cholinergic deficient
mouse model

Although cholinergic innervations are widespread in the CNS and ACh is
suggested to be involved in several cognitive and behavioural functions, the
exact role of ACh in these processes is not well understood. Likewise,
information about the specific cholinergic nuclei involved in the modulation of
these brain functions is still incomplete. One of the difficulties in understanding
the exact role of ACh in behavioural processes was the lack of a good animal
model. Previous work used immunotoxins to mimic cholinergic dysfunction in
mice and rats (Berger-Sweeney et al. 1994; Parent and Baxter 2004). Ablation of
cholinergic neurons using immunotoxins provided inconsistencies regarding the
involvement of the basal forebrain cholinergic system in memory tasks and it is
particularly problematic in mice, as immunotoxins are not as efficient (Baxter and
Gallagher 1996; Walsh et al. 1996; Janis et al. 1998). Immunotoxin ablations
display poor specificity depending on the dose used (Moreau et al. 2008) and
several side effects have been reported in mice, including seizures (Berger-
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Sweeney et al. 2001). Additionally, differences in size and location of the lesions;
as well as differences in the extent of cholinergic neuron ablation on individual
animal difficult analysis of the results. Furthermore, because cholinergic neurons
from different brain regions have been shown to co-release ACh with other
classical neurotransmitters toxin-based approaches do not allow differentiatiation
of the role of ACh from the other neurotransmitter co-secreted, such as
glutamate or GABA, by these cholinergic neurons (Guzman et al. 2011; Higley et
al. 2011; Saunders et al. 2015). Genetic targeting using the Cre/lox system has
provided a means to investigate how compromised forebrain release of ACh
influences cognitive performance, and molecular hallmarks of AD.

In this thesis we used the Cre-loxP system to specifically delete cholinergic
genes from the forebrain of mice and mimic cholinergic dysfunction. Specifically,
we used the Nkx2.1 promoter to restrict Cre expression
Biochemical

analyses

revealed

that

VAChT

expression

to the forebrain.
was

severely

compromised in the forebrain areas, including the hippocampus. Previously, work
from our laboratory used the Six3-Cre promoter to target VAChT expression
(VAChTSix3-Cre-flox/flox) in the mouse forebrain (Martyn et al. 2012). These mice are
very similar to the VAChTNkx2.1-Cre-flox/flox mice in that they show specificity to
forebrain regions and present similar behavioural phenotypes. When generating
VAChTSix3-Cre-flox/flox mice however, there was a propensity for germ line deletion
in the VAChT gene in these animals, resulting in the generation of hemizygous
del allele that would be present in all cells of the animal. These mice show 50%
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decrease in VAChT expression in all cholinergic expressing cells, including all
brain regions and the peripheral nervous system. Our current mouse model
circumvents these concerns as Nkx2.1-Cre mice are generated using a BAC
clone. Because BAC clones are usually very long sequences, they generally
contain all the regulatory regions necessary for cell specific gene expression and
therefore, mice generated with BAC clones have a reduced chance of ectopic
Cre expression. Furthermore, we show that Cre expression per se does not
interfere with cognitive nor motor behaviours. Thus, our data suggest that
VAChTNkx2.1-Cre-flox/flox is a good model to investigate how decreased ACh released
from forebrain cholinergic neurons influence brain function both at cellular and
behavioural level.

4.2 Long-term cholinergic loss and Alzheimer’s-like
pathology

Neurodegenerative changes in the basal forebrain cholinergic system are
characteristic in AD (Teipel et al. 2014) and prodromal AD (Teipel et al. 2016).
Long-term administration of drugs with anticholinergic side effects increases an
individual’s risk of developing AD (Gray et al. 2015). Moreover, use of drugs with
medium or high anticholinergic activity correlates with poorer cognitive
performance and increased brain atrophy in older adults (Risacher et al. 2016).
Our data show that aged VAChT-deficient mice display molecular hallmarks that
are common to AD and neurodegenerative diseases. We observed that aged
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VAChT-deficient mice presented alterations in tau and an age-dependent
increase in protein aggregation. This strongly supports a relationship between
cholinergic failure and pathology in AD. Aging has been linked with increased
neuronal vulnerability (Mattson and Magnus 2006). Moreover, studies in rats
have demonstrated that basal forebrain cholinergic neurons are particularly
vulnerable to aging (Biegon et al. 1986; Altavista et al. 1990; Casu et al. 2002). It
has been proposed that the selective vulnerability of the basal forebrain
cholinergic system pertains to the higher demand in these cholinergic neurons for
glucose production (Szutowicz et al. 2006). Indeed, gene expression analysis in
rats displayed enhanced metabolic activity in basal forebrain cholinergic neurons,
in comparison to brain stem cholinergic neurons (Baskerville et al. 2008). Our
findings are in line with the notion that basal forebrain cholinergic dysfunction
leads to increased neuronal vulnerability (Altavista et al. 1990; Casu et al. 2002),
but we also add that age-related cholinergic deprivation may have a
consequence on target cells’ health, and worsens cognitive performance.

The age-dependent increase of intracellular Thioflavin-S staining observed in the
hippocampus of VAChTNkx2.1-Cre-flox/flox mice suggests age-dependent protein
aggregation. Thioflavin-S is a fluorescent dye used to detect the aggregates of
-sheet proteins in cells (Bulic et al. 2007; Lim et al. 2014). While the identity of
these aggregates remain unclear, it is worth noting that we observed tau
hyperphosphorylation at Thr231 in VAChT-deficient mice. Because NFTs occur
as intracellular deposits (Iqbal and Grundke-Iqbal 2006) and contain

-sheets

130
when aggregated (Maeda et al. 2007), it is possible that these aggregates may
be composed of tau. The pathophysiology of protein aggregation in
neurodegenerative diseases including AD has been hypothesized to occur due to
a pathogenic propagation and/or selective vulnerability of groups of neurons.
According to the 'pathogenic spread' hypothesis (Brettschneider et al. 2015;
Walsh and Selkoe 2016), aggregation of proteins occur in one brain region and
propagate from neuron to neuron and thus spread into connected brain regions.
Whether this propagation occurs in our mice remains to be established. On the
other hand, the ‘selective vulnerability’ hypothesis suggests that in response to
certain stressful conditions, such as aging, protein aggregation is triggered in
neurons that are particularly vulnerable (Walsh and Selkoe 2016). Protein
aggregates appear first in the cells most susceptible to stressful conditions and
with time aggregates emerge in less-susceptible cells (Mattson and Magnus
2006). Based on this hypothesis, our findings suggest that impaired cholinergic
neurotransmission significantly increases stress and vulnerability of hippocampal
cells. This hypothesis also suggests that protein aggregation is mediated by the
spread of diffusible metabolic factors that result in the propagation of these
stressful conditions to an adjacent neuron, as opposed to direct physical transfer
of protein aggregates (Walsh and Selkoe 2016). Furthermore, these possibilities
may not be mutually exclusive.

Our data demonstrated that aged VAChT-mutants show increased T231/S235
phosphorylation, but not at S262. There have been 25 abnormal sites described
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at which tau in PHFs is hyperphosphorylated (Hanger et al. 1998).
Hyperphosphorylation

of

tau

can

increase

neuronal

vulnerability

via

destabilization of microtubules and disruption of axonal transport, which
ultimately leads to neuronal death (Billingsley and Kincaid 1997; Iqbal et al. 1998;
Brion et al. 2001). The exact relationship between cholinergic signalling and tau
pathology has not been established. However, human studies show that
intraneuronal tau pathology occurs prior to basal forebrain cholinergic neuronal
loss, which inversely correlated with tests of cognitive function (Vana et al. 2011).
Furthermore, cholinergic dysfunction occurs early in MCI and early AD, even
prior to cholinergic neuronal loss (Auld et al. 2002; Picciotto and Zoli 2002;
Mufson et al. 2007). Our data demonstrated that aged VAChT-mutants show
increased T231/S235 phosphorylation, but not at S262. There have been 25
abnormal sites described at which tau in PHFs is hyperphosphorylated (Hanger
et al. 1998). Hyperphosphorylation of tau can increase neuronal vulnerability via
destabilization of microtubules and disruption of axonal transport, which
ultimately leads to neuronal death (Billingsley and Kincaid 1997; Iqbal et al. 1998;
Brion et al. 2001). The exact relationship between cholinergic signalling and tau
pathology has not been established. It is interesting to note that in human studies
it has been shown that intraneuronal tau pathology occurs prior to basal forebrain
cholinergic neuronal loss, and is inversely correlated with cognitive dysfunction
(Vana et al. 2011). Tau hyperphosphorylation at Thr231 is consistently reported
in AD brains (Jicha et al. 1997; Vincent et al. 1997), suggesting that the formation
of PHFs in AD could be highly dependent on tau phosphorylation on Thr231. Our
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data further support a role for hyperphosphorylation of tau at Thr231 contributing
to inhibition of binding of tau to microtubules (Sengupta et al. 2006).

Phosphorylation of tau is mediated by several protein kinases, including GSK-3,
which co-localizes with neurofibrillary tangles in AD (Pei et al. 1998; Pei et al.
1999). In addition, mice overexpressing GSK-3 in the forebrain present tau
hyperphosphorylation and apoptosis, which could be rescued with silencing of
GSK-3 activity. Furthermore, GSK3

-mediated hyperphosphorylation of tau

leads to an array of impairments, including disruption of LTP (Hooper et al. 2007)
and in vitro cell death (Zheng et al. 2002). Interestingly, genome-wide
transcriptome analysis of the hippocampus of VAChT-deficient mice suggests
that the PI3-AKT pathway is upregulated compared to control mice. Western blot
analysis revealed that its downstream target GSK3 activity was increased
(Kolinsyk et al. 2016, submitted). Because tau phosphorylation can occur due to
the activity of GSK3

, which subsequently leads to impairments in synaptic

plasticity (Hooper et al. 2007), it could serve as a potential target. Importantly,
chronic treatment of aged VAChTNkx2.1-Cre-flox/flox mice with the GSK3 inhibitor ARA014418, known to significantly reduce neuritic plaque formation and rescued
memory impairments in AD transgenic mice (Ly et al. 2013), led to a significant
decrease in the levels of tau Thr231 hyperphosphorylion. Interestingly however,
treatment of AR-A014418 in VAChTNkx2.1-Cre-flox/flox mice was neither able to
reverse protein aggregation by Thioflavin S, nor caspase-3 activation, compared
to saline treated VAChTNkx2.1-Cre-flox/flox mice (Kolinsyk et al. 2016, under review).
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Given that treatment with AR-A014418 showed promise in terms of rescuing tau
hyperphosphorylation in VAChT-deficient mice, future experiments should
involve genetic targeting of GSK3 genes in VAChTNkx2.1-Cre-flox/flox mice to test the
long-term outcomes of inhibition of GSK3 activity to AD-related pathology and
cognitive impairments.

Experiments have demonstrated that immunolesioning the basal forebrain
cholinergic neurons in 3xTg-AD mice significantly increased neuropathology,
including tau hyperphosphorylation (Hartig et al. 2014). In 3xTg-AD mice, which
present amyloidosis and tau pathology, administration of a selective M1-agonist
was able to attenuate tau pathology and amyloid pathology (Caccamo et al.
2006). Similarly, genetic deletion of M1 mAChRs in 3xTg-AD mice exacerbated
tau hyperphosphorylation and amyloid pathology (Medeiros et al. 2011). These
findings suggest that M1 mAChR activity may mediate tau hyperphosphorylation
along with amyloidosis. However, it should be noted that experiments reported in
Alzheimer’s mouse models are usually a result of a change in pathology that
already exists. This is very different from our results in which cholinergic failure
per se can trigger these pathological hallmarks similar to AD. Whether
hyperphosphorylation of tau seen in our VAChT-deficient mice occurs due to
aberrant M1 mAChR activity remains to be elucidated.

Our studies also reveal that aged-VAChT deficient mice presented MC1-positive
immunoreactivity in the hippocampus, suggesting a conformational change of tau
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in these mice. The MC1 antibody detects the extreme N terminus and the third
binding domain repeat of tau, which is dependent on the folding of tau (Jicha et
al. 1997). Interestingly, experiments have demonstrated that this misfolding
occurs in close proximity of Thr231, suggesting that hyperphosphorylation of tau
on Thr231 may trigger conformational changes as observed in VAChT mutant
mice (Jicha et al. 1997).

Oligomeric protein aggregation has been linked to

toxicity and to neurodegenerative disorders, including AD (Maeda et al. 2006).
The formation of NFTs alone is insufficient for neurodegeneration; yet oligomeric
tau may contribute to neurodegeneration and synaptic loss in AD (Berger et al.
2007; de Calignon et al. 2012). Hyperphosphorylation of tau and the associated
age-dependent increase in protein aggregation in VAChT mutant mice suggest
that decreased cholinergic tone elicits tauopathy.

Our results also showed that selective cholinergic inhibition to the hippocampus
in aged control mice significantly increased immunoreactivity of activated
caspase-3, a marker of apoptosis, in AAV8-Cre injected mice compared to GFPinjected controls. On the other hand, AAV8-Cre injected mice did not differ from
controls in the number of silver deposits and tau Thr231 hyperphosphorylation. It
is possible that these differences result from the fact that the time and the extent
of cholinergic loss may have been insufficient to trigger these alterations in
AAV8-Cre mice. It is also possible that developmental loss of cholinergic tone
had a role on triggering tau pathology however, the fact that protein aggregation
and tau hyperphosphorylation was not observed in young VAChT-mutants
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argues against a prominent role for developmental ACh on tau pathology. Future
studies using chemogenetics to specifically silence basal forebrain cholinergic
neurons may help us to further clarify the effect of long-term cholinergic loss in
AD-like pathology.

In line with an age dependent neuronal vulnerability in the hippocampus, we
found that aged, but not young, VAChT-deficient mice were severely impaired in
their performance in the MWM task compared to age-matched controls. Using
detailed analysis of precision strategies during training, we found that at a young
age both cholinergic-deficient mice and controls were able to utilize more precise
spatial strategies, and showed intact retention in the probe trial. Similarly, young
adult mice lacking the

2 nAChR subunit are normal in the MWM; when aged

however, these mice displayed robust impairments in the MWM (Zoli et al. 1999).
To note, mice lacking the

2 nAChR subunit present progressive cell death in

the hippocampus and cortex (Zoli et al. 1999), which could influence spatial
navigation. Indeed, poor performance and acquisition on the MWM task has
been associated with loss of neurons in the hippocampus (Olsen et al. 1994). In
line with these studies, data from our laboratory show that long-term cholinergic
loss decreased the number of neurons in the hippocampus (Kolisnyk et al. 2016,
under review). These findings may be a major factor underlying the deterioration
in cognitive performance in VAChT-deficient mice.
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4.2.1 Neuroinflammation

In this thesis we demonstrated that inflammatory cytokine levels as well as
microglial activation are up regulated in the hippocampi of VAChT-deficient mice.
Central neuroinflammation has been shown to be a key mechanism in the
pathogenesis of AD (Wyss-Coray 2006; Heneka et al. 2014). The identification of
associations between mutations in genes such as the triggering receptor
expressed on myeloid cells 2 (TREM2) and the development of AD suggest a
critical role of the innate inflammatory response in the pathogenesis of AD
(Guerreiro et al. 2013; Jonsson et al. 2013). Microglial activation is necessary for
remodelling synapses, synaptic plasticity, and for responding to alterations in
neuronal health (Prokop et al. 2013; Prinz and Priller 2014). In vitro, soluble Aβ
oligomers bind to various microglial receptors, which results in the production of
inflammatory cytokines. Up regulation of inflammatory cytokines such as IL-1, IL6, and tumour necrosis factor (TNF) has been observed in mouse models of AD
(Benzing et al. 1999; Abbas et al. 2002). Another function of microglia is the
clearing of Aβ through receptor-mediated phagocytosis (Prokop et al. 2013;
Heppner et al. 2015). Recent findings demonstrate that activating microglia in
APP/PS1 mice by IL-33 injections enhances Aβ phagocytic activity and
decreased central proinflammatory gene expression (Fu et al. 2016). In the same
study, cognitive impairments in APP/PS1 mice were reversed, suggesting a
critical role for microglial for Aβ-related pathology and cognitive impairments in
AD (Fu et al. 2016). Alternatively, Aβ can impair microglial function as APP/PS1
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AD mice display marked reductions in levels of Aβ-binding scavenger receptor
and the Aβ-degrading enzyme (Hickman et al. 2008). Furthermore, abnormalities
in microglial function have been shown to significantly attenuate levels of trophic
factors, including brain-derived neurotrophic factor (BDNF) (Parkhurst et al.
2013). Indeed, BDNF produced by microglia plays a role in motor learning, and
increases neuronal tropomyosin-related kinase receptor B phosphorylation, a key
modulator of synaptic plasticity (Parkhurst et al. 2013). Whether this increase in
microglial activation due to long-term cholinergic loss plays a role in deteriorating
cognition and in triggering age-related pathology warrants further investigation.

Cholinergic neurons in the basal forebrain appear to be selectively vulnerable to
systemic administration of endotoxins, such as LPS (Wenk and Willard 1998;
Willard et al. 2000). Systemic injections of LPS in mice with selective lesions of
basal forebrain cholinergic neurons significantly impaired working memory in
lesioned mice, without having an effect in non-lesioned mice (Field et al. 2012).
These findings suggest that decreased basal forebrain cholinergic tone
accentuates inflammatory responses to LPS and impair cognitive performance.
Further evidence suggests that donepezil inhibits lipopolysaccharide-mediated
increase in proinflammatory cytokines in the rat brain (Tyagi et al. 2010).
Administration of methyllycaconitine, a α7 nAChR antagonist blocked the
protective

effect,

suggesting

that

the

protective

role

of

donepezil

in

neuroinflammation is at least in part mediated via α7 nAChRs (Tyagi et al. 2010).
Moreover, there is evidence-linking neuroinflammation to nicotinic receptor
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activity as aged mice lacking the β2 subunit exhibit high levels of astro- and
micro-gliosis

(Zoli

et

al.

1999).

Hence,

future

experiments

assessing

neuroinflammatory cytokines in α7 nAChR-knockout mice, or pharmacological
use of α7 nAChR-specific agonists in VAChT-deficient mice would further our
understanding on how central cholinergic activity modulates inflammatory
responses.

We have demonstrated that we are able to successfully express hM3Dq
DREADDs specifically in microglia in mice. These early but important findings
suggest that we could utilize DREADD technology to specifically activate
microglia in the brain without the peripheral inflammatory responses effects
observed when using LPS injections. Future experiments should address
whether activating microglia-using CNO elicits response through up regulation of
anti-inflammatory cytokines. The innate immune response has been suggested
to play a critical role in AD pathology (Heppner et al. 2015). Given that we could
successfully express hM3Dq in microglia, it would be critical to address the
inflammatory response of Gq activation of these cells using CNO. Given that M3
mAChRs are upregulated in adult cortical microglia treated with interferongamma (Pannell et al. 2016), it seems of importance to investigate how activation
of Gq signalling in microglia influences inflammatory responses. GPCR signalling
has been implicated in regulating the expression of inflammatory genes,
including nuclear factor-κB (NF-κB), which regulates a number of inflammatory
cytokines (Ye 2001). Indeed, it has been demonstrated that NF-κB, which is
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expressed in microglia (Qin et al. 2005), plays a critical role in hippocampal
synaptic plasticity (Albensi and Mattson 2000; Meffert et al. 2003). Hence, it is
tempting to hypothesize that activation of Gq signalling in microglia through CNO
induces an anti-inflammatory response or inhibits pro-inflammatory cytokine
release. Findings of these experiments will lay the groundwork for investigation of
the effects of central microglial activation on the innate immune system and the
consequences that may have on neuropathology and cognition in mouse models
of AD.

4.3 Cholinergic

deficiency

and

adult

hippocampal

neurogenesis

Adult hippocampal neurogenesis has been associated with a number of learning
and memory processes (Leuner et al. 2006; Aimone et al. 2009). An increase in
number and survival of newly born cells in the hippocampus has been reported
after exercise (van Praag et al. 1999), and hippocampal-dependent learning
tasks (Gould et al. 1999). Administration of cholinesterase inhibitors, such as
galantamine, for 14 days significantly increase the number of BrdU-positive cells
in the dentate gyrus in the adult mouse brain (Jin et al. 2006). Moreover,
selective lesions in rats using 192 IgG-saporin significantly increased apoptosis
in the dentate gyrus (Cooper-Kuhn et al. 2004). Separate basal forebrain 192
IgG-saporin lesion experiments in rats, however, suggest that cholinergic
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signalling is critical for cell proliferation rather than long-term survival (Mohapel et
al. 2005). Thus, the exact role of cholinergic signalling in regulating cell
proliferation and survival in the hippocampus is unclear. Our data support a role
for cholinergic signalling in proliferation and differentiation of newborn cell
survival in the hippocampus.

Previous work has demonstrated the involvement of cholinergic signalling in
regulating adult hippocampal neurogenesis via mAChRs. For example, increase
in cell proliferation in the SGZ post-administration of galantamine is blocked by
scopolamine (muscarinic receptor antagonist) (Kita et al. 2014). Interestingly, this
effect was also observed after administration of telenzepine, an M1 mAChR
subtype antagonist, but not by mecamylamine (nAChR antagonist) nor the

7

nAChR specific antagonist methyllcaconitine (Kita et al. 2014). Similarly, the
authors showed an enhancement in cell proliferation in the dentate gyrus after
administration of oxotremorine, a muscarinic agonist (Kita et al. 2014). Indeed,
data from separate studies demonstrate that M1 and M4 mAChRs are expressed
on newly formed cells in the dentate gyrus 24 hours-post BrdU injections
(Mohapel et al. 2005). Interestingly, impairments in cell proliferation induced by
forebrain 192 IgG-saporin lesions in rats were reversed by chronic activation of
M1 mAChRs (Van Kampen and Eckman 2010). These findings were
accompanied by the finding of an increase in the number of neurons expressing
a neuronal marker, suggestive of enhanced number of newly generated cells
(Van Kampen and Eckman 2010). Together, these findings support the notion
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that the increase in cell proliferation reported after administration of
cholinesterase inhibitors is mediated, at least in part, by activating M1 mAChRs.
Hence, M1 MAChRs may serve as a potential target to reverse the impairments
in adult neurogenesis in VAChT mutant mice.

These pro-proliferative effects of mAChRs may involve the activation of
downstream signalling pathways, including mitogen-activated protein kinases
(MAPK) and PI-3 kinases. Indeed, muscarinic receptors expressed by neural
precursor cells enhance DNA synthesis in neural precursor cells via the Ras
pathway, which leads to phosphorylation of MAPK (Crespo et al. 1994; Ma et al.
2000). Similarly, in vitro experiments demonstrate that carbachol (non-selective
cholinergic agonist)-mediated increase in [3H]thymidine levels was substantially
attenuated when a PI-3K inhibitor was used, suggesting a critical role for PI-3K
signalling in neural precursor cell proliferation (Li et al. 2001). Relevant targets of
PI-3K include GSK3, which phosphorylates β-catenin, a critical component of the
canonical Wnt/β-catenin pathway (Nelson and Nusse 2004). Activation of this
pathway promotes neural precursor differentiation, while inactivation impairs
differentiation (Lie et al. 2005). Further evidence shows that cholinergic signalling
via

7 nAChRs may also plays a critical role in cell survival, but not cell

proliferation (Kita et al. 2014). Activation of the

7 nAChR using PHA-543613

enhanced cell survival in the dentate gyrus of adult mice, an effect that was not
seen with donepezil injections (Kita et al. 2014). These observations indicate that
cholinergic

neurotransmission,

through

distinct

muscarinic

and

nicotinic

142
receptors, could modulate cell proliferation and survival in the adult
hippocampus. Our data further support a role for ACh in hippocampal
neurogenesis, whether the adult hippocampal neurogenesis deficits reported in
VAChT-deficient mice are mediated by M1 MAChRs and/or

7 nAChRs remains

to be established.

Cholinergic signalling could regulate neurogenesis by affecting the levels of
growth factors, including brain-derived neurotrophic factor (BDNF), which is
critical for adult hippocampal neurogenesis in mice (Lee et al. 2002). For
example, administration of galantamine in mice enhances phosphorylation of
BDNF and trkA (a nerve growth factor receptor) in the hippocampus (Autio et al.
2011). Moreover, rats with 192 IgG-saporin lesions displayed a decrease in
proBDNF protein expression, which is the precursor of BDNF (Gil-Bea et al.
2011). Interestingly, galantamine injections were sufficient to rescue the
decrease in proBDNF protein expression, suggesting that cholinergic tone may
regulate neurotrophic factor signalling in the adult brain (Gil-Bea et al. 2011). In
addition to BDNF, the insulin-like growth factor 2 (IGF2) is highly expressed in
neural precursor cells, and through AKT signalling, regulates neural cell
proliferation in the hippocampus of mice (Bracko et al. 2012). Indeed,
experiments demonstrate that galantamine selectively enhances IGF2 protein
levels in the hippocampus, but not the cortex, in adult mice (Kita et al. 2013).
Interestingly administration of methyllycaconitine, which is an

7 nAChR

antagonist, blocks the increase in IGF2 protein expression suggesting that
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enhancement of cholinergic tone using galantamine enhances IGF2 expression
via

7 nAChR signalling in the hippocampus (Kita et al. 2013). Our findings

indicate that deficient cholinergic signalling has profound consequences on
hippocampal neurogenesis. Because of the involvement of cholinergic tone in
regulating neurotrophic factors, further experiments are warranted to address if
the deficits in hippocampal neurogenesis in forebrain VAChT-deficient mice
occur via the down regulation of neurotrophic factors in the hippocampus.

Our findings demonstrate that impairments in neurogenesis have a functional
consequence for pattern separation as assessed in the two-choice discrimination
touchscreen task. A number of studies have demonstrated the role of the dentate
gyrus in pattern separation (Gilbert et al. 2001; Sahay et al. 2011). The synaptic
transmission pathway thought to mediate pattern completion is via the entorhinal
cortex to the dentate gyrus, and ultimately to the CA3 (Treves and Rolls 1994;
Leutgeb et al. 2007; Bakker et al. 2008). Indeed, lesions to the dentate gyrus
impair pattern separation in rats (Gilbert et al. 2001; Kesner et al. 2004).
Furthermore, electrophysiological recordings in rats have provided insight
regarding the specific role of the dentate gyrus in pattern separation. Leutgeb et
al. recorded from active hippocampal cell assemblies in rats that were in either a
square box with flexible walls that gradually transformed into a circular box (i.e.
small pattern separation), or in two or three different enclosures in a separate
room setting (i.e. large separation) (Leutgeb et al. 2007). Within an active cell
assembly, the dentate gyrus and the CA3 regions of the hippocampus were
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highly active when the environment was slightly modified (small separation)
(Leutgeb et al. 2007). Interestingly however, when a large separation was
presented (i.e. change of rooms), only the CA3 but not the dentate gyrus,
displayed higher activity within an active cell assembly (Leutgeb et al. 2007),
suggesting a critical role of the dentate gyrus in pattern separation. Conversely,
ablation of adult hippocampal neurogenesis in the SGZ in mice using low-dose xirradiation impaired pattern separation in a touchscreen based-task (Clelland et
al. 2009). Interestingly, mice with ablated neurogenesis were only impaired when
stimuli were presented with a small separation, but not when a high separation
was presented, suggesting that NSCs in the dentate gyrus may be required for
pattern separation (Clelland et al. 2009). Further experiments demonstrate that
BDNF expression in the dentate gyrus is required for pattern separation
(Bekinschtein et al. 2014). It is important to note that VAChT-deficient mice
exhibit an array of cognitive abnormalities even at a young age, and that these
abnormalities may interfere with performance in pattern separation. However,
because VAChT-deficient mice were able to perform comparably to controls on
the large separation, it is possible that the neurogenesis deficit may underlie their
poor performance in the small separation.

The involvement of cholinergic signalling in pattern separation is not fully
understood, however, it appears that cholinergic neurotransmission is required
for maintenance of the dentate gyrus-CA3 connections (Barnes et al. 2000).
Additionally, immature hippocampal granular cells express M1 mAChRs and play
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a critical role in enhancing neural precursor cell proliferation (Itou et al. 2011).
Moreover, septal cholinergic tone has been implicated in modulating the
excitability of neural precursor cells by enhancing their firing properties (Vogt and
Regehr 2001). Indeed, experiments show that the basal firing rate of cells in the
dentate gyrus is low, and is highly enhanced by muscarine (Vogt and Regehr
2001). This cholinergic-mediated enhancement of neuronal firing rates would
ultimately facilitate information output to the CA3. Moreover, there has been
evidence suggesting that NMDA plasticity is required for pattern separation. Mice
with genetic deletion of the NR1 subunit of the NMDAR specifically in the dentate
gyrus exhibited impairments in discriminating two similar contexts in contextual
fear discrimination learning (McHugh et al. 2007). Thus, it would be critical to
elucidate the type of synaptic plasticity that may underlie these cholinergicmediated impairments in pattern separation observed in VAChT-deficient mice.

4.4 Central cholinergic control of locomotor activity

Our findings demonstrate that forebrain-specific VAChT knockout mice are
significantly hyperactive compared to controls in a novel environment, and in a
24-hour metabolic cage. These findings supported our previous observations
from our laboratory in a separate mouse line of VAChT forebrain cholinergic
deficiency (Martyn et al. 2012). Importantly, our data demonstrating that
elimination of ChAT in the striatum has no effect on locomotor activity are in line
with our previous findings (Guzman et al. 2011), suggesting cortical/hippocampal
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cholinergic regulation of locomotion. Furthermore, the hyperactivity observed in
VAChT mutant mice support previous findings that show exploration in a novel
environment results in ACh release in the cortex and hippocampus (Acquas et al.
1996). Interestingly, however, mice with threefold increase in ACh release in the
hippocampus present normal locomotor activity (Kolisnyk et al. 2013). In an
attempt to dissect the region involved in mediating the cholinergic-induced
hyperactivity, we injected an adeno-associated virus AAV8-Cre or control virus
AAV8-GFP into the medial septum/vertical limb of the diagonal band of
VAChTflox/flox animals to selectively decrease VAChT levels in the hippocampus
(not shown; Gustavo Parfitt). Data from this study indicated that selectively
decreasing VAChT in the hippocampus showed a modest effect towards
increasing locomotor activity, but no statistical significance was reached,
compared to AAV8-GFP injected controls (not shown; Gustavo Parfitt). Hence,
our data in the VAChTNkx2.1-Cre-flox/flox mouse model support the notion that
perhaps both NBM and septohippocampal cholinergic signalling are required to
induce hyperactive behaviours.

Cholinergic dysfunction has been associated with many of the cognitive
symptoms observed in schizophrenia (Sarter and Bruno 1999; Heimer 2000).
Moreover, cholinergic deficiency has been implicated in modulating the activity of
dopaminergic neurons (Cachope et al. 2012; Threlfell et al. 2012), which in turn
elicits hyperactive behaviours (Mattsson et al. 2002; Patel et al. 2012). Studies in
rats with selective ablation of basal forebrain cholinergic neurons using 192-IgG-
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saporin demonstrate that they also present hyperactivity (Mattsson et al. 2002).
In contrast, others have reported that using 192-IgG-saporin showed a very
modest or no effect on locomotor activity (Leanza et al. 1995; Walsh et al. 1995).
The inconsistency in the reports using immunotoxins to study the role of the
basal forebrain cholinergic system could be due to the variability in size and
location of the lesions; as well as differences in the degree of ablation. Hence,
using immunolesion approaches to dissect the involvement of basal forebrain
cholinergic tone may not be ideal. Hyperactive behaviour has also been
associated with increased central glutamatergic activity. Indeed, mice with 192IgG-saporin lesions to the basal forebrain show increased NMDAR activity in the
CA1 region of the hippocampus (Jouvenceau et al. 1997). Moreover, stimulation
of NMDARs in the hippocampus enhances locomotor activity via dopamine
receptor 1 (D1) and D2 receptor activity in the nucleus accumbens (Wu and
Brudzynski 1995; Bardgett and Henry 1999). Indeed, rats with 192-IgG-saporin
lesions to the basal forebrain show enhanced sensitivity to amphetamine
(Mattsson et al. 2002). Because amphetamine acts by inhibition of dopamine
uptake (Heikkila et al. 1975), the increased sensitivity to amphetamine in mice
with ablation of cholinergic neurons could be due to alterations in dopaminergic
levels. In line with these studies, mice with genetic targeting of forebrain ChAT
neurons show increased phasic-to-tonic dopamine signalling from the striatum,
and display hyperactive behaviour (Patel et al. 2012). Whether the effect we
observed in our mice involves enhanced cholinergic-mediated enhancement of
dopaminergic activity remains to be established.
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Evidence from several studies highlighted the involvement of central muscarinic
receptors in regulating locomotion. For instance, mice lacking the M1 mAChR
subtype exhibit hyperactive behaviour with no changes in anxiety-related
behaviours, compared to controls (Miyakawa et al. 2001). Intriguingly, mice
lacking the M2 and M3 mAChR subtypes present normal locomotor activity
(Gomeza et al. 1999; Yamada et al. 2001), while mice lacking M4 mAChR
subtype exhibit only mild hyperactivity compared to the M1 knockout mice
(Gomeza et al. 1999; Miyakawa et al. 2001). Hence, future studies involving the
hyperactive behaviour observed in our mice should involve investigating whether
this phenotype is mediated by M1 mAChR activity. While the involvement of
cholinergic signalling in locomotion has been examined, the contribution of
cholinergic input from distinct brain regions remains unclear. For example,
optogenetic silencing of cholinergic neurons in the caudate putamen or the
nucleus accumbens has no effect on locomotor activity (Witten et al. 2010;
English et al. 2012). Conversely, previous studies showed that depletion of
striatal cholinergic cells using immunotoxin-mediated cell targeting caused
hyperactive behaviour in mice (Kaneko et al. 2000). Given that striatal cholinergic
interneurons co-release glutamate (Higley et al. 2011), the lack of effect on motor
activity observed in their studies could be attributed to spared glutamatergic
neurotransmission, as VGLUT3-knockout mice are hyperactive (Gras et al.
2008). Hence, it is of importance to investigate how cholinergic signalling
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influences other neurotransmitters involved in controlling locomotor activity,
including glutamate and dopamine.

4.5 Role of hippocampal cholinergic tone in paired
associates learning

In this thesis we uncovered a role for forebrain cholinergic signalling in the
acquisition of paired associates learning (PAL). We tested our mice using the
operant touchscreen technology (Bussey et al. 2001; Talpos et al. 2009; Bartko
et al. 2011), which is analogous to tests used in humans. Previous work using a
pairwise discrimination task touchscreen system has demonstrated that inhibition
of forebrain cholinergic signalling has no effect on acquisition of the task, but
impairs reversal learning when contingencies are switched (Kolisnyk et al. 2013).
Interestingly, overexpression of VAChT in mice impairs attention in a 5CSRTT
touchscreen task (Kolisnyk et al. 2013). These previous findings suggest a
critical role of cholinergic signalling in executive functions. However, the
involvement of hippocampal cholinergic tone in the acquisition of PAL is still
under debate. Systemic administration of donepezil after acquisition of PAL
significantly improved PAL performance in mice, an effect that was attenuated
with administration of muscarinic antagonists (Bartko et al. 2011). Similar results
have been observed in monkeys as mecamylamine (nicotinic antagonist) and
scopolamine (muscarinic antagonist) induced deficits in PAL performance (Taffe
et al. 2002; Katner et al. 2004). These results suggest that cholinergic signalling
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might be relevant for PAL. Also, rats previously trained in PAL that received
injections into the dorsal hippocampus of either scopolamine or mecamylamine
and were re-tested did not show deficits in performance (Talpos et al. 2009),
suggesting that hippocampal cholinergic signalling might not modulate recall in
this task.

Our data demonstrate that selective inhibition of cholinergic signalling in the
forebrain in mice leads to disruption of synaptic plasticity and specific cognitive
impairments. In particular, we show that forebrain cholinergic neurotransmission
is required for acquisition of the PAL task. The PAL task has been clinically used
as a potential cognitive marker of decline in psychosis (Wood et al. 2002). In
patients with schizophrenia, impairments were seen in the PAL task, which
correlated with negative symptoms (Barnett et al. 2005). Moreover, the PAL task
has also been considered a sensitive task for predicting cognitive decline in AD
(Swainson et al. 2001; Blackwell et al. 2004). Our results indicate that disruption
in forebrain cholinergic tone disturbs PAL learning. Importantly, these deficits
occurred in the absence of alterations in latency to touch the screen or to collect
the reward, indicating that motivation was not a factor in the poorer performance
of mice with deficient cholinergic tone. Interestingly, mice deficient for the M1
receptor were not impaired in the PAL task (Bartko et al. 2011).

PAL acquisition has been demonstrated to be associated with hippocampal
function in humans and rats (Talpos et al. 2009; de Rover et al. 2011). For
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example, inactivation of the rat hippocampus using lidocaine (non-selective Na+
channel blocker) significantly impairs performance post-acquisition of the PAL
task, suggesting that the hippocampus is required for performance in this task
(Talpos et al. 2009). In addition, human fMRI studies have shown bilateral BOLD
activation of the hippocampus during the encoding phase of the PAL task (de
Rover et al. 2011). Interestingly, subjects with memory deficits showed
decreased hippocampal activation with increased memory demand, whereas
healthy controls showed the opposite (de Rover et al. 2011). Moreover, PAL
performance correlates with hippocampal volume loss in schizophrenia and mild
cognitive impairment (MCI) (Keri et al. 2012). Intriguingly, recent reports indicate
that mice with hippocampal lesions are still able to acquire the PAL task
(Delotterie et al. 2015; Kim et al. 2015). One possible explanation (Kim et al.
2015) regarding these findings is that with a functional hippocampus the task is
acquired in a hippocampal-dependent manner, but with a dysfunctional
hippocampus, the task can be learnt using an alternative hippocampalindependent strategy. For example, mice with hippocampal lesions could have
used the dorsal striatum to acquire the task (Delotterie et al. 2015). Indeed, the
development of such behavioural plasticity has been shown in rats with unilateral
hippocampal lesions (Zou et al. 1999). To specifically address the contribution of
hippocampal cholinergic tone to PAL performance, we injected VAChTflox/flox mice
with AAV8-Cre or AAV8-GFP virus injected to the medial septum and vertical
limb of the diagonal band and tested their performance on the PAL task. We
determined that hippocampal VAChT levels positively correlated to PAL
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performance (Al-Onaizi et al. 2016). These data suggest that the hippocampal
cholinergic tone may facilitate acquisition of the PAL task. However, it is unlikely
that only one brain region is involved in such a complex task. Taken together, our
findings suggest that correlating levels of VAChT detected with PET ligands
(Efange 2000) to performance in the PAL test (Harel et al. 2013) might provide a
potential biomarker of remaining cholinergic function and cognitive reserve.

4.6 Cholinergic control of spatial navigation

We showed that acquisition of the spatial version of the MWM and recall of
platform location was mildly affected in VAChTNkx2.1-Cre-flox/flox mice. Interestingly,
impairments in the spatial version of the MWM have been observed in rats with
combined lesions of MS/VDB and NBM cholinergic neurons produced by
immunotoxin 192 IgG-saporin (Pizzo et al. 2002), while rats with immunotoxin
lesions restricted to MS/VDB did not show any impairment (Berger-Sweeney et
al. 1994; Baxter and Gallagher 1996; Pizzo et al. 2002; Frick et al. 2004).
Similarly, data from AAV8-Cre injected mice did not show any deficit in this
behavioural task (Al-Onaizi et al. 2016). Also, rats with 192 IgG-saporin lesions
restricted to NBM did not show behavioural impairments in the MWM (Pizzo et al.
2002). These data suggest that forebrain cholinergic signalling is necessary for
reference spatial learning and memory assessed using the MWM, however it
seems that both the cortical and hippocampal cholinergic projections need to be
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compromised in order to produce a severe spatial deficit. Thus, providing that
cortical cholinergic projections are intact, hippocampal cholinergic activity is not
absolutely required for this behavioural task. It remains to be established whether
GABA or glutamate, which could potentially be co-released with ACh (Guzman et
al. 2011; Saunders et al. 2015) contribute to regulation of spatial memory by
cholinergic neurons.

In contrast to reference memory in the MWM, VAChTNkx2.1-Cre-flox/flox mice
presented extensive deficits in the MWM reversal-learning task, suggesting a
prominent role for forebrain cholinergic signalling in reversal learning. Cognitive
flexibility is an important domain for survival. It refers to the ability to adapt goaldirected behaviour in response to changing environmental conditions. Deficits in
performance in tasks testing cognitive flexibility have been reported in early AD
(Traykov et al. 2007; Petrova et al. 2010). Our findings are in line with another
mouse line from our laboratory with selective deletion of forebrain-VAChT, which
displayed impairments in the reversal protocol of the MWM, while showing no
impairments in the acquisition (Martyn et al. 2012). Moreover, mice with
forebrain-specific VAChT deletion displayed deficits in reversal learning in the
touchscreen visual discrimination task (Kolisnyk et al. 2013).

In an attempt to dissect the contribution of hippocampal cholinergic tone to
reversal learning performance, we assessed mice with selectively decreased
VAChT expression in the medial septum (AAV8-Cre) in the MWM reversal-

154
learning task. These mice presented impairments in the MWM reversal-learning
task, suggesting a prominent role for septohippocampal cholinergic signalling in
reversal learning (Al-Onaizi et al. 2016). To account for compromised striatal
cholinergic signalling in VAChTNkx2.1-Cre-flox/flox mice for the performance in the
MWM, we also tested a mouse line with selective deletion of VAChT in striatal
neurons (VAChTD2-Cre-flox/flox), but spared hippocampal VAChT (Guzman et al.
2011). Interestingly, VAChTD2-Cre-flox/flox mice did not differ from controls
(VAChTflox/flox) in both acquisition and reversal versions on the MWM (Al-Onaizi et
al. 2016). Together with other findings from our laboratory, our data suggest that
deficits seen in reversal learning in VAChTNkx2.1-Cre-flox/flox mice are not likely due to
impaired striatal cholinergic transmission, but rather due to deficient hippocampal
cholinergic tone. Nonetheless, it remains possible that NBM-cortical cholinergic
inputs play an important role in modulating cognitive flexibility.

In terms of cognitive flexibility, the contribution of cholinergic signalling from the
NBM still remains unclear. For example, NMDA-induced excitotoxic lesions of the
NBM in marmosets, which decreased expression of acetylcholinesterase in the
prefrontal cortex to over 70%, had a mild effect on acquisition but produced
impairments in reversal learning on a visual discrimination task, suggesting a
critical role of NBM in behavioural flexibility (Roberts et al. 1990). Conversely,
ME20.4 IgG-saporin lesions to the NBM in marmosets showed no impairments in
reversal learning in a simple visual discrimination task (Fine et al. 1997).
Impairments, however, were observed after administration of scopolamine (Fine
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et al. 1997), suggesting muscarinic receptor involvement in cognitive flexibility. In
rats, infusion of non-selective quisqualic acid to lesion the NBM led to
impairments in reversal learning in an olfactory discrimination task (Bailey and
Thomas 2001). Similarly, infusions of 192 IgG-saporin into the NBM in rats
selectively impaired serial reversal learning in an operant chamber, while
performance on the first reversal was preserved (Cabrera et al. 2006). On the
other hand, 192 IgG-saporin lesions to the NBM in rats had no effect on
performance in reversal learning in an olfactory discrimination task (Bailey et al.
2003). Although IgG-saporin is selective in targeting cholinergic neurons, the
differences in findings regarding cognitive flexibility would suggest that reversal
learning could be dependent on a population of non-cholinergic cells located in
the NBM (Tait and Brown 2008), or a combination of both (Dunnett et al. 1987;
Bailey et al. 2003). From our findings (Al-Onaizi et al. 2016), it appears that input
to the hippocampus regulates cognitive flexibility; however, we cannot exclude
the possible involvement of NBM-cortical signalling in these tasks. Further
experiments are needed to determine the role of NBM-cortical cholinergic
signalling in cognitive flexibility.

The use of cholinergic antagonists has been shown to alter cognitive flexibility.
For example, systemic administration of scopolamine, a muscarinic receptor
antagonist, impaired set shifting and reversal learning in rats while having no
effect on discrimination performance (Chen et al. 2004). Similar findings have
been reported using systemic injections of scopolamine in rats, where a dose 0.5
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mg/kg was sufficient to significantly impair rats’ reversal performance, while
visual discrimination remained similar to controls (Soffie and Lamberty 1987). In
addition, systemic injections of CDD-0102A, a selective M1 muscarinic agonist,
had a significant effect on inhibition of a previously relevant strategy and acquire
a new strategy in a strategy-shifting task in rats (Ragozzino et al. 2012).
Administration of this drug however had no effect on acquisition of a place or
visual cue discrimination (Ragozzino et al. 2012), suggesting that central
muscarinic receptor activity is critical in mediating reversal learning. Nonetheless,
M1 knockout mice showed normal reversal learning in the visual discrimination
task (Bartko et al. 2011) suggesting that other muscarinic receptors and/or
nicotinic receptors are involved in facilitating reversal learning. In line with our
results, these findings suggest that cholinergic tone plays a critical role in
cognitive flexibility, however the involvement of the cholinergic receptor subtypes
needs to be elucidated.

We provided evidence that cholinergic dysfunction impairs hippocampal LTP.
Synaptic plasticity is considered the molecular correlate of learning and memory
(Morris et al. 1986; Morris 1989; Buzsaki 2005). Our findings are in line with
previous observations from our laboratory, which demonstrated that ex vivo LTP
is impaired in mice with 70% decrease in VAChT levels, and in mice with
forebrain deletion of VAChT (Martyn et al. 2012). These studies however, were
performed in hippocampal slices ex vivo, hence cholinergic terminals were not
activated (Martyn et al. 2012). Our current findings provide further evidence that
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Schaffer collateral-CA1 synapses-mediated LTP requires intact cholinergic input.
Previous observations have highlighted a critical role of cholinergic tone to
hippocampal synaptic plasticity. For example, in vitro studies using cholinergic
agonists significantly enhance LTP (Blitzer et al. 1990). Moreover, studies in
anaesthetized rats show that tetanic stimulation of the medial septum induces
hippocampal LTP, an effect that was blocked by atropine (muscarinic antagonist)
(Markevich et al. 1997). Also, experiments in wild-type walking rats reveal an
increase in LTP induction in the hippocampus compared with immobility, an
effect that was abolished in mice with 192 IgG-saporin immunotoxin lesions of
the medial septum (Leung et al. 2003). In line with our findings, these data
suggest that septohippocampal cholinergic tone plays a critical role in modulating
hippocampal plasticity.

The most common form of LTP underlying hippocampal synaptic plasticity in
spatial memory depends on the activation of NMDARs (Collingridge et al. 1983;
Martin et al. 2000; MacDonald et al. 2006). Intracerebroventricular administration
of a NMDAR antagonist (AP5) significantly impaired performance of rats during
reversal testing in the MWM (Morris et al. 1990). Moreover, genetically modified
mice with deletion of the GluN2B subunit of NMDARs in the CA1 region of the
hippocampus exhibited impairments in reversal learning (von Engelhardt et al.
2008). Similarly, mice with corticohippocampal deletion of GluN2B present
deficits in hippocampal synaptic plasticity, highlighted by abolished long-term
depression (LTD), a partial deficiency of LTP, and memory impairments (Brigman
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et al. 2010). Experiments have demonstrated that the induction of LTP and STD
in Schaffer collateral-CA1 synapses is dependent on α7 nAChR activation, and is
timing-dependent (Gu and Yakel 2011). In particular, ex vivo studies show that in
hippocampal slices of α7 nAChR-knockout mice, both presynaptic and
postsynaptic α7 nAChR activation is required for LTP and STD (Gu et al. 2012).
This suggests that cholinergic neurotransmission via both pre-and post-synaptic
α7 nAChRs regulates hippocampal synaptic plasticity. α7 nAChR-mediated
synaptic plasticity involves α7 nAChR activation of NMDARs. Indeed, induction of
α7 nAChR-mediated LTP requires the activation and prolongation of calcium
transients in NMDARs in CA1 pyramidal neurons (Gu and Yakel 2011). The
impairments observed in VAChTNkx2.1-Cre-flox/flox mice in LTP suggest that
cholinergic signalling may regulate NMDAR-mediated synaptic plasticity.

4.7 Future Studies

Our findings regarding neurogenesis impairments in VAChT-deficient mice
suggest that cholinergic tone regulates proliferation and cell survival of neural
precursor cells in the hippocampus. Because neurotrophic factors play a critical
role in adult hippocampal neurogenesis (Bekinschtein et al. 2014) future studies
should involve investigating the levels of distinct neurotrophic factors such as
BDNF, which is involved in enhancing neurogenesis by increasing dendritic spine
reorganization in the rat hippocampus (Pencea et al. 2001; Scharfman et al.
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2005; Kramar et al. 2012). Furthermore, it would be of interest to dissect the
involvement of muscarinic receptor activity in regulating neurogenesis. Because
M1 and M4 mAChRs are expressed early in neuroblasts (Mohapel et al. 2005),
potential experiments to rescue neurogenesis deficits should involve using M1 or
M4 mAChR agonists in VAChT-deficient mice. Importantly, it would be critical to
investigate if mAChR agonists or cholinesterase inhibitors would improve pattern
separation in these cholinergic-deficient mice. These experiments would further
our understanding regarding the specific cholinergic receptors involved in the
regulation of adult hippocampal neurogenesis.

Alternatively, it would be

intriguing to investigate whether exercise, which enhances adult hippocampal
neurogenesis, would have any significant impact on rescuing the neurogenesis
deficits in VAChT-deficient mice.

We demonstrated that forebrain cholinergic signalling is required for acquisition
in the paired associates learning touchscreen task in Chapter 3.4.1. These data
suggest that forebrain cholinergic tone is required for PAL, a task which MCI
patients are impaired in (Keri et al. 2012). Moreover, experiments from our
laboratory demonstrate that VAChT levels correlate with performance in PAL (AlOnaizi et al. 2016). Because the use of cholinesterase inhibitors has shown
promising effects on reducing the annual rate of hippocampal atrophy in
prodromal AD (Dubois et al. 2015), experiments involving administration of
donepezil in mice with selective decrease of VAChT (AAV8-Cre mice) would be
important. These experiments would address if donepezil has a positive effect in
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rescuing the cognitive impairments observed in VAChT deficient mice. Because
the mouse version of the PAL touchscreen task is analogous to the human
version, results from these experiments regarding the effects of donepezil of PAL
performance will be highly translatable to humans.

We demonstrate in this thesis that forebrain cholinergic signalling is required for
cognitive flexibility. Moreover, viral injection experiments from our laboratory
showed a critical role for septohippocampal cholinergic tone in behavioural
flexibility (Al-Onaizi et al. 2016). However, the exact involvement of the NBMcortical signalling to these behaviours remains unclear. Viral injections to
decrease VAChT levels in the NBM would aid elucidate the contribution of NBM
cholinergic signalling to behavioural flexibility. NBM AAV8-Cre injected mice
would not only be useful for assessment of behavioural flexibility, but could also
help in determining the role of NBM cholinergic signalling in PAL, and locomotor
activity.

4.8 Significance of Research and Conclusions

Neurodegeneration of basal forebrain cholinergic neurons constitute a major
hallmark in the AD. In addition, long-term use of drugs with anti-cholinergic side
effects significantly increases an individual’s risk of developing AD (Gray et al.
2015; Risacher et al. 2016). Although the cholinergic system remains the main
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target in treating AD symptoms, the efficacy of cholinesterase inhibitors has been
questioned (Kaduszkiewicz et al. 2005; Takeda et al. 2006). Therefore, new
potential targets need to be established as well as potential biomarkers to aid the
diagnosis and track disease progression. The data presented in this thesis show
how alterations in this system influences distinct cognitive behaviours, including
the PAL task, and adult hippocampal neurogenesis. As PAL performance may be
dependent on cholinergic integrity, the PAL task could be used to identify
individuals with cognitive dysfunction linked to cholinergic abnormalities. In this
thesis we also provided evidence that our mouse model of cholinergic
dysfunction mimics an array of behavioural and molecular abnormalities common
to AD. Importantly, our data sheds light on how long-lasting cholinergic deficiency
may relate to AD-like pathology.

Imaging studies involving volumetric measurement of basal forebrain cholinergic
nuclei in humans reveal a drastic decrease in the volume of basal forebrain
cholinergic neurons in AD and MCI patients, in comparison to healthy elderly
controls (Grothe et al. 2010; Grothe et al. 2012; Grothe et al. 2014; Teipel et al.
2014). Given that individuals with dementia may present long-term changes in
cholinergic tone, our mouse lines and approaches may be directly relevant to
understand molecular, cellular, circuitry and behavioural consequences of
cholinergic malfunction. The work presented in this thesis is relevant to
understand how cholinergic dysfunction or degenerative changes in cholinergic
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neurons contribute to cognitive alterations and neuropathology in several
neurodegenerative disorders, including AD.
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Abstract
Cholinergic dysfunction has been associated with cognitive abnormalities in a variety of neurodegenerative and
neuropsychiatric diseases. Here we tested how information processing is regulated by cholinergic tone in genetically modiﬁed
mice targeting the vesicular acetylcholine transporter (VAChT), a protein required for acetylcholine release. We measured longterm potentiation of Schaffer collateral-CA1 synapses in vivo and assessed information processing by using a mouse
touchscreen version of paired associates learning task (PAL). Acquisition of information in the mouse PAL task correlated to
levels of hippocampal VAChT, suggesting a critical role for cholinergic tone. Accordingly, synaptic plasticity in the hippocampus
in vivo was disturbed, but not completely abolished, by decreased hippocampal cholinergic signaling. Disrupted forebrain
cholinergic signaling also affected working memory, a result reproduced by selectively decreasing VAChT in the hippocampus.
In contrast, spatial memory was relatively preserved, whereas reversal spatial memory was sensitive to decreased hippocampal
cholinergic signaling. This work provides a reﬁned roadmap of how synaptically secreted acetylcholine inﬂuences distinct
behaviors and suggests that distinct forms of cognitive processing may be regulated in different ways by cholinergic activity.
Key words: Alzheimer’s disease, long-term potentiation, Morris water maze, paired associates learning, vesicular acetylcholine
transporter, working memory

Introduction
Basal forebrain cholinergic neurons provide input to the entire cortex and hippocampus. In particular, the hippocampus receives
most of its cholinergic innervation from neurons in the medial
septal nucleus (MS) and vertical limb of the diagonal band of
Broca (vdB), whereas the cerebral cortex and the amygdala receive
cholinergic inputs from neurons located in the nucleus basalis of
Meynert (NBM) (Mesulam et al. 1992; Kitt et al. 1994). Abnormalities
in forebrain cholinergic nuclei have been implicated in several

cognitive disorders (Bartus 2000; Mesulam 2004), including Alzheimer’s disease (AD ; Grothe, Schuster, et al. 2014; Teipel et al. 2014).
Moreover, cumulative use of drugs with anticholinergic activity is
associated with increased risk for dementia and AD (Gray et al.
2015). However, the relationship between cholinergic dysfunction
and maintenance of cognitive abilities in these diseases is not
fully understood, due to concomitant pathologies that may contribute to cognitive abnormalities (Mesulam 2013).
Cholinergic signaling is involved in the regulation of hippocampal synaptic transmission and plasticity (Ji et al. 2001;
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facilitating translational studies between species (Morton et al.
2006; Talpos et al. 2009, 2010; Romberg et al. 2011; Mar et al.
2013). The paired associates learning (PAL) test has been shown
to efﬁciently detect cognitive alterations that are consistently observed in AD (Swainson et al. 2001; Blackwell et al. 2004; de Rover
et al. 2011) and schizophrenia (Wood et al. 2002; Barnett et al.
2005). In dementia, PAL has been shown to differentiate between
mild cognitive impairment and AD (Blackwell et al. 2004). Here we
investigated cognitive performance in mice with deletion of
VAChT, a protein required for synaptic release of ACh, in either
forebrain cholinergic neurons or selectively in septohippocampal
cholinergic neurons. Our experiments reveal that dysfunction in
hippocampal cholinergic activity inﬂuences synaptic plasticity in
vivo and disturbs performance in PAL and working memory,
whereas spatial navigation seems relatively preserved.

Material and Methods
Animals
Generation of VAChTﬂox/ﬂox mice was previously described (Martins-Silva et al. 2011). VAChTﬂox/ﬂox mice (mixed C57BL/6J × 129/
SvEv background, backcrossed to C57BL/6J for 5 generations) were
crossed to VAChTNkx2.1-Cre-ﬂox/ﬂox mice so that offspring from this
mating provided control and test littermates. VAChTNkx2.1-Cre-ﬂox/
ﬂox
mice were generated by crossing VAChTﬂox/ﬂox with the
Nkx2.1-Cre mouse line (C57BL/6J-Tg(Nkx2-1-cre)2Sand/J), purchased from The Jackson Laboratory (JAX stock no. 008661).
This line has been previously used to eliminate ChAT from forebrain neurons (Patel et al. 2012). Unless otherwise stated, all control mice used for behavioral studies were VAChTﬂox/ﬂox
littermates. The reporter mouse line Nkx2.1(td-Tomato) was generated by crossing B6.Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J mice,
purchased from The Jackson Laboratory (JAX stock no. 007909)
with the Nkx2.1-Cre mouse line (JAX stock no. 008661).
Animals were housed in groups of 3 per cage without environmental enrichment in a temperature controlled room (12:12 light
to dark cycles), and food and water were provided ad libitum for
most experiments. Animals that underwent touchscreen testing
were housed in pairs; food restricted to no more than 85% of their
original weight, and they were maintained at the target weight
for the duration of behavioral testing. Male mice 3 months old
were used for behavioral studies. We followed the ARRIVE guidelines (Kilkenny et al. 2010); hence, mice were randomized for behavioral tests and the experimenter was blind to the genotype.
All procedures were performed in accordance with the Canadian
Council of Animal Care guidelines at the University of Western
Ontario with an approved animal protocol (2008–127).

Immunoﬂourescence Microscopy
Mice were anesthetized with ketamine (100 mg/kg) and xylazine
(25 mg/kg) in 0.9% sodium chloride, and then sacriﬁced by transcardial perfusion: phosphate-buffered saline (PBS, pH = 7.4) for
3 min and 4% paraformaldehyde for 5 min. Brains were harvested
and placed in 4% paraformaldehyde in 1× PBS at 4 °C for 4 h; they
were kept at 4 °C until sliced using a vibratome. Brain sections
(40 µm) were prepared and free-ﬂoating sections in 1× PBS
(1 per well in a 24-well plate) were permeabilized with 0.4% Triton
X-100 in 1× PBS for 1 h. Non-speciﬁc epitopes were blocked using
a solution of 1× PBS/0.4% Triton X-100 containing 0.1% glycine
(wt/vol), 0.1% lysine (wt/vol), 1% BSA (wt/vol), and 1% normal
donkey serum (wt/vol). The primary antibodies used were
anti-VAChT (catalog no. 139103; Synaptic Systems), anti-ChAT
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Leung et al. 2003; Seeger et al. 2004; Ge and Dani 2005; Gu and
Yakel 2011). Septal cholinergic activation, either by electrical
stimulation or by optogenetics, allows the expression of distinct
time-dependent forms of hippocampal plasticity (Gu and Yakel
2011). Pharmacological (Decker and Majchrzak 1992; Anagnostaras et al. 1999; Gale et al. 2001; Wallenstein and Vago 2001; Chudasama et al. 2004; Pichat et al. 2007; Timmermann et al. 2007;
Ragozzino et al. 2012) and genetic studies (Anagnostaras et al.
2003; Seeger et al. 2004; Poulin et al. 2010) have shown that
modulation of cholinergic receptors inﬂuence learning and
memory processes. Indeed, both nicotinic receptors (nAChRs)
and muscarinic receptors (mAChRs) have been linked with various forms of plasticity (Vidal and Changeux 1993; Gray et al. 1996;
Ji and Dani 2000; Seeger et al. 2004; Gautam et al. 2006; Giessel and
Sabatini 2010; Zheng et al. 2012). For example, M1 knockout mice
exhibit selective cognitive impairments in tasks requiring interactions between the hippocampus and cortex (Anagnostaras
et al. 2003), while M2 knockout mice display impairments in
working memory, cognitive ﬂexibility, and hippocampal plasticity (Seeger et al. 2004). Moreover, recent evidence shows that
activation of M1 mAChRs induces long-term potentiation (LTP),
suggesting that M1 mAChRs could play a role in regulating hippocampal plasticity (Dennis et al. 2015). Furthermore, the nAChR
β2-subunit knockout mice are impaired in learning the MWM,
suggesting that the β2-subunit may mediate effects of ACh on
learning and memory (Zoli et al. 1999). However, long-term
changes in cholinergic activity, as observed in a number of
neurodegenerative diseases, are more complex to model using
speciﬁc receptor knockouts, given the plethora of subtypes of
muscarinic and nicotinic receptors.
One widespread alternative to mimic cholinergic dysfunction
is the selective elimination of these neurons using toxins in rodents (Baxter and Bucci 2013; Prado et al. 2013). It is somewhat
controversial whether selective 192 IgG-saporin lesion of septohippocampal cholinergic neurons can lead to signiﬁcant impairments in hippocampal-dependent learning and memory tasks in
rodents, with some authors ﬁnding little effect (Berger-Sweeney
et al. 1994; Baxter and Gallagher 1996; Pizzo et al. 2002; Frick et al.
2004; Parent and Baxter 2004), whereas others ﬁnd a miriad of
deﬁcits (Walsh et al. 1996; Janis et al. 1998; Gil-Bea et al. 2011).
In addition, cholinergic neurons have been shown to contain
more than one class of neurotransmitter transporters and secrete 2 neurotransmitters (Gras et al. 2008; El Mestikawy et al.
2011; Guzman et al. 2011; Prado et al. 2013; Nelson et al. 2014;
Saunders et al. 2015). Therefore, it is difﬁcult to interpret results
with toxin lesions for speciﬁc contributions of neurotransmitters
in neurons that release 2 chemical messengers. Indeed, recent
work has shown that some basal forebrain cholinergic neurons
can also secrete GABA which acts as a neurotransmitter in the
cortex (Saunders et al. 2015).
Genetic targeting of either the vesicular acetylcholine transporter (VAChT; Guzman et al. 2011; Martyn et al. 2012) or choline
acetyltransferase (ChAT; Patel et al. 2012) using the Cre/lox system has provided a way for investigating speciﬁc contributions of
ACh when there is co-transmission (Prado et al. 2013). Decreased
VAChT levels severely compromise packaging of acetylcholine
(ACh) into synaptic vesicles and thus reduce ACh release by nerve
terminals (Prado et al. 2006; de Castro, De Jaeger, et al. 2009). Conversely, overexpression of VAChT enhances ACh secretion proportionally (Song et al. 1997; Kolisnyk, Guzman, et al. 2013) .
The recent development of automated touchscreen behavioral testing for rodents has greatly improved mouse behavioral assessment. Touchscreen tasks were designed using almost
identical paradigms and methodologies used in humans,
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(1:200) (catalog no. AB144P, Merck Millipore), and anti-Choline
Transporter (CHT1; 1:200), which was kindly donated by
Dr R. Jane Rylett, University of Western Ontario, London, Ontario.
The primary antibody was incubated in blocking buffer overnight
at 4 °C. Sections were then washed 5 times in 1× PBS/0.4% Triton
X-100 (10 min each). Hoechst 3342 (Life Technologies, Bibco, Carlsbad, CA, USA) (2–5 µg/mL) and secondary antibodies (1:500; anti488, catalog no. A-11034, ThermoFisher; 1:500 anti-633, catalog
no. A-21082, ThermoFisher) were diluted in blocking buffer and
slices were incubated for 1 h at RT. Sections were visualized by
Zeiss LSM 510Meta (Carl Zeiss, Oberkochen, Germany) confocal
system (63 × objective, 488-nm Ar laser and 633-nm HeNe laser
were used for excitation of ﬂuorophores).

Western Blotting

Training on the PAL Task
Prior to training, both groups of mice (3 months old) were food restricted until they reached approximately 85% of their original
weight. Training of the animals to the PAL task was previously described (Talpos et al. 2009). Brieﬂy, the training phase for the mice
in the touchscreen chambers involved a habituation session,
where they were placed in the chambers with the lights off for
20 min to habituate to the environment for 2 days. Next, mice
were put in the chamber with the same parameters as in the habituation phase, but this time a 150 µL reward (strawberry milkshake; Saputo Dairy Products, Canada) was introduced in the
reward receptacle. Every time the mouse attended to the reward
in the reward receptacle, a tone was played. This 40 min training
session was done for the next 2 days until mice completed 36 trials
in 60 min (Habituation; Phase 1)
The mice were then trained to associate the reward with a 30 s
presentation of training stimuli, which varied in brightness,
shape, and pattern, on one of the 3 screens (Initial touch training;
Phase 2). Mice were required to touch any of the screens whenever the stimulus was presented to receive the reward, which
was paired with a tone. A new trial was automatically initiated
once the mice collected the reward. This was done until the
mice completed 36 trials in 60 min for 1 day. Next, mice are required to touch the stimulus that is displayed randomly in one
of the 3 windows to receive the reward (must touch stimuli training; Phase 3). Mice are only moved to next training after completing 36 trials in 60 min for 1 day. In the next training phase, food is
delivered and tray light is turned on. The mouse must nose poke
and exit the reward tray before a stimulus is displayed randomly
on the screen (Must initiate; Phase 4). This was done until mice
completed 36 trials in 60 min for 1 day. Next, animals go to the
last phase of the training program required for the PAL task.
This training phase is referred to as “punish incorrect” (Phase
5). This phase is similar to the previous one, but if the mouse
touched the incorrect screen, that is, one of the blank screens,
it was presented with a 5-s time-out. This time-out was accompanied by the presentation of a bright light in the chamber.
Criterion to successfully proceed from this training phase
was 23 correct responses out of 30 trials in 60 min for 2 consecutive days. Next, both experimental groups were subjected to acquisition training, where 2 stimuli are displayed at the same
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time during a trial. One will be in the correct location (S+) and
the other will be in the incorrect location (S−). Mice were required
to touch the correct stimulus (S+) presented on one of the 3 screens
to complete a trial and receive the reward. In this acquisition phase,
mice were on an unpunished version in which touching the S− was
ignored. A completion of a trial was only considered when the
mouse touches the S+. Criterion for this training phase is completion of 36 trials in 1 session (1 day). All mice from both experimental
groups were able to reach criterion in acquisition training.

PAL Task
After successfully completing the training phase, the mice were
placed on a PAL task (dPAL), which involves a different stimulus
being presented in each trial. A trial starts in dPAL when the
mouse initiates it by touching the food receptacle, which triggers
the display of both S+ and S− on the screen. S+ refers to when the
stimulus is in the correct location, and S− refers to when the
stimulus is in the incorrect location. There were 6 possible trial
types and 3 different stimuli were presented (ﬂower, plane, and
spider). Within trials, an S+ is the ﬂower presented in the left window, the plane in the middle window, or the spider in the right
window. Thus, mice are required to learn to associate a stimulus
to its correct location. A response by touching the S− resulted in a
10 s time-out and the chamber light was activated for 10 s, acting
as an indication for an incorrect response for the mouse. After
10 s, the next initiation by the mouse was considered a correction
error trial, where the same S+ and S− were presented as for the
unsuccessful previous trial. The number of correction trials was
not counted toward the total number of trials performed per session. An S+ response, however, led to a tone, as well as the reward
being dispensed in the receptacle.

Electrophysiology
Animals were anesthetized with urethane (1 g/kg i.p.) and placed
in a stereotaxic apparatus. Atropine methyl nitrate was administered (5 mg/kg i.p.) to reduce airway secretions during stereotaxic
surgery. Animal body temperature was monitored between
36.5 °C and 37 °C using a feedback controlled rectal thermometer
and heating pad. Stimulating electrodes were placed into stratum
radiatum at P 1.8, L 2.3 or P 2.5, L2.4 (Franklin and Paxinos 2008) to
stimulate Schaeffer collaterals projecting from CA3 to CA1
(Hutchison et al. 2009). A silicon probe, with 16 electrodes separated by 50 µm on a vertical shank, was placed in area CA1 at
P 2.2, L 1.8. Laminar proﬁles of the average (4 sweeps) ﬁeld excitatory postsynaptic potentials evoked by single pulse stimulation
of the Schaffer collaterals at 1.5-2 × threshold stimulus intensity.
Current-source density analysis using 100 µm step size was used
to determine current sources and sinks. The maximal slope (of
1 ms duration) during the rising phase of the excitatory sink, at
its maximum in CA1 stratum radiatum, was used for LTP assessment. After a stable baseline of the excitatory sink slope was established for 30 min (coefﬁcient of variation [SEM/mean] of the
sink slopes <0.05), a high-frequency tetanus (100 Hz for 1 s) was
delivered at 2–3 times the threshold intensity, and the response
was measured for 120 min after the tetanus. For each mouse,
the slope of the excitatory sink was normalized by the average
value of the baseline, and LTP across mice was averaged and reported as a multiple of the baseline slope.

Rotarod and Neuromuscular Tests
The rotarod task was conducted as previously described (Prado
et al. 2006; de Castro, Pereira, et al. 2009). Forelimb and hind

Downloaded from http://cercor.oxfordjournals.org/ at University of Western Ontario on May 2, 2016

Immunoblotting was performed as previously described (MartinsSilva et al. 2011; Kolisnyk, Al-Onaizi, et al. 2013; Kolisnyk, Guzman,
et al. 2013). Antibodies used were anti-VAChT (catalog no. 139103;
Synaptic Systems) and anti-Synaptophysin (catalog no. S5768;
Sigma-Aldrich).
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limb grip strength was assessed using a previously described
protocol (Prado et al. 2006). The hang-wire experiments were performed as described (Sango et al. 1996).

Morris Water Maze

Two-Trial Morris Water Maze
A task used to assess working memory was the 2-trial variation of
the MWM. The task was carried out using previously described
protocols (Vorhees and Williams 2006; Kolisnyk, Guzman, et al.
2013). The mice were trained on the task over the course of
5 days. During the training period, the mouse was ﬁrst given a
90-s trial with a 15 s inter-trial interval. Next, the mouse was
given a second trial with the same platform location and starting
point; this was repeated 3 additional times. After completing the
training phase, the mouse was ﬁrst given a 90 s trial with a 15 s
inter-trial-interval. The mouse was then given a second trial
with identical platform location and starting point. This was repeated with 4 unique starting location/platform location combinations a day. Mean latency and distance savings ratios were
then calculated as previously described (Kolisnyk, Guzman,
et al. 2013). Sessions were recorded for both tests and were analyzed using the ANY-Maze video tracking software (Stoelting Co.)

Spontaneous Alterations Y-maze
To assess working memory in the mice, we used the spontaneous
alternations Y-maze as previously described (Kolisnyk, Guzman,
et al. 2013). Brieﬂy, mice were placed in a symmetrical plastic
Y-maze apparatus, and both the number and order of arm entries
were recorded. A spontaneous alternation was deﬁned as when
the mouse visited all 3 of the arms in a row, without having revisited a previous arm of the maze. Sessions were recorded and
analyzed using the ANY-Maze Software.

Stereotaxic Injections of Adeno-Associated Virus
To obtain selective deletion of VAChT in the medial septum, mice
were anesthetized with ketamine (100 mg/kg) and xylazine
(25 mg/kg) in 0.9% sodium chloride, and 1 µL (titer of ∼1013 GC/mL)
of adeno-associated virus (AAV)8-GFP-Cre- or control virus
(AAV8-GFP, Vector BioLabs, Eagleville, PA, USA) was injected
into the medial septum/vertical limb of the diagonal band (0.98
AP, 0.1 LL and 4.1 DV) of VAChTﬂox/ﬂox mice. The injecting

Statistical Analysis
All data are expressed as mean ± SEM. Sigmastat 3.5 software was
used for statistical analysis. Comparison between 2 experimental
groups was done with Student’s t-test. When several experimental groups or treatments were analyzed, 2-way analysis of variance (ANOVA) or 2-way ANOVA with repeated measures (RM)
were used as required. When appropriate, a Bonferonni post hoc
analysis test was used.

Results
Deletion of VAChT in Forebrain Projection Neurons
Nkx2.1-driven Cre is expressed in forebrain cholinergic neurons
as assessed using a reporter mouse line (see Supplementary
Fig. 1A and Table 1). Immunoblot analysis shows that VAChT
levels in the prefrontal cortex (t (4) = 6.162, P = 0.0035), hippocampus (t (4) = 4.461, P = 0.0097), and striatum (t (4) = 8.625, P = 0.0010)
were severely diminished in VAChTNkx2.1-Cre-ﬂox/ﬂox mice (see
Supplementary Fig. 1B–D). In contrast, VAChT levels remained
unchanged in the brainstem of VAChTNkx2.1-Cre-ﬂox/ﬂox compared
with controls (t (4) = 1.040, P = 0.3571, see Supplementary Fig. 1E).
Moreover, immunoﬂuorescence imaging indicated decreased
VAChT immunoreactivity in the hippocampus of VAChTNkx2.1Cre-ﬂox/ﬂox
mice compared with controls (Fig. 1A,B). Importantly,
these mice presented no neuromuscular deﬁcits (see Supplementary Fig. 2A–C). We have previously shown that reduced
VAChT levels proportionally decrease the release of ACh in vivo
and in vitro (Prado et al. 2006; Guzman et al. 2011; Kolisnyk,
Al-Onaizi, et al. 2013; Kolisnyk, Guzman, et al. 2013).
Forebrain VAChT is Required for Performance in the PAL Task
We tested VAChTNkx2.1-Cre-ﬂox/ﬂox mice on the PAL task, which requires sophisticated processing of information for proper association of images with speciﬁc locations. VAChTNkx2.1-Cre-ﬂox/ﬂox
mice and their matched controls were assessed on the dPAL
task using an automated touchscreen system (Fig. 1C and see
Supplementary Videos 3 and 4). Prior to being subjected to the
PAL task, both experimental groups are trained on a different
training sessions (initial touch, must touch stimuli, must initiate,
and punish incorrect) to learn how to operate the touchscreen,
which includes learning to touch the screen when a stimulus is
presented and initiating the task by inserting the head into the
reward chamber. In the “punish incorrect” training, when only
one stimulus is presented randomly in one of the 3 screens,
mice are taught to touch the screen that shows the stimulus.
Mice from both experimental groups were able to reach criterion
in this phase of the training and no differences were observed between the 2 genotypes (t (12) = 0.0749) (Fig. 1D), indicating that
VAChT-deﬁcient mice are able to learn that they need to touch
the screen when an image is shown. Additionally it argues that
VAChT-deﬁcient mice do not present any major visual impairment. During the course of the 9 weeks that mice were tested
on the dPAL task, we observed that control mice signiﬁcantly improved their accuracy performance, while VAChT deletion
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The spatial version of the MWM was performed as previously described (Vorhees and Williams 2006; Martyn et al. 2012; Kolisnyk,
Guzman, et al. 2013). Testing was performed in a 1.5-m diameter
pool with 25 °C water. A hidden platform was submerged in a
constant location 1 cm below the surface of the water in one of
the 4 arbitrarily deﬁned quadrants, and spatial cues were distributed around the pool. Brieﬂy, mice were given four 90-s trials for
the duration of 4 days to ﬁnd the hidden platform, with an ITI of
15 min. The animals were introduced to the pool from different
locations within the pool for each trial. Mice that did not ﬁnd
the platform within the 90 s were gently guided to the platform.
On the ﬁfth day, spatial memory recall was tested by a 60-s probe
trial, where the hidden platform is removed and the amount of
time the animal spends in the target quadrant is calculated. To
test reversal learning, the hidden platform was relocated to the
opposite quadrant, where the animals were given four 90-s trials
for 4 days. On the ﬁfth day, the animals were given a 60-s probe
trial. Data were analyzed using ANY-Maze video tracking software (Stoelting Co.).

micropipette was inserted and left for 2 min to stabilize. After
stabilization, a 0.2 µL/min infusion was performed using a micropump followed by a 30 min rest period to allow local diffusion of
the virus and avoid virus efﬂux. The micropipette was then
slowly removed and the scalp sutured. A recovery period of
4 weeks was given before behavioral testing to allow transgene
expression.
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experimental groups to reach criterion during the operant conditioning, pretraining, and training phases. (E–H) Data for the acquisition of the dPAL task for VAChTﬂox/ﬂox
(n = 7 clear squares) and VAChTNKx2.1-Cre-ﬂox/ﬂox (n = 7 dark circles) mice. Each week represents 5 testing sessions of 36 trials. (E) Mean accuracy; (F) Mean correction
errors; (G) Response latency; (H) Reward collection latency (Data are mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.0001).

mutants did not (2-way RM ANOVA shows signiﬁcant effect
of weeks F8,48 = 21.11, P < 0.0001, an effect of genotype F1,6 = 56.94,
P = 0.0003, and an interaction effect F8,48 = 2.871, P = 0.0074,
Fig. 1E). VAChTﬂox/ﬂox mice (controls) were able to improve performance reaching 77 ± 1% accuracy by Week 9 (Fig. 1E). In contrast, peak accuracy performance of VAChTNkx2.1-Cre-ﬂox/ﬂox mice in
the dPAL task during the same period was 58 ± 2% (Fig. 1E). Although
VAChTNkx2.1-Cre-ﬂox/ﬂox mice were able to perform the 36 trials required in each 1-h session, they failed to associate the stimulus to
its correct location. Their poorer performance was also reﬂected in
the number of correction errors performed (Fig. 1F). VAChTNkx2.1-Creﬂox/ﬂox
mice failed to decrease the number of correction errors made
over the course of 9 weeks, while control mice improved the number
of correction errors performed during the course of the study (2-way
RM ANOVA shows signiﬁcant effect of weeks F8,48 = 12.05, P < 0.0001,
an effect of genotype F1,6 = 39.41, P = 0.0008, and an interaction effect
F8,48 = 1.224, P = 0.0306, Fig. 1F). Correct response latency was not different between the 2 groups over the course of 9 weeks (2-way RM
ANOVA shows signiﬁcant effect of weeks F8,48 = 7.508, P < 0.0001,
no effect of genotype F1,6 = 2.437, P = 0.1695, and no interaction
F8,48 = 1.195, P = 0.3220, Fig. 1G). Furthermore, VAChTNkx2.1-Cre-ﬂox/ﬂox

mice were no different from controls when the latency to collect
the reward was measured, which indicated that motivation
was not a factor in their poorer performance (2-way RM ANOVA
shows a signiﬁcant effect of weeks F8,48 = 7.596, P < 0.0001, no effect
of genotype F1,6 = 0.0001380, P = 0.7681, and no interaction F8,48 =
0.6061, P = 0.7681 Fig. 1H). In summary, VAChTNkx2.1-Cre-ﬂox/ﬂox mice
were able to learn that they had to touch the screen when the
images were shown; however, they failed in making associations,
that is, they were unable to assign each image to a speciﬁc position.
Hippocampal LTP is Disrupted in Forebrain-Speciﬁc VAChT
Knockout Mice In Vivo
Formation of associations might depend on lasting increases in
synaptic strength. To determine whether VAChTNkx2.1-Cre-ﬂox/ﬂox
mice have intact synaptic plasticity, we examined LTP of the synapse of the Schaffer collaterals on hippocampal CA1 neurons in
anaesthetized mice in vivo. VAChTNkx2.1-Cre-ﬂox/ﬂox mice showed
decreased LTP which lasted about 90 min post-tetanus delivery
while LTP in VAChTﬂox/ﬂox mice was maintained for 120 min
(Fig. 2A,B). This indicated that the lack of cholinergic signaling
disturbs synaptic plasticity in hippocampal CA1 area in vivo.
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Figure 1. VAChTNKx2.1-Cre-ﬂox/ﬂox mice display impairments in the acquisition of dPAL. (A) Representative 3-dimensional reconstructed Z stack immunoﬂuorescence
images of VAChT (green) and Hoechst (blue) in the CA1 and CA3 regions of the hippocampus in VAChTﬂox/ﬂox (n = 3) and (B) VAChTNkx2.1-Cre-ﬂox/ﬂox mice (n = 3) (Scale
bar = 100 µm). (C) Image depicting a mouse performing the task, where the ﬂower is shown as S+ and the airplane as S−. (D) Number of sessions required by both
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did not correlate to mean response latency across the task (Pearson’s r = 0.1349, CI = −0.3273 to 0.5450, P = 0.5708, Fig. 3E) or mean
reward collection latency across the task (Pearson’s r = −0.1799,
CI = −0.5676 to 0.2731, P = 0.4352, Fig. 3F), suggesting that response patterns and motivation are unaltered by reduced
VAChT levels. Taken together these results show that the less
VAChT protein in the hippocampus the worse is the mouse performance in the dPAL task, indicating that dPAL learning is
modulated by septohippocampal cholinergic signaling.

VAChT and Spatial Navigation

mice in vivo. (A) Normalized slopes of the excitatory sink recorded at CA1
stratum radiatum (apical dendrites) of VAChTﬂox/ﬂox (clear squares, n = 5) and
VAChTNkx2.1-Cre-ﬂox/ﬂox (dark circles, n = 6) mice. Baseline was monitored for
30 min prior to tetanus delivery (t = 0), and posttetanic response was monitored
for 120 min. A 1-s 100 Hz train, delivered at 2–3 times the threshold intensity
(arrow), induced higher and more prolonged potentiation in VAChTNkx2.1-Cre-ﬂox/ﬂox
mice than VAChTﬂox/ﬂox controls. Insets show representative current sink time
response taken at 80 min (red traces), overlaid on the pretetanus baseline
response (black traces), from each genotype. (B) Normalized excitatory sink
slope averaged across 30-min time intervals (mean ± SEM) in VAChTﬂox/ﬂox and
VAChTNkx2.1-Cre-ﬂox/ﬂox mice, with signiﬁcant difference between mouse groups
at 90–120 min (t (9) = 3.911, P = 0.0036).

To speciﬁcally evaluate the contribution of hippocampal cholinergic tone to PAL performance, we stereotaxically injected
AAV8-GFP-Cre or AAV8-GFP virus to the medial septum and vertical limb of the diagonal band (MS/VDB) of VAChTﬂox/ﬂox mice
(AAV8-GFP-Cre n = 13; AAV8-GFP n = 7). Mice were trained on the
dPAL task 1 month after viral injection. Following completion of
the task, mice were sacriﬁced to evaluate VAChT protein levels.
Given the length of the experiment (≈4 months), and the observation that viral injection was only partially effective to reduce
hippocampal VAChT levels (see Supplementary Fig. 6B), we did
not exclude any mouse from the analysis, even if viral mediated
recombination was not effective to eliminate the transporter.
Instead, we correlated VAChT levels in the hippocampus from
both AAV8-GFP-Cre and AAV8-GFP to their performance on the
PAL task.
Performance on the ﬁnal week of the experiment was positively correlated to VAChT protein levels in terms of response
accuracy (Pearson’s r = 0.5208, CI = 0.1015–0.7829, P = 0.0186,
Fig. 3A) and negatively correlated to number of correction errors
(Pearson’s r = −0.6518, CI = −0.8494 to −0.2940, P = 0.0018, Fig. 3B).
We also evaluated the relationship between hippocampal VAChT
protein levels to learning the PAL task. We calculated the rate of
learning as the slope of the learning curve of both response
accuracy and correction errors across all the weeks of the task.
VAChT protein level was positively correlated to the rate of
learning of response accuracy (Pearson’s r = 0.5053, CI = 0.08072–
0.7747, P = 0.0231, Fig. 3C) and negatively correlated to the correction error rate of learning (Pearson’s r = −0.1799, CI = −0.7982 to
−0.1418, P = 0.0120, Fig. 3D). Importantly, VAChT protein levels
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Figure 2. Hippocampal LTP is disrupted in forebrain-speciﬁc VAChT knockout

Given the strong deﬁcit of association of the image with its correct location in the PAL task, it seemed of importance also to
evaluate spatial memory in these mice. Spatial memory is widely
used to assess information acquisition and storage in the hippocampus, but cholinergic dysfunction has only mild effects in
the MWM in mice (Moreau et al. 2008; Martyn et al. 2012). Our
data showed that spatial learning on the MWM was relatively
normal in VAChTNkx2.1-Cre-ﬂox/ﬂox mice compared with controls
(see Supplementary Fig. 5A–C). On the probe trial of the MWM,
both groups of mice spent signiﬁcantly more time in the target quadrant compared with the opposite quadrant (2-way ANOVA shows a
signiﬁcant effect of quadrant, F3,80 = 39.58, P < 0.0001, and an interaction effect F3,80 = 2.914, P = 0.0394, see Supplementary Fig. 5D), post
hoc analysis revealed that both groups spent signiﬁcantly more time
in the target quadrant. However, VAChTNkx2.1-Cre-ﬂox/ﬂox mice had
signiﬁcantly fewer platform crosses compared with littermate
controls (t (20) = 2.795, P = 0.0112, see Supplementary Fig. 5E).
To speciﬁcally evaluate the contribution of hippocampal cholinergic tone to learning and memory performance in the spatial
version of the MWM, we stereotaxically injected AAV8-GFP-Cre
(n = 25) virus to the MS/VDB in another cohort of VAChTﬂox/ﬂox
mice (see Supplementary Fig. 6A,B). VAChTﬂox/ﬂox mice injected
with AAV8-GFP (n = 14) were used as controls. AAV8-GFP-Cre-injected mice that showed more than 50% of hippocampal VAChT
protein levels (n = 11) compared with controls were excluded
from the analysis (see Supplementary Fig. 6E). In AAV8-GFPCre-injected mice with reduced hippocampal VAChT levels,
VAChT protein in the prefrontal cortex was not changed (97% of
AAV8-GFP VAChT levels, t (4) = 0.453, P = 0.665, see Supplementary
Figure 6C,D). AAV8-GFP-Cre-mediated deletion of VAChT from
the medial septum did not signiﬁcantly alter acquisition of the
spatial version of the MWM (Latency, 2-way RM ANOVA shows
an effect of days F3,39 = 22.84, P < 0.0001, no effect of Cre virus injection F1,13 = 0.2228, P = 0.6447, and no interaction, F3,39 = 1.302,
P = 0.2876, Fig. 4A). Similar results were obtained for distance
travelled (2-way RM ANOVA shows an effect of days, F3,39 = 23.5,
P < 0.0001, no effect of Cre expression F1,13 = 0.3125, P = 0.5856,
and no interaction, F3,39 = 1.329, P = 0.2787, Fig. 4B). In the probe
trial, mice injected with the AAV8-GFP-Cre virus did not differ
from controls in terms of preference for the target quadrant
(2-way ANOVA shows a signiﬁcant effect of quadrant, F3,104 = 37.81,
P < 0.0001, no effect of Cre expression, F1,104 = 0.6452, P = 0.4237, and
no interaction F3,104 = 0.3988, P = 0.7541, Fig. 4D) or platform crosses
(t (26) = 0.9547, P = 0.3603, Figure 4E). Taken together, these results
suggest that decreased levels of hippocampal cholinergic activity
do not seem to affect MWM performance.
VAChTNkx2.1-Cre-ﬂox/ﬂox mice were also tested on the reversal
learning protocol of the MWM. During the course of 4 days, control mice signiﬁcantly improved in their latency to ﬁnd the hidden platform in contrast to VAChTNkx2.1-Cre-ﬂox/ﬂox mice (2-way
RM ANOVA shows a signiﬁcant effect of days F3,30 = 8.632,
P = 0.0003, main effect of genotype F1,10 = 11.17, P = 0.0075, and
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n = 13) injected mice. (C,D) Linear regression and correlation between response accuracy (r = 0.4460, P = 0.0487) and correction errors (r = -0.1799, P = 0.0120) across all the
weeks of the PAL task and hippocampal VAChT protein expression levels. (E,F) The relationship between response latency (r = 0.1349, P = 0.5708) and reward collection
latency (r = −0.1799, P = 0.4352) across all the weeks of the PAL task and VAChT expression levels.

Figure 4. Performance of medial septum AAV8-GFP-Cre-injected mice in the MWM. VAChTﬂox/ﬂox injected with AAV8-GFP virus (clear squares, n = 14) or AAV8-GFP-Cre
virus (dark circles, n = 14) were tested in the spatial paradigm of the MWM. Data average of four 90-s trials per day were plotted. (A) Latency to reach the platform, (B)
distance to reach the platform, (C) speed to reach the platform, (D) the percentage of time spent in each quadrant of the pool measured on Day 5 in a 60-s probe trial
with the platform removed. (E) Number of platform crosses during the probe trial. (F) Representative path traces of 2 AAV8-GFP and 2 AAV8-GFP-Cre-injected mice in
the probe trial. The target quadrant is in the upper right. Data are mean ± SEM. *P < 0.05. T, target; O, opposite; L, left; R, right.

no interaction F3,30 = 1.501, P = 0.2342, Fig. 5A–C). Notably, on the
probe trial, control mice spent considerably more time in the target quadrant compared with the other quadrants (2-way ANOVA

shows a signiﬁcant effect of quadrant, F3,80 = 7.226, P = 0.0002, and
an interaction effect F3,80 = 3.133, P = 0.0301, Fig. 5D), while
VAChTNkx2.1-Cre-ﬂox/ﬂox mice visited all quadrants almost equally.
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Figure 3. Medial septum AAV8-GFP-Cre-injected mice show deﬁcits in dPAL. (A,B) Linear regression and correlation between response accuracy (r = 0.5208, P = 0.0186) and
correction errors (r = −0.5154, P = 0.0168) on Week 9 and hippocampal VAChT protein expression levels for AAV8-GFP (clear squares, n = 7) and AAV8-GFP-Cre (dark circles,
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(dark circles, n = 11) were tested in the reversal paradigm of the MWM. Data average of four 90-s trials per day were plotted. (A) Latency to reach the platform, (B) distance to
reach the platform, (C) speed to reach the platform, (D) the percentage of time spent in each quadrant of the pool measured on Day 5 in a 60-s probe trial with the platform
removed. (E) Number of platform crosses during the probe trial. (F) Representative path traces for 2 VAChTﬂox/ﬂox and 2 VAChTNkx2.1-Cre-ﬂox/ﬂox in the probe trial. The target
quadrant is in the upper left. (G–L) AAV8-GFP (clear squares, n = 14) or AAV8-GFP-Cre (dark circles, n = 14)-injected mice were tested in the reversal paradigm of the
MWM. The data average of four 90-s trials per day were plotted. (G) Latency to ﬁnd the platform, (H) distance, (I) speed, (J) the percentage of time spent in each
quadrant of the pool was measured on Day 5 in a 60-s probe trial with the platform removed. (K) Number of platform crosses during the probe trial. (L) Two AAV8GFP- and 2 AAV8-GFP-Cre-injected mice in the probe trial. The target quadrant is indicated with a T. Data are mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.0001. T, target; O,
opposite; L, left; R, right.

The number of platform crosses was also higher for control mice
compared with VAChT mutants (t (20) = 2.797, P = 0.0111, Fig. 5E).
These results indicate that, different from control mice,
VAChTNkx2.1-Cre-ﬂox/ﬂox mice were unable to extinguish the previously learned position and relearn the new position of the hidden
platform.
To account for compromised striatal cholinergic signaling in
VAChTNkx2.1-Cre-ﬂox/ﬂox mice for the performance in the MWM
(see Supplementary Fig. 1D), we also tested a mouse line with

selective deletion of VAChT in striatal neurons (VAChTD2-Cre-ﬂox/
), but spared hippocampal VAChT (Guzman et al. 2011; see
Supplementary Fig. 7). Interestingly, VAChTD2-Cre-ﬂox/ﬂox mice
did not differ from controls (VAChTﬂox/ﬂox) in both acquisition
and reversal versions on the MWM (see Supplementary Fig. 7D–
H). These results suggest that deﬁcits seen in reversal learning
in VAChTNkx2.1-Cre-ﬂox/ﬂox mice are not likely due to impaired striatal cholinergic transmission, but rather a result of hippocampal
or cortical deﬁcits or combined cortical hippocampal
ﬂox
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Figure 5. Reversal learning is affected in VAChTNkx2.1-Cre-ﬂox/ﬂox and medial septum AAV8-GFP-Cre-injected mice. VAChTﬂox/ﬂox (clear squares, n = 11) and VAChTNkx2.1-Cre-ﬂox/ﬂox

Cholinergic Regulation of Hippocampal Function

Regulation of Working Memory by Septohippocampal
VAChT
To determine whether other cognitive domains of importance in
neuropsychiatric disorders that could contribute to the PAL deﬁcits may also be regulated by synaptically released ACh, we evaluated the performance of the VAChTNkx2.1-Cre-ﬂox/ﬂox mice on 2
measures of working memory: the working memory version of
the MWM and spontaneous alternations in the Y-maze. In the
working memory version of the MWM, VAChTNkx2.1-Cre-ﬂox/ﬂox
mice failed to improve their performance from the ﬁrst to the
second trial resulting in signiﬁcant impairments in measures of
latency savings (t (12) = 3.580, P = 0.0030, Fig. 6A) and distance
savings (t (12) = 2.852, P = 0.0127, Fig. 6B), suggesting that the
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VAChTNkx2.1-Cre-ﬂox/ﬂox mice have impaired working memory.
Similarly, VAChTNkx2.1-Cre-ﬂox/ﬂox mice revisited arms in the
maze more often than controls resulting in a signiﬁcant decrease
in spontaneous alternations in the Y-maze (t (12) = 2.674,
P = 0.0182, Fig. 6C), suggesting that forebrain VAChT is required
for normal working memory performance.
When tested on the working memory MWM test, mice with
selective elimination of septohippocampal VAChT by virus injection (same cohort used in the MWM) also showed impaired latency savings ratio (t (26) = 2.847, P = 0.0111, Fig. 6D) and distance
savings ratio (t (26) = 2.149, P = 0.0473, Fig. 6E). On the spontaneous
alternations Y-maze task, AAV8-GFP-Cre-injected mice showed
impairments on working memory, measured as a signiﬁcant decreased rate of spontaneous alternations (t (26) = 3.347, P = 0.0041,
Fig. 6F). It is interesting to note that working memory deﬁcits observed for AAV8-GFP-Cre-injected mice were similar to deﬁcits
observed for VAChTNkx2.1-Cre-ﬂox/ﬂox mice. Taken together these
results indicate that working memory is highly sensitive to hippocampal cholinergic tone.

Discussion
The present work shows that selective inhibition of cholinergic
signaling in the hippocampus in mice leads to disruption of synaptic plasticity and speciﬁc cognitive impairments. In particular,
we show that hippocampal cholinergic signaling is important for
the modulation of cognitive tasks shown to be impaired in
schizophrenia and dementia, including the PAL task. Interestingly, some hippocampal-dependent tasks appear to be more sensitive to decreased cholinergic signaling than others. Our results
provide a comprehensive map of cholinergic-regulated hippocampal cognitive processing that may be useful to understand
similar deﬁcits in humans with cholinergic deﬁciency.
Notably, we report novel data indicating the importance of
cholinergic signaling in regulating the PAL task. Clinically, the
PAL task has been suggested as a potential cognitive marker of
decline in psychosis (Wood et al. 2002). Signiﬁcant impairments

Figure 6. Working memory depends on hippocampal cholinergic tone. (A) Latency savings ratio and (B) distance savings ratio for VAChTﬂox/ﬂox (clear, n = 7) and
VAChTNkx2.1-Cre-ﬂox/ﬂox (dark, n = 7) mice in the working memory version of the MWM. (C) Spontaneous alternations in the Y-maze for VAChTNkx2.1-Cre-ﬂox/ﬂox. (D)
Latency savings ratio and (E) distance savings ratio for AAV8-GFP (clear, n = 14) and AAV8-GFP-Cre (dark, n = 14) mice in the working memory version of the MWM. (F)
Spontaneous alternations in the Y-maze for virus-injected mice. Data are mean ± SEM. *P < 0.05, **P < 0.01.
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dysfunction. To discern among these possibilities, we used virusinjected mice.
Selective reduction of hippocampal cholinergic tone in
virus-injected mice also increased latency to ﬁnd the platform
in reversal learning (2-way RM ANOVA shows an effect of
days, F3,39 = 21.96, P < 0.0001 and a signiﬁcant interaction effect,
F3,39 = 7.507, P = 0.0004), with post hoc analysis revealing that
AAV8-GFP-Cre-injected mice performed signiﬁcantly worse on
Day 4 compared with controls (Fig. 5G). During the probe trial,
mice injected with AAV8-GFP-Cre virus showed signiﬁcant impairments, failing to show a preference for the target quadrant
(2-way ANOVA shows a signiﬁcant effect of quadrant, F3,104 = 23.3,
P < 0.0001, and an interaction effect, F3,104 = 7.173, P = 0.002,
Fig. 5J). Post hoc analysis revealed that the AAV8-GFP-Cre mice
did not prefer the target quadrant compared with the other
quadrants, while the AAV8-GFP-injected controls had a strong
preference for the target quadrant. Furthermore, the AAV8-GFPCre-injected mice showed a decrease in the number of platform
crosses (t (26) = 0.9547, P = 0.0010, Fig. 5K). These results reveal
that disruption of hippocampal cholinergic tone, but not striatal
or cortical cholinergic activity, compromises information
processing in the MWM reversal learning.
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hippocampus decrease acquisition performance, suggest that
the hippocampal cholinergic tone may facilitate acquisition of
the PAL task. However, it is unlikely that only one brain region
is involved in such a complex task.
The mechanisms by which ACh tone facilitates PAL performance are not fully understood. It is possible that cholinergic tone
is required for speciﬁc types of synaptic plasticity. Indeed, hippocampal LTP in vitro is disturbed in a different mouse line lacking
forebrain VAChT (Martyn et al. 2012). We corroborated this ﬁnding
in vivo in VAChTNkx2.1-Cre-ﬂox/ﬂox mice and demonstrated that in
the absence of VAChT expression, hippocampal LTP is compromised, suggesting that disturbances of synaptic plasticity might
contribute to the deﬁcit. To note, previous studies have shown
that levels of VAChT are correlated to levels of ACh release
(Prado et al. 2006; de Castro, Pereira, et al. 2009, reviewed in
Prado et al. (2013)); an increase in VAChT levels increases ACh release whereas decreased levels have the opposite effect (Song
et al. 1997; Prado et al. 2006; Kolisnyk, Guzman, et al. 2013).
VAChT is decreased in AD (Parent et al. 2013). These results suggest that correlating levels of VAChT detected with PET ligands
(Efange 2000) to performance in the PAL test (Harel et al. 2013)
might provide a potential biomarker of remaining cholinergic
function and cognitive reserve.
We showed that acquisition of the spatial version of the MWM
and recall of platform location was mildly affected in
VAChTNkx2.1-Cre-ﬂox/ﬂox mice, while AAV8-GFP-Cre-injected mice
did not show any deﬁcit in this behavioral task. Similarly, impairments in the spatial version of the MWM have been observed
in rats with combined lesions of MS/VDB and nucleus basalis
magnocellularis (NBM) cholinergic neurons produced by immunotoxin 192 IgG-saporin (Pizzo et al. 2002), while rats with immunotoxin lesions restricted to MS/VDB did not show any
impairment (Berger-Sweeney et al. 1994; Baxter and Gallagher
1996; Pizzo et al. 2002; Frick et al. 2004). Interestingly, rats with
192 IgG-saporin lesions restricted to NBM also did not show behavioral impairments in the MWM (Pizzo et al. 2002). These
data suggest that forebrain cholinergic signaling is necessary
for reference spatial learning and memory assessed using the
MWM; however, it seems that both the cortical and hippocampal
cholinergic projections need to be compromised to produce a
severe spatial deﬁcit. Thus, providing that cortical cholinergic
projections are intact, hippocampal cholinergic activity is not
absolutely required for this behavioral task. It remains to be established whether GABA or glutamate, which could potentially
be co-released with ACh (Guzman et al. 2011; Saunders et al.
2015) in both the hippocampus and cortex, may contribute to
regulation of spatial memory by cholinergic neurons.
In contrast to the reference memory test, both VAChTNkx2.1-Cre-ﬂox/
ﬂox
and AAV8-GFP-Cre-GFP-injected mice when tested in the
MWM reversal learning task presented extensive deﬁcits,
suggesting a prominent role for hippocampal cholinergic signaling in reversal learning. The impairments seen in VAChTdeﬁcient mice in reversal learning could relate to the loss of
muscarinic presynaptic inhibition of excitatory feedback within
cortical circuits (Hasselmo and McGaughy 2004), which would
slow the extinction of a previously learned strategy (Hasselmo
et al. 2002; Hasselmo 2006). To note, the ﬁndings with
VAChTNkx2.1-Cre-ﬂox/ﬂox mice recapitulated the deﬁcits seen in reversal learning in a different mouse line with deﬁcient forebrain
cholinergic tone we generated previously (Martyn et al. 2012;
Kolisnyk, Al-Onaizi, et al. 2013). Interestingly, rats with 192 IgGsaporin lesions restricted to NBM also show behavioral ﬂexibility
impairments (Cabrera et al. 2006). Taken together, these results
suggest that both NBM-cortical and septohippocampal cholinergic
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in PAL have been observed in patients with schizophrenia with a
positive correlation between failure on the PAL task and negative
symptoms (Barnett et al. 2005). Additionally, hippocampal activation during PAL is changed in patients with mild cognitive impairment compared with aged-matched controls (de Rover et al.
2011). Hence, PAL has also been considered a sensitive task for
predicting cognitive decline in AD (Swainson et al. 2001; Blackwell et al. 2004).
Nonetheless, whether cholinergic signaling is required for acquisition of the task has not been clearly established. Systemic
administration of donepezil, a cholinesterase inhibitor, improved
post-acquisition PAL performance in mice, an effect that was attenuated with administration of muscarinic antagonists (Bartko,
Vendrell et al. 2011). Similar results have been observed in monkeys where both mecamylamine (nicotinic antagonist) and scopolamine (muscarinic antagonist) induced deﬁcits in PAL
performance (Taffe et al. 2002; Katner et al. 2004). These results
suggest that cholinergic signaling might be relevant for PAL.
Also, rats previously trained in PAL that received injections into
the dorsal hippocampus of either scopolamine or mecamylamine and that were re-tested did not show deﬁcits in performance, suggesting that hippocampal cholinergic signaling might
not modulate recall in this task (Talpos et al. 2009). Our results indicate that disruption in forebrain cholinergic tone disturbs PAL
learning. Additionally, our data suggest that dysfunctional hippocampal cholinergic signaling may decrease PAL performance,
as performance of mice in the PAL task correlates with hippocampal VAChT protein levels. Importantly, these deﬁcits occurred in
the absence of alterations in latency to touch the screen or to collect the reward, indicating that motivation was not a factor in the
poorer performance of mice with lower cholinergic tone. Interestingly, mice deﬁcient for the M1 receptor presented no differences
compared with controls in their acquisition of the PAL task (Bartko,
Romberg et al. 2011), suggesting that nicotinic and/or other muscarinic receptors might be involved in mediating learning in this
hippocampal-dependent task.
Performance in PAL, as well as in other paired-associated
tasks, may depend on intact hippocampal function in humans
and rats (Talpos et al. 2009; de Rover et al. 2011). For example,
short-lasting inactivation of the rat hippocampus using lidocaine
(non-selective Na+ channel blocker) signiﬁcantly impairs performance postacquisition of the PAL task, suggesting that the
hippocampus is required at least for performance in this task
(Talpos et al. 2009). In addition, human fMRI studies have
shown bilateral BOLD activation of the hippocampus during the
encoding phase of the PAL task (de Rover et al. 2011). Interestingly,
subjects with memory deﬁcits showed decreased hippocampal
activation with increased memory demand, whereas healthy
controls showed the opposite (de Rover et al. 2011). Moreover,
PAL performance correlates with hippocampal volume loss in
schizophrenia and mild cognitive impairment (MCI) (Keri et al.
2012). Intriguingly, recent reports indicate that mice with hippocampal lesions are still able to acquire the PAL task (Delotterie
et al. 2015; Kim et al. 2015). One possible explanation (Kim et al.
2015) regarding these ﬁndings is that with a functional hippocampus the task is acquired in a hippocampal-dependent manner, but with a dysfunctional hippocampus, the task can be
learnt using an alternative hippocampal-independent strategy.
For example, mice with hippocampal lesions could have used
the dorsal striatum to acquire the task (Delotterie et al. 2015). Indeed, the development of such behavioral plasticity has been
shown in rats with unilateral hippocampal lesions (Zou et al.
1999). Our ﬁndings that forebrain VAChT-deﬁcient mice seem unable to acquire the task, whereas decreased VAChT levels in the
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Abstract
The relationship between long-term cholinergic dysfunction and risk of developing dementia is poorly understood. Here we
used mice with deletion of the vesicular acetylcholine transporter (VAChT) in the forebrain to model cholinergic abnormalities
observed in dementia. Whole-genome RNA sequencing of hippocampal samples revealed that cholinergic failure causes
changes in RNA metabolism. Remarkably, key transcripts related to Alzheimer’s disease are affected. BACE1, for instance, shows
abnormal splicing caused by decreased expression of the splicing regulator hnRNPA2/B1. Resulting BACE1 overexpression leads
to increased APP processing and accumulation of soluble Aβ1-42. This is accompanied by age-related increases in GSK3
activation, tau hyperphosphorylation, caspase-3 activation, decreased synaptic markers, increased neuronal death, and
deteriorating cognition. Pharmacological inhibition of GSK3 hyperactivation reversed deﬁcits in synaptic markers and tau
hyperphosphorylation induced by cholinergic dysfunction, indicating a key role for GSK3 in some of these pathological changes.
Interestingly, in human brains there was a high correlation between decreased levels of VAChT and hnRNPA2/B1 levels with
increased tau hyperphosphorylation. These results suggest that changes in RNA processing caused by cholinergic loss can
facilitate Alzheimer’s-like pathology in mice, providing a mechanism by which decreased cholinergic tone may increase risk of
dementia.
Key words: acetylcholine, Alzheimer’s disease, cognition, pathology, RNA metabolism
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Introduction

Materials and Methods
Mouse Lines
ﬂox/ﬂox

Generation of VAChT
mice was previously described
(de Castro et al. 2009). VAChTNkx2.1-Cre-ﬂox/ﬂox mice were generated
by crossing VAChTﬂox/ﬂox (crossed for 5 generations with C57BL/6J)
with the Nkx2.1-Cre mouse line (C57BL/6J-Tg(Nkx2-1- cre)2Sand/J),
purchased from The Jackson Laboratory (JAX stock no. 008661).
Unless otherwise stated, all control mice used were VAChTﬂox/ﬂox
littermates. All procedures were conducted in accordance with
guidelines of the Canadian Council of Animal Care (CCAC) and in
accordance with ARRIVE guidelines, at the University of Western
Ontario with an approved institutional animal protocol (2008127). Only male mice were used for all experiments.

RNA Sequencing
Mouse hippocampal tissue was rapidly dissected, and total RNA
was extracted from individual samples using the PureLink RNA
Mini Kit (Ambion). Two micrograms of total RNA were then
sent to the Centre for Applied Genomics, The Hospital for Sick

Immunoﬂuorescence
Immunoﬂuorescence experiments were performed as previously
described (de Castro et al. 2009). Primary antibodies used were
anti-Cleaved caspase-3 (1:500 Thermo Fisher Scientiﬁc, Catalog
no. PA5-16335), anti-AT180 (1:1000 Thermo Fisher Scientiﬁc,
Catalog no. EN-MN1040), and anti-PSD95. Sections were visualized by Zeiss LSM 510 Meta (Carl Zeiss, Oberkochen, Germany)
confocal system (×40, ×63 objectives, with an N.A. of 1.3 and 1.4,
respectively) and by Leica TCS SP8 (Leica Microsystems Inc., Ontario, Canada) confocal system (×63 objective, with an N.A. of 1.4),
a 488-nm Ar laser and 633-nm HeNe laser were used for excitation
of ﬂuorophores.

Western Blotting
Mouse hippocampi were collected, protein was isolated, and immunoblotting was performed as previously described using RIPA
lysis buffer supplemented with protease and phosphatase inhibitors (Guzman et al. 2011). Band intensities were quantiﬁed
using FluoroChemQ software (Thermo Fisher Scientiﬁc).
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Alzheimer’s disease (AD), the predominant form of dementia, is
pathologically characterized by accumulation of amyloid plaques
and neuroﬁbrillary tangles that ultimately lead to neuronal
death. One of the early alterations identiﬁed in AD-affected individuals with cognitive decline is a profound decrease in basal
forebrain cholinergic neurons (Whitehouse et al. 1982), which
gave rise to the cholinergic hypothesis of AD (Bartus et al.
1982). Accordingly, Alzheimer’s Disease Neuroimaging Initiative
data reveal atrophy of the basal forebrain in individuals with mild
cognitive impairment (Grothe et al. 2014) and increased forebrain
cholinergic atrophy in Alzheimer’s-affected individuals (Grothe
et al. 2013). Cholinergic dysfunction correlates with decreased
hippocampal volume and pathology (Teipel et al. 2014). Furthermore, recent epidemiological data suggest that long-term use of
drugs with anticholinergic activity by elderly individuals increases the future risk of dementia (Gray et al. 2015). These observations reveal an intimate, but poorly understood relationship,
between cholinergic dysfunction and the pathological and cognitive deﬁcits in AD. However, whether cholinergic malfunction
has a causal role in increasing the risk of dementia or regulating
pathology is unknown. Moreover, the causal and temporal relationships between cholinergic malfunctioning and long-term
changes in hippocampal neurons in AD are still unclear.
To test the capacity of cholinergic tone to regulate long-term
functions in target cells, we examined the hippocampal transcriptome in genetically modiﬁed mice with compromised hippocampal cholinergic tone. Using forebrain-speciﬁc deletion of
the vesicular acetylcholine transporter (VAChT), a protein required for acetylcholine (ACh) release (de Castro et al. 2009;
Prado et al. 2013), we unveil that long-term cholinergic deﬁciency
causes global changes in gene expression and alternative splicing
in the hippocampus. This leads to abnormal alternative splicing
of BACE1 with consequent age-dependent changes in amyloid
precursor protein (APP) processing, tau hyperphosphorylation,
hippocampal neuronal loss, and cognitive decline. Comparative
analyses in the AD brain enabled us to identify links between
cholinergic deﬁciency and AD pathology, together supporting
the notion that early cholinergic dysfunction may be a pivotal
step in AD pathology initiation and progression. Our data provide
potential mechanisms to explain how cholinergic deﬁciency may
facilitate pathology in AD.

Children, where the cDNA library was prepared using the TruSeq
Stranded Total Sample Preparation kit (Illumina) and run in a
HiSeq 2500 platform with coverage of 200–250 million pair reads
per lane. Five animals were run per lane to obtain enough coverage for alternative splicing analysis (50 million pair reads per
sample). The sequenced reads were aligned to the mouse genome using the TopHat program against the mouse genome in
Ensembl (version EnsMart72) to enable quantiﬁcation of splice
junctions in addition to gene-level measurements. Differential
gene expression analysis was conducted using the Bioconductor
DESeq package which accounts for the counts binomial distribution (Anders and Huber 2010). Datasets are available on ArrayExpress (http://www.ebi.ac.uk/arrayexpress/) under accession
number E-MTAB-3897.
For human brains, we used the SQUARE™ RNA library construction approach that utilizes different sets of 5′- and 3′-site
speciﬁc primers to segregate all full-length transcripts into subpools deﬁned by the selective nucleotides in the respective primers. Unlike traditional sequencing, which is based on the use
of universal primers that produce a pool of fragmented RNA products for a given gene, we used 12 different sets of 3′-primers that
complement all distinct di-nucleotides at transcript 3′-polyadenylation sites and enable separate sequencing of the corresponding intact RNA molecules for each of the primer sets through
barcoding. This unprecedented depth of segregated brain RNASeq data was made publicly accessible by establishing a user
friendly website where the sequenced variants for any given
brain-expressed transcript can be found (http://apainad.weebly.
com/). Sequencing ﬁles were processed and analyzed for differential expression and functional enrichment.
RNA sequencing libraries made from the temporal gyrus samples yielded an average of 6.0 × 106 (STD = 2.0 × 106) uniquely
aligned 75 base pair (bp) single end reads or approximately
7.0 × 107 (STD = 1.8 × 107) total read counts when combining all
12 SQUARE ﬁelds for each sample. These reads were mapped
against the GRGCh37/hg19 version of the Homo sapiens genome
(http://genome.ucsc.edu/). Transcripts with >1 read per kilobase
per million (RPKM) per SQUARE ﬁeld were deﬁned as being
detected (Hebenstreit and Teichmann 2011). An average of 6610
± 1367 genes per ﬁeld were detected across the 12 ﬁelds (details in
Supplementary Table 3). Expression criteria were set to RPKM > 1
in at least one of the SQUARE ﬁelds, in at least 80% of the tested
donor cohorts.
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Gene Ontology Analysis

Silver Staining

Gene ontology functional analysis was performed using the GOrilla software through the web application. Using the 2 unranked
lists method as described (Eden et al. 2009). KEGG pathway
analysis was performed using the ClueGO plug-in of Cytoscape
(Bindea et al. 2009).

Assessment of argyrophilic cells in the hippocampus was done
by using NeuroSilverTM staining kit II (FD NeuroTechnologies,
Inc., Baltimore, MD, USA), which provides detection of degenerating neurons, including neuronal somata, axons, and terminals.

RNA-Binding Protein Analysis

NeuN immunohistochemistry was performed to estimate the
volume of and number of neurons of hippocampal regions CA1,
CA3, and the dentate gyrus (DG) as described (Beauquis et al.
2014). Brieﬂy, tissue sections were stained with mouse monoclonal anti-NeuN (1:500 PhosphoSolutions, Catalog no. 583-FOX3),
using the ABC kit (Vector Laboratories) and developed with
2 mM diaminobenzidine (Sigma, USA) and 0.5 mM H2O2 in 0.1 M
Tris buffer. The total number of NeuN (T) cells in the various hippocampal regions was estimated using the following formula:
T = (N × V)/t, where N is the cell density, V is the volume of the
structure, and t is the thickness of the section.

qPCR
To measure mRNA expression, total RNA was extracted from
freshly dissected hippocampal tissue, using the Aurum Total
RNA for fatty and ﬁbrous tissue kit (Bio-Rad) according to the
manufacturer’s instructions. cDNA synthesis and qPCR analysis
were performed as previously described (Guzman et al. 2011).
For alternative splicing experiments, the alternative exon levels
were normalized to a constitutively expressed exon from the
same gene.

Primary Neuronal Cultures
Primary mouse hippocampal neurons were produced from E16
embryos as previously described (Ostapchenko et al. 2013). Neurons were cultured for 15 days. Knockdown of hnRNPA2/B1 from
the cultured neurons was achieved by treatment with a shRNA,
as previously described (Berson et al. 2012). A separate set of
cultured neurons was treated with 10 μM of carbachol, 10 μM of
carbachol and 100 μM Atropine, or 100 μM Atropine alone for 48 h.

APP Processing
Biochemical analysis of the processing of APP was performed as
previously described (Dewachter et al. 2002). Forebrains from
VAChT-deﬁcient and control mice were homogenized in 50 mM
Tris–HCl ( pH 8.5); samples were then ultracentrifuged at 135 000
× g for 1 h at 4 °C; and the supernatant was collected and analyzed
by western blotting and ELISA. The pellet was re-suspended and
ultracentrifuged again and diluted in 8 M guanidine HCl to obtain
the insoluble fraction for ELISA analysis.

ELISA
Murine β-amyloid was measured from the hippocampal homogenate using the Wako Human/Rat (Mouse) β-Amyloid (42)
ELISA High-Sensitive Kit (Catalog Number: 292-64501). The
ELISA assay was performed according to the manufacturer’s
protocol.

Congo Red Staining
Congo red staining was performed as previously described
(Thompson and Walker 2015), using a Congo Red solution
(Sigma C-6277) in 100% ethanol.

GSK3 Inhibition
To inhibit GSK3 in VAChTNkx2.1-Cre-ﬂox/ﬂox mice, a cohort of aged
animals (12 months old, n = 5 AR-A014418 treated, n = 4 saline
treated) were implanted with Alzet micro-osmotic pumps
(Model 1004; DURECT Corp, Cupertino, CA, USA). The pumps
were implanted subcutaneously in the intrascapular region
of each mouse. The reservoir of each pump was preloaded with
96 μL of either sterile saline solution or the GSK3 inhibitor
AR-A014418. The pumps administered 5 mg/kg/day of ARA014418, a dose shown to produce a signiﬁcant inhibition of
GSK3 in vivo (Ly et al. 2013). During the implantation procedure,
mice were anesthetized with ketamine (100 mg/kg) and xylazine
(15 mg/kg). Drug treatment lasted for 28 days.

Morris Water Maze
The spatial version of the Morris water maze (MWM) was conducted as described previously to investigate spatial memory
(Vorhees and Williams 2006; Martyn et al. 2012; Kolisnyk et al.
2013a). Brieﬂy, animals were given 4 training trials a day (90 s
each) for 4 days, with a 15-min intertrial interval. If the mice
did not ﬁnd the platform after 90 s during the learning phase,
they were gently directed to the platform. On the ﬁfth day, memory was assessed via a probe trial (60 s), during which the platform is removed and time spent in the target quadrant is
measured. The task was performed in a 1.5-m diameter pool
with 25 °C water. The platform was submerged 1 cm below the
surface of the water, and spatial cues ( posters, streamers, and
plastic props) were distributed around the pool. Sessions were
recorded and analyzed using the ANY-Maze Software.
The classiﬁcation of search strategies mice employed during
training was deﬁned as previously described (Garthe et al. 2009).
An experimenter blind to genotypes scored search strategies as
follows: 1) thigmotaxis, characterized by maintaining close proximity to the wall (>70% trial within 10 cm of wall); 2) random
search, illustrated by global swimming with no classiﬁed strategy;
3) scanning, characterized by a preference for the central pool area
(>50% trial within 35 cm of pool center); 4) chaining, characterized
by searching near the correct radial distance of the platform to the
wall (>75% trial 20–50 cm from the pool center, <15% within 10 cm
of wall, and <10% within 20 cm of pool center); 5) directed search,
characterized by a preference for a passageway toward the
platform or platform quadrant (>80% trial within a 50-cm-wide
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To predict potential RNA-binding proteins that may be implicated in the observed changes in alternative splicing, alternatively spliced sequences were run through the RBPmap software (Paz
et al. 2014) to detect potentially altered RNA-binding proteins.
The list of RNA-binding proteins that were suggested by the software was then run through the Allen Brain Atlas (http://mouse.
brain-map.org/) to ensure that they were expressed in the murine
hippocampus. All RNA-binding proteins not expressed in the
hippocampus were excluded.
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region from the start point to the platform); 6) focal search, characterized by a highly localized search near the platform (≥50%
trial in a circular target zone with a 15-cm radius); and 7) direct
swim, characterized by a maintained heading toward the platform (little to no deviation in path to reach platform from start
point). Total block lengths were the sum of all blocks for 1 strategy and 1 mouse.

Protein Isolation from Human Postmortem Brain Tissue

Statistical Analysis
Sigmastat 3.5 software was used for statistical analysis. Student’s
t-test was used for comparison between 2 experimental groups.
Two-way ANOVA or 2-way ANOVA with repeated measures (RM)
were used when >2 groups were compared.

Results
Forebrain Cholinergic Dysfunction Modiﬁes Expression
Levels of Hippocampal Transcripts and Alternative
Splicing
To determine the contribution of cholinergic tone to the regulation
of hippocampal transcript levels, we used VAChTNkx2.1-Cre-ﬂox/ﬂox
mice, a mouse line with selective deletion of the VAChT gene
from forebrain regions, including the medial septum, which contains cholinergic neurons that project to the hippocampus.
VAChT has been shown to be essential for ACh packaging and
release (Prado et al. 2006; de Castro et al. 2009; Lima Rde et al.
2010). Non-biased, whole-genome transcriptome RNA sequencing of hippocampal samples from 3 VAChT-deﬁcient and 4 control mice yielded a total of 14 200 expressed genes. Comparative
analysis revealed that 1098 genes were differentially expressed
in VAChTNkx2.1-Cre-ﬂox/ﬂox hippocampi compared with control
mice (Fig. 1A,B, FDR corrected P < 0.05). Of those, 763 genes were
upregulated and 362 downregulated in the VAChT-deﬁcient
mice. In addition, a linear regression analysis on reciprocal junction pairs detected roughly 4% of hippocampal transcripts in
VAChTNkx2.1-Cre-ﬂox/ﬂox mice as alternatively spliced in high conﬁdence compared with control mice. Equal proportion of exon inclusion and exclusion events was observed; mainly events of
cassette exons were detected (Fig. 1C), suggesting widespread
changes in several splicing regulation-related pathways and/or
cellular mechanisms (Soreq et al. 2014).
We interrogated these differentially expressed/spliced genes
for involvement in neuronal function and AD-like pathology. A
number of genes involved in critical pathways including PI3KAkt signaling pathway (a regulator of neuronal vulnerability
(Gary and Mattson 2001; Endo et al. 2006)), spliceosome regulation, and regulation of microtubule-based processes were identiﬁed using Gene Ontology (GO) KEGG pathway analysis (Fig. 1D;
see Supplementary Table 1). qPCR validation and correlation
between changes observed in RNA-Seq and in an independent
mouse cohort are shown in Supplementary Figure 1 for the different gene pathways and alternative splicing events. These results

Cholinergic Deﬁcit Triggers Abnormal BACE1
Alternative Splicing and APP Processing
One of the detected abnormally alternatively spliced genes in our
database was the protease BACE1 (Fig. 1D), which is responsible
for the cleavage of APP (Luo et al. 2001). The predicted alternative
splicing event in VAChT-deﬁcient mice is expected to increase
expression of BACE1-501, the active protein isoform (Mowrer
and Wolfe 2008). qPCR analysis validated the predicted splicing
event and demonstrated increased exon 3/4 inclusion for BACE1
(Fig. 2A).
Bioinformatics analysis using the RBP-Map tool revealed an enrichment of binding sites for hnRNPA2/B1 in BACE1 mRNA.
hnRNPA2/B1 is part of a family of RNA-binding proteins that regulate pre-mRNA splicing, trafﬁcking, and maturation (Bekenstein
and Soreq 2013). Notably, AD-associated impairments in cholinergic signaling are accompanied by decreased expression of
hnRNPA2/B1 protein in the AD cerebral cortex and in cholinergic
impaired mice (Berson et al. 2012; Kolisnyk et al. 2013b). Correspondingly, the hippocampus of VAChTNkx2.1-Cre-ﬂox/ﬂox mice
showed reduced hnRNPA2/B1 protein levels (Fig. 2B). We then
investigated whether hnRNPA2/B1 regulates BACE1 splicing by
exposing primary hippocampal cultured neurons to lentiviruscarrying shRNA against hnRNPA2B1. Our results showed changes
in BACE1 splicing similar to cholinergic deﬁciency (Fig. 2C), directly implicating hnRNPA2/B1 in the regulation of BACE1 splicing.
To test for the role of cholinergic signaling and the different
cholinergic receptors in mediating this splicing event, we treated
cultured hippocampal neurons with the cholinergic mimetic carbachol. This treatment was able to decrease the proportion of
BACE1-501. This decrease was blocked by cotreatment with the
muscarinic antagonist atropine (Fig. 2D). These data implicate
muscarinic receptors in the regulation of BACE1 splicing. This
splicing event in BACE1 predicts an increase in the levels of the
mature BACE1 protein, and indeed, immunoblot analysis revealed a 2-fold increase of BACE1 levels in the hippocampus of
VAChT-deﬁcient mice (Fig. 2E).
In late-onset AD, BACE1 expression is upregulated (Hebert
et al. 2008), and it is thought to contribute to age-dependent progression in AD pathology (Ly et al. 2013). We therefore tested for
changes in APP processing in VAChTNkx2.1-Cre-ﬂox/ﬂox mice. Aged
VAChT-deﬁcient mice (11–14 month old) displayed a modiﬁed
pattern of Tris-soluble APP fragments (Fig. 2F), similar to that
of mouse models with APP/PS1 mutations (Oddo et al. 2003;
Jankowsky et al. 2004). In contrast, membrane-bound C-terminal
fragments of APP (α and β CTFs), alterations of which can suggest
impaired proteolytic processing of the protein (reviewed in
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Samples from parietal cortical tissues from age-/sex-matched
controls (n = 6, 3 females and 3 males) and AD-affected individuals
(n = 6, 3 females and 3 males), and information related to age and
demographics have been previously published (Ostapchenko et al.
2013). The samples were homogenized in RIPA buffer supplemented with protease inhibitor cocktail (Calbiochem), and Western
blotting was performed as described above.

suggest that abnormal cholinergic signaling can effectively
modulate several major gene pathways with potential to inﬂuence the function of target cells in the hippocampus.
We also performed small molecule RNA-Seq and additional
miRNA microarray hybridization experiments and observed limited changes in miRNA expression in the hippocampus of VAChTdeﬁcient mice (see Supplementary Fig. 2). VAChTNkx2.1-Cre-ﬂox/ﬂox
hippocampus showed a mature miRNA expression proﬁle with
only marginal differences from controls. Only 7 of 700 detectable
miRNAs were differentially expressed, and of the 20 miRNAs
most highly expressed in the hippocampus, comprising 82% of
total counts, none were differentially expressed (see Supplementary Fig. 2). These ﬁndings point to alternative splicing and transcription, or changes in mRNA turnover, rather than miRNA, as
potential main contributors to phenotypes in VAChT-deﬁcient
mice.
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Figure 1. Forebrain deletion of VAChT induces alterations in hippocampal transcriptome. (A) Principal component analysis of transcripts from the hippocampi of control
(VAChTﬂox/ﬂox; gray circles) and VAChTNKx2.1-Cre-ﬂox/ﬂox (red circles) mice. (B) Cluster analysis of differentially regulated transcripts in the hippocampus of VAChTNKx2.1-Cre-ﬂox/ﬂox
(n = 3) mice compared with controls (n = 4). (C) Number of genes at indicated signiﬁcance cutoff that were found to have an exon inclusion or exclusion event and summary
of alternative splicing events. (D) List of genes from the PI3K-AKT pathway (gray shading), Spliceosome pathway (blue shading), Microtubule polymerization pathway
(green shading) and other AD genes of interest (yellow shading), identiﬁed from KEGG pathway analysis of altered transcripts in VAChTNKx2.1-Cre-ﬂox/ﬂox mice. For each
gene, corresponding fold change, corrected statistical signiﬁcance levels, and RNA expression change are also shown. Altered mRNA expression of these genes has
been conﬁrmed by qPCR (see Supplementary Fig. 1).

(Selkoe 2000)), were similar in VAChT-deﬁcient mice and controls
(Fig. 2G). APP processing was not modiﬁed in aged Nkx2.1-Cre
mice (see Supplementary Fig. 3A), suggesting that this effect is
due to cholinergic dysfunction rather than to Cre expression.
We then assessed the levels of mouse amyloid peptides
using an ELISA kit validated for both mouse and human
Aβ peptides (Teich et al. 2013). The hippocampus of aged

VAChTNkx2.1-Cre-ﬂox/ﬂox mice showed increased levels of soluble
mouse Aβ peptide compared with controls (Fig. 2H), reaching
about one-third of the levels of those found in aged 5XFAD
mouse model of AD, which is one of the most aggressive models
of AD amyloidosis. In comparison, insoluble amyloid peptide
was undetectable in the brains of VAChT-deﬁcient mice, whereas it was highly abundant in the 5XFAD mice (Fig. 2H). In
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the same gene (n = 6, data are mean ± SEM; **P < 0.01). (B) Representative western blot and quantiﬁcation of hnRNPA2/B1 protein expression in the hippocampus of
controls (VAChTﬂox/ﬂox; gray bars) and VAChTNKx2.1-Cre-ﬂox/ﬂox (red bars) mice. hnRNPA2/B1 expression was normalized to actin (n = 4, data are mean ± SEM;
**P < 0.01). (C) Quantiﬁcation of the BACE1 alternative splicing in primary neuron cultures treated with hnRNPA2B1-shRNA (*P < 0.05). (D) Quantiﬁcation of the BACE1
alternative splicing in primary neuron cultures treated with 10 mM Carbachol and Atropine (n = 4, data are mean ± SEM; **P < 0.05). (E) Representative western blot and
quantiﬁcation of BACE1 protein levels in the hippocampus of controls (VAChTﬂox/ﬂox; gray bars) and VAChTNKx2.1-Cre-ﬂox/ﬂox (red bars) mice. BACE1 expression
was normalized to actin (n = 3, data are mean ± SEM; *P < 0.05). (F) Biochemical analysis and quantiﬁcation of murine APP fragments in brain homogenates of aged
expressed as a % ([Signal intensity of the fragment/signal intensity of full-length protein] × 100). Eleven- to 14-month-old controls (VAChTﬂox/ﬂox; gray bars),
VAChTNKx2.1-Cre-ﬂox/ﬂox (red bars), and APPswe/PS1dE9 (green bars) hippocampal tissue extracts were resolved by western blotting (data are mean ± SEM n = 3). (G)
Analysis of membrane-bound APP fragments in aged controls (VAChTﬂox/ﬂox; gray bars) and VAChTNKx2.1-Cre-ﬂox/ﬂox (red bars) and APPswe/PS1dE9 (green bars)
(data are mean ± SEM, n = 3). (H) Murine soluble and insoluble levels of Aβ42 in aged (11–14 months old) controls (VAChTﬂox/ﬂox; gray bars), VAChTNKx2.1-Cre-ﬂox/
ﬂox (red bars), and 5xFAD (black bars) measured by ELISA (n = 4). (I) Congo red staining in the CA1 region of the hippocampus in aged (11–14 months old) controls,
VAChTNKx2.1-Cre-ﬂox/ﬂox, and 5xFAD mice. Arrowheads indicate positive Congo red staining suggestive of amyloid plaques. (n = 3, Scale bar, 100 μm).

addition, neither control nor VAChT-deﬁcient mice displayed
positive Congo red staining, unlike brain sections from 5XFAD
mice, which exhibited numerous Congo red plaques (Fig. 2I).
These data indicate that although VAChT-deﬁcient mice
show increased levels of soluble Aβ peptides, they do not
seem to accumulate in extracellular amyloid plaques. Indeed,
the murine amyloid peptide is much less prone to aggregation
than human Aβ due to 2 amino acid changes (Jankowsky et al.
2007).

Cholinergic Deﬁcit Leads to Age-Dependent
Hippocampal Tauopathy
In AD, increased levels of soluble Aβ peptides are thought to precede abnormal phosphorylation of the microtubule-associated

protein tau (Iqbal et al. 2010). Previous reports suggested
that cholinergic activity and tau phosphorylation might be
interrelated (Hellstrom-Lindahl 2000). Therefore, we used immunoﬂuorescence to assess levels of the AT180 tau epitope
(T231/S235) in the hippocampus of VAChT-deﬁcient mice. This
phosphorylation-dependent antibody speciﬁc to pT231 has been
shown to label approximately 70% of paired helical ﬁlaments
(PHF) in AD brains (Goedert et al. 1994). Phosphorylation at this
epitope reduces the binding of tau to microtubules potentially
increasing its toxicity (Lim et al. 2008). Immunoﬂuorescence
imaging revealed a robust increase of AT180 immunoreactivity
in the hippocampus of VAChTNkx2.1-Cre-ﬂox/ﬂox mice compared
with aged-matched controls (Fig. 3A; 11–14 months old mice). To
test whether the positive immunoreactivity of pTau in VAChTdeﬁcient mice is associated with an induction of pathological
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Figure 2. Disrupted APP processing and alternative splicing of BACE1 in cholinergic-deﬁcient mice. (A) qPCR analysis of alternative splicing events for BACE1 in the
hippocampus of controls and (VAChTﬂox/ﬂox; gray bars) and VAChTNKx2.1-Cre-ﬂox/ﬂox (red bars). Alternative exon levels are normalized to a constitutive exon from
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Cholinergic Deﬁciency Exacerbates Age-Dependent
Neuronal Vulnerability and Impaired Learning
Synaptic health is compromised in mouse models of AD,
and synaptic loss is a consistent ﬁnding in AD-affected individuals (Klein 2006). To examine synaptic integrity, we stained
hippocampal sections with the synaptic marker PSD95. Aged
VAChTNkx2.1-Cre-ﬂox/ﬂox mice displayed hippocampal decreases
in PSD95 immunoreactivity, increased microglial activation,
and upregulation of inﬂammatory markers, in comparison to
age-matched controls, suggesting large-scale synaptic dysfunction in these mutants (Fig. 4A–C). These observations predict
neuronal vulnerability; therefore, we stained brain sections
with silver, which accumulates in neurons that are more vulnerable to neurodegeneration (DeOlmos and Ingram 1971). Aged
VAChT-deﬁcient mice presented intensiﬁed silver staining compared with controls; this increased silver staining was not observed in young VAChT-deﬁcient mice (Fig. 4D,E), suggesting
that long-lasting decrease in cholinergic signaling may increase
the vulnerability of hippocampal neurons. Parallel staining of

Figure 3. Hippocampal cholinergic failure triggers tauopathy in an age-dependent manner. (A) Phosphorylated Tau levels monitored by immunolabeling with
phosphorylation-dependent antibodies speciﬁc to pT231. Representative images of pT231 and Hoeschst labeling in the hippocampus of aged (11–14 month old)
controls (left) and VAChTNKx2.1-Cre-ﬂox/ﬂox (right) mice. (n = 3, Scale bar, 100 μm). (B) Representative images of MC1 and Hoeschst labeling in the CA1 region of
the hippocampus of controls (left) and VAChTNKx2.1-Cre-ﬂox/ﬂox (right) mice. (n = 3, Scale bar, 100 μm). (C) Western blot analysis of controls (VAChTﬂox/ﬂox) and
VAChTNKx2.1-Cre-ﬂox/ﬂox aged (11–14 months old) hippocampal samples for tau using phosphorylation-dependent anti-tau antibodies pT231, Ser 262, and for total Tau
protein expression. (D) Quantiﬁcation of Western blots. pT231, Ser 262, and total tau expression were normalized to actin (n = 4, data are mean ± SEM; **P < 0.01).
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tau, immunoﬂuorescence with MC1 antibody was performed.
Positive reactivity of conformation-dependent MC1 antibody
depends on the proximity of N-terminal (aa 7–9) and C-terminal
(313–333) amino acid sequences of tau, which is one of the
earliest alterations of tau in AD (Wolozin et al. 1986; Weaver
et al. 2000). Immunostaining with MC1 revealed positive immunoreactivity in the hippocampus of aged cholinergic-deﬁcient
mice, but not in age-matched controls (Fig. 3B).
In agreement with the immunoﬂuorescence data, hippocampal extracts of VAChTNkx2.1-Cre-ﬂox/ﬂox mice showed approximately 4-fold increases in pTau immunoreactive bands,
including higher order oligomers detected with AT180, compared with controls (Fig. 3C,D). On the other hand, total tau
and pTauS262 levels were unmodiﬁed in VAChT-deﬁcient mice
(Fig. 3C,D). Taken together, our data indicate that deletion of
hippocampal VAChT induces hyperphosphorylation of tau and
leads to tau pathological conformation as detected by MC1,
both of which are consistently observed in AD. These data suggest the potential for neuronal toxicity due to cholinergic
dysfunction.
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protein levels in the hippocampus of aged controls or VAChTNkx2.1-Cre-ﬂox/ﬂox mice and corresponding (B) Western blot analysis for PSD-95 protein levels in the
hippocampus of VAChTNkx2.1-Cre-ﬂox/ﬂox mice compared with controls (t (6) = 4.286, P = 0.0052, n = 4). (C) Immunoﬂuorescence imaging and quantiﬁcation showing CD-68
immunoreactivity in the hippocampus of aged VAChTNkx2.1-Cre-ﬂox/ﬂox mice and levels of IL-1 transcripts as measured by qRT–PCR (t (10) = 2.312, P = 0.0434, n = 6) and IL-6
transcripts as measured by qRT–PCR (t (10) = 2.882, P = 0.0204) (data are mean ± SEM, *P < 0.05, n = 6). (D) Representative images of silver staining in the CA1 region of young (3–
6 months) and aged (11–14 months) mice. Scale bar, 100 μm. (E) Quantiﬁcation of silver stain-positive cells between young and aged hippocampi of controls (VAChTﬂox/ﬂox;
gray bars) and VAChTNKx2.1-Cre-ﬂox/ﬂox (red bars) (n = 5, data are mean ± SEM, **P < 0.01). (F) Representative immunoﬂuorescence images for activated caspase 3 labeling in
the hippocampi of young (Top) and aged (Bottom) mice. Quantiﬁcation of activated caspase-3 immunolabeling in young and aged hippocampi of controls (VAChTﬂox/ﬂox;
gray bars) and VAChTNKx2.1-Cre-ﬂox/ﬂox (red bars) (n = 3, data are mean ± SEM, *P < 0.05, **P < 0.01, Scale bar, 100 μm). (G) Distribution of neuron-speciﬁc nuclear antigen
(NeuN)-positive neurons in the CA1 region of the hippocampus in young (top) and aged (bottom) mice (Scale bar, 100 μm). Quantitative comparison of the number of
neurons labeled by NeuN in the CA1 region of the hippocampus in young (top) and aged (bottom) mice (n = 6, data are mean ± SEM, *P < 0.05). (H) Representative
examples of the 7 classiﬁed criteria to score the strategies mice used to perform in the MWM. Strategies are color coded. (I) Strategy plot reﬂecting the mean strategyrecruitment values for the ﬁrst and fourth trials of each day for young (left) and aged (right) mice. Quantiﬁcation comparison of total block length values of individual
mice and their employed strategies over the course of 4-day training period. Gray bars represent control mice and red bars represent VAChT-deﬁcient mice (n = 8, data
are mean ± SEM; *P < 0.05, **P < 0.01).

hippocampal sections from aged 5XFAD mice compared with
control mice performed as a positive control revealed similar
increases in silver staining as that for VAChT-deﬁcient mice
(see Supplementary Fig. 4).
Activated caspase-3, a marker of apoptosis, was augmented
in young VAChTNkx2.1-Cre-ﬂox/ﬂox mice compared with controls
(Fig. 4F). However, aging signiﬁcantly increased the number of activated caspase-positive cells in VAChT-deﬁcient mice compared
with controls (Fig. 4F). Also, young VAChT-deﬁcient mice showed
no alteration in the number of NeuN-positive cells across all regions of the hippocampus (Fig. 4G; see Supplementary Fig. 4);
while NeuN-positive cells in CA1 and CA3 region, but not dentate
gyrus, were decreased in aged VAChT-deﬁcient mice (Fig. 4G;
see Supplementary Fig. 4), predicting functional implications
for this aging-related hippocampal neuronal vulnerability.
Thus, impaired cholinergic signaling induces global changes in
transcript levels, followed by age-related exacerbation of synaptic and neuronal vulnerability.
To test whether long-lasting cholinergic failure may have agedependent consequences in cognitive function, we subjected
aged (11–14 months old) VAChT-deﬁcient mice to the MWM
task. Young VAChT-deﬁcient mice (3–6 months old) show
little difference from controls in acquisition performance
on the MWM task (Al-Onaizi et al. 2016). In contrast, aged
VAChT-deﬁcient mice took signiﬁcantly longer and swam a

greater distance than age-matched controls to ﬁnd the platform
across the 4 days of acquisition (see Supplementary Fig. 4E,F).
Furthermore, aged VAChT-deﬁcient mice used distinct strategy
preferences to ﬁnd the platform, indicating that their deteriorated performance was due to modiﬁed learning capacities. Briefly, the analysis of search strategies used by each animal was
based on a ﬁxed set of criteria (Fig. 4H). At a young age, both controls and VAChTNkx2.1-Cre-ﬂox/ﬂox mice predominantly used a more
direct strategy to reach the platform (strategies 5/6/7, Fig. 4I). In
contrast, aged VAChT-deﬁcient mice used random swimming
predominantly as their strategy to acquire the task (strategy 2,
Fig. 4I), while aged control mice maintained the use of more direct strategies. Aged VAChT-deﬁcient mice also exhibited deﬁcits
in the probe trial (see Supplementary Fig. 4G). Taken together,
these results suggest that long-term cholinergic deﬁciency in
VAChTNkx2.1-Cre-ﬂox/ﬂox mice led to progressive loss of neurons in
the hippocampus that worsened spatial information acquisition
and cognitive functioning.

Cholinergic-induced Age-Dependent Pathology Is
Partially Mediated by GSK3 Activation
In addition to APP processing and tau hyperphosphorylation, we
observed other critical biochemical pathways altered in response
to cholinergic deﬁciency, including aberrant GSK3 signaling,
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Figure 4. Hippocampal cholinergic failure leads to increased neuronal vulnerability and worsens cognitive functioning. (A) Immunoﬂuorescence imaging showing PSD-95
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and pAKT(Thr308) levels in the hippocampus of VAChTNkx2.1-Cre-ﬂox/ﬂox mice. (n = 4, data are mean ± SEM, *P < 0.05) (B) Representative Western blot and quantiﬁcation
analysis of phospho-GSK3α and β in the hippocampus of aged (11–14 months old) controls (left) and VAChTNKx2.1-Cre-ﬂox/ﬂox (right) mice. Levels of pGSK3α and β to the
respective GSK3 (n = 5 and 3, data are mean ± SEM, **P < 0.01, ***P < 0.001). (C) Implantation of osmotic pumps and delivery of AR-A014418 to aged VAChTNKx2.1-Cre-ﬂox/ﬂox
mice. (D) Representative western blot and quantiﬁcation analysis of phospho-GSK3α and β in the hippocampus of aged VAChTNKx2.1-Cre-ﬂox/ﬂox mice treated with ARA014418 or saline. (E) Western blot analysis aged VAChTNKx2.1-Cre-ﬂox/ﬂox treated with AR-A014418 or saline for Tau hyperphosphorylation at T231, MCI
immunopositive tau, and total Tau protein expression. (F) Representative immunolabeling of reduced T231 Tau in the hippocampus of aged VAChTNKx2.1-Cre-ﬂox/ﬂox
mice (Scale bar, 100 μm). (G) Western blot analysis for PSD-95 protein levels in the hippocampus of VAChTNkx2.1-Cre-ﬂox/ﬂox mice treated with AR-A014418 or saline.
(n = 4 saline treated, n = 5 AR-A014418 treated, data are mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001).

which has also been shown to play multiple roles in AD (Gary and
Mattson 2001; Endo et al. 2006). As several genes that regulate the
PI3-AKT pathway were upregulated in VAChT-deﬁcient mice
(Fig. 1D; see Supplementary Fig. 1), we tested for dysregulation
of PI3-AKT signaling pathway in these mice by evaluating
the phosphorylation status of the AKT protein and its downstream target GSK3. AKT presented decreased phosphorylation
at residue Ser473, with unmodiﬁed Thr308 phosphorylation, in
VAChTNkx2.1-Cre-ﬂox/ﬂox hippocampus compared with controls
(Fig. 5A). Additionally, GSK3α/β tyrosine phosphorylation, which
reﬂects activation of GSK3, was increased in these mutants
(Fig. 5B). Hence, in addition to increased levels of proteins involved in AD pathology, these results suggest potential contributions of GSK3 activation in cholinergic-induced deﬁcits.

To test the role of GSK3 in the abnormal hippocampal changes
in cholinergic-deﬁcient mice, we chronically treated a cohort of
aged (11 months old) VAChTNKx2.1-Cre-ﬂox/ﬂox mice with the GSK3
inhibitor AR-A014418 (Fig. 5C). After 28 days of treatment, we
found that VAChT-deﬁcient mice treated with AR-A014418
showed a signiﬁcant decrease in GSK3 α and β tyrosine phosphorylation compared with VAChTNKx2.1-Cre-ﬂox/ﬂox mice treated with
saline (Fig. 5D). Increased phosphorylation at Tyr residues 216
or 279 augments GSK3 activity (Hur and Zhou 2010), and examining GSK3 phosphorylation at these residues has been used to determine the effectiveness of AR-A014418 (Carter et al. 2014;
Yadav et al. 2014). We then assessed some of the key alterations
detected in the hippocampus of aged VAChTNKx2.1-Cre-ﬂox/ﬂox
mice. AR-A014418 treatment was able to signiﬁcantly decrease
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Figure 5. Cholinergic-mediated tau hyperphosphorylation is regulated by GSK3 activation. (A) Representative Western blot and quantiﬁcation analysis of pAKT(S473)
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Cholinergic Dysfunction in Human AD Brains
Whether cholinergic genes are expressed in lower levels in
human AD brain compared with cognitively alert controls and
may contribute to phenotypes detected herein is not fully understood. To examine that, we extracted total RNA from a cohort of
24 adult human temporal gyrus samples collected at the

Netherland Brain Bank (sample information in Supplementary
Table 2), including 8 sporadic AD patients and 16 from agematched controls. We then proﬁled AD-related transcript differences by adopting the particularly deep SQUARE™ RNA library
construction approach (Hebenstreit and Teichmann 2011). Of
those, 10 885 genes that were expressed showed a signiﬁcant
change. Next, we quantiﬁed the levels of those transcripts composing the expanded family of cholinergic regulator genes (Soreq
2015). Detected cholinergic transcripts showed signiﬁcantly
lower expression levels than other protein-coding genes in the
temporal gyrus of AD patients compared with age-matched
controls (Fig. 6A).
Brain samples from a distinct cohort of AD patients (Ostapchenko et al. 2013) supported the RNA-Seq analysis results by
showing a signiﬁcant VAChT loss in AD brains compared with
age- and sex-matched controls (Fig. 6B), in agreement with previous observations (Efange et al. 1997; Chen et al. 2011). Furthermore, the cohort of AD brains exhibited 50% decrease in
hnRNPA2/B1 protein levels compared with age-/gender-matched
controls (Fig. 6C), conﬁrming previous results obtained with a distinct AD cohort (Berson et al. 2012). Additionally, we found a signiﬁcant positive correlation between VAChT and hnRNPA2/B1
protein levels (Fig. 6D). AD brain samples also showed drastic
increases in tau-Thr231 phosphorylation (Fig. 6E), which was inversely proportional to the levels of VAChT (Fig. 6F). Our ﬁndings
using cholinergic-deﬁcient mice support an intricate timeline
whereby cholinergic dysfunction per se precedes and may have
strong inﬂuence in pathological changes observed in AD.

Figure 6. Cholinergic failure in human AD brain associates with loss of hnRNPA2/B1 and hyperphosporylation of tau. (A) Cholinergic genes are downregulated in the AD
temporal gyrus. Shown are cumulative distribution functions (CDFs) for the global change in the expanded family of cholinergic genes (as listed in Soreq 2015) compared
with global expression patterns between AD and control brain tissues (n = 8, Kolmogorov–Smirnov P = 0.03, red and blue lines, correspondingly). (B) Western blot analysis of
VAChT protein levels in AD brains. (C) Western blot analysis of hnRNPA2/B1 protein levels in AD brains. (D) Correlation between hnRNPA2/B1 protein levels and VAChT
protein levels in AD brains. (E) Western blot analysis of Tau-Thr231 phosphorylation levels and (F) correlation between VAChT protein levels and Tau Thr-231
phosphorylation levels. (n = 6, data are mean ± SEM, *P < 0.05, **P < 0.01).
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tau T231 hyperphosphorylation and MC1-immunopositive tau in
Western blots (Chai et al. 2011; Petry et al. 2014), by approximately
50% in VAChTNKx2.1-Cre-ﬂox/ﬂox mice compared with saline-treated
VAChTNKx2.1-Cre-ﬂox/ﬂox mice. Total levels of tau were unchanged
(Fig. 5E). Immunoﬂuorescence staining (Fig. 5F) also demonstrated
reduced levels of T231 hyperphosphorylated tau in AR-A014418treated mice. Compared with saline-treated animals, AR-A014418
treatment was able to signiﬁcantly increase levels of PSD-95
protein (Fig. 5G).
Interestingly, we observed no changes in protein levels of BACE1
following AR-A014418 treatment in aged VAChTNKx2.1-Cre-ﬂox/ﬂox
mice (see Supplementary Fig. 5A). Furthermore, AR-A014418
treatment did not alter the alternative splicing event in the
BACE1 gene (see Supplementary Fig. 5A). Together, these data
suggest that the hnRNPA2/B1-mediated alternative splicing and
subsequent increase in BACE1 protein level are not mediated by
GSK3 activation. Surprisingly, despite reduced levels of hyperphosphorylated tau, 1-month AR-A014418 treatment was unable
to decrease the elevated levels of activated caspase-3, (see Supplementary Fig. 5C,D).

Cholinergic Control of Transcription and Pathology

Discussion

| 11

AD (Hebert et al. 2008). Our data suggest potential mechanisms
by which cholinergic regulation can affect BACE1 expression
and AD pathology. Interestingly, our data suggest that changes
in alternative splicing occurs post-transcriptionally and independent of GSK3 signaling. Thus, cholinergic deﬁciency may
affect BACE1 expression differently than previously described
in AD, in which GSK3 can regulate BACE1 transcription by increasing promoter activity (Ly et al. 2013). Our ﬁndings promote
upstream cholinergic mechanisms as a target for diminishing
aberrant APP processing in AD.
In addition to increased levels of soluble Aβ, VAChTNkx2.1-Creﬂox/ﬂox
mice also show tau hyperphosphorylation, which destabilizes microtubules and signiﬁcantly disrupts axonal transport.
Tau hyperphosphorylation may also contribute to increased
vulnerability leading to neuronal death (Billingsley and Kincaid
1997). In fact, VAChT-deﬁcient mice show age-dependent
increases in hippocampal argyrophilic staining and neuronal
death.
Oligomeric protein aggregation has been linked to toxicity
and to neurodegenerative disorders, including AD (Maeda et al.
2006). The formation of NFTs alone is insufﬁcient for neurodegeneration, yet oligomeric tau may contribute to neurodegeneration and synaptic loss in AD (Berger et al. 2007; de Calignon et al.
2012). These observed changes in tau in VAChT-deﬁcient mice
(i.e., increased oligomer formation), the associated age-dependent
increase in immunoreactivity of activated caspase-3, and ultimately neuronal loss all support a relationship between cholinergic
failure and AD-like pathology in mice.
Tau hyperphosphorylation can occur due to the increased
activity of GSK3, which subsequently leads to an array of impairments, including disruption of LTP (Hooper et al. 2007) and cell
death in vitro (Zheng et al. 2002). GSK3 overactivation is an
important hallmark in AD (Hooper et al. 2008). Thus, the GSK3
overactivation observed in VAChT-mutant mice represents a
potential mechanism by which reduced cholinergic activity
may have multiple inﬂuences in AD pathology in target cells.
We tested this hypothesis by pharmacological inhibition of
GSK3 in aged VAChT-deﬁcient mice. GSK3 inhibition was able
to decrease tau hyperphosphorylation. Also, GSK3 inhibition
partially restored PSD95 protein levels, but did not decrease caspase-3 activation. These ﬁndings demonstrate that cholinergicinduced changes in tau and in amyloid processing are potentially
independent of each other and suggest that cholinergic dysfunction is contributing to the pathological outcomes in these
animals by altering multiple pathways. The pharmacological
inhibition of GSK3 was tested in mice in which pathology was already present (11- to 12-month-old mice). Hence, further experiments should test longer treatments with the compound or
genetic ablation of GSK3 genes in VAChT-deﬁcient mice to comprehensively dissect the contribution of overactive GSK3 in other
phenotypes.
Aged VAChT-deﬁcient mice showed a decrease in the number
of hippocampal neurons, a result that was not observed in young
mutants, suggesting that cholinergic tone may play a role in
guarding hippocampal neuronal health. Additionally, aged
VAChT-deﬁcient mice showed increased neuroinﬂammation
and reduced number of synapses, which are pathologies
observed in AD brains (DeKosky and Scheff 1990; Smale et al.
1995; Rogers and Shen 2000). Mice with excess acetylcholinesterase, which present decreased cholinergic function, also show
neuroinﬂammation (Shaked et al. 2009). Furthermore, similar to
our observation, mice lacking the β2 nicotinic receptor subunit
show age-dependent loss of hippocampal neurons (Zoli et al.
1999). Of note, hippocampal neuronal loss is a critical feature in
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We employed transcriptome and biochemical assays on cholinergic-deﬁcient mouse brain samples to explore the impact of
long-lasting forebrain cholinergic dysfunction. Whole-genome
RNA sequencing demonstrated that cholinergic deﬁciency modiﬁes expression levels and isoform abundance of several key transcripts related to Alzheimer’s disease in the hippocampus of
VAChT-deﬁcient mice. Cholinergic-mediated abnormal BACE1
mRNA splicing in VAChT-mutant mice increased BACE1 protein
levels and APP processing. Accordingly, cholinergic deﬁciency
caused a 10-fold increase in soluble mouse Aβ peptides, agedependent hippocampal tauopathy, synaptic abnormalities,
neuronal inﬂammation, neuronal vulnerability, and cognitive
decline. We also showed that GSK3 activation is critical for cholinergic modulation of tau hyperphosphorylation and synaptic
vulnerability. Furthermore, we conﬁrmed that human AD brains
present cholinergic dysfunction and showed that it correlates to
changes in the levels of hnRNP A2/B1 and hyperphosphorylated
tau. Our ﬁndings indicate that cholinergic impairments confer
widespread hippocampal damage and malfunction. Furthermore, our data support a causal role for cholinergic signaling as
a surveillance mechanism controlling hippocampal transcript
levels, maintenance of cognitive function, and neuronal viability
in mice.
Our RNA sequencing analysis revealed a group of differentially expressed transcripts related to spliceosome regulation in
the hippocampus of VAChTNkx2.1-Cre-ﬂox/ﬂox mice, suggesting
that the splicing machinery in these mutants could be altered.
In fact, a signiﬁcant number of alternative splicing event abnormalities were observed in the hippocampus of VAChT-deﬁcient
mice. These results are consistent with previously reported global changes of alternative splicing in the AD brain (Tollervey
et al. 2011; Berson et al. 2012; Bai et al. 2013). Importantly, spliceosome signaling pathway changes can have broad implications for
gene regulation (reviewed in (Shin and Manley 2004)).
Alternative splicing in the nervous system is particularly
widespread and is essential for multiple aspects of neuronal
function (Raj and Blencowe 2015). However, the signal transduction pathways that regulate splicing are not well known (Shin and
Manley 2004). Our study adds a role for cholinergic signaling in
the maintenance of balanced alternative splicing. At least part
of the cholinergic control of alternative splicing seems to involve
hnRNPA2/B1. We have shown that cholinergic deﬁciency in the
cortex (Berson et al. 2012; Kolisnyk et al. 2013b) and hippocampus
(Fig. 2B) leads to decreased expression of the hnRNPA2/B1 protein. Related work demonstrated that hnRNPA2/B1 is a cholinergic regulated splicing factor (Kolisnyk et al. 2016). Importantly,
knockdown of hnRNPA2/B1 in cultured hippocampal neurons
shifted splicing of BACE1 mRNA towards increased expression
of mRNA species coding for the BACE1-501 protein isoform
as observed in the hippocampus of VAChT-deﬁcient mice. This
splicing change led to increased expression of the BACE1
protein that was accompanied by a pattern of APP processing
similar to that observed in commonly used mouse models
of AD. The alternative splicing event in BACE1 observed in
VAChT-mutant mice is regulated by M1 muscarinic receptors
(Kolisnyk et al. 2016).
Cholinergic tone has been thought to regulate APP processing
through muscarinic receptors (Nitsch et al. 1992; Davis et al.
2010). Speciﬁcally, M1 signaling has been shown to regulate the
stability of the BACE1 protein (Davis et al. 2010). BACE1-501 is a
more stable and active form of the protein (Mowrer and Wolfe
2008). Remarkably, BACE1 expression is increased in late-onset
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muscarinic acetylcholine receptors. Long-term cholinergic signaling maintains transcriptome integrity likely by a combination of muscarinic and nicotinic activation.
These maintain balance of signaling pathways that regulate AD-like pathology. (B) Conversely, in cholinergic-deﬁcient mice, which models long-term cholinergic
dysfunction, lack of signaling by muscarinic and nicotinic receptors affects differential expression of spliceosome-related genes and reductions in hnRNPA2/B1.
BACE1 mRNA is abnormally spliced leading to an increase of BACE1 expression. As a consequence, APP processing is altered, yielding accumulation of soluble Aβ
peptides. Furthermore, abnormal gene expression inﬂuences AKT-GSK3 modulatory genes with consequences for AKT and GSK3 phosphorylation. These changes
contribute to increases in pathological tau phosphorylation and misfolding, neuroinﬂammation, synaptic loss, hippocampal neuronal death, and ultimately leading
to cognitive decline in these animals.

AD, which is not observed in mouse models overexpressing
APP and/or presenilin 1 with human AD mutations (Stein and
Johnson 2002). Hence, long-term cholinergic deﬁciency may
model this aspect of AD in a better way. Potential mechanisms involved in cholinergic dysfunction-induced pathology are shown
in Figure 7.
In line with an age-dependent loss of hippocampal neurons,
we found that aged VAChT-deﬁcient mice showed signiﬁcant
impairments in their learning strategy in the MWM task. Poor
performance and acquisition on the MWM task have been associated with loss of neurons in the hippocampus (Olsen et al.
1994). This suggests that neuronal loss in the hippocampus has
functional consequences in mice as well. In AD brains,
we found evidence of cholinergic decline and showed a striking relationship between VAChT levels and tau hyperphosphorylation. Together with the mouse data, these observations
support the notion that deﬁcient cholinergic signaling in
AD may correlate to key pathological events, including tau
hyperphosphorylation.
Our data reveal that cholinergic deﬁciency can affect a number of transcriptional processes, disturb splicing of key genes, and
interfere with protein networks that normally protect neurons.
Interestingly, recent work revealed that basal forebrain cholinergic neurons present intraneuronal Aβ accumulation even in
young adults, which may contribute to their selective vulnerability in AD (Baker-Nigh et al. 2015). Cholinergic neurons are
thought to be highly dependent on the presence of trophic factors
for their optimal function and survival (Naumann et al. 2002;
Boskovic et al. 2014), which may also contribute to their demise.
Regardless of the mechanisms for increased cholinergic vulnerability in AD, it seems that cholinergic dysfunction persisting
for a long period is highly related to hippocampal pathology
and amyloid accumulation (Teipel et al. 2014).

In short, our results suggest that long-term cholinergic failure
per se, which we model by disrupting synaptic cholinergic function, can trigger AD-like pathology in mice. More importantly, we
ﬁnd that long-term cholinergic deﬁciency leads to age-dependent
cognitive decline that is related to neuronal death, a key feature
of late-onset AD that is not modeled in mice overexpressing
human genes with AD-related mutations. Our experiments provide a mechanism to explain how decreased cholinergic tone,
for example due to long-term use of anticholinergic drugs,
could lead to increased risk of dementia (Gray et al. 2015),
which may depend on global changes of RNA metabolism,
including alternative splicing and gene expression. It remains
to be determined whether rescuing cholinergic function prior
to development of AD could have an impact in the risk of dementia or AD-related pathology. However, it is noteworthy that recent
observations in potential prodromal AD-affected individuals indicate that cholinesterase inhibition decreases the rate of hippocampal atrophy by 45% during 1-year treatment (Dubois et al.
2015). Our data point towards cholinergic signaling being a global
mediator of several distinct processes that when dysfunctional
lead to pathology. Developing effective strategies to reverse the
cholinergic deﬁcits in the AD brain may therefore prove to be
more fruitful than speciﬁc therapies based on reversing the individual processes it regulates.
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Figure 7. Summary of ﬁndings. (A) In control animals, cholinergic input from the medial septum regulates target neurons in the hippocampus, through nicotinic and
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1

Cholinergic vulnerability, characterized by loss of acetylcholine (ACh), is one of the hallmarks of Alzheimer’s disease (AD). Previous work
has suggested that decreased ACh activity in AD may contribute to pathological changes through global alterations in alternative splicing.
This occurs, at least partially, via the regulation of the expression of a critical protein family in RNA processing, heterogeneous nuclear
ribonucleoprotein (hnRNP) A/B proteins. These proteins regulate several steps of RNA metabolism, including alternative splicing, RNA
trafficking, miRNA export, and gene expression, providing multilevel surveillance in RNA functions. To investigate the mechanism by
which cholinergic tone regulates hnRNPA2/B1 expression, we used a combination of genetic mouse models and in vivo and in vitro
techniques. Decreasing cholinergic tone reduced levels of hnRNPA2/B1, whereas increasing cholinergic signaling in vivo increased
expression of hnRNPA2/B1. This effect was not due to decreased hnRNPA2/B1 mRNA expression, increased aggregation, or degradation
of the protein, but rather to decreased mRNA translation by nonsense-mediated decay regulation of translation. Cell culture and knockout mice experiments demonstrated that M1 muscarinic signaling is critical for cholinergic control of hnRNPA2/B1 protein levels. Our
experiments suggest an intricate regulation of hnRNPA2/B1 levels by cholinergic activity that interferes with alternative splicing in
targeted neurons mimicking deficits found in AD.
Key words: Alzheimer’s disease; acetylcholine; alternative splicing; hippocampus; VAChT

Significance Statement
In Alzheimer’s disease, degeneration of basal forebrain cholinergic neurons is an early event. These neurons communicate with
target cells and regulate their long-term activity by poorly understood mechanisms. Recently, the splicing factor hnRNPA2/B,
which is decreased in Alzheimer’s disease, was implicated as a potential mediator of long-term cholinergic regulation. Here, we
demonstrate a mechanism by which cholinergic signaling controls the translation of hnRNPA2/B1 mRNA by activation of M1
muscarinic type receptors. Loss of cholinergic activity can have profound effects in target cells by modulating hnRNPA2/B1 levels.

Introduction
Dementia affects roughly 44 million individuals worldwide and
represents a large economic burden (Wimo et al., 2013). Individ-
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uals affected with Alzheimer’s disease (AD) present a profound
decrease in basal forebrain cholinergic neurons (Whitehouse et
al., 1982). These findings led to the cholinergic hypothesis of AD
and the use of cholinesterase inhibitors to mitigate cholinergic
failure (Bartus et al., 1982). Previous work suggests that the use of
cholinesterase inhibitors for one year in possible prodromal ADaffected individuals halved rates of hippocampal atrophy, suggesting an intricate relationship between cholinergic tone and
neurodegeneration (Dubois et al., 2015).
Cholinergic tone can modulate signal processing by changing
electrical properties of cells and by modulating intracellular sigCorrespondence should be addressed to either Marco Prado or Vania Prado, The University of Western Ontario,
1151 Richmond Street North, London, Ontario, Canada N6A 5B7. E-mail: mprado@robarts.ca or vprado@robarts.ca.
DOI:10.1523/JNEUROSCI.4614-15.2016
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naling (Dajas-Bailador and Wonnacott, 2004; Soreq, 2015). In
addition, it has become clear that cholinergic signaling can also
regulate long-term gene expression, miRNAs (Shaked et al., 2009;
Soreq, 2015), and alternative splicing (Berson et al., 2012; Kolisnyk et al., 2013a), all of which can modulate functional properties
of cells (Blencowe, 2006; Novarino et al., 2014). A key protein
that regulates splicing events in AD is the heterogeneous nuclear
ribonucleoprotein (hnRNP) A2/B1, which is reduced in brains of
AD patients due to cholinergic deficiency (Berson et al., 2012;
Kolisnyk et al., 2013a) and is reduced in mice with a conditional
deletion of the vesicular acetylcholine (ACh) transporter in the
forebrain (VAChT) (Kolisnyk et al., 2013a).
hnRNPs are a large family of proteins that package pre-mRNA
into larger hnRNP particles (Dreyfuss et al., 1993). Each of the hnRNPs contain distinct RNA binding motifs, which allows them to
exert their roles in pre-mRNA processing (Weighardt et al., 1996;
Black, 2003). hnRNPA2/B1 is one of the major hnRNP isoforms in
the brain regulating alternative splicing and the transport of mRNA
to distal cellular processes (Han et al., 2010). Importantly, knockdown of hnRNPA2/B1 in vivo caused impairments in learning and
memory (Berson et al., 2012). Together, these findings suggest a
critical role for this RNA binding protein in neuronal function and
cognition.
Previous work suggests that cholinergic tone can regulate levels of
hnRNPA2/B1; however, the mechanisms involved are unclear.
Here, we show that hnRNPA2/B1 is a cholinergic controlled splicing
factor. M1 muscarinic receptor activity is critical for cholinergic regulation of hnRNPA2B1 translation. This work provides a new mechanism by which acetylcholine can influence targeted neurons,
leading to potential widespread changes in neuronal function.

Materials and Methods
Mouse lines. All animals with targeted elimination of VAChT were generated
using the VAChT flox/flox mouse described by Martins-Silva et al. (2011). To
eliminate VAChT from the forebrain, VAChT flox/flox mice were crossed with
C57BL/6J-Tg(Nkx2–1-cre)2Sand/J mice (Xu et al., 2008) to generate
VAChT Nkx2.1-Cre-flox/flox (Al-Onaizi et al., 2016). To eliminate VAChT from
the striatum, the VAChT flox/flox mice were crossed with D2-Cre mice (Drd2,
line ER44) to generate VAChT D2-Cre-flox/flox (Guzman et al., 2011). VAChToverexpressing ChAT-ChR2-EYFP mice were from The Jackson Laboratory
[B6.Cg-Tg(Chat-Cop4*H134R/EYFP)6Gfng/J; Zhao et al., 2011]. Generation of TgR (Shaked et al., 2009), M1 KO (Hamilton et al., 1997), and M4 KO
mice (Gomeza et al., 1999) was described previously. All procedures were
conducted in accordance with guidelines of the Canadian Council of Animal
Care at the University of Western Ontario with an approved institutional
animal protocol (2008-127). Only male mice were used for all experiments.
Immunofluorescence. Immunofluorescence experiments were performed as described previously (Guzman et al., 2011). Primary antibodies used were anti-hnRNPA2/B1 (1:200; Santa Cruz Biotechnology,
catalog #sc-10035), anti-NeuN (1:200; PhosphoSolutions, catalog #583FOX3), and anti-GFAP (1:500; Abcam, catalog #ab7260). Sections were
visualized with a Zeiss LSM 510 Meta confocal system (10!, 40!, and
63! objectives), and a 488 nm Ar laser and 633 nm HeNe laser were used
for excitation of fluorophores.
Western blotting. Mouse hippocampi were collected, proteins were
isolated, and immunoblotting was performed as described previously
using RIPA lysis buffer supplemented with protease and phosphatase
inhibitors (Guzman et al., 2011). Band intensities were quantified using
FluoroChemQ software (Thermo Fisher Scientific).
Subcellular fractionation. To isolate nuclear and cytoplasmic proteins from hippocampal tissue, the NE-PER Nuclear Protein Extraction Kit (Thermo Fisher Scientific) was used following the
manufacturer’s instructions.
Sarkosyl insolubility. Isolation of sarkosyl-insoluble protein was performed as described previously (Bai et al., 2013). Hippocampal tissue was
homogenized in a low salt buffer [10 mM Tris, pH 7.5, 5 mM EDTA, 1 mM
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DTT, 10% (w/v) sucrose, Sigma protease inhibitor cocktail; "10 ml
buffer per gram tissue] to detect total protein, a detergent buffer [the low
salt buffer with the addition of 1% (w/v) sarkosyl (N-lauroylsarcosine)]
for the sarkosyl-soluble fraction, and finally 8 M urea with 2% (w/v) SDS
for the sarkosyl-insoluble fraction.
Ubiquitination assay. The ubiquitination status of the hnRNPA2/B1
protein was determined using previously described protocols (Choo and
Zhang, 2009). Briefly, the hnRNPA2/B1 protein was immunoprecipitated using the Santa Cruz Biotechnology (catalog #sc-10035) antibody
and run on an SDS-PAGE gel. The gel was then blotted with an antiubiquitin antibody (Abcam, catalog #ab7780).
Stereotaxic injections of adeno-associated virus. Injection of AAV virus
was described previously (Al-Onaizi et al., 2016). Briefly, mice were anesthetized with ketamine (100 mg/kg) and xylazine (25 mg/kg), and 1 !l
(titer of "1013 Gene Copies/ml) of AAV8-GFP-Cre or control virus
(AAV8-GFP, Vector BioLabs) was injected into the medial septum (0.98
anteroposterior, 0.1 laterolateral, and 4.1 dorsoventral) of VAChT flox/flox
mice. A recovery period of 4 weeks was given to allow transgene expression before subsequent analyses.
RNA sequencing. Total RNA was extracted from hippocampal tissues.
The cDNA library was prepared using a TruSeq Stranded Total Sample
Preparation kit (Illumina) and run in a HiSeq 2500 platform. Data sets
are available on ArrayExpress (http://www.ebi.ac.uk/arrayexpress/) under accession number E-MTAB-3897.
qPCR and RT-PCR. To measure mRNA expression, total RNA was
extracted from freshly dissected hippocampal tissue using the Aurum
Total RNA for Fatty and Fibrous Tissue kit (Bio-Rad) according to the
manufacturer’s instructions. cDNA synthesis and qPCR analysis were
performed as described previously (Guzman et al., 2011). For alternative
splicing experiments, the alternative exon levels were normalized to a
constitutively expressed exon from the same gene. RT-PCR was performed as described previously (Ribeiro et al., 2007).
Isolation of polysomal RNA. Isolation of polysomal RNA was performed as described previously (Wagnon et al., 2012). Samples were
homogenized in 1.5 ml of ice-cold lysis buffer [20 mM Tris-HCl, pH 7.4,
3 mM MgCl2, 10 mM NaCl, 2% sucrose, 0.3% Triton X-100, 2 mM vanadyl
ribonucleoside complexes (VRCs)] supplemented with protease inhibitors (cOmplete, mini, EDTA-free, Roche). The homogenate was then
centrifuged at 10,000 ! g for 10 min at 4°C, and the supernatant was
transferred to a fresh tube. The lysate was treated with either 30 mM
EDTA or 0.1 mg/ml RNase A for 30 min on ice; if it was to be treated with
EDTA, VRCs were not included in the lysis buffer. Lysate was then carefully layered onto 15–55% of sucrose in 25 mM Tris-HCl, pH 7.4, 25 mM
NaCl, 5 mM MgCl2 (and 30 mM EDTA for the EDTA samples). Gradients
were ultracentrifuged in a Beckman Instruments SW40Ti rotor at
150,000 ! g for 2 h and 25 min at 4°C.
To isolate RNA from the fractions, RNA was collected into 1.5 ml of
7.7 M guanidine-HCl, 2 ml of 100% ethanol was added, and samples were
stored at #20°C. Samples were then centrifuged at 4000 ! g for 50 min at
4°C. The supernatant was removed, and 200 !l DEPC-treated H2O was
added to the pellet. To precipitate the RNA, 500 !l of 100% ethanol, 20 !l
of 3 M sodium acetate, pH 5.2, and 10 !g glycogen were added, and the
samples were stored overnight at #20°C. The samples were then centrifuged at 14,000 ! g for 30 min at 4°C. Pellets were washed with ice-cold
75% ethanol and air dried for 15 min at room temperature. RNA was
resuspended in 30 !l DEPC-treated H2O and quantified by nanodrop
before being converted into cDNA using the Applied Biosystems cDNA
conversion kit. RT-PCR was then performed using primers designed to
amplify hnRNPA2/B1 or "-Actin.
Primary neuronal cultures. Primary cultures of hippocampal neurons
from embryonic day 17 mouse embryos were obtained as described previously (Beraldo et al., 2013). Cultures were maintained in Neurobasal
medium with 2% B-27 supplement (Invitrogen). On day 4, cytosine
arabinoside (2 !M; Sigma) was added to prevent astrocyte growth. Half of
the culture medium was changed every 2 or 3 d. Neurons were cultured
for 15 d.
Pharmacological manipulations in primary neuronal cultures. On the
15th day of culture, neurons were treated with different doses of carbachol (0, 5, 10, or 50 !M) dissolved in saline, and 48 h later, total protein
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Figure 1. Analysis of hnRNPA2/B1 protein levels in genetically modified mice with differential expression of VAChT. A, Representative Western blot and quantification of hnRNPA2/B1 protein
expression in the hippocampus of VAChT flox/flox and VAChT Nkx2.1-Cre-flox/flox mice. hnRNPA2/B1 expression was normalized to actin (n " 6). B, hnRNPA2/B1 protein levels positively correlate with
AAV induced reduction of VAChT. The graph shows values for each individual mice injected either with GFP or CRE. The image is from the medial septum of a virus-injected mice. C, Striatal elimination
of VAChT does not alter hnRNPA2/B1 protein levels in the striatum of VAChT D2-Cre-flox/flox mice (n " 4). D, Transgenic mice overexpressing VAChT have increased hnRNPA2/B1 protein levels
compared to controls (n " 4). E, hnRNPA2/B1 protein levels from the hippocampus of TgR transgenic mice (n " 3). F, No change in hnRNPA2/B1 protein levels compared to controls in the
hippocampus of c567BL/6J-Nkx2.1-Cre mice (n " 3). Data are mean ! SEM. *p # 0.05; **p # 0.01.

was isolated and levels of hnRNPA2/B1 were determined by Western
blotting and immunofluorescence. To evaluate the contribution of nicotinic and muscarinic receptors in regulating hnRNPA2/B1 protein levels, neurons were pretreated with mechamylamine (100 !M), atropine
(100 !M), or both. Then, 1 h later, neurons were treated with carbachol
(10 !M). Finally, to assess the effect of M1 muscarinic activation, neurons
were treated with different doses of AF102B (0, 10, or 100 !M) dissolved
in saline.
Statistical analysis. Data are presented as mean ! SEM unless otherwise stated. GraphPad Prism 6 software was used for statistical analysis.
Comparison between two experimental groups was done by Student’s t
test. When several experimental groups or treatments were analyzed,

one-way ANOVA and, when appropriate, a Tukey’s HSD post hoc comparison test were used.

Results
Cholinergic modulation of hnRNPA2/B1 protein levels
Previous experiments indicated that hnRNPA2/B1 is decreased
in AD brains, but this is not modeled in genetic mouse models of
AD (Berson et al., 2012). In contrast, either genetic or immunotoxin disruption of cholinergic tone led to decreased expression
of hnRNPA2/B1 (Berson et al., 2012; Kolisnyk et al., 2013a). As
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Figure 2. Characterization of decreased hnRNPA2/B1 protein levels in the hippocampus of VAChT-deficient mice. A, B, Representative images of slices stained for NeuN, hnRNPA2/B1 and
Hoeschst in the CA1 region of the hippocampus in controls (A) and VAChT Nkx2.1-Cre-flox/flox mice (B). C, D, Expression of hnRNPA2/B1 in the CA3 (C) and dentate gyrus (D) by immunofluorescence
reveals general decrease of the protein and nuclear localization in VAChT-deficient mice. E, Localization of hnRNPA2/B1 with GFAP glial marker in the hippocampus of VAChT Nkx2.1-Cre-flox/flox mice
(arrowheads). F, Subcellular fractionation assay of hnRNPA2/B1 protein shows that hnRNPA2/B1 is mainly nuclear. Scale bars: 50 !m. Data are mean ! SEM. *p " 0.05.

expected, VAChT Nkx2.1-Cre-flox/flox animals presented a robust decrease in hnRNPA2/B1 levels in the hippocampus (Fig. 1A).
The Nk2.1 promoter turns on Cre expression early during
development (Xu et al., 2008), and, therefore, the resulting decrease in hnRNPA2/B1 levels could potentially be a result of de-

velopmental suppression of cholinergic tone, rather than being
cholinergic regulated in adult mice. To test this possibility, we
deleted the VAChT gene specifically in medial septum neurons
and parts of the diagonal band (Al-Onaizi et al., 2016), which
provides most of the hippocampal cholinergic innervation, of
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Figure 3. Mechanisms of cholinergic regulation of hnRNPA2/B1 protein levels. A, No change in ubiquitination status of hnRNPA2/B1 was observed when hnRNPA2/B1 from the hippocampus of
VAChT deficient mice ( p ! 0.3067; control, n ! 7; VAChT Nkx2.1-Cre-flox/flox mice, n ! 6) was immunoprecipitated using anti-hnRNPA2/B1 antibody and probed with anti-ubiquitin antibody. B,
Sarkosyl insolubility assay shows no aggregation of hnRNPA2/B1 in VAChT Nkx2.1-Cre-flox/flox mice (n ! 4). C, Transcript level of hnRNPA2/B1 in the RNA-Seq data set ( p ! 0.9124, FDR ! 1). D,
Diagram of the alternative splicing in the 3#UTR of hnRNPA2/B1 transcripts. The FL transcript is predicted to be stable and undergo translation, whereas the NMD-sensitive transcript is not (Bonomi
et al., 2013). Primers used to assay this event are show in the schematic. E, Increase in the proportion of NMD$ hnRNPA2/B1 transcripts in the hippocampus of VAChT Nkx2.1-Cre-flox/flox mice (n ! 4).
**p " 0.01.

adult VAChT flox/flox mice using AAV8-Cre virus. AAV8-Creinjected mice showed interrelated decline of both VAChT and
hnRNPA2/B1 proteins, whereas AAV8-GFP-injected mice did
not (Fig. 1B). There was a significant relationship between
VAChT and hnRNPA2/B1 levels (r 2 ! 0.755, p " 0.001; Fig. 1B).
In addition, we tested whether, in the striatum, elimination of
cholinergic tone would affect hnRNPA2/B1 expression by using
VAChT D2-Cre-flox/flox mice with selective striatal VAChT deficiency (Guzman et al., 2011). These mice showed no changes in
hnRNPA2/B1 in their striatum (Fig. 1C), indicating hippocampal
specificity of these effects.
If expression of hnRNPA2/B1 is a cholinergic-regulated
process, one would expect that increased cholinergic tone
should have opposite effects than those observed by decreased
VAChT expression. ChAT-ChR2-EGFP mice overexpress
VAChT in the hippocampus and consequently present increased cholinergic tone and ACh release (Kolisnyk et al.,
2013b). These mice present increased hnRNPA2/B1 protein
levels (Fig. 1D), suggesting that VAChT levels critically regulate hnRNPA2/B1 expression.
Decline of hnRNPA2/B1 could be solely related to VAChT
depletion, or, alternatively, it could reflect the functional loss of
ACh signaling in the CNS. To distinguish between these possibilities, we tested the hippocampus of TgR mice overexpressing
soluble AChE (Shaked et al., 2009), which causes cholinergic insufficiency. TgR mice showed decrease in hnRNPA2/B1 levels
similar to mice with decreased VAChT (Fig. 1E), suggesting that
ACh synaptic levels are causally involved in the regulation of
hnRNPA2/B1 expression. Cre expression by itself had no effect
on hnRNPA2/B1 levels, as can be seen when we compared ex-

pression of hnRNPA2/B1 in the hippocampus of Nkx2.1-Cre and
WT mice (Fig. 1F ). Together, these data give strong support for
the hypothesis that hnRNPA2/B1 is a cholinergic-regulated splicing factor.
RNA binding proteins such as hnRNPA2/B1 are predominantly expressed in the nucleus, but they can accumulate in the
cytoplasm and cause neuronal toxicity (Wolozin, 2012; Kim et
al., 2013). We therefore determined by immunofluorescence
staining whether the localization of hnRNPA2/B1 is changed in
response to decreased cholinergic tone. Compared to controls,
VAChT Nkx2.1-Cre-flox/flox had a decrease in hnRNPA2/B1 immunostaining in the CA1, CA3, and dentate gyrus regions of the
hippocampus (Fig. 2A–D). hnRNPA2/B1 was present mainly in
the nucleus of both neurons (labeled by NeuN; Fig. 2A–D) as well
as in astrocytes ( E) in control mice. We did not observe any shift
in the localization of hnRNPA2/B1 in VAChT-deficient mice,
only an overall decrease in the levels of staining. To confirm these
observations, we used subcellular fractionation to assess whether
VAChT Nkx2.1-Cre-flox/flox mice show changes in hnRNPA2/B1 distribution between the nuclear and cytoplasmic fractions (Fig.
2F ). In both control and VAChT-deficient mice, hnRNPA2/B1
was predominantly nuclear, following the distribution of
the nuclear enzyme PIAS1 (Soares et al., 2013). However,
VAChT Nkx2.1-Cre-flox/flox mice showed consistently reduced nuclear hnRNPA2/B1 levels (Fig. 2F ).
Mechanisms of cholinergic modulation of hnRNPA2/B1
To investigate mechanisms by which cholinergic tone may
regulate the levels of hnRNPA2/B1 protein, we evaluated
ubiquitination, a modification that can facilitate protein deg-
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Figure 4. Forebrain cholinergic tone regulates translation of hNRNPA2/B1 in the hippocampus. A, Hippocampal brain tissue was fractionated on a linear sucrose gradient. Fractions were collected
and analyzed by spectrophotometry to determine position of the monosome (80s), polysomes, and RNA granules. B, RT-PCR of hnRNPA2/B1 transcripts in VAChT flox/flox and VAChT Nkx2.1-Cre-flox/flox
mice in the absence or presence of EDTA. C, RT-PCR of !-actin transcripts in VAChT flox/flox and VAChT Nkx2.1-Cre-flox/flox mice in the absence or presence of EDTA. D, E, Quantification of data for the
hnRNPA2/B1 transcripts from the three different VAChT-deficient and three control mice in the absence or presence of EDTA. F, G, Quantification results for !-actin transcripts from the three different
VAChT-deficient and three control mice in the absence or presence of EDTA. The numbers 1–12 are the fraction numbers. The values plotted are averaged from gels in C. Data shown are means.

radation by the proteasome (Hochstrasser, 1996). Immunoprecipitated hnRNPA2/B1 from the hippocampi of controls
and VAChT Nkx2.1-Cre-flox/flox mice was resolved by SDS-PAGE
and probed with ubiquitin antibodies. VAChT-deficient mice
showed no change in ubiquitination status of hnRNPA2/B1
protein when normalized to total hnRNPA2/B1 protein levels
(Fig. 3A).
We also examined whether cholinergic tone affects aggregation
of hnRNPA2/B1. Notably, hnRNPA2/B1 has a prion-like domain
that favors increased aggregation when mutated (Kim et al., 2013).
Protein aggregation was investigated by fractionating hippocampal
extracts into sarkosyl-soluble and sarkosyl-insoluble fractions (Fig.
3B). In both controls and VAChT-deficient mice, hnRNPA2/B1 was
mainly present in soluble fractions, unlike the U1-70k small nuclear
ribonucleoprotein, which has been shown to be present in insoluble
fractions (Bai et al., 2013; Fig. 3B). This result excluded the option
that cholinergic tone increases aggregation of hnRNPA2/B1. Interestingly, despite different levels of hnRNPA2/B1 protein expression,
both control and VAChT-deficient mice exhibited similar hnRNPA2/B1 mRNA levels as determined by RNA sequencing (Fig.
3C), as observed in AD brains (Berson et al., 2012).
It was reported previously that protein levels of hnRNPA2/B1 are
directly proportional to changes in the RNA editing of the 3! UTR of
its mRNA, with a shift away from a nonsense-mediated decay
(NMD)-sensitive transcript increasing protein levels (Bonomi et al.,
2013; Fig. 3D). We evaluated by qPCR the ratio of NMD-sensitive to
NMD-insensitive versions of the hnRNPA2/B1 transcript in the hippocampus of VAChT Nkx2.1-Cre-flox/flox mice. Compared to controls,
we observed a significant shift toward the NMD" product in
VAChT-deficient mice (Fig. 3E).
We then tested whether cholinergic tone modulation of NMD"
transcript could regulate hnRNPA2/B1 protein expression levels by
limiting protein translation. For this, we studied the recruitment of

hnRNPA2/B1 mRNA to ribosomes. Ribonucleotide-protein complexes (RNPs) were isolated from hippocampal lysates, and sucrose
density gradient fractionation was used to separate polyribosomes
from large neuronal RNA granules (Fig. 4A; Wagnon et al., 2012).
Distribution of hnRNPA2/B1 transcripts in individual fractions was
determined by RT-PCR in three individual mice of each genotype
(Fig. 4B,C). In control mice, hnRNPA2/B1 mRNAs associated
with polysomes and RNA granules, and treatment with EDTA,
which dissociates mRNA from polysomes, equally distributed
hnRNPA2/B1 mRNAs across fractions (Fig. 4D,E). However, in
VAChT Nkx2.1-Cre-flox/flox mice, distribution of hnRNPA2/B1 mRNAs
was widespread throughout the fractions, resembling the distribution observed after EDTA treatment (Fig. 4D,E). The abundant
!-actin mRNA remained unaltered between genotypes, demonstrating specificity toward hnRNPA2/B1 (Fig. 3F,G). These results
indicate that decreased cholinergic tone leads to diminished translational capacity of hnRNPA2/B1 mRNA transcripts to modulate the
efficiency of hnRNPA2/B1 protein translation.
Muscarinic signaling regulates hnRNPA2/B1 translation by
an NMD mechanism
To further understand how cholinergic signaling regulates hnRNPA2/B1 levels, we treated neuronal hippocampal cultures from
wild-type mice with the cholinergic mimetic carbachol (10 "M; Fig.
5A,B). This treatment effectively increased hnRNPA2/B1 protein
levels in immunofluorescence and immunoblot experiments, and
this effect could be blocked by muscarinic, but not by nicotinic antagonist treatment (Fig. 5C).
To study the contribution of muscarinic receptor subtypes, we
evaluated hnRNPA2/B1 levels in the hippocampus of muscarinic receptor knock-out mice. Compared to wild-type mice, M1,
but not M4, receptor knock-out mice showed a decrease in hnRNPA2/B1 protein levels resembling that in VAChT Nkx2.1-Cre-flox/flox
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mice (Fig. 5D). Together, these experiments suggest that decreased
cholinergic tone, likely due to insufficient M1 receptor activation, changes hnRNPA2/B1 protein levels by regulating mRNA
translation.
To further investigate the importance of M1 muscarinic receptors in the regulation of hnRNPA2/B1 protein levels in hippocampal neurons, we treated neuronal hippocampal cultures
from wild-type mice with the M1 muscarinic agonist AF102B
(Fisher et al., 1989). Compared to saline-treated neurons, those
treated with 100 !M of AF102B showed a significant increase in
protein levels of hnRNPA2/B1 (Fig. 5E).
We then evaluated whether in vitro cholinergic regulation also
changes the NMD! product. Compared to saline treatment, carbachol shifted the expression of hnRNPA2/B1 RNA toward the
NMD insensitive full-length mRNA product (Fig. 5F ). Furthermore, cotreatment with atropine blocked this effect and returned
the ratio to control levels, similar to what we observed for
hnRNPA2/B1 protein levels (Fig. 5C). These data suggest that the
ratio of NMD! hnRNPA2/B1 gene products predicts change in
protein levels, and that the regulation of NMD sensitivity is dependent on muscarinic signaling.

Discussion
In this study, we combined a variety of in vivo and in vitro techniques to evaluate the contribution of cholinergic signaling to
expression levels of hippocampal hnRNPA2/B1 protein. Using a
number of mouse lines, we demonstrated that hnRNPA2/B1 protein levels in the hippocampus are exquisitely sensitive to changes
in cholinergic tone.
Interestingly, we observed no change in hnRNPA2/B1 protein
levels in striatum- specific VAChT mutants, whereas there is a
body of evidence that cholinergic signaling can affect the levels of
this protein in both cortical and hippocampal regions in vivo
(Berson et al., 2012; Kolisnyk et al., 2013a). Given these findings,
it is likely that it is an intrinsic property of the target cells themselves that dictate their change in hnRNPA2/B1 translation in
response to cholinergic activity. Our results highlight the critical
role of the Gq coupled M1 muscarinic receptor in governing
hnRNPA2/B1 protein levels.
Unlike the rare hnRNPA2/B1 mutation that increases aggregation and nuclear exclusion (Kim et al., 2013), we did not find
aggregation of hnRNPA2/B1 in mice with forebrain cholinergic
deficiency, suggesting that in these mice, and likely in AD brains,
hnRNPA2/B1 dysfunction occurs by a separate and distinct
mechanism. Furthermore, we did not see an increase in ubiquitination, suggesting that changes in hnRNPA2/B1 protein levels do
not occur at the posttranslational level. In line with this, we found
4
Figure 5. Muscarinic regulation of hnRNPA2/B1 translation. A, B, Representative immunofluorescence images (A) and Western blots (B) with quantification of hnRNPA2/B1 protein
levels in primary hippocampal neurons after treatment with carbachol for 48 h. hnRNPA2/B1
expression was normalized to actin (n # 3). C, Representative Western blot and quantification
of hnRNPA2/B1 expression in primary hippocampal neurons after treatment with carbachol,
mecamylamine (meca.), and atropine. hnRNPA2/B1 expression was normalized to actin (n #
4). The values plotted are averaged from the gels of each individual experiment. D, Representative Western blot and quantification of hnRNPA2/B1 expression in hippocampal tissue of M4
muscarinic knock-out mice (M4-KO; n # 7) and M1 receptor knock-out mice (M1-KO; control,
n # 7; M1-KO mice, n # 8). E, M1 muscarinic receptor agonist AF102B significantly increased
hnRNPA2/B1 protein levels in primary hippocampal cultures (n # 5). F, Increased expression of
the full-length hnRNPA2/B1 transcripts of cells treated with carbachol is blocked by the administration of atropine (n # 5). G, Proposed model wherein muscarinic M1 receptors signaling
would shift the ratio of hnRNPA2/B transcripts, favoring the full length transcripts, and therefore increase translation of the protein. Data are mean $ SEM. *p % 0.05.
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that it may in fact be abnormal translation that drives regulation
of hnRNPA2/B1.
A common mechanism for the regulation of the translation of
RNA binding proteins (RBPs) is regulation by unproductive
splicing and translation (RUST), where the alternative spicing of
a transcript affects its translation efficiency (Lareau et al., 2007;
McGlincy and Smith, 2008). This may serve as a potential mechanism for cholinergic control of the translation of this RBP. Accordingly, we found that the levels of hnRNPA2/B1 transcripts
were maintained in cholinergic-deficient mice or AD brains (Berson et al., 2012), but hnRNPA2/B1 translation was selectively
decreased. Notably, hnRNPA2/B1 has been shown to be autoregulated by a RUST mechanism involving alternative splicing in
its 3" untranslated region that leads to NMD driven by mTOR1C
(McGlincy et al., 2010; Dempsey, 2012), which is a key effector of
muscarinic receptor signaling (Slack and Blusztajn, 2008). Correspondingly, we found that cholinergic control of hnRNPA2/B1
translation is mediated by M1 muscarinic receptors (Fig. 5G).
Targeting the interactions between RBPs and RNA may serve
as a new potential therapeutic avenue to restore the RNA-editing
deficits observed in neurodegenerative diseases (Tollervey et al.,
2011; Berson et al., 2012; Bai et al., 2013; Qian and Liu, 2014). A
number of substances, including regularly prescribed antibiotics,
have been shown to nonselectively alter alternative splicing in the
brain (Graveley, 2005; Tollervey et al., 2011; Kole et al., 2012);
however, this approach lacks the ability to specifically target “impaired” RBP-RNA interactions.
Cholinergic failure is one of the hallmarks of AD, with the
basal forebrain cholinergic system being heavily affected by the
disease (Whitehouse et al., 1982). Data from the Alzheimer’s Disease Neuroimaging Initiative has linked cholinergic failure in AD
to both pathological outcomes (Teipel et al., 2014) as well as
cognitive impairments in AD (Grothe et al., 2014). Further evidence for the importance of cholinergic signaling to the etiology
of AD comes from clinical evidence that the long-term use of
anticholinergic medication, specifically antimuscarinic drugs,
significantly increases the risk of developing dementia (Gray et
al., 2015). Interestingly, administration of antimuscarinic agents
to AD patients exacerbates their symptoms (Lim et al., 2015).
Together, these results suggest a crucial role for cholinergic tone
in AD, with specific importance of muscarinic signaling.
The main pathological hallmarks of AD are the accumulation
of A" plaques and of hyperphosphorylated tau (Huang and Jiang,
2009). M1 muscarinic signaling has been linked to both of these
processes. Activation of the receptor has been shown to alter tau
phosphorylation both in vitro (Sadot et al., 1996) and in vivo
(Genis et al., 1999). Moreover, deletion of M1 muscarinic receptors increases A" related pathology in a transgenic mouse model
overexpressing mutated APP (Davis et al., 2010). Furthermore,
M1 agonists have been shown to reverse A" related pathology in
mouse models of AD (Caccamo et al., 2006). These findings suggest that M1 receptors are key mediators of AD pathology. How
hnRNPA2/B1 protein expression may contribute to pathology
remains to be determined.
Cholinergic failure also plays an important role in one of the
most important and apparent cognitive deficits of AD, memory
loss (Bartus et al., 1982). There is a strong correlation between
loss of basal forebrain cholinergic neurons and cognitive functioning in AD patients. Furthermore, mice with a forebrain specific deletion of VAChT have severe deficits in performance on
the paired-associates learning touch-screen task (Al-Onaizi et al.,
2016), a rodent version of the Cambridge Neuropsychological
Test Automated Battery tests used in humans, which has been

Kolisnyk et al. • Cholinergic Regulation of hnRNPA2/B1

shown to be selective for the memory impairments in AD patients
(Egerhazi et al., 2007). Importantly, lentiviral mediated knockdown of hnRNPA2/B1 also produced cognition impairments in
mice (Berson et al., 2012).
Together, our findings indicate an intricate relationship between M1 muscarinic signaling and hnRNPA2/B1 translation.
These findings lay the ground work for new therapeutic avenues
for the treatment of AD. Specifically, they point to the potential of
M1 muscarinic positive allosteric modulators to improve longterm changes in RNA metabolism and cognitive deficits due to
cholinergic malfunction in AD. Noteworthy M1 muscarinic positive allosteric modulators have shown promising results to improve cognition in nonhuman primates (Lange et al., 2015).
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BACKGROUND AND PURPOSE
Disruptions of executive function, including attentional deﬁcits, are a hallmark of a number of diseases. ACh in the prefrontal
cortex regulates attentive behaviour; however, the role of α7 nicotinic ACh receptor (α7nAChR) in attention is contentious.

EXPERIMENTAL APPROACH
In order to probe attention, we trained both wild-type and α7nAChR knockout mice on a touch screen-based ﬁve-choice serial
reaction time task (5-CSRT). Following training procedures, we then tested sustained attention using a probe trial experiment. To
further differentiate the role of speciﬁc nicotinic receptors in attention, we then tested the effects of both α7nAChR and β2nAChR
agonists on the performance of both wild-type and knockout mice on the 5-CSRT task.

KEY RESULTS
At low doses, α7nAChR agonists improved attentional performance of wild-type mice, while high doses had deleterious effects on
attention. α7nAChR knockout mice displayed deﬁcits in sustained attention that were not ameliorated by α7nAChR agonists.
However, these deﬁcits were completely reversed by the administration of a β2nAChR agonist. Furthermore, administration of a
β2nAChR agonist in α7nAChR knockout mice elicited similar biochemical response in the prefrontal cortex as the administration of
α7nAChR agonists in wild-type mice.

CONCLUSIONS AND IMPLICATIONS
Our experiments reveal an intricate relationship between distinct nicotinic receptors to regulate attentional performance and
provide the basis for targeting β2nAChRs pharmacologically to decrease attentional deﬁcits due to a dysfunction in
α7nAChRs.

Abbreviations
5-CSRT, ﬁve-choice serial reaction time task; VAChT, vesicular ACh transporter
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Introduction
Attentional performance can be severely compromised in
different neuropsychiatric and neurodegenerative diseases,
including schizophrenia and Alzheimer’s disease (Mega and
Cummings, 1994; Buckner, 2004). ACh release in the prefrontal cortex (PFC), a brain area known to play a central
role in attention (Kastner and Ungerleider, 2000; Corbetta
and Shulman, 2002; Buschman and Miller, 2007), is important for the regulation of attentive behaviour (Elliott,
2003). Schizophrenic patients present severe physiological
and molecular dysfunctions in the PFC (Weinberger et al.,
1986; Mirnics et al., 2000; Guillozet-Bongaarts et al., 2014).
One of the more profound molecular changes is the loss of
the α7 nicotinic ACh receptor (α7nAChR), encoded by the
CHRNA7 gene. Although the genetic linkage between the
CHRNA7 gene and schizophrenia is complex, with studies
pointing towards and against CHRNA7 as a risk gene for
the disease (Xu et al., 2001; Zammit et al., 2007), robust decreases in protein and mRNA expression of the α7nAChR
have been shown in the PFC of patients with schizophrenia
(Guan et al., 1999; Guillozet-Bongaarts et al., 2014). Moreover, in Alzheimer’s disease, Aβ peptides can bind to
α7nAChRs (Wang et al., 2000) and disrupt their function
(Chen et al., 2006).
There is accumulating evidence demonstrating that cue
detection during attentional efforts is mediated by nicotinic
receptor signalling (McGaughy et al., 1999a; Grottick and
Higgins, 2000; Parikh et al., 2007, 2010). β2nAChRs are both
necessary and sufﬁcient to regulate attention in mice using a
non-demanding ﬁve-choice serial reaction time task (5CSRT) paradigm (Guillem et al., 2011). On the other hand,
the role of α7nAChRs in attention is still not completely understood. Initial studies suggest that CHRΝΑ7!/! mice present deﬁcits in sustained attention (Hoyle et al., 2006;
Young et al., 2007). However, it has been reported that for
less demanding tasks no deﬁcits were observed in
α7nAChR-null mice (Guillem et al., 2011). Taken together,
these results suggest that attentional deﬁcits in CHRΝΑ7!/!
mice may depend on the attentional load. Pharmacological
manipulations of α7nAChRs have also produced conﬂicting
results, most likely because of the poor selectivity of the
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drugs used (Grottick and Higgins, 2000; Pichat et al., 2007;
Rezvani et al., 2009; Wallace et al., 2011a). Interestingly,
studies in humans have shown that agonists for the
α7nAChR can improve the performance of patients suffering
from schizophrenia on neurocognitive tests (Olincy et al.,
2006; Olincy and Stevens, 2007).
Here, we report that α7nAChR-null mice present deﬁcits
in their ability to sustain attention in a demanding paradigm.
Moreover, we found that activation of α7nAChRs increased
biochemical signalling and attention in wild-type (WT) mice,
but not in CHRΝΑ7!/! mice. Interestingly, activation of
β2nAChRs triggered similar biochemical pathways as
α7nAChR agonists and reversed attentional deﬁcits in
α7nAChR-null mice. These results suggest that α7nAChRs
may contribute to attention performance, but activation of
β2nAChRs can bypass the deﬁcits triggered by deﬁcient
α7nAChR signalling. Our results suggest that the α7nAChR
plays a role in sustained attention during demanding tasks
and that β2nAChR drugs may be of potential use for
correcting cognitive and molecular signalling deﬁcits seen
in psychiatric or neurological disorders in which α7nAChRs
are affected.

Methods
Animals

CHRΝΑ7!/! mice (B6.129S7 nAChR Chrna7tm1Bay/J) were
purchased from Jackson Laboratories (Bar Harbor, ME, USA).
Mice were housed in groups of three or four per cage in a
temperature-controlled room with 12/12 h light/dark cycle
(07:00–19:00 h), and water was provided ad libitum. Only
male mice were used in these studies. For the 5-CSRT studies,
mice were housed in pairs and restricted to 85% of their
free-feed weight and maintained on 85% of their weight for
the duration of the studies as described (Kolisnyk et al.,
2013a,b). All behavioural experiments were conducted between 12:00 and 17:00 h. We followed the ARRIVE guidelines
(Kilkenny et al., 2010); hence, mice were randomized for behavioural tests, and the experimenter was blind to the genotype. All procedures were conducted in accordance with
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guidelines from the Canadian Council of Animal Care at the
University of Western Ontario with an approved institutional
animal protocol (2008-127).

Five-choice serial reaction time task training

A cohort of WT and CHRΝΑ7!/! mice (n = 7 per genotype,
5–6 months old) was trained in the 5-CSRT task using the automated Bussey–Saksida Mouse Touch Screen System model
81426 (Campden Instruments, Lafayette, IN, USA). Schedules
were designed, and data were collected using the ABET II
TOUCH software v.2.15 (Lafayette Instruments, Lafayette, IN,
USA). Mice were trained to respond to the touch screen chambers using a previously described operant training procedure
(Kolisnyk et al., 2013a, b).
Training on the 5-CSRT task was performed as previously
described (Romberg et al., 2011). Once the performance of a
mouse reached criterion (80% accuracy, 20% omissions for
three consecutive days) at 4 s stimulus duration, stimulus duration was reduced to 2 s. After reaching criterion at a 2 s stimulus duration, the mouse was tested on probe trials.

Probe trial
To probe attention in mice, we used a previously described
probe trial schedule with reduced stimulus durations
(Romberg et al., 2011; Kolisnyk et al., 2013a). Mice were tested
for 2 days at a given stimulus duration (1.5, 1, 0.8 or 0.6 s).
Each day, sessions lasted 50 trials or 1 h. After each test, the
animal was retested at the 2 s stimulus duration for 2 days,
until the mice had been tested at all stimulus durations. The
order of the probe trial sessions was semi-randomized using
a Latin square method. Behavioural data were averaged over
the 2 days of each stimulus duration.

Drug injections
For all drug experiments, mice were tested at the 0.6 s stimulus duration. The same mice used for the initial 5-CSRT experiments were used for the drug studies. Animals were injected
30 min before testing for the PHA-543,613 (Sigma-Aldrich, St
Louis, MO, USA) and PNU-228,927 (Tocris Bioscience, Bristol,
UK) experiments and 15 min before testing for the ABT-418
(Sigma-Aldrich) experiment (McGaughy et al., 1999b). Doses
of PHA-543,613 [0.33, 1 and 3 mg kg!1, i.p. (Acker et al.,
2008)], PNU-282,927 [1, 3 and 5 mg kg!1, i.p. (Hajos et al.,
2005; Vicens et al., 2013)] and ABT-418 [0.04, 0.13 and
0.39 mg kg!1, i.p. (McGaughy et al., 1999a)] were chosen
based on previous studies. In control experiments, vehicle
(saline) was injected. The order of drug injections was semirandomized using a Latin square method. Between different
doses in the drug injection experiments, mice were given
two washout days during which they were baselined with a
2 s stimulus duration.

Analysis of 5-CSRT task
On all 5-CSRT task sessions, accuracy was calculated as the
number of correct responses divided by the number of correct
and incorrect responses (touches to a wrong window while
the correct stimulus was still displayed). Omissions were calculated as the total number of omitted trials divided by the
number of total trials. Response latency was the time the
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mouse took to touch the correct stimulus after the onset of
its display. Reward collection latency was deﬁned as the time
it took the mouse to enter the reward magazine following a
correct response. A premature response was counted when
the mouse touched one of the windows prior to the stimulus
being displayed. Finally, a perseverative response was any
identical response that occurred following a correct, incorrect
or premature response.

Food intake in food-deprived mice
Feeding behaviour was analysed as previously described
(Semenova and Markou, 2007). Naive groups of WT and
CHRΝΑ7!/! mice (n = 8 per genotype) were housed individually and were deprived of food overnight before the test. During the test, mice were placed in a clean cage and given 20 g of
standard chow. Food intake was measured 20, 40, 60 and
80 min after the start of the test. Food intake was normalized
to the body weight of the animals.

Quantitative PCR
Total RNA was extracted from freshly dissected PFC tissue,
using the Aurum Total RNA for fatty and ﬁbrous tissue kit
(Bio-Rad Laboratories, Hercules, CA, USA); cDNA synthesis
and quantitative PCR (qPCR) analysis of nicotinic receptor
expression were performed as previously described (Guzman
et al., 2011; Kolisnyk et al., 2013a).

Western blotting
Western blotting was performed as previously described
(Martins-Silva et al., 2011). For analysis of phospho-proteins
in the PFC, mice were given i.p. drug injections and were
killed 30 min later. Tissue was then homogenized in lysis
buffer supplemented with protease and phosphatase inhibitor cocktails (Thermo Fisher Scientiﬁc, Waltham, MA, USA).
The antibodies used were anti-vesicular ACh transporter
(VAChT) (catalogue #139103; Synaptic Systems, Göttingen,
Germany), anti-ChAT (catalogue #1DB-001-0000849693;
Millipore, Billerica, MA, USA), anti-synaptophysin (catalogue
#S5768; Sigma-Aldrich), anti-ERK1/2 (catalogue #4695; Cell
Signaling Technology, Danvers, MA, USA), anti-phosphoERK1/2 (catalogue #4372; Cell Signaling Technology),
anti-cFos (catalogue #4384; Cell Signaling Technology) and
anti-β-actin (catalogue #ab49900; Abcam, Cambridge, UK).
Band intensity was quantiﬁed using FLUOROCHEMQ software
(Thermo Fisher Scientiﬁc).

Statistical analyses
All data are expressed as mean ± SEM. SIGMASTAT 3.5 (Systat
Software, San Jose, CA, USA) was used for all statistical analysis. Comparisons between two experimental groups were
made by Student’s t-test. When several experimental groups
or treatments were analysed, one-way ANOVA or two-way
ANOVA with repeated-measures tests were used as required.
Statistically signiﬁcant effects were further analysed using
Tukey’s honestly signiﬁcant difference post hoc tests. In all
analyses, P < 0.05 was considered statistically signiﬁcant.
British Journal of Pharmacology (2015) 172 4919–4931
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Results
α7nAChR-null mice present normal acquisition
on the 5-CSRT task

No difference between CHRΝΑ7!/! mice and WT controls
was observed in the number of sessions required to reach
criterion at any of the pre-training phases for the 5-CSRT
task [Supporting Information Fig. 1; RM-ANOVA: no effect
of genotype, F(1,14) = 2.814, P = 0.1156; main effect of training phase, F(4,14) = 104.3, P < 0.0001; no interaction effect,
F(4,14) = 1.126, P = 0.3535]. During training on the 5-CSRT
task as well, CHRΝΑ7!/! mice took as many sessions as WT
controls to achieve criterion at both the 4 and 2 s stimulus
durations [RM-ANOVA: no effect of genotype, F(1,14) = 2.552,
P = 0.1325; main effect of stimulus duration, F(1,14) = 57.78,
P < 0.0001; no interaction, F(1,14) = 4.472, P = 0.0529; Supporting
Information Fig. 1B]. It should be noted that there was a strong
tendency for the CHRΝΑ7!/! mice to take longer to learn the
task at the 4 s stimulus duration, which may reﬂect previously
documented impairments in procedural learning in these
mice (Young et al., 2011).

α7nAChR-null mice have impaired sustained
attention
Once mice reached criterion at 2 s stimulus duration, we
assessed attention performance by using a probe trial, with reduced stimulus durations (1.5, 1, 0.8 and 0.6 s stimulus durations) as previously described (Romberg et al., 2011). Across all
four stimulus durations, CHRΝΑ7!/! mice performed similarly
to controls in both total measures of omissions [RM-ANOVA:
no effect of genotype, F(1,36) = 3.235, P = 0.0972; main effect
of stimulus duration, F(3,36) = 14.50, P < 0.001; no interaction,

F(3,36) = 0.5136, P = 0.6755; Figure 1A] and accuracy [RMANOVA: no effect of genotype, F(1,36) = 0.06134, P = 0.8086;
main effect of stimulus duration, F(3,36) = 9.208, P < 0.001;
no interaction, F(3,36) = 0.6347, P = 0.5975; Figure 1B]. To
assess sustained attention, we analysed rate of omissions and
response accuracy over blocks of 25 trials across the various
stimulus durations of the probe trial experiment. As each probe
trial session ends after 50 trials or 1 h, analysing blocks of 25
trials divided the performance between two halves: block A
and block B. This procedure allowed us to determine if mice
can sustain attention during the full period of the probe trial
and maintain performance between the ﬁrst and second periods
of testing. Performance of control WT mice did not differ across
the probe trial in terms of omissions [RM-ANOVA: no difference
between blocks A and B, F(1,6) = 1.904, P = 0.2168; main effect of
stimulus duration, F(3,18) = 8.661, P < 0.001; and no interaction,
F(3,18) = 0.4736, P = 0.7045; Figure 1C) or accuracy [RM-ANOVA:
no effect of blocks, F(1,6) = 4.319, P = 0.0829; main effect of
stimulus duration, F(3,18) = 4.897, P = 0.0166; and no interaction, F(3,18) = 0.4947, P = 0.6905; Figure 1D]. In contrast,
CHRΝΑ7!/! mice displayed increased omission errors in the
second half of the probe trial experiment compared with the
ﬁrst half [RM-ANOVA: main effect of block, F(1,6) = 20.59,
P < 0.001; main effect of stimulus duration, F(3,18) = 9.471,
P < 0.001; and main interaction effect, F(3,18) = 12.13,
P < 0.001; Figure 1E). Post hoc analysis conﬁrmed that
CHRΝΑ7!/! mice had signiﬁcantly more omission errors
during the second half of the task at both the 0.8 and 0.6 s
stimulus durations, suggesting that these mice display impaired
ability to sustain attention. Interestingly, CHRΝΑ7!/! mice
did not present accuracy impairments across the two blocks
[RM-ANOVA: no effect of block, F(1,6) = 1.348, P = 0.2897; main
effect of stimulus duration, F(3,18) = 5.877, P = 0.0056; and no
interaction effect, F(3,18) = 0.6404, P = 0.5989; Figure 1F].

Figure 1
!/!

CHRNA7
mice have impaired sustained attention. Comparison between genotypes of (A) omissions and (B) accuracy during the probe trial
experiment using the 5-CSRT task. (C) Omissions and (D) accuracy across bins of 25 trials in WT mice. (E) Omissions and (F) accuracy across bins
!/!
mice (data are presented as mean ± SEM; *P < 0.05,**P < 0.01, ***P < 0.001).
of 25 trials in CHRNA7
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Increases in omission on the 5-CSRT task have been proposed to be due to lack of attention, lack of motivation or motor impairments (Robbins, 2002). Given that CHRΝΑ7!/!
mice were no different from controls in terms of latency to respond to stimulus or latency to collect the reward, it is unlikely that motivation or motor impairments are causing the
deﬁcits in sustained attention (Robbins, 2002; Spinelli et al.,
2004). To address this, we measured several other parameters
to test for motivational or aberrant behaviour in CHRΝΑ7!/!
mice. α7nAChR-null mice showed no difference in latency
to respond to the stimulus [RM-ANOVA: no effect of genotype,
F(1,36) = 0.01533, P = 0.9035; no effect of stimulus duration,
F(3,36) = 2.003, P = 0.1310; no interaction, F(3,36) = 1.223,
P = 0.3154; Figure 2A]. We then assessed response latency
across blocks of trials to determine if the sustained attention
deﬁcits in CHRΝΑ7!/! mice may be due to delayed responsiveness. Response latency did not differ across blocks for
either the WT [RM-ANOVA: no effect of block, F(1,6) = 0.07218,
P = 0.7972; no effect of stimulus duration, F(3,18) = 2.749,
P = 0.0792; and no interaction effect, F(3,18) = 0.7886,
P = 0.5159; Figure 2B] or CHRΝΑ7!/! mice [RM-ANOVA: no
effect of block, F(1,6) = 0.2481, P = 0.6362; no effect of stimulus
duration, F(3,18) = 2.2557, P = 0.1166; and no interaction
effect, F(3,18) = 1.490, P = 0.2501; Figure 2C]. We also assessed
the time to retrieve their reward following a correct response
[RM-ANOVA, no effect of genotype, F(1,36) = 0.2025,
P = 0.6607; no effect of stimulus duration, F(3,36) = 1.153,
P = 0.3410; no interaction, F(3,36) = 0.2954, P = 0.8284;
Figure 2D] when compared with WT controls. Furthermore,
we assessed reward latency across blocks of trials, and neither
the WT [RM-ANOVA: no effect of block, F(1,6) = 2.345,
P = 0.1766; no effect of stimulus duration, F(3,18) = 2.176,
P = 0.1262; and no interaction effect, F(3,18) = 0.5404,
P = 0.6677; Figure 2E) nor CHRΝΑ7!/! mice [RM-ANOVA, no
effect of block, F(1,6) = 0.02162, P = 0.8879; no effect of
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stimulus duration, F(3,18) = 0.6190, P = 0.6617; and no interaction effect, F(3,18) = 0.3581, P = 0.7839; Figure 2F) showed alteration in reward collection latency. To test whether CHRΝΑ7!/!
mice differ from WTcontrols in satiety, we measured food intake
following food restriction in a group of naive mice. Compared
with controls, CHRΝΑ7!/! mice did not differ in food
consumption over the course of the test [RM-ANOVA: no
effect of genotype, F(1,48) = 1.280, P = 0.2800; main effect
of time, F(4,48) = 73.88, P < 0.001; and no interaction effect,
F(4,48) = 1.296, P = 0.2849; Figure 2G]. This is in line with
previous work showing that these mice have normal motivation (Hoyle et al., 2011) and suggests that CHRΝΑ7!/! mice
have speciﬁc deﬁcits in sustained attention.
Impulsivity and compulsivity were also assessed in
CHRΝΑ7!/! mice during the probe trial experiment. Compared with controls, CHRΝΑ7!/! mice were no different in
terms of premature responses, a measure of impulsivity
[RM-ANOVA: no effect of genotype, F(1,36) = 0.9222,
P = 0.3575; no effect of stimulus duration, F(3,36) = 0.4541,
P = 0.7161; no interaction effect, F(3,36) = 0.09521, P = 0.9621;
Supporting Information Fig. 2C, D], or perseverative responses, a measure of compulsive behaviour [RM-ANOVA:
no effect of genotype, F(1,36) = 0.04477, P = 0.8363, main effect of stimulus duration, F(3,36) = 4.105, P = 0.0140; no interaction effect, F(3,36) = 0.8660, P = 0.4685, Supporting
Information Fig. 2C, D].
The ability to release normal levels of ACh is critical to
attention (Kolisnyk et al., 2013a,b); therefore, we investigated
expression levels of the cholinergic machinery in the PFC of
CHRΝΑ7!/! mice. Compared with WT controls, CHRΝΑ7!/!
mice showed no signiﬁcant change in expression of the VAChT
[t(4) = 0.375, P = 0.7291] or ChAT. The sustained attention deﬁcits
in CHRΝΑ7!/! mice are therefore not a result of an inherent
dysfunction in the machinery required for ACh release
(Figure 3A).

Figure 2
!/!

CHRNA7
mice have normal motivation and motor function during the 5-CSRT task. Comparison between genotypes of response latencies (A).
!/!
Response latencies across bins of 25 trials in wild-type (B) and CHRNA7
mice (C). Comparison between genotypes of reward collection laten!/!
mice (F). (G) Food consumption following food depcies (D). Reward collection latencies across bins of 25 trials in wild-type (E) and CHRNA7
rivation as a measure of motivation (data are presented as mean ± SEM).
British Journal of Pharmacology (2015) 172 4919–4931
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Figure 3
Evaluation of the expression of cholinergic markers and relevant
!/!
signalling pathways in the PFC of CHRNA7
mice. (A) Immunoblot
of VAChT and ChAT expression in the PFC. (B) qPCR expression of
nicotinic receptors and AChE in the PFC. (C) cFos protein levels and
(D) ERK1/2 phosphorylation in the PFC (data are presented as
mean ± SEM).

α7 nicotinic ACh receptor deletion has been suggested to
cause compensatory changes in other nicotinic receptors during development (Yu et al., 2007). To determine if the PFC of
adult CHRΝΑ7!/! mice displayed altered expression of nicotinic receptors, we examined their expression by qPCR analysis. The PFC of CHRΝΑ7!/! mice showed no signiﬁcant
change in the expression of CHRNA4 [t(8) = 1.104, P = 0.3016]
or of CHRNB2 expression [t(8) = 0.4893, P = 0.6378]. In
addition, we evaluated the expression of the enzyme AChE
and observed no signiﬁcant difference between genotypes
[t(8) = 0.0409, P = 0.9684]. As expected, we did not detect
CHRNA7 expression in CHRΝΑ7!/! animals (Figure 3B).
To evaluate the biochemical correlates of neuronal activity in the PFC of CHRΝΑ7!/! mice, we determined protein
levels of the immediate-early gene cFos, a known marker of
activated neurons. Compared with the WT control,
CHRΝΑ7!/! mice showed no signiﬁcant change in cFos
protein levels [t(4) = 0.779, P = 0.4792, Figure 3C]. Moreover,
to test if the CHRΝΑ7!/! had impaired activation of relevant
second messenger signalling cascades involved with
nicotinic response in attention (Wallace and Porter, 2011b),
we evaluated the phosphorylation status of ERK1/2
and observed no signiﬁcant difference between genotypes
[t(4) = 0.331, P = 0.7575, Figure 3D].

Effect of α7nAChR agonists on attention

To evaluate acute roles of α7nAChR in regulating sustained attention behaviour, we investigated two selective α7nAChR
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agonists, PHA-543,613 (Acker et al., 2008) and PNU-282,987
(Hajos et al., 2005), in WT mice using the 5-CSRT task. Mice
were tested at a 0.6 s stimulus duration, which represents a
cognitively demanding version of the task (Romberg et al.,
2011; Kolisnyk et al., 2013a). PHA-543,613 signiﬁcantly
improved rate of omissions [RM-ANOVA: main effect of dose,
F(3,18) = 12.52, P < 0.001; Figure 4A], with post hoc analysis
conﬁrming that the 1 mg kg!1 dose signiﬁcantly improved
performance over saline. Conversely, PHA-543,613 signiﬁcantly altered response accuracy in higher doses [RM-ANOVA:
main effect of dose, F(3,18) = 12.55, P < 0.001; Figure 4B]. Post
hoc analysis revealed that at the highest dose tested
(3 mg kg!1), PHA-543,613-injected mice performed signiﬁcantly worse than mice injected with saline. PHA-543,613
did not signiﬁcantly alter response latency [RM-ANOVA: no
effect of dose, F(3,18) = 1.568, P = 0.2318, Supporting Information Fig. 3A] or reward collection latency [RM-ANOVA: no
effect of dose, F(3,18) = 0.7517, P = 0.5382; Supporting
Information Fig. 3B]. In addition, PHA-543,613 did not alter
premature [RM-ANOVA: no effect of dose, F(3,18) = 0.7599,
P = 0.4930) nor perseverative responses [RM-ANOVA: no effect of dose, F(3,18) = 0.1404, P = 0.8821, Supporting Information Fig. 3C, D]. To address the effects of PHA-543,613 on
sustained attention, we analysed performance of mice over
blocks of 25 trials and observed that PHA-543,613 did not signiﬁcantly alter sustained omissions between the two blocks
of testing [RM-ANOVA: main effect of dose, F(3,36) = 13.20,
P < 0.0001; no effect of block, F(1,12) = 0.7069, P = 0.4327;
and no interaction, F(3,36) = 1.288, P = 0.3088; Figure 4C],
nor did it alter accuracy in WT mice [RM-ANOVA: main effect
of dose, F(3,36) = 14.63, P < 0.0001; no effect of block, F(1,12)
= 1.729, P = 0.101; and no interaction effect, F(3,18) = 0.0713,
P = 0.9749; Figure 4D). At 1 mg kg!1, the percentage of omissions seemed to be slightly reduced in the second block, suggesting modest improvement in the performance.
The second α7nAChR agonist tested, PNU-282,987, also
signiﬁcantly improved rate of omissions [RM-ANOVA: main
effect of dose, F(3,18) = 2.767, P = 0.0437, Figure 4E], with post
hoc analysis conﬁrming that both the 1 and 3 mg kg!1 doses
signiﬁcantly improved performance over saline. Conversely,
PNU-282,978 signiﬁcantly altered response accuracy [RMANOVA: main effect of dose, F(3,18) = 5.637, P = 0.0066;
Figure 4F). Post hoc analysis revealed that at the highest dose
tested (5 mg kg!1) mice injected with PNU-282,978 performed signiﬁcantly worse than mice injected with saline.
PNU-282,978 did not signiﬁcantly alter response latency
[RM-ANOVA: no effect of dose, F(3,18) = 0.9985, P = 0.4018;
Supporting Information Fig. 3E] nor reward collection
latency [RM-ANOVA: no effect of dose, F(3,18) = 1.131,
P = 0.3375; Supporting Information Fig. 3F]. PNU-282,978
did not alter the number of premature [RM-ANOVA: no effect of
dose, F(3,18) = 3.015, P = 0.1157] or perseverative responses [RMANOVA: no effect of dose, F(3, 18) = 0.4522, P = 0.6707, Supporting
Information Fig. 3G, H]. In terms of the effects of PNU-282,978
on sustained attention, analysis of injected mice over two blocks
of 25 trials showed that PNU-282,978 did alter the rate of omissions, with 3 mg kg!1 improving omission rates over the two
blocks [RM-ANOVA: main effect of dose, F(3,36) = 6.095,
P = 0.0031; no effect of block, F(1,12) = 0.5240, P = 0.4761; and
main interaction effect, F(3,36) = 3.218, P = 0.0407; Figure 4G],
but did not alter sustained accuracy [RM-ANOVA: main effect of
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Figure 4
α7nAChR agonists improve attention in wild-type mice. (A) Omission and (B) accuracy following injections of PHA-543,613 in WT mice.
(C)Omissions and (D) accuracy over bins of 25 trials following administration of PHA-543,613. (E) Omission and (F) accuracy following
injections of PNU-282,987 in WT mice. (G) Omissions and (H) accuracy over bins of 25 trials following administration of PNU-282,987.
(I) cFos protein levels and (J) ERK1/2 phosphorylation following injection of PHA-543,613 (data are presented as mean ± SEM; *P < 0.05,
**P < 0.01, ***P < 0.001).

dose, F(3,36) = 6.044, P = 0.0019; no effect of block, F(1,12) = 0.222,
P = 0.6458; and no interaction effect, F(3,18) = 0.0701, P = 0.9755;
Figure 4H].
To evaluate the biochemical correlates of acute α7nAChR
agonist activation in the PFC, we injected PHA-543,613 on
WT mice and determined protein levels of cFos and the phosphorylation status of ERK1/2. These experiments used a separate cohort of mice, which were injected with drug or saline
and then killed 30 min later and had their PFC dissected to
obtain protein extracts. Compared with saline, PHA543,613 injected in mice led to a signiﬁcant increase in the
levels of cFos protein in their PFC [one-way ANOVA: main
effect of dose, F(2,6) = 7.404, P = 0.0240; Figure 4I], with post
hoc analysis showing that cFos levels were increased at both
doses of PHA-543,613. Similarly, injections of PHA-543,613
signiﬁcantly increased ERK1/2 phosphorylation levels in a
dose-dependent way [one-way ANOVA: main effect of dose,
F(2,6) = 28.80, P < 0.001; Figure 4J].

Positive and negative effects of α7nAChR
agonists are abolished in CHRΝΑ7!/! mice
To conﬁrm the speciﬁcity of both PHA-543,613 and PNU282,987 for α7nAChRs, we administered both compounds
to CHRΝΑ7!/! mice prior to testing them on the 5-CSRT task
with a 0.6 s stimulus duration. Compared with saline, PHA543,613 had no effect on the performance of the mice at
any dose tested. PHA-543,613 did not alter rate of omissions
[RM-ANOVA: no effect of dose, F(3,18) = 1.528, P = 0.2515;
Figure 5A] or response accuracy [RM-ANOVA: no effect of
dose, F(3,18) = 0.1121, P = 0.8733; Figure 5B], response latency
[RM-ANOVA: no effect of dose, F(3,18) = 0.2490, P = 0.7348;
Supporting Information Fig. 4A] or reward collection latency
[RM-ANOVA: no effect of dose, F(3,18) = 0.3018, P = 0.6621;
Supporting Information Fig. 4B]. PHA-543,613 did not alter

the number of premature [RM-ANOVA: no effect of dose, F
P = 0.3579] or perseverative responses [RMANOVA: no effect of dose, F(3,18) = 2.101, P = 0.1738,
Supporting Information Fig. 4C, D]. Furthermore, when we
analysed performance over blocks of 25 trials, we observed
that PHA-543,613 did not alter impaired omission deﬁcit of
CHRΝΑ7!/! mice at 0.6 s, which remained signiﬁcantly
higher in block B across all doses [RM-ANOVA: no effect
of dose, F(3,36) = 1.528, P = 0.2414; main effect of block,
F(1,12) = 14.89, P = 0.0084; and no interaction F(3,12) = 0.2209,
P = 0.8806; Figure 5C]. PHA-543,613 did not alter sustained
accuracy in CHRΝΑ7!/! mice either [RM-ANOVA: no effect
of dose, F(3,36) = 0.2017, P = 0.8945; no effect of block, F(1,12) =
0.00701, P = 0.9343; and no interaction, F(3,36) = 0.02177,
P = 0.9956; Figure 5D].
As with the PHA-543,613, PNU-282,987 had no effect on
the performance of CHRΝΑ7!/! mice at any of the tested
doses. The drug did not alter rate of omissions [RM-ANOVA:
no effect of dose, F(3,18) = 0.1515, P = 0.9277; Figure 5E], response accuracy [RM-ANOVA: no effect of dose, F(3,18) = 0.1458,
P = 0.9310; Figure 5F], response latency [RM-ANOVA: no effect
of dose, F(3,18) = 0.0586, P = 2.808, Supporting Information
Fig. 4E] or reward collection latency [RM-ANOVA: no effect of
dose, F(3,18) = 0.8089, P = 0.4603, Supporting Information
Fig. 4F]. PNU-282,978 did not alter the number of premature
[RM-ANOVA: no effect of dose, F(3,18) = 0.2767, P = 0.8316]
or perseverative responses [RM-ANOVA: no effect of dose,
F(3,18) = 0.2218, P = 0.8036, Supporting Information Fig. 4G, H].
Also, analysis of performance of injected mice over blocks of
25 trials showed that the α7nAChR agonist had no effect on
the impaired omission deﬁcit that we consistently observed on
CHRΝΑ7!/! mice [RM-ANOVA: main effect of block, F(1,6) =
9.112, P = 0.0234; no effect of dose, F(3,18) = 0.2542, P = 0.8573;
and no interaction, F(3,18) = 0.2546, P = 0.8570; Figure 5G]
nor on sustained accuracy [RM-ANOVA: no effect of blocks,
(3,18) = 1.104,
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Figure 5
α7nAChR agonists do not alter attention in mice lacking α7nAChR. (A) Omission and (B) accuracy following injections of PHA-543,613 in
!/!
!/!
mice. (C) Omissions and (D) accuracy over bins of 25 trials following administration of PHA-543,613 in CHRNA7
mice. (E) OmisCHRNA7
!/!
sion and (F) accuracy following injections of PNU-282,987 in CHRNA7
mice. (G) Omissions and (H) accuracy over bins of 25 trials following
administration of PNU-282,987. (I) cFos protein levels and (J) ERK1/2 phosphorylation following injection of PHA-543,613 (data are presented
as mean ± SEM; *P < 0.05,**P < 0.01, ***P < 0.001).

F(1,6) = 0.0258, P = 0.9945; no effect of dose, F(3,18) = 1.123,
P = 0.3729; and no interaction, F(3,18) = 0.2665, P = 0.8491;
Figure 5H]. Taken together, these results demonstrate that
modulation of attention performance on the 5-CSRT task by
both PHA-543,613 and PNU-282,987 depends on their activity on α7nAChR.
Additionally, to conﬁrm the selectivity of the molecular
changes observed following PHA-543,613 administration in
WT mice, we injected CHRΝΑ7!/! mice with the highest dose
of the drug (3 mg kg!1) and then, 30 min later, measured the
effects on cFos protein levels and ERK1/2 phosphorylation
in the PFC. Unlike PHA-543,613-injected WT mice,
CHRΝΑ7!/! mice exhibited no change in cFos levels
[t(4) = 0.387, P = 0.7186; Figure 5I] or ERK1/2 phosphorylation
[t(4) = 0.1029, P = 0.9230; Figure 5J], suggesting that both the
behaviour and molecular effects of the drug are speciﬁc to
activation of α7nAChR.

P = 0.6764, Supporting Information Fig. 5C, D]. To evaluate
the effects of ABT-418 on sustained attention, we analysed accuracy and omissions across blocks of 25 trials. ABT-418 did
not signiﬁcantly alter sustained omissions across blocks for
WT mice [RM-ANOVA: no effect of block, F(1,6) = 0.6582,
P = 0.6013; main effect of dose, F(3,18) = 0.2542, P = 0.8573;
and no interaction, F(3,18) = 0.6582, P = 0.5847; Figure 6C].

The β2nAChR agonist ABT-418 improves
attention
In order to explore the relationship between distinct types of
nicotinic receptors on attentional performance, we used ABT418, a β2nAChR agonist, and treated WT mice that were
tested with the 0.6 s stimulus duration paradigm. Injections
of ABT-418 were able to signiﬁcantly improve both rate of
omissions [RM-ANOVA: main effect of dose, F(3,18) = 4.544,
P = 0.0132; Figure 6A] and response accuracy [RM-ANOVA:
main effect of dose, F(3,18) = 6.950, P = 0.0020; Figure 6B]
without altering response latency [RM-ANOVA: no effect of dose,
F(3,18) = 0.06377, P = 0.9014; Supporting Information Fig. 5A]
or reward collection latency [RM-ANOVA: no effect of dose,
F(3,18) = 0.2936, P = 0.8797; Supporting Information Fig. 5B].
ABT-418 did not alter the number of premature [RM-ANOVA:
no effect of dose, F(3,18) = 1.228, P = 0.3103] or perseverative
responses [RM-ANOVA: no effect of dose, F(3,18) = 0.3062,
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Figure 6
β2nAChR agonists improve attention in wild-type mice. (A) Omission
and (B) accuracy following injections of ABT-418 in WT mice. (C)
Omissions and (D) accuracy over bins of 25 trials following administration of ABT-418 in WT mice (data are presented as mean ± SEM;
*P < 0.05,**P < 0.01.
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ABT-418 had no effect on sustained accuracy in WT mice,
with the improvements brought on by the drug spanning
across both blocks of trials [RM-ANOVA: no effect of block,
F(1,6) = 0.7267, P = 0.4083; main effect of dose, F(3,18) = 7.744,
P = 0.0003; and no interaction F(3,18) = 1.084, P = 0.3662;
Figure 6D).
Given that nicotinic receptors may be expressed in similar
populations of neurons and could crosstalk (Azam et al.,
2003), we evaluated whether β2nAChR receptor activation
could impact attention in mice lacking α7nAChR. As with
the WT mice, ABT-418 was able to signiﬁcantly improve both
omissions [RM-ANOVA: main effect of dose, F(3,18) = 5.466,
P = 0.0066; Figure 7A] and accuracy [RM-ANOVA: main effect
of dose, F(3,18) = 3.383, P = 0.0373; Figure 7B] in CHRΝΑ7!/!
mice, without altering response latency [RM-ANOVA: no effect of dose, F(3,18) = 1.622, P = 0.2495; Supporting Information Fig. 6A] or reward collection latency [RM-ANOVA: no
effect of dose, F(3,18) = 0.8793, P = 0.4359; Supporting Information Fig. 6B]. ABT-418 did not alter the number of premature [RM-ANOVA: no effect of dose, F(3,18) = 0.1450,
P = 0.81133] or perseverative responses [RM-ANOVA: no effect
of dose, F(3,18) = 0.1254, P = 0.8336; Supporting Information
Fig. 6C, D]. Importantly, ABT-418 was able to reverse the
sustained attention deﬁcits observed in CHRΝΑ7!/! mice
(Figure 7C) and improved the sustained omission deﬁcits in
these mice [RM-ANOVA: main effect of block, F(1,6) = 11.82,
P = 0.0138; main effect of dose, F(3,18) = 7.640, P = 0.0017;
and no interaction effect, F(3,18) = 1.707, P = 0.2013;
Figure 7C]. Post hoc analysis revealed that this occurred even
at the lowest dose administered. Sustained accuracy was not
altered [RM-ANOVA: no effect of block, F(1,6) = 0.1284,
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P = 0.7324; main effect of dose, F(3,18) = 5.017, P = 0.0106;
and no interaction, F(3,18) = 1.054, P = 0.3929; Figure 7D].
To determine the biochemical correlates of treatment with
ABT-418 on CHRΝΑ7!/! mice, we injected a new cohort of
CHRNA7!/! mice with 0.39 mg kg!1 of ABT-418 and 30 min
later evaluated cFos and ERK1/2 phosphorylation levels in the
PFC of the mice. Compared with saline-injected mice,
CHRΝΑ7!/! mice injected with ABT-418 showed a signiﬁcant
increase in cFos protein levels 30 min after injection [t(4) =
5.610, P = 0.0050; Figure 7E]. ABT-418 was also able to signiﬁcantly increase ERK1/2 phosphorylation levels in the PFC of
mice lacking α7nAChR [t(4) = 5.300, P = 0.0061; Figure 7F].
Importantly, given that the mice had been exposed to the
task numerous times, we evaluated the performance of the
mice over the course of the various injections in order to ensure
that the improvements brought on by the ABT-418 were not
due to the mice becoming better at the task. We compared the
performance (both rates of omission and accuracy) of the mice
from the vehicle injections of each drug experiment with their
naive performance (the performance at a 0.6 s stimulus duration
during the probe trial experiments). Both the WT {omission
[one-way ANOVA: no effect of treatment, F(6,18) = 0.7467,
P = 0.4692; Supporting Information Fig. 7A] and accuracy [oneway ANOVA: no effect of treatment, F(6,18) = 0.6749, P = 0.6716;
Supporting Information Fig. 7B]} and CHRΝΑ7!/! mice
{omission [one-way ANOVA: no effect of treatment, F(6,18) =
2.565, P = 0.1154; Supporting Information Fig. 7C] and accuracy
[one-way ANOVA: no effect of treatment, F(6,18) = 1.005,
P = 0.3876; Supporting Information Fig. 7D]} demonstrated no
signiﬁcant change in performance in both omissions and
accuracy from their naive performance across all injections.

Figure 7
Sustained attention deﬁcits of CHRNA7 null mice are reversed by β2nAChR agonists. (A) Omission and (B) accuracy following injections of
!/!
mice. (C) Omissions and (D) accuracy over bins of 25 trials following administration of ABT-418. (E) cFos protein levels
ABT-418 in CHRNA7
and (F) ERK1/2 phosphorylation following injection of ABT-418 (data are presented as mean ± SEM; *P < 0.05,**P < 0.01.
British Journal of Pharmacology (2015) 172 4919–4931
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Discussion
In this study, we demonstrated that the genetic elimination of
the CHRNA7 gene disturbs sustained attentional performance,
as measured by the 5-CSRT task, and that this deﬁcit is reversed
by administration of ABT-418, a β2nAChR agonist. CHRΝΑ7!/!
mice exhibited impaired performance (increased omission errors) during the second half of testing sessions of the 5-CSRT,
suggestive of deﬁcits in sustained attention, or vigilance. Increases in omission errors on the 5-CSRT task may reﬂect either
decreased attentional processing or a lack of motivation
(Robbins, 2002; Spinelli et al., 2004). However, given the normal
performance of CHRΝΑ7!/! mice on the food intake test, this
phenotype is unlikely to represent a motivational issue, suggesting that the lack of α7nAChRs impairs the ability to maintain
performance levels during the task. Pharmacological activation
of α7nAChRs in WT mice by two distinct α7nAChR agonists,
PHA-543,613 and PNU-282,987, in lower doses improved
attentional performance but did not change sustained attention. These effects were speciﬁc to their actions on α7nAChRs,
as these compounds were ineffective on CHRΝΑ7!/! mice.
Pharmacological activation of the β2nAChR by ABT-418 was
able to reverse the sustained attention deﬁcit in CHRΝΑ7!/!
mice, suggesting that the deﬁcits observed in these mice can
be rescued by β2nAChR signalling.
Post-mortem analysis of human patient samples has shown
that ERK1/2 MAP kinase signalling is reduced in brains of
schizophrenic patients (Yuan et al., 2010). Moreover, an inability
to induce phosphorylation of ERK1/2 MAP kinases in the PFC is
thought to underlie certain cognitive deﬁcits in animal models
of schizophrenia (Kamei et al., 2006). α7nAChR activation has
been shown to induce phosphorylation of ERK1/2 MAP kinases
both in vitro and in vivo (Bitner et al., 2007). Similar effects have
been observed in second-generation antipsychotics (Lu et al.,
2004). We showed that pharmacological activation of the
α7nAChR by PHA-543,613 induced a dose response increase in
both ERK1/2 phosphorylation levels and cFos in WT mice.
These effects were not detected in CHRΝΑ7!/! mice. Whether
this biochemical correlation of α7nAChR activation relates to
the biochemical and attentional deﬁcits observed in schizophrenia is unknown. Interestingly, when CHRΝΑ7!/! mice were
treated with the β2nAChR agonist ABT-418, both ERK1/2
phosphorylation and cFos protein levels were increased and
were correlated with the reversal of the sustained attention
deﬁcits. Although it is currently unclear if the neurons that
respond to ABT-418 and the α7nAChR drugs PHA-543,613 and
PNU-282,987 are the same, one potential important implication
of the behavioural data is that ABT-418 can reverse the sustained
attention deﬁcits due to abnormal CHRNA7 expression.
Interestingly, in WT mice, all α7nAChR targeting drugs used
presented an inverted ‘U’-shaped behavioural response. This is
not uncommon with nicotinic signalling with similar responses
observed across cognitive domains and even species (Picciotto,
2003; Olincy et al., 2006; Wallace et al., 2011a; Braida et al.,
2013). Desensitization of the receptor is often suggested as a
potential mechanism underlying this U-shaped behavioural
response. Our data suggest that this may not be the case for
α7nAChR activation, given that we see increases in the levels
of phospho-ERK1/2 following administration of a high dose of
α7nAChR agonist in WT mice, which results in poor performance on the 5-CSRT task. Interestingly, it has been proposed
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that overactivity of this second messenger signalling pathway
can actually impair executive function and lead to distractibility
(Birnbaum et al., 2004). We have also recently shown that
increased cholinergic tone by overexpression of VAChT and
increased cholinergic signalling in BAC ChAT-Chr2-EYFP mice
disturbs attentional processing (Kolisnyk et al., 2013b).
The ability of nicotine to improve attention has been well
documented in rodents (Young et al., 2004), non-human primates (Prendergast et al., 1998) and humans (Lawrence et al.,
2002). A common technique to evaluate the role of α7nAChR
signalling in attention has been to co-treat rodents with both
nicotine and the α7nAChR antagonist MLA. These studies have,
however, provided mixed results. Some investigators obtained
evidence for α7nAChR signalling in the pro-attentive effects of
nicotine (Hahn et al., 2011), and others failed to implicate
α7nAChR signalling in nicotine-induced improvements in
attention (Grottick and Higgins, 2000). Studies using ARR17779, a full agonist of the α7nAChR, have failed to demonstrate pro-attentive effects of α7nAChR stimulation (Grottick
and Higgins, 2000; Grottick et al., 2003; Hahn et al., 2003). This
compound, however, has also been shown to poorly penetrate
the blood brain barrier (Mullen et al., 2000). On the other hand,
R3487/MEM 3454, an α7nAChR agonist and 5-HT3 receptor
antagonist, has been shown to improve measures of sustained
attention in both rats (Rezvani et al., 2009) and macaque
monkeys (Wallace et al., 2009). Our experiments utilized both
PHA-543,613 and PNU-282,987, α7nAChR agonists, which
have been previously reported to easily cross the blood brain
barrier (Acker et al., 2008). Indeed, the biochemical activation
reﬂected by increased cFos levels or phospho-ERK supports the
contention that these drugs were able to activate the PFC in
mice. Importantly, our data further support results from
previous studies, suggesting that α7nAChR signalling has a role
in sustained attention (Young et al., 2007), speciﬁcally characterized by increased omission errors on the 5-CSRT task in
α7nAChR-null mice (Young et al., 2004).
Cholinergic transients in the PFC have been shown to be
important for cue detection and attentional processing
(Parikh et al., 2007). α7nAChR activation increases the duration of these transients 10–15-fold, and interestingly, this effect is lost when dopaminergic afferents to the PFC are
eliminated, suggesting a complex interplay between neurotransmitter systems (Parikh et al., 2010).
An important role of nicotinic receptors in the CNS is to inﬂuence the release of other neurotransmitters. Nicotinic receptors have been shown to inﬂuence the release of glutamate
(Gioanni et al., 1999), dopamine (Zhou et al., 2001), GABA
(Alkondon et al., 1999), noradrenaline (Fu et al., 1998), 5-HT
(Kenny et al., 2000) and ACh itself (Rowell and Winkler, 1984).
Efﬂux of all of these neurotransmitters in PFC has been associated with performance on the 5-CSRT task (reviewed in Robbins,
2002). Electron microscopy studies point to ACh release potentially being auto-regulated by presynaptic α7nAChRs in the PFC
(Duffy et al., 2009). On the other hand, post-synaptic β2nAChRs
have been shown to be necessary and sufﬁcient to regulate performance on the 5-CSRT task (Guillem et al., 2011; Poorthuis
and Mansvelder, 2013). In addition to the possibility that α7
and β2 receptors can form functional heteromeric receptors
(Liu et al., 2009; Moretti et al., 2014), our data reveal a complex
interplay between these two receptors in regulating sustained
attention. Given that our results suggest that activation of
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β2nAChRs can bypass α7nAChRs, it is possible that activation of
α7nAChRs could induce ACh release in the PFC, which would
then activate post-synaptic β2nAChRs to regulate sustained
attention. If this model is correct, it may explain the inconsistency amongst studies using non-selective nicotinic
agonists and antagonists. Co-treatment with nicotine and
methyllycaconitine, a α7nAChR antagonist, would still activate β2nAChRs and thus improve attentive processing.
Therefore, these previous experiments would not exclude a
role of α7nAChRs in attentional performance.
In conclusion, our data support a role for α7nAChRs in
sustained attention and reveal an intricate relationship between distinct nicotinic receptors to regulate attentional performance. Our results indicate that activation of β2nAChRs
can bypass attentional deﬁcits due to α7nAChR deﬁciency,
suggesting that β2nAChRs may be an important pharmacological target in cognitive dysfunctions in which impaired
α7nAChRs have been implicated, such as schizophrenia and
Alzheimer’s disease (Parri et al., 2011).
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Forebrain Deletion of the Vesicular Acetylcholine
Transporter Results in Deficits in Executive Function,
Metabolic, and RNA Splicing Abnormalities in the Prefrontal
Cortex
Benjamin Kolisnyk,1,2 Mohammed A. Al-Onaizi,1,4 Pedro H. F. Hirata,1 Monica S. Guzman,1,3 Simona Nikolova,1
Shahar Barbash,6 Hermona Soreq,6 Robert Bartha,1,5 Marco A. M. Prado,1,2,3,4 and Vania F. Prado1,2,3,4
1Robarts Research Institute, 2Graduate Program in Neuroscience, 3Department of Physiology and Pharmacology, 4Department of Anatomy and Cell
Biology, 5Department of Medical Biophysics, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada, N6A
5K8, and 6Department of Biological Chemistry and The Edmond and Lily Safra Center of Brain Science, The Hebrew University of Jerusalem, Jerusalem
91904, Israel

One of the key brain regions in cognitive processing and executive function is the prefrontal cortex (PFC), which receives cholinergic input
from basal forebrain cholinergic neurons. We evaluated the contribution of synaptically released acetylcholine (ACh) to executive
function by genetically targeting the vesicular acetylcholine transporter (VAChT) in the mouse forebrain. Executive function was assessed using a pairwise visual discrimination paradigm and the 5-choice serial reaction time task (5-CSRT). In the pairwise test, VAChTdeficient mice were able to learn, but were impaired in reversal learning, suggesting that these mice present cognitive inflexibility.
Interestingly, VAChT-targeted mice took longer to reach criteria in the 5-CSRT. Although their performance was indistinguishable from
that of control mice during low attentional demand, increased attentional demand revealed striking deficits in VAChT-deleted mice.
Galantamine, a cholinesterase inhibitor used in Alzheimer’s disease, significantly improved the performance of control mice, but not of
VAChT-deficient mice on the 5-CSRT. In vivo magnetic resonance spectroscopy showed altered levels of two neurochemical markers of
neuronal function, taurine and lactate, suggesting altered PFC metabolism in VAChT-deficient mice. The PFC of these mice displayed a
drastic reduction in the splicing factor heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNPA2/B1), whose cholinergic-mediated
reduction was previously demonstrated in Alzheimer’s disease. Consequently, several key hnRNPA2/B1 target transcripts involved in
neuronal function present changes in alternative splicing in VAChT-deficient mice, including pyruvate kinase M, a key enzyme involved
in lactate metabolism. We propose that VAChT-targeted mice can be used to model and to dissect the neurochemical basis of executive
abnormalities.

Introduction
The prefrontal cortex (PFC) is essential for the modulation of
executive function, which is loosely defined as a set of cognitive
tools that allows hierarchical and timely control of actions leading to specific behaviors (Alvarez and Emory, 2006; Robbins and
Roberts, 2007; Chudasama, 2011). Disruption in executive function is a key symptom in neurological and neuropsychiatric disorders, including Alzheimer’s disease (AD; Perry and Hodges,
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1999; Traykov et al., 2007; McGuinness et al., 2010), schizophrenia (Morice, 1990), autism (Hill, 2004; Sala et al., 2011), and drug
addiction (Stalnaker et al., 2009). The basic neurochemical underpinnings of executive function are, however, still poorly
understood.
Cholinergic deficits are a hallmark of AD (Perry et al., 1977;
Whitehouse et al., 1981, 1982). Moreover, amyloid ! (A!) oligomers, potential toxins in AD, disrupt cholinergic synaptic
transmission in the PFC (Chen et al., 2013). Cholinergic deficiency in AD can have widespread effects, including global
changes in alternative splicing of genes involved in synaptic plasticity (Berson et al., 2012).
Acetylcholine (ACh) in the PFC has been implicated in controlling attention (Elliott, 2003; Jurado and Rosselli, 2007), one of
the components of executive function. Cue detection and topdown modulation of attentive behavior have both been shown to
activate PFC cholinergic activity and to be modulated by cholinergic signaling (Sarter et al., 2001; Parikh et al., 2007). Cholinergic transients in the PFC have been linked to cue detection, and
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both tonic and phasic PFC ACh release seem to regulate attentional demand (Parikh et al., 2007; for review, see Hasselmo and
Sarter, 2011), which may depend mainly on nicotinic receptor
signaling (McGaughy et al., 1999; Grottick and Higgins, 2000;
Parikh et al., 2010; Guillem et al., 2011).
Cognitive flexibility, the ability to alter strategy according to
changing environmental cues, is another key component of executive function (Elliott, 2003; Jurado and Rosselli, 2007). The
neurochemical basis of cognitive flexibility is not fully understood, but serotonin is thought to play critical roles (Schmitt et
al., 2006; Evers et al., 2007; Brigman et al., 2010).
Release of ACh is a tightly regulated process, with the vesicular
acetylcholine transporter (VAChT) controlling a limiting key
step (de Castro et al., 2009a; Kolisnyk et al., 2013; for review, see
Prado et al., 2013). Genetic elimination of VAChT from the forebrain causes deficits in reversal learning assessed using the Morris
Water Maze (MWM) (Martyn et al., 2012). Deficits in reversal
learning may be related to hippocampal dysfunction, but could
also reflect alterations in behavioral flexibility. To examine if decreased levels of VAChT, a change observed in AD (Efange et al.,
1997; Chen et al., 2011), affects executive function we have used
touchscreen tasks. We report that elimination of forebrain
VAChT caused severe deficits in cognitive flexibility and in sustained attention. In addition, we found that these mutant mice
have profound changes in RNA processing in the PFC, which
correlate with behavioral and metabolic deficits. Our results suggest that elimination of forebrain cholinergic activity in mice
provides a model for understanding the neurochemical basis of
executive function.

Materials and Methods
Animals. Generation of VAChT Six3-Cre-flox/flox mice was previously described (Martyn et al., 2012). In short, VAChT Six3-Cre-flox/flox mice were
generated by crossing VAChT flox/flox (mixed C57BL/6J ! 129/SvEv
background, backcrossed to C57BL/6J for five generations) with the
Six3-Cre mouse line (NMRI background, backcrossed to C57BL/6J for
five generations). We then intercrossed VAChT Six3-Cre-flox/wt mice to
obtain VAChT Six3-Cre-flox/flox. For the galantamine experiments, the
mice used were wild-type C57BL/6J. Mice were housed in groups of three
or four per cage without environmental enrichment in a temperaturecontrolled room with 14/10 h light/dark cycle, and water was provided ad
libitum. Only male mice were used in these studies. Mice were restricted
to 85% of their free-feed weight and maintained on 85% of their weight
for the duration of the study. All procedures were conducted in accordance with guidelines from the Canadian Council of Animal Care at the
University of Western Ontario with an approved institutional animal
protocol (2008 –127).
Western blotting. Mouse PFC was collected, protein was isolated, and
immunoblotting was performed as previously described (Martins-Silva
et al., 2011). The antibodies used were anti-VAChT (catalog #139103;
Synaptic Systems) at a 1:3000 dilution, anti-Synaptophysin (catalog
#S5768; Sigma-Aldrich) at a 1:500 dilution, anti-hnRNP A2/B1 (catalog
#sc-10035; Santa Cruz Biotechnology) at a 1:500 dilution, and anti-!Actin (catalog #ab49900; Abcam), at a 1:15000 dilution. Band intensity
was quantified using FluoroChemQ software (Thermo Fisher Scientific).
ACh release. ACh release from prefrontal cortical brain slices was
quantified by labeling slices with [ 3H] methyl-choline before using KCl
to stimulate release of labeled ACh as previously described (Guzman et
al., 2011).
qPCR. To measure mRNA expression, total RNA was extracted from
freshly dissected PFC tissue, using the Aurum Total RNA for fatty and
fibrous tissue kit (Bio-Rad) according to the manufacturer’s instructions. cDNA synthesis and qPCR analysis were performed as previously
described (Guzman et al., 2011). Primer sequences used to determine
alternative spliced transcripts are found in Table 1. !-Actin was used as a
reference transcript for all reactions. For alternative splicing experi-
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Table 1. Primers for alternative splicing assay
Target

Forward primer(5# 3 3#)

Reverse primer (5# 3 3#)

CD55 exon 8
CD55 exon 1
DRAM2 exon 2
DRAM2 exon 4
SIPA1L1 intron 5
SIPA1L1 exon 4
DYSTONIN exon 41
DYSTONIN exon 7
REELIN exon 3
REELIN exon 18
REELIN exon 1
mENAH
mENAH invasive
PKM1
PKM2

CCCAGCATGTACCTGTTACC
TGTCTCTGTTGCTGCTGTCC
TGATTCAAGGTTCACACTCACA
TTCAGCAAGGCCTCAGTTTT
TCAGGCATGCAGTTCTTTTG
TAGTGTGGACGCTGCTGTCT
ATGGCATTTCCCCCATTAG
GAGCGGGACAAAGTTCAAAA
ATCATGTCCGACCACCAGTT
GCAGTGCCAGACTTTCCTCT
GGCAACCCCACCTACTACG
CGGCAGTAAGTCACCTGTCA
GATTCAAGACCATCAGGTTGTG
CATGCAGCACCTGATAGCTC
GCAGTGGGGCCATTATCGT

TCACATGCAAAACTGTCAAGG
TGCTCAGCAAACTTGGAGTG
AAAACTGAGGCCTTGCTGAA
TCAGGAGGTATTGTCCCTGTG
GAAAGCAGGCAGTACCTTCG
GGCTCTGTGGTCACCAGAAT
GGAGGTTGGTTTTGCTTCAA
CCCGTCCCTCAGATCCTC
ATCATGTCCGACCACCAGTT
GCCTCCCATCTTTGTTGAAA
GACTGGATGCTTGTCGAGGT
C TTCAGCTTTGCCAGCTCTT
CAATGTTGGCCCTAAATAGAA
TTATAAGAGGCCTCCACGCTG
GGGATTTCGAGTCACGGCAA

ments, the alternative exon levels were normalized to a constitutively
expressed exon from the same gene.
Magnetic resonance imaging. Magnetic resonance spectroscopy of the
prefrontal region was performed in four VAChT Six3-Cre-flox/flox mice and
four littermates (VAChT flox/flox). Spectroscopic localization of a 24 "l
voxel was achieved by adiabatic selective refocusing (DelaBarre and Garwood, 1998) on a 9.4 tesla horizontal bore small animal Agilent magnetic
resonance imaging (MRI) scanner. Water-suppressed full spectra (TR/
TE " 3250/20 ms, 128 acquisitions), water-suppressed macromolecule
spectra (TR/TE " 5000/20 ms, inversion time TI " 873 ms, 128 acquisitions), and water-unsuppressed spectra (TR/TE " 3250/20 ms, 8 acquisitions) were acquired. All animals were anesthetized with 2%
isoflurane during the procedure and were maintained at 37° by blowing
warm air into the bore of the magnet using a Model 1025 Small Animal
Monitoring and Gating System (SA Instruments).
Metabolite analysis. Magnetic resonance spectra were analyzed using
purpose-built software (fitMAN; Bartha et al., 1999) to determine the
contribution of each metabolite relative to total creatine as previously
described (Bartha, 2007, 2008). Briefly, spectra were lineshape corrected
(Bartha et al., 2000b) and the macromolecule and residual water contribution was removed (Kassem and Bartha, 2003). Then, the spectrum was
fitted in the time domain to a basis set of 19 metabolite lineshapes
(Pfeuffer et al., 1999; Bartha et al., 2000a). Five metabolites (measured
relative to creatine) were reliably measured and included in group comparisons: N-acetylaspartate (NAA), myo-inositol (Myo), choline (Cho),
taurine (Tau), and lactate (Lac).

Touchscreen behavioral assessment
Apparatus and task. Mice were trained in the 5-choice serial reaction time
task (5-CSRT) and in the pairwise visual discrimination in automated
Bussey–Saksida Mouse Touchscreen Systems model 81426 (Campden
Instruments). Schedules were designed and data were collected using the
ABET II Touch software v.2.15 (Lafayette Instruments).
Pretraining. Before being trained on the pairwise visual discrimination
or the 5-CSRT task, mice were first put through a pretraining program.
This consisted of first habituating the mice to the testing chamber with
the lights off for 15 min. The next day, mice were left in the chamber with
the lights off for 20 min, this time with the reward tray primed with a 150
"l reward (strawberry milkshake; Saputo Dairy Products), and a tone
was played whenever the mouse entered the reward tray. Whenever the
mouse returned to the reward tray, it received a reward (7 "l) paired with
the tone. This training was repeated the next 2 d for 40 min sessions
(phase 1).
The next training phase (phase 2) involved pairing the reward with the
presentation of the stimulus on the touchscreen. The stimulus appeared
randomly in one of the windows and after 30 s, it was removed and a
reward (7 "l) was given paired with a tone. If the mouse touched the
screen while the image was displayed, it immediately received a reward (7
"l). Once the mouse collected the reward a new trial was initiated. This
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phase was repeated until the mouse completed
30 trials within 60 min (phase 2).
Phase 3 was used to further shape behavior.
It involved displaying the stimulus randomly
in one of the windows. The mouse was required to touch the stimulus on the screen to
receive a reward (7 !l) paired with a tone.
There was no response to the mouse touching
anything but the stimulus. Once again, this was
repeated until the mouse completed 30 trials
within 60 min. Phase 4 was identical to phase 3
except that the mouse was required to initiate
each trial by nose poking the reward tray. Criterion was 30 correct trials within 60 min.
Finally, in the last pretraining phase (phase
5), the previous procedure was repeated but if
the mouse touched an incorrect screen, it received a 5 s time-out, during which the light
was turned on. The final phase had a stricter
criterion, requiring the mouse to perform 30
trials in 60 min with at least 23 correct responses in 2 consecutive days.
Pairwise visual discrimination and reversal.
Pairwise visual discrimination and reversal
task were performed as previously described
(Romberg et al., 2013). Mice used in this experiment were 6 – 8 months old. At the beginning
of each session, the reward tray was primed
with 7 !l of milkshake. Briefly, the mice were
first trained to discriminate between two visual
stimuli, which were presented simultaneously,
with their spatial location randomized over a
30 trial session. If mouse nose poked the correct stimulus (S!), a tone was played and
mouse received a reward (7 !l), whereas if the
incorrect stimulus (S") was nose poked, light
in the chamber was turned on for 5 s (timeout) followed by a correction trial. During the
correction trial, the trial was repeated until the
mouse poked the correct stimulus. Criterion
was reached when the mouse selected the correct image (S!) on 80% of the trials, excluding
correction trials, for 2 consecutive days. Once
mice reached criteria, they were given two sessions to assess baseline performance on the
task. For reversal learning the rule associated to
each stimulus was switched, that is, the rewarded image (S!) during acquisition became
the (S") image in reversal and was punished,
while the (S") image from acquisition became
the correct stimulus and was rewarded. Reversal learning was assessed over the course of 10
sessions.
Training in 5-CSRT. The 5-CSRT task was
performed as previously described (Romberg
et al., 2011). A distinct cohort of mice (8 –10
months old) was trained in the 5-CSRT task. At
the beginning of each session, the reward tray
was primed with 7 !l of milkshake. Each trial
was initiated after the mouse nose poked the
magazine. In this phase, the stimulus was delivered after a variable 5–10 s delay (delay period), during which the animal was required to
attend to the screen. In case the mouse prematurely touched the screen during this delay, the
response was recorded as premature and
the mouse was punished with a 10 s time-out.
The stimulus duration was initially set to 4 s,
followed by a limited holding period of 5 s,
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Figure 1. Expression of VAChT in the PFC of VAChT Six3-Cre-flox/flox mice. A, VAChT protein expression in the PFC with representative immunoblots inset (n # 4). B, Release of newly synthesized [ 3H]ACh in PFC slices (n # 3). C, qPCR analysis of nAChR
expression (n # 6, data are mean $ SEM, *p % 0.05).

Figure 2. VAChT Six3-Cre-flox/flox mice show normal visual discrimination learning. A, Mean number of trials required to reach criteria
during the operant conditioning, pretraining phases. B, Image of a mouse performing the task, with the fan shown as the S! and the
marblesastheS".C,Numberofsessionstocriteriainthepairwisevisualdiscriminationlearningtask. D,Correctionerrorsmadetoachieve
discrimination criteria. E, Mean response latency. F, Mean reward collection latency. n # 8, data are mean $ SEM.
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reward tone, was played semirandomly at five
different time points during the delay period: 0
(corresponding to when the mouse initiates the
task), 0.5, 2.5, 4.5, and 5 s (corresponding to
when the stimulus is displayed on the touchscreens). Stimulus duration was set to 2 s. For
each distractor tone time point mice were
tested for five sessions. At the end of the five
sessions one baseline task (50 trial, 2 s stimulus
duration, no distractor sounds) was performed
before moving to the next distractor time
point.
5-CSRT task measures. On all 5-CSRT task
sessions, accuracy was defined as the total
number of correct responses, divided by the
number of correct and incorrect (touches to a
wrong window while the correct stimulus was
still displayed) responses. The rate of omissions was the proportion of omitted responses
to total trials. Response latency was the time for
the mouse to touch the correct stimulus after
its onset. Reward collection latency was the
time for the mouse to return to the reward tray
once it had touched the correct stimulus. A
premature response was counted when the
mouse touched one of the windows before
stimulus onset. Finally, a perseverative response was any identical response that occurred following a correct, incorrect, or
premature response.
Drug treatment. Galantamine hydrobromide, a cholinesterase inhibitor, (SigmaAldrich) was dissolved in physiological saline
(0.9% NaCl) before administration. Sixty minutes before being tested on the 5-CSRT mice
received an intraperitoneal injection of drug
Figure 3. VAChT Six3-Cre-flox/flox mice have impaired reversal learning. A, Image of a mouse performing the task, this time with (100 !l, 1 mg/kg) or saline. The dose for galanthe fan shown as the S$ and the marbles as the S%. B, Choice accuracy before (B1 and B2) and during reversal trials (R2–R10), tamine was selected based on previous studies
dashed line denotes chance (50%). C, Number of correction errors made across reversal trials. D, Response latency across reversal (Prado et al., 2006; de Castro et al., 2009b; De
trials. E, Reward collection latency across reversal trials (n & 8, data are mean " SEM, *p ! 0.05, **p ! 0.01, and ***p ! 0.001). Jaeger et al., 2013). Previously, we have tested 3
mg/kg galantamine in other tasks, but this dose
was no more effective than 1 mg/kg and it produced hypersalivation in mice (de Castro et al.,
during which the stimulus was absent, but the mouse could still respond
2009b). Moreover, at 1 mg/kg wild-type mice were able to increase their
to the location (holding period). Responses to the stimulus window durperformance in the 5-CSRT (see below). Mice were tested at the 0.6 s
ing stimulus presence or the holding period were recorded as correct and
stimulus duration, which represents a high attention demanding task
a 7 !l reward was administered, while responses to any other window
(Romberg et al., 2011). The order of the injections was counterbalanced.
were recorded as incorrect. A correct choice was rewarded with a tone
Between injections mice had three washout days wherein their perforand food delivery. An incorrect response was punished with a 10 s timemance on the 5CSRT was re-baselined at the 2 s stimulus duration.
out. A failure to respond to any window either during stimulus display,
Statistical analysis. For the pairwise visual discrimination task response
or during the holding period, was recorded as an omission and punished
accuracy
was calculated as the number of correct trials divided by the
with a 10 s time-out. Perseverative responses to the screen after prematotal number of trials, excluding correction trials. Data are expressed as
ture, correct, and incorrect choices were also recorded. Once the performean " SEM. SigmaStat 3.5 software was used for statistical analysis.
mance of a mouse reached criterion at 4 s stimulus duration (80%
Comparison between two experimental groups was made by Student’s t
accuracy, 20% omissions for 3 consecutive days), the stimulus duration
test or Mann–Whitney rank sum test, when the data did not follow a
was reduced to 2 s. After reaching criterion with the 2 s stimulus, mice
normal distribution. When several experimental groups or treatments
were tested for two more days. The mean measurement of those 2 d was
were analyzed, two-way ANOVA or two-way ANOVA with repeated
used to assess baseline performance. If the mouse completed !30 trials,
measures was used as required. When appropriate, a Tukey’s HSD post
it was considered not to have reached criteria, even if it met accuracy and
hoc comparison test was used. In all comparisons, p ! 0.05 was considomissions thresholds.
ered statistically significant.
Probe trial. To probe attention in mice we used a previously described
probe trial schedule with reduced stimulus durations (Romberg et al., 2011).
Briefly, each mouse was tested for 2 consecutive days at a given stimulus
Results
duration (1.5, 1, 0.8, and 0.6 s). After each test, the animal was retested onto
VAChT Six3-Cre-flox/flox mice have reduced VAChT and ACh
the 2 s stimulus duration for 2 d or until criteria were reached (80% accuracy,
release in the PFC
20% omission), to assess baseline performance. The order of the probe trial
We have previously reported that VAChT Six3-Cre-flox/flox mice
sessions were semirandomized using a Latin square method.
have the VAChT gene deleted from #90% of their basal forebrain
Distraction task. To further test attentional demand, and assess suscepcholinergic neurons (Martyn et al., 2012). To confirm that this
tibility to distraction, we developed a distraction version of the 5-CSRT
task. During this task, a 1000 ms distractor tone, different from the
deletion affected prefrontal cortical cholinergic signaling, we per-
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formed Western blot analysis to assess VAChT expression.
VAChT Six3-Cre-flox/flox mice have a significant reduction in PFC
VAChT protein expression (t(6) ! 2.706, p ! 0.0353; Fig. 1A).
Moreover, this reduction in VAChT protein levels results in a
significant decrease in newly synthesized [ 3H] ACh release in
slices of PFC from VAChT Six3-Cre-flox/flox mice when compared
with control mice (t(4) ! 2.899, p ! 0.0442; Fig. 1B). We used
qPCR to assess the expression of nicotinic receptors (nAChRs),
which have been shown previously to be critical for attentional
performance. The PFC of VAChT Six3-Cre-flox/flox mice shows no
significant change in the expression of !7nAChR mRNA (t(10) !
0.9300, p ! 0.3743) nor "2nAChR mRNA (t(10) ! 0.8359, p !
0.4227). Interestingly, !4nAChR mRNA is slightly upregulated
(t(10) ! 2.550, p ! 0.0289; Fig. 1 C).
Decreased forebrain cholinergic tone specifically disturbs
reversal learning in the pairwise visual discrimination task.
We have previously demonstrated that VAChT Six3-Cre-flox/flox
mice have impairments in reversal learning in the MWM
(Martyn et al., 2012), suggesting the possibility that these mice
have behavior flexibility deficits. To determine whether
VAChT Six3-Cre-flox/flox mice present alterations in cognitive flexibility we used a “nonhippocampal” pairwise visual discrimination task (Romberg et al., 2013). This task has been previously
shown to depend on the PFC and also on striatal-cortical loops
(Graybeal et al., 2011). The performance of VAChT Six3-Cre-flox/flox
mice did not differ from that of controls (VAChT flox/flox) when
they were trained to operate the touchscreen (pretraining phase).
The number of sessions the mice took to acquire each training
phase did not differ from control (RM-ANOVA, no effect of
genotype F(1,54) ! 0.3950, p ! 0.5398; main effect of training
phase F(4,54) ! 5.227, p ! 0.0012; and no interaction effect F(4,54) !
1.389, p ! 0.2495; Figure 2A). Acquisition of the pairwise visual
discrimination task (Fig. 2B; for stimuli used) did not differ
between genotypes, in terms of sessions to criteria (Fig. 2C; t(14) !
0.2446, p ! 0.8117), correction errors made (Fig. 2D; t(14) !
0.2942, p ! 0.7746), response latency (Fig. 2E; t(14) ! 1.019,
p ! 0.3256), or reward collection latency (Fig. 2F; t(14) ! 0.2606,
p ! 0.7988). We have previously reported that these mice are
hyperactive in novel environments, but they are able to habituate
to the environment (Martyn et al., 2012). Hence, due to the extensive training for the performance in the touchscreen tasks the
lack of differences in response and reward collection latencies is
not surprising. However, VAChT Six3-Cre-flox/flox mice showed severe reversal learning impairment (Fig. 3A; for the stimuli used),
measured by the percentage of correct responses (Fig. 3B; RMANOVA, main effect of genotype F(1,132) ! 19.78, p ! 0.0008;
main effect of session F(11,132) ! 23.28, p ! 0.0001; and significant interaction effect F(1,12) ! 5.035, p ! 0.0001) and by its
increased correction errors (Fig. 3C; RM-ANOVA, main effect of
genotype F(1,132) ! 14.72, p ! 0.0024; main effect of session
F(11,132) ! 14.37, p ! 0.0001; and significant interaction effect
F(1,12) ! 2.817, p ! 0.0025). Post hoc analysis showed that
VAChT Six3-Cre-flox/flox mice never improved significantly from
the first reversal session and in 10 sessions they performed only
at chance level. Importantly, during the reversal trials, the
VAChT Six3-Cre-flox/flox mice did not differ from controls in terms
of response latency (Fig. 3D; RM-ANOVA, no effect of genotype
F(1,154) ! 0.4233, p ! 0.5258; main effect of session F(11,154) !
4.705, p ! 0.0001; and no interaction effect F(11,154) ! 0.9997, p !
0.4493) or reward collection latency (Fig. 3E; RM-ANOVA, no
effect of genotype F(1,154) ! 1.107, p ! 0.3105; main effect of
session F(11,132) ! 3.965, p ! 0.0001; and no interaction effect

Figure 4. Training in the 5-CSRT task. A, Mean number of trials required to reach criteria
during the operant conditioning, pretraining phases. B, Mean number of trials required to reach
criteria at 4 and 2 s stimulus duration (n ! 6, data are mean # SEM, *p " 0.05).

F(11,154) ! 1.141, p ! 0.3333). These results suggest that forebrain
cholinergic tone is important for cognitive flexibility.
VAChT Six3-Cre-flox/flox mice have impaired acquisition of the
5-CSRT task
Similar to the results for visual discrimination experiments, the
performance of the second cohort of VAChT Six3-Cre-flox/flox mice
did not differ from that of control mice for touchscreen operation
training (pretraining phase). The number of sessions necessary to
reach criteria across all pretraining phases did not differ between
genotypes (RM-ANOVA, no effect of genotype F(1,32) ! 1.528,
p ! 0.2515; no effect of training phase F(4,32) ! 1.492, p ! 0.2280;
Figure 4A). However, when mice were trained to respond to
flashes of light displayed in one of the five spatial locations on the
touchscreen (training phase), VAChT Six3-Cre-flox/flox showed a
significantly worse performance, needing more sessions to reach
criteria (RM-ANOVA, main effect of genotype, F(1,8) ! 10.06,
p ! 0.0132; main effect of stimulus duration, F(1,8) ! 5.731, p !
0.0436, no interaction effect, F(1,8) ! 4.252, p ! 0.0731; Fig. 4B).
Deletion of forebrain VAChT results in inattentive but not
impulsive or compulsive behavior
Once mice reached criteria they were tested for attentional performance by decreasing stimulus duration to 1.5, 1, 0.8, and 0.6 s
as previously described (Romberg et al., 2011). At 1.5 s,
VAChT Six3-Cre-flox/flox mice were able to perform identically to
control mice in both accuracy and omissions (Fig. 5 A, B). In
contrast, increasing attentional demand by diminishing the stimuli period revealed an attentional deficit in VAChT Six3-Cre-flox/flox
mice. Response accuracy did not differ between genotypes (RMANOVA, no effect of genotype F(1,24) ! 0.0007548, p ! 0.9788;
main effect of stimulus duration F(3,24) ! 10.28, p " 0.001; Figure
5A). However, VAChT Six3-Cre-flox/flox mice presented an increased rate of omission (RM-ANOVA, main effect of genotype
F(1,24) ! 57.99, p " 0.0001; main effect of stimulus duration

Kolisnyk et al. • Decreased Cholinergic Tone Impairs PFC Function

J. Neurosci., September 11, 2013 • 33(37):14908 –14920 • 14913

Figure 5. VAChT Six3-Cre-flox/flox mice have attentional deficits. Performance and response measures during 5-CSRT task probe trials. Mice were subjected to a series of probe trials and the average
values of 50 trial sessions are plotted. A, Mean accuracy. B, Mean rate of omissions. C, Mean premature responses. D, Mean perseverative responses. E, Mean response latency. F, Mean reward
collection latency (n ! 6, data are mean # SEM, *p " 0.05 and **p " 0.01).

from littermate controls in response latency (RM-ANOVA, no effect of genotype
F(1,24) ! 2.279, p ! 0.1818; no effect of
stimulus duration F(3,24) ! 0.09686, p !
0.7662; Figure 5E) and reward collection
latency (RM-ANOVA, no effect of genotype F(1,24) ! 2.279, p ! 0.1818; no effect
of stimulus duration F(3,24) ! 1.189, p !
0.3420; Figure 5F ).

Deletion of forebrain VAChT impairs
sustained attention
To assess sustained attention (vigilance), we analyzed both response accuracy and rate of omissions over blocks of
10 trials (Romberg et al., 2011). Response accuracy of control mice did not
significantly vary across blocks, but did
reduce significantly with decreases in
stimuli duration (RM-ANOVA, main
effect of stimulus duration F(3,48) !
5.893, p ! 0.0104; no effect of block
Figure 6. VAChT Six3-Cre-flox/flox mice have impaired sustained attention. Mean response accuracy for blocks of 10 trials for (A) F(4,48) ! 1.214, p ! 0.317; Figure 6A). In
response
accuracy
of
VAChT flox/flox and (B) VAChT Six3-Cre-flox/flox mice. Mean rate of omission for blocks of 10 trials for (C) VAChT flox/flox and (D) contrast,
VAChT Six3-Cre-flox/flox mice reduced sigVAChT Six3-Cre-flox/flox mice (n ! 6, data are mean # SEM, *p " 0.05).
nificantly across blocks and stimuli duration (RM-ANOVA, main effect of
F(3,24) ! 36.44, p " 0.0001; no interaction effect F(3,24) ! 2.176,
stimulus
duration
F
(3,48) ! 4.257, p ! 0.0077; main effect of
p ! 0.1171; Figure 5B). Post hoc analysis revealed that
Six3-Cre-flox/flox
block
F
!
3.933,
p ! 0.0289; Figure 6B). As with response
(4,48)
VAChT
mice omitted more at 0.6 –1 s stimulus
accuracy,
rate
of
omissions
of control mice did not vary across
durations. Interestingly, VAChT-deficient mice had no
blocks, only with stimuli duration (RM-ANOVA, main effect
alterations in premature responses (RM-ANOVA, no effect of
of stimulus duration F(3,48) ! 5.803, p ! 0.0228; no effect of
genotype F(1,24) ! 0.07440, p ! 0.7874; no effect of stimulus
block
F(4,48) ! 0.5352, p ! 0.7105; Figure 6C), whereas rate of
duration F(3,24) ! 0.9891, p ! 0.4146; Figure 5C) or perseverative
omissions of VAChT Six3-Cre-flox/flox mice increased signifiresponses (RM-ANOVA, no effect of genotype F(1,24) ! 0.04610,
cantly across stimuli duration and blocks (RM-ANOVA, main
p ! 0.9695; no effect of stimulus duration F(3,24) ! 1.244, p !
0.3232; Figure 5D). Additionally, mutant mice did not differ
effect of stimulus duration F(3,48) ! 9.387, p ! 0.0018; main
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effect of block F(4,48) ! 2.803, p !
0.0360; Figure 6D). Together the data
suggest that VAChT Six3-Cre-flox/flox mice
have impaired ability to sustain
attention.
Deletion of forebrain VAChT increases
susceptibility to distractions
To assess distractibility of VAChT Six3-Cre-flox/
flox mice, we increased attentional demand
by testing them on a distraction variation of
the 5-CSRT. Stimulus duration was set to
2 s, where performance of both genotypes
was identical, and distractor sounds were
played at set time points during trials. Response accuracy of VAChT Six3-Cre-flox/flox
mice tended to be reduced by distractions
compared with controls (RM-ANOVA,
near significant effect of genotype F(1,32) !
4.825, p ! 0.0589; main effect of distractor
onset F(4,32) ! 3.583, p ! 0.0159; Figure
7A). Rate of omission was significantly
higher in VAChT Six3-Cre-flox/flox mice than
controls (RM-ANOVA, significant effect of
genotype F(1,32) ! 6.809, p ! 0.0312; no ef- Figure 7. VAChT Six3-Cre-flox/flox mice are more susceptible to distraction. Mice were subjected to a series of distraction trials and
fect of distractor onset F(4,32) ! 2.564, p ! the average values of 50 trial sessions per distractor onset are plotted. A, Mean response accuracy. B, Mean rate of omission. C,
0.0572; Figure 7B). Importantly, neither re- Mean response latency. D, Mean reward collection latency (n ! 6, data are mean # SEM, * represents significant differences
sponse latency (RM-ANOVA, no effect of between genotypes, # represents significant differences within genotypes; *p " 0.05).
genotype F(1,32) ! 1.045, p ! 0.3367; main
effect of distractor onset F(4,32) ! 7.069, p !
t(7) ! 0.390, p ! 0.7080) were not changed by galantamine injec0.0003; Figure 7C) nor reward collection latency varied between getions (data not shown). These results suggest that increased chonotypes (RM-ANOVA, no effect of genotype F(1,32) ! 0.7467, p !
linergic tone can increase attentional performance when the
0.4127; main effect of distractor onset F(4,32) ! 3.226, p ! 0.0248;
probe trial is sufficiently demanding to avoid a potential ceiling
Figure 7D).
effect.
Galantamine improves attention in wild-type mice on a
demanding task
Detection of pro-attentive effects of pharmacological manipulations on the 5-CSRT is hampered by possible ceiling effects (Robbins, 2002). To detect differences in mice it is important to test
the drug on challenging conditions, which can be achieved by
shortening the duration of the stimulus presentation (Romberg
et al., 2011). To find a suitably challenging task in which we could
observe increased attention, we trained a group (n ! 8) of wildtype mice on the 5-CSRT, and ran them through the probe trial
series, serially reducing stimulus duration (1.5, 1, 0.8, and 0.6 s).
Choice accuracy (F(4,31) ! 13.77, p " 0.0001; Fig. 8A) and rate of
omissions (F(4,31) ! 6.716, p ! 0.0024; Fig. 8B) were significantly
affected by reducing stimulus duration. Post hoc analysis revealed
that at 0.6 s stimulus duration the rate of accuracy was significantly reduced, and omissions significantly increased from the
1.5 s stimulus duration. We therefore chose both, 0.8 s stimulus
duration and the more challenging 0.6 s stimulus duration, for
pharmacological testing. Administration of galantamine (1 mg/
kg, i.p.) 1 h before 5-CSRT testing at 0.8 s did not improve accuracy (paired t test, t(7) ! 1.287, p ! 0.2544; Fig. 8C) or omissions
(paired t test, t(7) ! 0.4581, p ! 0.6661; Fig. 8D). However, when
administered before a 0.6 s stimulus duration session, galantamine (1 mg/kg) significantly improved accuracy compared
with saline (paired t test, t(7) ! 2.405, p ! 0.0471; Fig. 8E) and
significantly reduced the rate of omission (paired t test, t(7) !
2.379, p ! 0.0489;Fig. 8F ). Response latency (paired t test, t(7) !
1.296, p ! 0.2360), and reward collection latency (paired t test,

Galantamine does not improve attention deficits in
VAChT Six3-Cre-flox/flox mice
To investigate if the deficits observed in VAChT Six3-Cre-flox/flox are
exclusively related to decreased levels of synaptic ACh, we injected mice with galantamine (1 mg/Kg IP), a dose that effectively
improved performance of wild-type mice (Fig. 8), and tested
both VAChT Six3-Cre-flox/flox and VAChT flox/flox mice at 0.6 s (50
trials). Galantamine tended to improve choice accuracy, albeit
this effect did not reach statistical significance (paired t test, t(5) !
1.954, p ! 0.1224; Fig. 8G). However, the drug was able to significantly reduce rate of omissions (paired t test, t(5) ! 3.383, p ! 0.0277;
Fig. 8H) in VAChT flox/flox mice. Interestingly, galantamine had no
effect on the performance of VAChT Six3-Cre-flox/flox mice, neither improving accuracy (paired t test, t(5) ! 0.162, p ! 0.880; Fig. 8G) nor
rate of omission (paired t test, t(5) ! 0.868, p ! 0.434; Fig. 8H).
Deletion of forebrain VAChT results in metabolic
abnormalities in the PFC
The lack of effect of galantamine in VAChT Six3-Cre-flox/flox suggests that diminished ACh release in mutant mice may not be
sufficiently increased by galantamine to reverse the attentional
deficits in these mice. In addition to that, a chronic decrease in
cholinergic tone may cause circuitry or metabolic changes that
could affect how neuronal circuitries are recruited for specific
cognitive tasks. We used in vivo magnetic resonance spectroscopy
to assess if metabolic parameters were affected in the prefrontal
region of VAChT-deficient mice (Fig. 9A; representative spectra).
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Figure 8. Galantamine improves attention in wild-type, but not in VAChT Six3-Cre-flox/flox mice. Wild-type mice (n ! 8) were subjected to a series of probe trials and the average values of 50 trial
sessions are plotted. A, Mean accuracy. B, Mean rate of omissions. Effect of galantamine (1 mg/kg i.p.) on (C) response accuracy and (D) rate of omission in wild-type mice at a 0.8 s stimulus duration
(n ! 8). Effect of galantamine on (E) response accuracy and (F ) rate of omission in wild-type mice at a 0.6 s stimulus duration (n ! 8). Effect of galantamine (1 mg/Kg I.P.) on (G) choice accuracy
and (H ) rate of omission in VAChT flox/flox and VAChT Six3-Cre-flox/flox mice (n ! 6, data are mean " SEM, *p # 0.05).

This analysis revealed that VAChT Six3-Cre-flox/flox mice had significantly less Lac (t(6) ! 2.600, p ! 0.0428; Fig. 9B) and Tau
(t(6) ! 2.522, p ! 0.0452; Fig. 9C) than controls. Levels of NAA
(t(6) ! 0.0907, p ! 0.9307; Fig. 9D), Myo (t(6) ! 0.9598, p !
0.3742; Fig. 9E), and Cho (t(6) ! 0.1461, p ! 0.8886; Fig. 9F )
remained unchanged.
Deletion of forebrain VAChT results in altered RNA
metabolism in the PFC
Cholinergic deficits in AD have been proposed to cause major
transcriptome changes via aberrant hnRNPA2/B1 expression
(Berson et al., 2012). hnRNPA2/B1 refers to a family of proteins
that functions as splicing factors and mRNA chaperones (Hoek et
al., 1998; Kamma et al., 1999). This gene family is critical for
regulating alternative splicing in numerous genes involved with
synaptic plasticity and cognition (Berson et al., 2012). Its expression is severely reduced in Alzheimer brain and appears enhanced
in primary mouse neurons under carbachol induction (Berson et
al., 2012), suggesting cholinergic regulation of hnRNPA2/B1 proteins. To determine whether the PFC of VAChT Six3-Cre-flox/flox
shows parallel suppression of the hnRNPA2/B1 proteins, their
levels were assessed. Compared with controls, the PFC of
VAChT Six3-Cre-flox/flox mice showed a significant reduction in hnRNPA2/B1 expression (75% decrease, t(6) ! 4.941, p ! 0.0026;
Fig. 10A). We then used qPCR to assess whether the decrease in
hnRNPA2/B1 could have a functional impact on RNA processing
in the PFC. We evaluated the alternative splicing of the key genes,
SIPA1L1(SIPA), REELIN(RELN), DRAM2, CD55, DYSTONIN

(DST), and ENAH, as manifested by increased exon inclusion
tested both in Alzheimer’s brain and in mouse brain depleted of
its cholinergic neurons by saporin-mediated treatment (Berson
et al., 2012). This analysis revealed that VAChT Six3-Cre-flox/flox
mice had significant changes in the splicing of these genes in the
PFC, with significantly increased inclusion of exon 8 of CD55
(t(10) ! 2.550, p ! 0.0289), exon 41 of DST (t(10) ! 7.436, p !
0.0001), exon 18 of RELN (t(10) ! 3.230, p ! 0.0090), and exon 2
of DRAM2 (t(10) ! 3.990, p ! 0.0260). In addition the inv isoform of the ENAH gene was also significantly increased (t(10) !
2.522, p ! 0.0303). In contrast, intron 5 of SIPA (t(10) ! 0.5449, p !
0.5978) and exon 3 of RELN (t(10) ! 2.215, p ! 0.0511), which have
also been shown to be affected in AD, were unchanged, although we
detected a trend for the latter (Fig. 10B).
hnRNPA2/B1 has been shown to regulate the splicing of
pyruvate kinase M (PKM) enzyme, which in turn dictates lactate metabolism (David et al., 2010). Knockdown of hnRNPA2/B1 expression in vitro favors the PKM1 isoform,
which leads to reduced levels of Lac, whereas upregulation
hnRNPA2/B1 favors the PKM2 isoform and increased Lac levels (Clower et al., 2010; for review, see Chen et al., 2010). To
test whether alternative splicing of PKM occurs in VAChT Six3Cre-flox/flox mice, we performed qPCR to determine the expression
of the PKM1 and PKM2 splice variants. Interestingly the
VAChT Six3-Cre-flox/flox mice showed a significant upregulation of
the PKM1 variant (t(10) ! 4.277, p ! 0.0016), and a significant
reduction in the PKM2 variant (t(10) ! 3.073, p ! 0.0110; Fig.
10C), effectively changing the ratio between these two enzymes.
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Discussion
In this report we show that forebrain
VAChT knock-out mice present deficits
in two domains of executive function,
cognitive flexibility and attention. Additionally, VAChT-deficient mice exhibit
metabolic deficits in the PFC suggestive of
changes in PFC circuitry. Furthermore,
these mice have reduced expression of a
key splicing factor, hnRNPA2/B1, which
has been previously implicated in synaptic
plasticity deficits in AD (Berson et al.,
2012) and in mutations that were recently
discovered in rare proteinopathies (Kim
et al., 2013). These changes have a functional impact on RNA metabolism in the
PFC of VAChT-deficient mice. These results suggest that VAChT Six3-Cre-flox/flox
mice may represent a powerful tool to dissect the molecular and neurochemical basis of executive dysfunction.
Cognitive flexibility in
VAChT Six3-Cre-flox/flox mice
VAChT Six3-Cre-flox/flox mice were able to
associate an image with a reward, and another with a punishment, in the pairwise
visual discrimination task. Acquisition of
this task has been shown to be dependent
on glutamatergic signaling, with mice
lacking the GLAST glutamate transporter
Six3-Cre-flox/flox
mice have metabolic abnormalities in the PFC. In vivo magnetic resonance spectroscopy of
being unable to acquire the task (Karlsson Figure 9. VAChT
neuronal metabolites. A, 9.4 tesla 1H magnetic resonance spectroscopy data from VAChT flox/flox (top) and VAhT six3cre-flox/flox
et al., 2009). Evidence suggests that the
(bottom) mice. The VAChT flox/flox data are shown in gray with fit superimposed (black line) and residual shown above. Individual
NMDA receptor is an important molecu- component spectra for Tau and Lac are also provided. B, Levels of Lac. C, Levels of Tau. D, Levels of NAA. E, Levels of Myo. F, Levels
lar switch for the acquisition of the task of Cho (n ! 4, data shown are the median and individual values per mouse, *p " 0.05).
(Brigman et al., 2008; Barkus et al., 2012).
Our results indicate that cholinergic sigfinding with the VAChT Six3-Cre-flox/flox mouse line having learnnaling is not required for such learning. In contrast, when coning and memory deficits (Martyn et al., 2012), these mice showed
tingencies of the pairwise task were reversed, forebrain VAChT
impairments in acquisition of the 5-CSRT, taking nearly twice as
knock-out mice were unable to adapt and learn the new rule.
long as controls to reach criteria at the 4 and 2 s phase of the
Reversal learning in a visual discrimination task has been protraining process. Interestingly, they were not impaired during the
posed to serve as a measure of cognitive flexibility in rodents
pretraining phase, wherein mice are taught to respond to the
(Izquierdo et al., 2006; Brigman et al., 2008). Neurochemical
touchscreen. These results suggest that simple operant condimodulation of reversal learning is complex, as it can be entioning is not dependent on forebrain cholinergic signaling, but
hanced by targeting multiple neurotransmitter signaling systems inrather that forebrain ACh is responsible for the use of such inforcluding serotonergic (Brigman et al., 2010), dopaminergic
mation to perform higher order cognitive tasks. Attentional de(Izquierdo et al., 2006), and glutamatergic (Balschun et al., 2010).
mand deficits were probed by reducing stimulus duration.
The role of cholinergic signaling has been focused predominantly on
Choice accuracy, perseverative, and premature responses of
muscarinic receptors (Ridley et al., 1984, 1985). Determining the
VAChT Six3-Cre-flox/flox mice were unaffected. However, the rate
exact mechanism has been difficult, as M1 receptor agonists facilitate
of omission for VAChT Six3-Cre-flox/flox was significantly incognitive flexibility (McCool et al., 2008; Shirey et al., 2009), but no
creased. Additionally, in the presence of a noise distractor
effects on cognitive flexibility were observed in M1-null mice
VAChT Six3-Cre-flox/flox mice were significantly less attentive than
(Bartko et al., 2011). There is evidence suggesting that M2 and M4
controls, showing a much higher rate of omissions. This test was
receptors may be involved in cognitive flexibility (Nieves-Martinez
performed under a condition in which the performance of
et al., 2012). Our results indicate that cholinergic signaling is essenVAChT-deficient mice was on par with controls without the autial for modulation of cognitive flexibility.
ditory distraction. The auditory distraction task gives a clear indication that the attention deficits observed in VAChT Six3-CreAttention deficits in VAChT-deficient mice
flox/flox mice were not due to visual abnormalities. These findings
To further understand the role of forebrain ACh in executive funcare aligned with previous work, given that cue detection has been
tion we evaluated attention on forebrain VAChT knock-out
shown to involve transient rises in ACh release (Himmelheber et
mice using the 5-CSRT task, a test suggested to be dependent on
al., 2000; Parikh et al., 2007). Our experiments agree with previPFC cholinergic signaling (Guillem et al., 2011; for review, see
ous work indicating a key role for cholinergic activity in improvRobbins, 2000; Dalley et al., 2004a). In line with our previous
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ing response to distractors in attentional
tasks (Gill et al., 2000; Terry et al., 2002;
Newman and McGaughy, 2008; Broussard et al., 2009; Howe et al., 2010; St Peters et al., 2011).
Regulation of attentional performance
by endogenous ACh has been investigated
in rats using immunolesion with IgG-192
saporin (Walsh et al., 1996; Risbrough et al.,
2002; Lehmann et al., 2003; Chudasama et
al., 2004; Dalley et al., 2004b). Specifically,
deficits in choice accuracy and increases in
perseverative responses were observed in
rats following 192 IgG-saporin-induced lesions (McGaughy et al., 2002; Dalley et al.,
2004b). In these studies no effects were observed on rates of omissions. Our experiments show a somewhat distinct feature,
demonstrating increased rates of omission,
without changes in perseverative response.
Interestingly, selective elimination of the !2
nAChR in mice also revealed an increase in
rate of omissions (Guillem et al., 2011). The
differences between genetically modified
and lesioned animals could therefore be
species related. Alternatively, this difference
may reflect the capacity of cholinergic neurons to secrete more than one neurotransmitter (El Mestikawy et al., 2011; Prado et
al., 2013). Basal forebrain cholinergic neurons can release glutamate in vitro (Allen et
al., 2006). There is also evidence that these
neurons possess the machinery to release
GABA (Henny and Jones, 2008). Recent experiments targeting striatum cholinergic
neurons revealed striking behavioral differences between mice that had cholinergic
elimination, using immunolesion, or mice
that were genetically targeted to eliminate
striatal ACh release (Kitabatake et al., 2003;
Guzman et al., 2011; for review, see Prado et
al., 2013). Immunolesion of cholinergic
neurons can therefore have effects beyond
impairing ACh release and could affect
cotransmission. Whether cotransmission
has a role in the small phenotypic differences between our experiments and previous work using rats injected with IgG-192saporin remains to be determined.

Figure 10. VAChT Six3-Cre-flox/flox mice have abnormal RNA processing in the PFC. A, hnRNPA2/B1 protein expression in
the PFC with representative immunoblots (inset, n ! 4). B, qPCR analysis of alternative splicing events for CD55, ENAH,
SIPA, Dystonin (DST), Reelin (RELN), and DRAM2. C, Expression of the PKM1 and PKM2 isoforms. Alternative exon levels are
normalized to a constitutive exon from the same gene (n ! 6, data are mean " SEM, *p # 0.05, **p # 0.01, and
***p # 0.001).

Alterations in PFC function in VAChTdeficient mice
Galantamine was unable to rescue the attention deficits in VAChT Six3-Cre-flox/flox
mice. We have previously shown, using a
mouse line with decreased VAChT expression, that galantamine could reverse
social memory deficits (Prado et al., 2006)
and object recognition memory deficits
(de Castro et al., 2009b; De Jaeger et al.,
2013). Hence, the fact that galantamine can
improve performance of control mice, but
not of VAChT Six3-Cre-flox/flox mice, suggests
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that the latter may not release sufficient synaptic ACh to be enhanced by galantamine. Alternatively, these sophisticated tasks
may be more affected by changes in neuronal circuitry. The in
vivo 1H spectroscopy data suggest that critical metabolic changes
occur in VAChT-deficient mice; namely, reduced levels of both
Tau and Lac in the prefrontal region. Lac has been proposed as
the preferred metabolic substrate for neurons (for review, see
Pellerin et al., 2007), suggesting that decreased cholinergic tone
may lead to a general decrease in neuronal activity.
The reduction in PFC hnRNPA2/B1 observed in
VAChT Six3-Cre-flox/flox mice is in line with previous work indicating
cholinergic-mediated regulation of its expression in AD (Berson et
al., 2012). Furthermore, we found that alternative splicing alteration
pattern in the PFC of these mice is similar to the pattern found in
both AD patient samples and hypocholinergic animal models (Berson et al., 2012). Overall, these changes suggest alterations in the PFC
circuitry. Furthermore, the splicing change found in the PKM gene
indicates a potential mechanism for cholinergic regulation of Lac
metabolism. Of note, nearly significant differential expression of the
PKM variants was observed in exon array datasets from the entorhinal cortices of three AD patients and three matched controls studied
previously, despite the small number of samples (Berson et al., 2012;
p ! 0.051; raw data deposited in the GenBank).
Decreased Lac levels have been observed in mouse models of
AD (Du Yan et al., 2000; Marjanska et al., 2005). Moreover, in the
CRND8 transgenic mouse model of AD, lower levels of Tau were
observed in vivo by H 1-NMR (Salek et al., 2010). Interestingly,
high levels of Lac in cultured neurons decrease susceptibility to
A!-derived peptides and oxidative stress in vitro (Newington et
al., 2012). Together, these data suggest that VAChT Six3-Cre-flox/flox
mice may be useful for understanding metabolic abnormalities
that occur in dementia.
Conclusion
In summary, by eliminating VAChT from the forebrain we determined that cholinergic signaling regulates executive function,
affects metabolism, and also RNA processing in the PFC. The
PFC has been shown to mediate salient cue detection (Himmelheber et al., 2000; Parikh et al., 2007), and it serves as a hub that
regulates numerous neurotransmitter interactions (Dalley et al.,
2004a; Carr et al., 2007; Tait and Brown, 2008). Our work helps to
define the specific role played by ACh in behaviors related to
cortical functioning, and its potential underlying mechanisms.
Decreased levels of VAChT in the brain have been reported in AD
(Efange et al., 1997; Chen et al., 2011), therefore the executive
dysfunction and mRNA processing abnormalities we observed in
VAChT-deficient mice may be of relevance to model this specific
deficiency in humans. Therefore, this work provides novel insights into the basic neurochemical contributors governing executive function.
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